id	sid	tid	token	lemma	pos
ihlr-25462	1	1	a	a	DET
ihlr-25462	1	2	survey	survey	NOUN
ihlr-25462	1	3	of	of	ADP
ihlr-25462	1	4	three	three	NUM
ihlr-25462	1	5	patent	patent	NOUN
ihlr-25462	1	6	-	-	PUNCT
ihlr-25462	1	7	based	base	VERB
ihlr-25462	1	8	approaches	approach	NOUN
ihlr-25462	1	9	that	that	PRON
ihlr-25462	1	10	may	may	AUX
ihlr-25462	1	11	play	play	VERB
ihlr-25462	1	12	a	a	DET
ihlr-25462	1	13	role	role	NOUN
ihlr-25462	1	14	in	in	ADP
ihlr-25462	1	15	drug	drug	NOUN
ihlr-25462	1	16	prices	price	NOUN
ihlr-25462	1	17	megan	megan	VERB
ihlr-25462	1	18	fuller	full	ADJ
ihlr-25462	1	19	*	*	PUNCT
ihlr-25462	1	20	i.	i.	PROPN
ihlr-25462	1	21	an	an	DET
ihlr-25462	1	22	introduction	introduction	NOUN
ihlr-25462	1	23	to	to	ADP
ihlr-25462	1	24	the	the	DET
ihlr-25462	1	25	interplay	interplay	NOUN
ihlr-25462	1	26	between	between	ADP
ihlr-25462	1	27	patents	patent	NOUN
ihlr-25462	1	28	and	and	CCONJ
ihlr-25462	1	29	drug	drug	NOUN
ihlr-25462	1	30	prices	price	NOUN
ihlr-25462	1	31	the	the	DET
ihlr-25462	1	32	founders	founder	NOUN
ihlr-25462	1	33	considered	consider	VERB
ihlr-25462	1	34	intellectual	intellectual	ADJ
ihlr-25462	1	35	property	property	NOUN
ihlr-25462	1	36	(	(	PUNCT
ihlr-25462	1	37	“	"	PUNCT
ihlr-25462	1	38	ip	ip	ADJ
ihlr-25462	1	39	”	"	PUNCT
ihlr-25462	1	40	)	)	PUNCT
ihlr-25462	1	41	rights	right	NOUN
ihlr-25462	1	42	so	so	ADV
ihlr-25462	1	43	important	important	ADJ
ihlr-25462	1	44	toward	toward	ADP
ihlr-25462	1	45	the	the	DET
ihlr-25462	1	46	goal	goal	NOUN
ihlr-25462	1	47	of	of	ADP
ihlr-25462	1	48	producing	produce	VERB
ihlr-25462	1	49	technological	technological	ADJ
ihlr-25462	1	50	advances	advance	NOUN
ihlr-25462	1	51	to	to	PART
ihlr-25462	1	52	benefit	benefit	VERB
ihlr-25462	1	53	society	society	NOUN
ihlr-25462	1	54	at	at	ADP
ihlr-25462	1	55	large	large	ADJ
ihlr-25462	1	56	that	that	SCONJ
ihlr-25462	1	57	they	they	PRON
ihlr-25462	1	58	codified	codify	VERB
ihlr-25462	1	59	them	they	PRON
ihlr-25462	1	60	in	in	ADP
ihlr-25462	1	61	the	the	DET
ihlr-25462	1	62	u.s	u.s	PROPN
ihlr-25462	1	63	.	.	PROPN
ihlr-25462	1	64	constitution.1	constitution.1	PROPN
ihlr-25462	1	65	today	today	NOUN
ihlr-25462	1	66	,	,	PUNCT
ihlr-25462	1	67	ip	ip	NOUN
ihlr-25462	1	68	rights	right	NOUN
ihlr-25462	1	69	,	,	PUNCT
ihlr-25462	1	70	including	include	VERB
ihlr-25462	1	71	patent	patent	NOUN
ihlr-25462	1	72	rights	right	NOUN
ihlr-25462	1	73	,	,	PUNCT
ihlr-25462	1	74	can	can	AUX
ihlr-25462	1	75	play	play	VERB
ihlr-25462	1	76	an	an	DET
ihlr-25462	1	77	important	important	ADJ
ihlr-25462	1	78	role	role	NOUN
ihlr-25462	1	79	in	in	ADP
ihlr-25462	1	80	the	the	DET
ihlr-25462	1	81	development	development	NOUN
ihlr-25462	1	82	and	and	CCONJ
ihlr-25462	1	83	pricing	pricing	NOUN
ihlr-25462	1	84	of	of	ADP
ihlr-25462	1	85	prescription	prescription	NOUN
ihlr-25462	1	86	drugs.2	drugs.2	NOUN
ihlr-25462	1	87	patents	patent	NOUN
ihlr-25462	1	88	are	be	AUX
ihlr-25462	1	89	particularly	particularly	ADV
ihlr-25462	1	90	important	important	ADJ
ihlr-25462	1	91	because	because	SCONJ
ihlr-25462	1	92	the	the	DET
ihlr-25462	1	93	u.s	u.s	PROPN
ihlr-25462	1	94	.	.	PROPN
ihlr-25462	1	95	patent	patent	NOUN
ihlr-25462	1	96	and	and	CCONJ
ihlr-25462	1	97	trademark	trademark	NOUN
ihlr-25462	1	98	office	office	NOUN
ihlr-25462	1	99	(	(	PUNCT
ihlr-25462	1	100	“	"	PUNCT
ihlr-25462	1	101	uspto	uspto	X
ihlr-25462	1	102	”	"	PUNCT
ihlr-25462	1	103	)	)	PUNCT
ihlr-25462	1	104	grants	grant	VERB
ihlr-25462	1	105	patent	patent	NOUN
ihlr-25462	1	106	holders	holder	NOUN
ihlr-25462	1	107	a	a	DET
ihlr-25462	1	108	temporary	temporary	ADJ
ihlr-25462	1	109	“	"	PUNCT
ihlr-25462	1	110	monopoly	monopoly	NOUN
ihlr-25462	1	111	”	"	PUNCT
ihlr-25462	1	112	on	on	ADP
ihlr-25462	1	113	their	their	PRON
ihlr-25462	1	114	new	new	ADJ
ihlr-25462	1	115	inventions	invention	NOUN
ihlr-25462	1	116	or	or	CCONJ
ihlr-25462	1	117	products	product	NOUN
ihlr-25462	1	118	–	–	PUNCT
ihlr-25462	1	119	a	a	DET
ihlr-25462	1	120	practice	practice	NOUN
ihlr-25462	1	121	essential	essential	ADJ
ihlr-25462	1	122	to	to	ADP
ihlr-25462	1	123	the	the	DET
ihlr-25462	1	124	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	1	125	industry	industry	NOUN
ihlr-25462	1	126	due	due	ADP
ihlr-25462	1	127	to	to	ADP
ihlr-25462	1	128	the	the	DET
ihlr-25462	1	129	need	need	NOUN
ihlr-25462	1	130	to	to	PART
ihlr-25462	1	131	recoup	recoup	VERB
ihlr-25462	1	132	the	the	DET
ihlr-25462	1	133	substantial	substantial	ADJ
ihlr-25462	1	134	amount	amount	NOUN
ihlr-25462	1	135	of	of	ADP
ihlr-25462	1	136	money	money	NOUN
ihlr-25462	1	137	that	that	PRON
ihlr-25462	1	138	was	be	AUX
ihlr-25462	1	139	invested	invest	VERB
ihlr-25462	1	140	in	in	ADP
ihlr-25462	1	141	research	research	NOUN
ihlr-25462	1	142	and	and	CCONJ
ihlr-25462	1	143	development.3	development.3	PROPN
ihlr-25462	1	144	as	as	ADP
ihlr-25462	1	145	a	a	DET
ihlr-25462	1	146	reward	reward	NOUN
ihlr-25462	1	147	for	for	ADP
ihlr-25462	1	148	their	their	PRON
ihlr-25462	1	149	innovation	innovation	NOUN
ihlr-25462	1	150	,	,	PUNCT
ihlr-25462	1	151	patent	patent	NOUN
ihlr-25462	1	152	holders	holder	NOUN
ihlr-25462	1	153	generally	generally	ADV
ihlr-25462	1	154	have	have	VERB
ihlr-25462	1	155	exclusive	exclusive	ADJ
ihlr-25462	1	156	rights	right	NOUN
ihlr-25462	1	157	“	"	PUNCT
ihlr-25462	1	158	to	to	PART
ihlr-25462	1	159	make	make	VERB
ihlr-25462	1	160	,	,	PUNCT
ihlr-25462	1	161	use	use	NOUN
ihlr-25462	1	162	,	,	PUNCT
ihlr-25462	1	163	sell	sell	VERB
ihlr-25462	1	164	,	,	PUNCT
ihlr-25462	1	165	or	or	CCONJ
ihlr-25462	1	166	import	import	NOUN
ihlr-25462	1	167	”	"	PUNCT
ihlr-25462	1	168	their	their	PRON
ihlr-25462	1	169	invention	invention	NOUN
ihlr-25462	1	170	within	within	ADP
ihlr-25462	1	171	the	the	DET
ihlr-25462	1	172	u.s	u.s	PROPN
ihlr-25462	1	173	.	.	PROPN
ihlr-25462	1	174	for	for	ADP
ihlr-25462	1	175	a	a	DET
ihlr-25462	1	176	period	period	NOUN
ihlr-25462	1	177	that	that	PRON
ihlr-25462	1	178	begins	begin	VERB
ihlr-25462	1	179	when	when	SCONJ
ihlr-25462	1	180	the	the	DET
ihlr-25462	1	181	patent	patent	NOUN
ihlr-25462	1	182	is	be	AUX
ihlr-25462	1	183	issued	issue	VERB
ihlr-25462	1	184	by	by	ADP
ihlr-25462	1	185	the	the	DET
ihlr-25462	1	186	uspto	uspto	NOUN
ihlr-25462	1	187	and	and	CCONJ
ihlr-25462	1	188	ends	end	VERB
ihlr-25462	1	189	approximately	approximately	ADV
ihlr-25462	1	190	twenty	twenty	NUM
ihlr-25462	1	191	years	year	NOUN
ihlr-25462	1	192	from	from	ADP
ihlr-25462	1	193	the	the	DET
ihlr-25462	1	194	date	date	NOUN
ihlr-25462	1	195	the	the	DET
ihlr-25462	1	196	applicant	applicant	NOUN
ihlr-25462	1	197	applied	apply	VERB
ihlr-25462	1	198	for	for	ADP
ihlr-25462	1	199	the	the	DET
ihlr-25462	1	200	patent.4	patent.4	PROPN
ihlr-25462	1	201	during	during	ADP
ihlr-25462	1	202	this	this	DET
ihlr-25462	1	203	time	time	NOUN
ihlr-25462	1	204	,	,	PUNCT
ihlr-25462	1	205	the	the	DET
ihlr-25462	1	206	“	"	PUNCT
ihlr-25462	1	207	monopoly	monopoly	NOUN
ihlr-25462	1	208	”	"	PUNCT
ihlr-25462	1	209	is	be	AUX
ihlr-25462	1	210	in	in	ADP
ihlr-25462	1	211	effect	effect	NOUN
ihlr-25462	1	212	,	,	PUNCT
ihlr-25462	1	213	and	and	CCONJ
ihlr-25462	1	214	competition	competition	NOUN
ihlr-25462	1	215	from	from	ADP
ihlr-25462	1	216	generic	generic	ADJ
ihlr-25462	1	217	companies	company	NOUN
ihlr-25462	1	218	is	be	AUX
ihlr-25462	1	219	delayed.5	delayed.5	PROPN
ihlr-25462	1	220	upon	upon	SCONJ
ihlr-25462	1	221	expiration	expiration	NOUN
ihlr-25462	1	222	of	of	ADP
ihlr-25462	1	223	a	a	DET
ihlr-25462	1	224	patent	patent	NOUN
ihlr-25462	1	225	’s	’s	PART
ihlr-25462	1	226	exclusivity,6	exclusivity,6	ADV
ihlr-25462	1	227	generic	generic	ADJ
ihlr-25462	1	228	or	or	CCONJ
ihlr-25462	1	229	biosimilar	biosimilar	ADJ
ihlr-25462	1	230	products	product	NOUN
ihlr-25462	1	231	can	can	AUX
ihlr-25462	1	232	*	*	PUNCT
ihlr-25462	1	233	j.d	j.d	PROPN
ihlr-25462	1	234	.	.	PROPN
ihlr-25462	1	235	candidate	candidate	NOUN
ihlr-25462	1	236	,	,	PUNCT
ihlr-25462	1	237	2021	2021	NUM
ihlr-25462	1	238	,	,	PUNCT
ihlr-25462	1	239	indiana	indiana	PROPN
ihlr-25462	1	240	university	university	PROPN
ihlr-25462	1	241	robert	robert	PROPN
ihlr-25462	1	242	h.	h.	PROPN
ihlr-25462	1	243	mckinney	mckinney	PROPN
ihlr-25462	1	244	school	school	PROPN
ihlr-25462	1	245	of	of	ADP
ihlr-25462	1	246	law	law	NOUN
ihlr-25462	1	247	,	,	PUNCT
ihlr-25462	1	248	indianapolis	indianapolis	PROPN
ihlr-25462	1	249	,	,	PUNCT
ihlr-25462	1	250	indiana	indiana	PROPN
ihlr-25462	1	251	;	;	PUNCT
ihlr-25462	1	252	m.s	m.s	PROPN
ihlr-25462	1	253	.	.	PROPN
ihlr-25462	1	254	,	,	PUNCT
ihlr-25462	1	255	2014	2014	NUM
ihlr-25462	1	256	,	,	PUNCT
ihlr-25462	1	257	michigan	michigan	PROPN
ihlr-25462	1	258	state	state	PROPN
ihlr-25462	1	259	university	university	PROPN
ihlr-25462	1	260	,	,	PUNCT
ihlr-25462	1	261	east	east	PROPN
ihlr-25462	1	262	lansing	lansing	PROPN
ihlr-25462	1	263	,	,	PUNCT
ihlr-25462	1	264	michigan	michigan	PROPN
ihlr-25462	1	265	;	;	PUNCT
ihlr-25462	1	266	b.s	b.s	PROPN
ihlr-25462	1	267	.	.	PROPN
ihlr-25462	1	268	,	,	PUNCT
ihlr-25462	1	269	2010	2010	NUM
ihlr-25462	1	270	,	,	PUNCT
ihlr-25462	1	271	purdue	purdue	PROPN
ihlr-25462	1	272	university	university	NOUN
ihlr-25462	1	273	,	,	PUNCT
ihlr-25462	1	274	west	west	PROPN
ihlr-25462	1	275	lafayette	lafayette	PROPN
ihlr-25462	1	276	,	,	PUNCT
ihlr-25462	1	277	indiana	indiana	PROPN
ihlr-25462	1	278	.	.	PUNCT
ihlr-25462	2	1	any	any	DET
ihlr-25462	2	2	views	view	NOUN
ihlr-25462	2	3	expressed	express	VERB
ihlr-25462	2	4	herein	herein	NOUN
ihlr-25462	2	5	are	be	AUX
ihlr-25462	2	6	my	my	PRON
ihlr-25462	2	7	own	own	ADJ
ihlr-25462	2	8	and	and	CCONJ
ihlr-25462	2	9	do	do	AUX
ihlr-25462	2	10	not	not	PART
ihlr-25462	2	11	necessarily	necessarily	ADV
ihlr-25462	2	12	reflect	reflect	VERB
ihlr-25462	2	13	the	the	DET
ihlr-25462	2	14	views	view	NOUN
ihlr-25462	2	15	of	of	ADP
ihlr-25462	2	16	my	my	PRON
ihlr-25462	2	17	employer	employer	NOUN
ihlr-25462	2	18	.	.	PUNCT
ihlr-25462	3	1	1	1	X
ihlr-25462	3	2	.	.	X
ihlr-25462	3	3	see	see	VERB
ihlr-25462	3	4	u.s	u.s	PROPN
ihlr-25462	3	5	.	.	PROPN
ihlr-25462	3	6	const	const	PROPN
ihlr-25462	3	7	.	.	PUNCT
ihlr-25462	4	1	art	art	NOUN
ihlr-25462	4	2	.	.	PUNCT
ihlr-25462	5	1	i	i	PRON
ihlr-25462	5	2	,	,	PUNCT
ihlr-25462	5	3	§	§	PROPN
ihlr-25462	5	4	8	8	NUM
ihlr-25462	5	5	,	,	PUNCT
ihlr-25462	5	6	cl	cl	NOUN
ihlr-25462	5	7	.	.	NOUN
ihlr-25462	5	8	8	8	NUM
ihlr-25462	5	9	(	(	PUNCT
ihlr-25462	5	10	“	"	PUNCT
ihlr-25462	5	11	the	the	DET
ihlr-25462	5	12	congress	congress	PROPN
ihlr-25462	5	13	shall	shall	AUX
ihlr-25462	5	14	have	have	VERB
ihlr-25462	5	15	power	power	NOUN
ihlr-25462	5	16	.	.	PUNCT
ihlr-25462	5	17	.	.	PUNCT
ihlr-25462	5	18	.	.	PUNCT
ihlr-25462	6	1	[	[	X
ihlr-25462	6	2	t]o	t]o	NOUN
ihlr-25462	6	3	promote	promote	VERB
ihlr-25462	6	4	the	the	DET
ihlr-25462	6	5	progress	progress	NOUN
ihlr-25462	6	6	of	of	ADP
ihlr-25462	6	7	science	science	NOUN
ihlr-25462	6	8	and	and	CCONJ
ihlr-25462	6	9	useful	useful	ADJ
ihlr-25462	6	10	arts	art	NOUN
ihlr-25462	6	11	,	,	PUNCT
ihlr-25462	6	12	by	by	ADP
ihlr-25462	6	13	securing	secure	VERB
ihlr-25462	6	14	for	for	ADP
ihlr-25462	6	15	limited	limited	ADJ
ihlr-25462	6	16	times	time	NOUN
ihlr-25462	6	17	to	to	ADP
ihlr-25462	6	18	authors	author	NOUN
ihlr-25462	6	19	and	and	CCONJ
ihlr-25462	6	20	inventors	inventor	NOUN
ihlr-25462	6	21	the	the	DET
ihlr-25462	6	22	exclusive	exclusive	ADJ
ihlr-25462	6	23	right	right	NOUN
ihlr-25462	6	24	to	to	ADP
ihlr-25462	6	25	their	their	PRON
ihlr-25462	6	26	respective	respective	ADJ
ihlr-25462	6	27	writings	writing	NOUN
ihlr-25462	6	28	and	and	CCONJ
ihlr-25462	6	29	discoveries	discovery	NOUN
ihlr-25462	6	30	.	.	PUNCT
ihlr-25462	6	31	”	"	PUNCT
ihlr-25462	7	1	)	)	PUNCT
ihlr-25462	7	2	2	2	X
ihlr-25462	7	3	.	.	X
ihlr-25462	7	4	see	see	VERB
ihlr-25462	7	5	kevin	kevin	PROPN
ihlr-25462	7	6	j.	j.	PROPN
ihlr-25462	7	7	hickey	hickey	PROPN
ihlr-25462	7	8	et	et	PROPN
ihlr-25462	7	9	al	al	PROPN
ihlr-25462	7	10	.	.	PROPN
ihlr-25462	7	11	,	,	PUNCT
ihlr-25462	7	12	cong	cong	PROPN
ihlr-25462	7	13	.	.	PUNCT
ihlr-25462	8	1	research	research	NOUN
ihlr-25462	8	2	serv	serv	PROPN
ihlr-25462	8	3	.	.	PROPN
ihlr-25462	8	4	,	,	PUNCT
ihlr-25462	8	5	r45666	r45666	ADJ
ihlr-25462	8	6	,	,	PUNCT
ihlr-25462	8	7	drug	drug	NOUN
ihlr-25462	8	8	pricing	pricing	NOUN
ihlr-25462	8	9	and	and	CCONJ
ihlr-25462	8	10	intellectual	intellectual	ADJ
ihlr-25462	8	11	property	property	NOUN
ihlr-25462	8	12	law	law	NOUN
ihlr-25462	8	13	:	:	PUNCT
ihlr-25462	8	14	a	a	DET
ihlr-25462	8	15	legal	legal	ADJ
ihlr-25462	8	16	overview	overview	NOUN
ihlr-25462	8	17	for	for	ADP
ihlr-25462	8	18	the	the	DET
ihlr-25462	8	19	116th	116th	ADJ
ihlr-25462	8	20	congress	congress	PROPN
ihlr-25462	8	21	1	1	NUM
ihlr-25462	8	22	(	(	PUNCT
ihlr-25462	8	23	2019	2019	NUM
ihlr-25462	8	24	)	)	PUNCT
ihlr-25462	8	25	,	,	PUNCT
ihlr-25462	9	1	https://	https://	PROPN
ihlr-25462	9	2	crsreports.congress.gov/product/pdf/r/r45666	crsreports.congress.gov/product/pdf/r/r45666	PROPN
ihlr-25462	10	1	[	[	X
ihlr-25462	10	2	https://perma.cc/kbx4-khjn	https://perma.cc/kbx4-khjn	X
ihlr-25462	10	3	]	]	PUNCT
ihlr-25462	10	4	.	.	PUNCT
ihlr-25462	11	1	3	3	X
ihlr-25462	11	2	.	.	X
ihlr-25462	11	3	see	see	VERB
ihlr-25462	11	4	joseph	joseph	PROPN
ihlr-25462	11	5	a.	a.	PROPN
ihlr-25462	11	6	dimasi	dimasi	PROPN
ihlr-25462	11	7	et	et	PROPN
ihlr-25462	11	8	al	al	PROPN
ihlr-25462	11	9	.	.	PROPN
ihlr-25462	11	10	,	,	PUNCT
ihlr-25462	11	11	innovation	innovation	NOUN
ihlr-25462	11	12	in	in	ADP
ihlr-25462	11	13	the	the	DET
ihlr-25462	11	14	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	11	15	industry	industry	NOUN
ihlr-25462	11	16	:	:	PUNCT
ihlr-25462	11	17	new	new	ADJ
ihlr-25462	11	18	estimates	estimate	NOUN
ihlr-25462	11	19	of	of	ADP
ihlr-25462	11	20	r&d	r&d	NOUN
ihlr-25462	11	21	costs	cost	NOUN
ihlr-25462	11	22	,	,	PUNCT
ihlr-25462	11	23	47	47	NUM
ihlr-25462	11	24	j.	j.	PROPN
ihlr-25462	11	25	health	health	PROPN
ihlr-25462	11	26	econ	econ	PROPN
ihlr-25462	11	27	.	.	PUNCT
ihlr-25462	12	1	20	20	NUM
ihlr-25462	12	2	(	(	PUNCT
ihlr-25462	12	3	2016	2016	NUM
ihlr-25462	12	4	)	)	PUNCT
ihlr-25462	12	5	.	.	PUNCT
ihlr-25462	13	1	research	research	NOUN
ihlr-25462	13	2	showed	show	VERB
ihlr-25462	13	3	that	that	SCONJ
ihlr-25462	13	4	the	the	DET
ihlr-25462	13	5	average	average	ADJ
ihlr-25462	13	6	cost	cost	NOUN
ihlr-25462	13	7	to	to	PART
ihlr-25462	13	8	develop	develop	VERB
ihlr-25462	13	9	and	and	CCONJ
ihlr-25462	13	10	secure	secure	VERB
ihlr-25462	13	11	approval	approval	NOUN
ihlr-25462	13	12	of	of	ADP
ihlr-25462	13	13	a	a	DET
ihlr-25462	13	14	new	new	ADJ
ihlr-25462	13	15	medicine	medicine	NOUN
ihlr-25462	13	16	in	in	ADP
ihlr-25462	13	17	2013	2013	NUM
ihlr-25462	13	18	was	be	AUX
ihlr-25462	13	19	$	$	SYM
ihlr-25462	13	20	2.6	2.6	NUM
ihlr-25462	13	21	billion	billion	NUM
ihlr-25462	13	22	dollars	dollar	NOUN
ihlr-25462	13	23	,	,	PUNCT
ihlr-25462	13	24	considering	consider	VERB
ihlr-25462	13	25	trial	trial	NOUN
ihlr-25462	13	26	and	and	CCONJ
ihlr-25462	13	27	error	error	NOUN
ihlr-25462	13	28	,	,	PUNCT
ihlr-25462	13	29	the	the	DET
ihlr-25462	13	30	research	research	NOUN
ihlr-25462	13	31	failures	failure	NOUN
ihlr-25462	13	32	along	along	ADP
ihlr-25462	13	33	the	the	DET
ihlr-25462	13	34	way	way	NOUN
ihlr-25462	13	35	,	,	PUNCT
ihlr-25462	13	36	and	and	CCONJ
ihlr-25462	13	37	the	the	DET
ihlr-25462	13	38	cost	cost	NOUN
ihlr-25462	13	39	of	of	ADP
ihlr-25462	13	40	capital	capital	NOUN
ihlr-25462	13	41	.	.	PUNCT
ihlr-25462	14	1	see	see	VERB
ihlr-25462	15	1	i	i	PRON
ihlr-25462	15	2	d.	d.	PROPN
ihlr-25462	15	3	also	also	ADV
ihlr-25462	15	4	,	,	PUNCT
ihlr-25462	15	5	note	note	VERB
ihlr-25462	15	6	that	that	SCONJ
ihlr-25462	15	7	the	the	DET
ihlr-25462	15	8	dimasigrabowski	dimasigrabowski	ADJ
ihlr-25462	15	9	approach	approach	NOUN
ihlr-25462	15	10	to	to	ADP
ihlr-25462	15	11	pricing	pricing	NOUN
ihlr-25462	15	12	is	be	AUX
ihlr-25462	15	13	one	one	NUM
ihlr-25462	15	14	,	,	PUNCT
ihlr-25462	15	15	but	but	CCONJ
ihlr-25462	15	16	not	not	PART
ihlr-25462	15	17	the	the	DET
ihlr-25462	15	18	only	only	ADJ
ihlr-25462	15	19	,	,	PUNCT
ihlr-25462	15	20	approach	approach	NOUN
ihlr-25462	15	21	to	to	ADP
ihlr-25462	15	22	pricing	pricing	NOUN
ihlr-25462	15	23	in	in	ADP
ihlr-25462	15	24	the	the	DET
ihlr-25462	15	25	u.s	u.s	PROPN
ihlr-25462	15	26	.	.	PROPN
ihlr-25462	15	27	in	in	ADP
ihlr-25462	15	28	the	the	DET
ihlr-25462	15	29	u.s	u.s	PROPN
ihlr-25462	15	30	.	.	PROPN
ihlr-25462	15	31	,	,	PUNCT
ihlr-25462	15	32	value	value	NOUN
ihlr-25462	15	33	-	-	PUNCT
ihlr-25462	15	34	based	base	VERB
ihlr-25462	15	35	and	and	CCONJ
ihlr-25462	15	36	cost	cost	NOUN
ihlr-25462	15	37	-	-	PUNCT
ihlr-25462	15	38	plus	plus	CCONJ
ihlr-25462	15	39	approaches	approach	NOUN
ihlr-25462	15	40	are	be	AUX
ihlr-25462	15	41	also	also	ADV
ihlr-25462	15	42	used	use	VERB
ihlr-25462	15	43	,	,	PUNCT
ihlr-25462	15	44	among	among	ADP
ihlr-25462	15	45	others	other	NOUN
ihlr-25462	15	46	.	.	PUNCT
ihlr-25462	16	1	4	4	NUM
ihlr-25462	16	2	.	.	NOUN
ihlr-25462	16	3	35	35	NUM
ihlr-25462	16	4	u.s.c	u.s.c	NOUN
ihlr-25462	16	5	.	.	PUNCT
ihlr-25462	17	1	§	§	PROPN
ihlr-25462	17	2	§	§	PROPN
ihlr-25462	17	3	154(a)(2	154(a)(2	NUM
ihlr-25462	17	4	)	)	PUNCT
ihlr-25462	17	5	,	,	PUNCT
ihlr-25462	17	6	271(a	271(a	NUM
ihlr-25462	17	7	)	)	PUNCT
ihlr-25462	17	8	(	(	PUNCT
ihlr-25462	17	9	2020	2020	NUM
ihlr-25462	17	10	)	)	PUNCT
ihlr-25462	17	11	;	;	PUNCT
ihlr-25462	17	12	see	see	VERB
ihlr-25462	17	13	also	also	ADV
ihlr-25462	17	14	hickey	hickey	PROPN
ihlr-25462	17	15	et	et	PROPN
ihlr-25462	17	16	al	al	PROPN
ihlr-25462	17	17	.	.	PROPN
ihlr-25462	17	18	,	,	PUNCT
ihlr-25462	17	19	supra	supra	PROPN
ihlr-25462	17	20	note	note	NOUN
ihlr-25462	17	21	2	2	NUM
ihlr-25462	17	22	,	,	PUNCT
ihlr-25462	17	23	at	at	ADP
ihlr-25462	17	24	3	3	NUM
ihlr-25462	17	25	.	.	NOUN
ihlr-25462	17	26	5	5	NUM
ihlr-25462	17	27	.	.	PUNCT
ihlr-25462	17	28	hickey	hickey	PROPN
ihlr-25462	17	29	et	et	PROPN
ihlr-25462	17	30	al	al	PROPN
ihlr-25462	17	31	.	.	PROPN
ihlr-25462	17	32	,	,	PUNCT
ihlr-25462	17	33	supra	supra	PROPN
ihlr-25462	17	34	note	note	NOUN
ihlr-25462	17	35	2	2	NUM
ihlr-25462	17	36	,	,	PUNCT
ihlr-25462	17	37	at	at	ADP
ihlr-25462	17	38	4	4	NUM
ihlr-25462	17	39	(	(	PUNCT
ihlr-25462	17	40	stating	state	VERB
ihlr-25462	17	41	that	that	SCONJ
ihlr-25462	17	42	“	"	PUNCT
ihlr-25462	17	43	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	17	44	products	product	NOUN
ihlr-25462	17	45	are	be	AUX
ihlr-25462	17	46	frequently	frequently	ADV
ihlr-25462	17	47	protected	protect	VERB
ihlr-25462	17	48	by	by	ADP
ihlr-25462	17	49	ip	ip	DET
ihlr-25462	17	50	rights	right	NOUN
ihlr-25462	17	51	,	,	PUNCT
ihlr-25462	17	52	and	and	CCONJ
ihlr-25462	17	53	some	some	DET
ihlr-25462	17	54	studies	study	NOUN
ihlr-25462	17	55	have	have	AUX
ihlr-25462	17	56	shown	show	VERB
ihlr-25462	17	57	that	that	SCONJ
ihlr-25462	17	58	ip	ip	ADJ
ihlr-25462	17	59	rights	right	NOUN
ihlr-25462	17	60	are	be	AUX
ihlr-25462	17	61	the	the	DET
ihlr-25462	17	62	most	most	ADV
ihlr-25462	17	63	important	important	ADJ
ihlr-25462	17	64	factors	factor	NOUN
ihlr-25462	17	65	driving	drive	VERB
ihlr-25462	17	66	high	high	ADJ
ihlr-25462	17	67	drug	drug	NOUN
ihlr-25462	17	68	prices	price	NOUN
ihlr-25462	17	69	.	.	PUNCT
ihlr-25462	18	1	for	for	ADP
ihlr-25462	18	2	example	example	NOUN
ihlr-25462	18	3	,	,	PUNCT
ihlr-25462	18	4	[	[	X
ihlr-25462	18	5	the	the	X
ihlr-25462	18	6	]	]	X
ihlr-25462	18	7	fda	fda	PROPN
ihlr-25462	18	8	has	have	AUX
ihlr-25462	18	9	found	find	VERB
ihlr-25462	18	10	that	that	SCONJ
ihlr-25462	18	11	increased	increase	VERB
ihlr-25462	18	12	competition	competition	NOUN
ihlr-25462	18	13	from	from	ADP
ihlr-25462	18	14	generic	generic	ADJ
ihlr-25462	18	15	drug	drug	NOUN
ihlr-25462	18	16	manufacturers	manufacturer	NOUN
ihlr-25462	18	17	is	be	AUX
ihlr-25462	18	18	associated	associate	VERB
ihlr-25462	18	19	with	with	ADP
ihlr-25462	18	20	lower	low	ADJ
ihlr-25462	18	21	prices	price	NOUN
ihlr-25462	18	22	for	for	ADP
ihlr-25462	18	23	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	18	24	”	"	PUNCT
ihlr-25462	18	25	)	)	PUNCT
ihlr-25462	18	26	.	.	PUNCT
ihlr-25462	19	1	6	6	X
ihlr-25462	19	2	.	.	X
ihlr-25462	19	3	kevin	kevin	PROPN
ihlr-25462	19	4	o’connor	o’connor	PROPN
ihlr-25462	19	5	,	,	PUNCT
ihlr-25462	19	6	how	how	SCONJ
ihlr-25462	19	7	patents	patent	NOUN
ihlr-25462	19	8	play	play	VERB
ihlr-25462	19	9	a	a	DET
ihlr-25462	19	10	role	role	NOUN
ihlr-25462	19	11	in	in	ADP
ihlr-25462	19	12	drug	drug	NOUN
ihlr-25462	19	13	pricing	pricing	NOUN
ihlr-25462	19	14	,	,	PUNCT
ihlr-25462	19	15	pharma	pharma	NOUN
ihlr-25462	19	16	letter	letter	NOUN
ihlr-25462	19	17	(	(	PUNCT
ihlr-25462	19	18	jan	jan	PROPN
ihlr-25462	19	19	.	.	PROPN
ihlr-25462	19	20	19	19	NUM
ihlr-25462	19	21	,	,	PUNCT
ihlr-25462	19	22	2018	2018	NUM
ihlr-25462	19	23	)	)	PUNCT
ihlr-25462	19	24	,	,	PUNCT
ihlr-25462	19	25	https://www.thepharmaletter.com/article/how-patents-play-a-role-in-drug-pricing	https://www.thepharmaletter.com/article/how-patents-play-a-role-in-drug-price	VERB
ihlr-25462	19	26	398	398	NUM
ihlr-25462	19	27	indiana	indiana	PROPN
ihlr-25462	19	28	health	health	PROPN
ihlr-25462	19	29	law	law	PROPN
ihlr-25462	19	30	review	review	NOUN
ihlr-25462	19	31	[	[	X
ihlr-25462	19	32	vol	vol	NOUN
ihlr-25462	19	33	.	.	PUNCT
ihlr-25462	19	34	18:397	18:397	NUM
ihlr-25462	19	35	enter	enter	VERB
ihlr-25462	19	36	the	the	DET
ihlr-25462	19	37	market	market	NOUN
ihlr-25462	19	38	,	,	PUNCT
ihlr-25462	19	39	driving	drive	VERB
ihlr-25462	19	40	the	the	DET
ihlr-25462	19	41	price	price	NOUN
ihlr-25462	19	42	of	of	ADP
ihlr-25462	19	43	the	the	DET
ihlr-25462	19	44	product	product	NOUN
ihlr-25462	19	45	down.7	down.7	ADP
ihlr-25462	19	46	this	this	DET
ihlr-25462	19	47	change	change	NOUN
ihlr-25462	19	48	can	can	AUX
ihlr-25462	19	49	be	be	AUX
ihlr-25462	19	50	significant	significant	ADJ
ihlr-25462	19	51	:	:	PUNCT
ihlr-25462	19	52	the	the	DET
ihlr-25462	19	53	first	first	ADJ
ihlr-25462	19	54	generic	generic	ADJ
ihlr-25462	19	55	competitor	competitor	NOUN
ihlr-25462	19	56	’s	’s	PART
ihlr-25462	19	57	product	product	NOUN
ihlr-25462	19	58	is	be	AUX
ihlr-25462	19	59	typically	typically	ADV
ihlr-25462	19	60	offered	offer	VERB
ihlr-25462	19	61	at	at	ADP
ihlr-25462	19	62	a	a	DET
ihlr-25462	19	63	20	20	NUM
ihlr-25462	19	64	-	-	SYM
ihlr-25462	19	65	30	30	NUM
ihlr-25462	19	66	%	%	NOUN
ihlr-25462	19	67	discount	discount	NOUN
ihlr-25462	19	68	,	,	PUNCT
ihlr-25462	19	69	and	and	CCONJ
ihlr-25462	19	70	subsequent	subsequent	ADJ
ihlr-25462	19	71	generic	generic	ADJ
ihlr-25462	19	72	entry	entry	NOUN
ihlr-25462	19	73	can	can	AUX
ihlr-25462	19	74	push	push	VERB
ihlr-25462	19	75	the	the	DET
ihlr-25462	19	76	price	price	NOUN
ihlr-25462	19	77	down	down	ADV
ihlr-25462	19	78	to	to	ADP
ihlr-25462	19	79	15	15	NUM
ihlr-25462	19	80	%	%	NOUN
ihlr-25462	19	81	,	,	PUNCT
ihlr-25462	19	82	or	or	CCONJ
ihlr-25462	19	83	even	even	ADV
ihlr-25462	19	84	less	less	ADJ
ihlr-25462	19	85	,	,	PUNCT
ihlr-25462	19	86	of	of	ADP
ihlr-25462	19	87	the	the	DET
ihlr-25462	19	88	product	product	NOUN
ihlr-25462	19	89	’s	’s	PART
ihlr-25462	19	90	original	original	ADJ
ihlr-25462	19	91	price.8	price.8	NOUN
ihlr-25462	19	92	notably	notably	ADV
ihlr-25462	19	93	,	,	PUNCT
ihlr-25462	19	94	“	"	PUNCT
ihlr-25462	19	95	many	many	ADJ
ihlr-25462	19	96	factors	factor	NOUN
ihlr-25462	19	97	other	other	ADJ
ihlr-25462	19	98	than	than	ADP
ihlr-25462	19	99	ip	ip	PRON
ihlr-25462	19	100	rights	right	NOUN
ihlr-25462	19	101	contribute	contribute	VERB
ihlr-25462	19	102	to	to	ADP
ihlr-25462	19	103	”	"	PUNCT
ihlr-25462	19	104	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	19	105	drug	drug	NOUN
ihlr-25462	19	106	prices.9	prices.9	NOUN
ihlr-25462	19	107	furthermore	furthermore	ADV
ihlr-25462	19	108	,	,	PUNCT
ihlr-25462	19	109	while	while	SCONJ
ihlr-25462	19	110	there	there	PRON
ihlr-25462	19	111	are	be	VERB
ihlr-25462	19	112	significant	significant	ADJ
ihlr-25462	19	113	government	government	NOUN
ihlr-25462	19	114	interventions	intervention	NOUN
ihlr-25462	19	115	on	on	ADP
ihlr-25462	19	116	pricing	pricing	NOUN
ihlr-25462	19	117	within	within	ADP
ihlr-25462	19	118	government	government	NOUN
ihlr-25462	19	119	programs	program	NOUN
ihlr-25462	19	120	(	(	PUNCT
ihlr-25462	19	121	i.e.	i.e.	X
ihlr-25462	19	122	,	,	PUNCT
ihlr-25462	19	123	mandatory	mandatory	ADJ
ihlr-25462	19	124	rebates	rebate	NOUN
ihlr-25462	19	125	,	,	PUNCT
ihlr-25462	19	126	consumer	consumer	NOUN
ihlr-25462	19	127	price	price	NOUN
ihlr-25462	19	128	index	index	NOUN
ihlr-25462	19	129	penalties	penalty	NOUN
ihlr-25462	19	130	,	,	PUNCT
ihlr-25462	19	131	or	or	CCONJ
ihlr-25462	19	132	best	good	ADJ
ihlr-25462	19	133	price	price	NOUN
ihlr-25462	19	134	provisions	provision	NOUN
ihlr-25462	19	135	in	in	ADP
ihlr-25462	19	136	medicaid	medicaid	PROPN
ihlr-25462	19	137	)	)	PUNCT
ihlr-25462	19	138	,	,	PUNCT
ihlr-25462	19	139	the	the	DET
ihlr-25462	19	140	u.s	u.s	PROPN
ihlr-25462	19	141	.	.	PROPN
ihlr-25462	19	142	currently	currently	ADV
ihlr-25462	19	143	has	have	VERB
ihlr-25462	19	144	no	no	DET
ihlr-25462	19	145	direct	direct	ADJ
ihlr-25462	19	146	price	price	NOUN
ihlr-25462	19	147	controls	control	NOUN
ihlr-25462	19	148	on	on	ADP
ihlr-25462	19	149	pharmaceuticals.10	pharmaceuticals.10	PROPN
ihlr-25462	19	150	the	the	DET
ihlr-25462	19	151	complexities	complexity	NOUN
ihlr-25462	19	152	of	of	ADP
ihlr-25462	19	153	drug	drug	NOUN
ihlr-25462	19	154	pricing	pricing	NOUN
ihlr-25462	19	155	extend	extend	VERB
ihlr-25462	19	156	far	far	ADV
ihlr-25462	19	157	beyond	beyond	ADP
ihlr-25462	19	158	a	a	DET
ihlr-25462	19	159	single	single	ADJ
ihlr-25462	19	160	law	law	NOUN
ihlr-25462	19	161	review	review	NOUN
ihlr-25462	19	162	note	note	NOUN
ihlr-25462	19	163	.	.	PUNCT
ihlr-25462	20	1	however	however	ADV
ihlr-25462	20	2	,	,	PUNCT
ihlr-25462	20	3	this	this	DET
ihlr-25462	20	4	note	note	NOUN
ihlr-25462	20	5	examines	examine	VERB
ihlr-25462	20	6	three	three	NUM
ihlr-25462	20	7	patent	patent	NOUN
ihlr-25462	20	8	law	law	NOUN
ihlr-25462	20	9	approaches	approach	NOUN
ihlr-25462	20	10	that	that	PRON
ihlr-25462	20	11	have	have	AUX
ihlr-25462	20	12	recently	recently	ADV
ihlr-25462	20	13	made	make	VERB
ihlr-25462	20	14	substantial	substantial	ADJ
ihlr-25462	20	15	impacts	impact	NOUN
ihlr-25462	20	16	on	on	ADP
ihlr-25462	20	17	drug	drug	NOUN
ihlr-25462	20	18	prices	price	NOUN
ihlr-25462	20	19	and	and	CCONJ
ihlr-25462	20	20	drug	drug	NOUN
ihlr-25462	20	21	pricing	pricing	NOUN
ihlr-25462	20	22	legislation	legislation	NOUN
ihlr-25462	20	23	.	.	PUNCT
ihlr-25462	21	1	first	first	ADV
ihlr-25462	21	2	,	,	PUNCT
ihlr-25462	21	3	this	this	DET
ihlr-25462	21	4	note	note	NOUN
ihlr-25462	21	5	examines	examine	VERB
ihlr-25462	21	6	the	the	DET
ihlr-25462	21	7	doctrine	doctrine	NOUN
ihlr-25462	21	8	of	of	ADP
ihlr-25462	21	9	patent	patent	NOUN
ihlr-25462	21	10	exhaustion	exhaustion	NOUN
ihlr-25462	21	11	and	and	CCONJ
ihlr-25462	21	12	,	,	PUNCT
ihlr-25462	21	13	subsequently	subsequently	ADV
ihlr-25462	21	14	,	,	PUNCT
ihlr-25462	21	15	the	the	DET
ihlr-25462	21	16	patent	patent	NOUN
ihlr-25462	21	17	practices	practice	NOUN
ihlr-25462	21	18	of	of	ADP
ihlr-25462	21	19	“	"	PUNCT
ihlr-25462	21	20	patent	patent	NOUN
ihlr-25462	21	21	thicketing	thicketing	NOUN
ihlr-25462	21	22	”	"	PUNCT
ihlr-25462	21	23	and	and	CCONJ
ihlr-25462	21	24	“	"	PUNCT
ihlr-25462	21	25	product	product	NOUN
ihlr-25462	21	26	hopping	hopping	NOUN
ihlr-25462	21	27	.	.	PUNCT
ihlr-25462	21	28	”	"	PUNCT
ihlr-25462	22	1	it	it	PRON
ihlr-25462	22	2	analyzes	analyze	VERB
ihlr-25462	22	3	the	the	DET
ihlr-25462	22	4	impact	impact	NOUN
ihlr-25462	22	5	of	of	ADP
ihlr-25462	22	6	each	each	PRON
ihlr-25462	22	7	on	on	ADP
ihlr-25462	22	8	the	the	DET
ihlr-25462	22	9	price	price	NOUN
ihlr-25462	22	10	of	of	ADP
ihlr-25462	22	11	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	22	12	in	in	ADP
ihlr-25462	22	13	the	the	DET
ihlr-25462	22	14	u.s	u.s	PROPN
ihlr-25462	22	15	.	.	PROPN
ihlr-25462	22	16	this	this	DET
ihlr-25462	22	17	note	note	NOUN
ihlr-25462	22	18	begins	begin	VERB
ihlr-25462	22	19	with	with	ADP
ihlr-25462	22	20	section	section	PROPN
ihlr-25462	22	21	ii	ii	PROPN
ihlr-25462	22	22	,	,	PUNCT
ihlr-25462	22	23	analyzing	analyze	VERB
ihlr-25462	22	24	the	the	DET
ihlr-25462	22	25	doctrine	doctrine	NOUN
ihlr-25462	22	26	of	of	ADP
ihlr-25462	22	27	patent	patent	NOUN
ihlr-25462	22	28	exhaustion	exhaustion	NOUN
ihlr-25462	22	29	,	,	PUNCT
ihlr-25462	22	30	which	which	PRON
ihlr-25462	22	31	has	have	VERB
ihlr-25462	22	32	an	an	DET
ihlr-25462	22	33	important	important	ADJ
ihlr-25462	22	34	relationship	relationship	NOUN
ihlr-25462	22	35	to	to	ADP
ihlr-25462	22	36	recently	recently	ADV
ihlr-25462	22	37	publicized	publicize	VERB
ihlr-25462	22	38	legislation	legislation	NOUN
ihlr-25462	22	39	that	that	PRON
ihlr-25462	22	40	proposes	propose	VERB
ihlr-25462	22	41	prescription	prescription	NOUN
ihlr-25462	22	42	drug	drug	NOUN
ihlr-25462	22	43	re	re	NOUN
ihlr-25462	22	44	-	-	NOUN
ihlr-25462	22	45	importation	importation	NOUN
ihlr-25462	22	46	from	from	ADP
ihlr-25462	22	47	canada	canada	PROPN
ihlr-25462	22	48	.	.	PUNCT
ihlr-25462	23	1	further	far	ADV
ihlr-25462	23	2	,	,	PUNCT
ihlr-25462	23	3	section	section	NOUN
ihlr-25462	23	4	ii	ii	PROPN
ihlr-25462	23	5	explains	explain	VERB
ihlr-25462	23	6	how	how	SCONJ
ihlr-25462	23	7	a	a	DET
ihlr-25462	23	8	2017	2017	NUM
ihlr-25462	23	9	u.s	u.s	PROPN
ihlr-25462	23	10	.	.	PROPN
ihlr-25462	23	11	supreme	supreme	PROPN
ihlr-25462	23	12	court	court	PROPN
ihlr-25462	23	13	decision	decision	NOUN
ihlr-25462	23	14	,	,	PUNCT
ihlr-25462	23	15	coupled	couple	VERB
ihlr-25462	23	16	with	with	ADP
ihlr-25462	23	17	proposed	propose	VERB
ihlr-25462	23	18	health	health	NOUN
ihlr-25462	23	19	law	law	NOUN
ihlr-25462	23	20	legislation	legislation	NOUN
ihlr-25462	23	21	by	by	ADP
ihlr-25462	23	22	the	the	DET
ihlr-25462	23	23	u.s	u.s	PROPN
ihlr-25462	23	24	.	.	PROPN
ihlr-25462	23	25	department	department	PROPN
ihlr-25462	23	26	of	of	ADP
ihlr-25462	23	27	health	health	PROPN
ihlr-25462	23	28	and	and	CCONJ
ihlr-25462	23	29	human	human	PROPN
ihlr-25462	23	30	services	service	NOUN
ihlr-25462	23	31	(	(	PUNCT
ihlr-25462	23	32	“	"	PUNCT
ihlr-25462	23	33	hhs	hhs	PROPN
ihlr-25462	23	34	”	"	PUNCT
ihlr-25462	23	35	)	)	PUNCT
ihlr-25462	23	36	,	,	PUNCT
ihlr-25462	23	37	could	could	AUX
ihlr-25462	23	38	potentially	potentially	ADV
ihlr-25462	23	39	enable	enable	VERB
ihlr-25462	23	40	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	23	41	drug	drug	NOUN
ihlr-25462	23	42	re	re	NOUN
ihlr-25462	23	43	-	-	NOUN
ihlr-25462	23	44	importation	importation	NOUN
ihlr-25462	23	45	into	into	ADP
ihlr-25462	23	46	the	the	DET
ihlr-25462	23	47	u.s	u.s	PROPN
ihlr-25462	23	48	.	.	PROPN
ihlr-25462	23	49	from	from	ADP
ihlr-25462	23	50	canada	canada	PROPN
ihlr-25462	23	51	as	as	ADP
ihlr-25462	23	52	a	a	DET
ihlr-25462	23	53	means	means	NOUN
ihlr-25462	23	54	of	of	ADP
ihlr-25462	23	55	lowering	lower	VERB
ihlr-25462	23	56	u.s	u.s	PROPN
ihlr-25462	23	57	.	.	PROPN
ihlr-25462	23	58	drug	drug	PROPN
ihlr-25462	23	59	prices.11	prices.11	PROPN
ihlr-25462	23	60	section	section	PROPN
ihlr-25462	23	61	ii	ii	PROPN
ihlr-25462	23	62	is	be	AUX
ihlr-25462	23	63	divided	divide	VERB
ihlr-25462	23	64	into	into	ADP
ihlr-25462	23	65	four	four	NUM
ihlr-25462	23	66	subsections	subsection	NOUN
ihlr-25462	23	67	:	:	PUNCT
ihlr-25462	23	68	(	(	PUNCT
ihlr-25462	23	69	a	a	X
ihlr-25462	23	70	)	)	PUNCT
ihlr-25462	23	71	an	an	DET
ihlr-25462	23	72	overview	overview	NOUN
ihlr-25462	23	73	of	of	ADP
ihlr-25462	23	74	the	the	DET
ihlr-25462	23	75	landscape	landscape	NOUN
ihlr-25462	23	76	of	of	ADP
ihlr-25462	23	77	re	re	NOUN
ihlr-25462	23	78	-	-	NOUN
ihlr-25462	23	79	importation	importation	NOUN
ihlr-25462	23	80	of	of	ADP
ihlr-25462	23	81	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	23	82	into	into	ADP
ihlr-25462	23	83	the	the	DET
ihlr-25462	23	84	u.s	u.s	PROPN
ihlr-25462	23	85	.	.	PROPN
ihlr-25462	23	86	from	from	ADP
ihlr-25462	23	87	canada	canada	PROPN
ihlr-25462	23	88	;	;	PUNCT
ihlr-25462	23	89	(	(	PUNCT
ihlr-25462	23	90	b	b	X
ihlr-25462	23	91	)	)	PUNCT
ihlr-25462	23	92	the	the	DET
ihlr-25462	23	93	legal	legal	ADJ
ihlr-25462	23	94	relationship	relationship	NOUN
ihlr-25462	23	95	between	between	ADP
ihlr-25462	23	96	a	a	DET
ihlr-25462	23	97	recent	recent	ADJ
ihlr-25462	23	98	u.s	u.s	PROPN
ihlr-25462	23	99	.	.	PROPN
ihlr-25462	23	100	supreme	supreme	PROPN
ihlr-25462	23	101	court	court	PROPN
ihlr-25462	23	102	decision	decision	NOUN
ihlr-25462	23	103	and	and	CCONJ
ihlr-25462	23	104	international	international	ADJ
ihlr-25462	23	105	patent	patent	NOUN
ihlr-25462	23	106	exhaustion	exhaustion	NOUN
ihlr-25462	23	107	;	;	PUNCT
ihlr-25462	23	108	(	(	PUNCT
ihlr-25462	23	109	c	c	X
ihlr-25462	23	110	)	)	PUNCT
ihlr-25462	23	111	how	how	SCONJ
ihlr-25462	23	112	the	the	DET
ihlr-25462	23	113	international	international	ADJ
ihlr-25462	23	114	exhaustion	exhaustion	NOUN
ihlr-25462	23	115	doctrine	doctrine	NOUN
ihlr-25462	23	116	might	might	AUX
ihlr-25462	23	117	affect	affect	VERB
ihlr-25462	23	118	the	the	DET
ihlr-25462	23	119	market	market	NOUN
ihlr-25462	23	120	prices	price	NOUN
ihlr-25462	23	121	of	of	ADP
ihlr-25462	23	122	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	23	123	;	;	PUNCT
ihlr-25462	23	124	and	and	CCONJ
ihlr-25462	23	125	(	(	PUNCT
ihlr-25462	23	126	d	d	X
ihlr-25462	23	127	)	)	PUNCT
ihlr-25462	23	128	how	how	SCONJ
ihlr-25462	23	129	the	the	DET
ihlr-25462	23	130	current	current	ADJ
ihlr-25462	23	131	hhs	hhs	PROPN
ihlr-25462	23	132	has	have	AUX
ihlr-25462	23	133	designed	design	VERB
ihlr-25462	23	134	legislation	legislation	NOUN
ihlr-25462	23	135	to	to	PART
ihlr-25462	23	136	target	target	VERB
ihlr-25462	23	137	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	23	138	drug	drug	NOUN
ihlr-25462	23	139	re	re	NOUN
ihlr-25462	23	140	-	-	NOUN
ihlr-25462	23	141	importation	importation	NOUN
ihlr-25462	23	142	and	and	CCONJ
ihlr-25462	23	143	u.s	u.s	PROPN
ihlr-25462	23	144	.	.	PROPN
ihlr-25462	23	145	price	price	NOUN
ihlr-25462	23	146	controls	control	NOUN
ihlr-25462	23	147	.	.	PUNCT
ihlr-25462	24	1	the	the	DET
ihlr-25462	24	2	next	next	ADJ
ihlr-25462	24	3	two	two	NUM
ihlr-25462	24	4	sections	section	NOUN
ihlr-25462	24	5	of	of	ADP
ihlr-25462	24	6	this	this	DET
ihlr-25462	24	7	note	note	NOUN
ihlr-25462	24	8	describe	describe	VERB
ihlr-25462	24	9	practices	practice	NOUN
ihlr-25462	24	10	by	by	ADP
ihlr-25462	24	11	patentees	patentee	NOUN
ihlr-25462	24	12	(	(	PUNCT
ihlr-25462	24	13	e.g.	e.g.	ADV
ihlr-25462	24	14	,	,	PUNCT
ihlr-25462	24	15	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	24	16	manufacturers	manufacturer	NOUN
ihlr-25462	24	17	)	)	PUNCT
ihlr-25462	24	18	purportedly	purportedly	ADV
ihlr-25462	24	19	designed	design	VERB
ihlr-25462	24	20	to	to	PART
ihlr-25462	24	21	extend	extend	VERB
ihlr-25462	24	22	or	or	CCONJ
ihlr-25462	24	23	maintain	maintain	VERB
ihlr-25462	24	24	the	the	DET
ihlr-25462	24	25	[	[	X
ihlr-25462	24	26	https://perma.cc/ub4t-qtzu	https://perma.cc/ub4t-qtzu	X
ihlr-25462	24	27	]	]	X
ihlr-25462	24	28	(	(	PUNCT
ihlr-25462	24	29	discussing	discuss	VERB
ihlr-25462	24	30	how	how	SCONJ
ihlr-25462	24	31	regulatory	regulatory	ADJ
ihlr-25462	24	32	exclusivity	exclusivity	NOUN
ihlr-25462	24	33	,	,	PUNCT
ihlr-25462	24	34	in	in	ADP
ihlr-25462	24	35	addition	addition	NOUN
ihlr-25462	24	36	to	to	ADP
ihlr-25462	24	37	patent	patent	NOUN
ihlr-25462	24	38	exclusivity	exclusivity	NOUN
ihlr-25462	24	39	,	,	PUNCT
ihlr-25462	24	40	plays	play	VERB
ihlr-25462	24	41	a	a	DET
ihlr-25462	24	42	role	role	NOUN
ihlr-25462	24	43	in	in	ADP
ihlr-25462	24	44	drug	drug	NOUN
ihlr-25462	24	45	pricing	pricing	NOUN
ihlr-25462	24	46	)	)	PUNCT
ihlr-25462	24	47	.	.	PUNCT
ihlr-25462	25	1	7	7	X
ihlr-25462	25	2	.	.	X
ihlr-25462	26	1	i	i	PRON
ihlr-25462	26	2	d.	d.	PROPN
ihlr-25462	26	3	8	8	NUM
ihlr-25462	26	4	.	.	PUNCT
ihlr-25462	27	1	i	i	PRON
ihlr-25462	27	2	d.	d.	PROPN
ihlr-25462	27	3	9	9	NUM
ihlr-25462	27	4	.	.	PUNCT
ihlr-25462	27	5	hickey	hickey	PROPN
ihlr-25462	27	6	et	et	PROPN
ihlr-25462	27	7	al	al	PROPN
ihlr-25462	27	8	.	.	PROPN
ihlr-25462	27	9	,	,	PUNCT
ihlr-25462	27	10	supra	supra	PROPN
ihlr-25462	27	11	note	note	NOUN
ihlr-25462	27	12	2	2	NUM
ihlr-25462	27	13	,	,	PUNCT
ihlr-25462	27	14	at	at	ADP
ihlr-25462	27	15	4	4	NUM
ihlr-25462	27	16	.	.	PUNCT
ihlr-25462	27	17	examples	example	NOUN
ihlr-25462	27	18	of	of	ADP
ihlr-25462	27	19	some	some	PRON
ihlr-25462	27	20	of	of	ADP
ihlr-25462	27	21	these	these	DET
ihlr-25462	27	22	factors	factor	NOUN
ihlr-25462	27	23	include	include	VERB
ihlr-25462	27	24	“	"	PUNCT
ihlr-25462	27	25	demand	demand	NOUN
ihlr-25462	27	26	,	,	PUNCT
ihlr-25462	27	27	manufacturing	manufacturing	NOUN
ihlr-25462	27	28	costs	cost	NOUN
ihlr-25462	27	29	,	,	PUNCT
ihlr-25462	27	30	r&d	r&d	NOUN
ihlr-25462	27	31	costs	cost	NOUN
ihlr-25462	27	32	,	,	PUNCT
ihlr-25462	27	33	the	the	DET
ihlr-25462	27	34	terms	term	NOUN
ihlr-25462	27	35	of	of	ADP
ihlr-25462	27	36	private	private	ADJ
ihlr-25462	27	37	health	health	NOUN
ihlr-25462	27	38	insurance	insurance	NOUN
ihlr-25462	27	39	,	,	PUNCT
ihlr-25462	27	40	and	and	CCONJ
ihlr-25462	27	41	the	the	DET
ihlr-25462	27	42	involvement	involvement	NOUN
ihlr-25462	27	43	of	of	ADP
ihlr-25462	27	44	a	a	DET
ihlr-25462	27	45	government	government	NOUN
ihlr-25462	27	46	insurance	insurance	NOUN
ihlr-25462	27	47	program	program	NOUN
ihlr-25462	27	48	such	such	ADJ
ihlr-25462	27	49	as	as	ADP
ihlr-25462	27	50	medicaid	medicaid	PROPN
ihlr-25462	27	51	,	,	PUNCT
ihlr-25462	27	52	”	"	PUNCT
ihlr-25462	27	53	to	to	PART
ihlr-25462	27	54	name	name	VERB
ihlr-25462	27	55	a	a	DET
ihlr-25462	27	56	few	few	ADJ
ihlr-25462	27	57	.	.	PUNCT
ihlr-25462	28	1	i	i	PRON
ihlr-25462	28	2	d.	d.	PROPN
ihlr-25462	28	3	10	10	NUM
ihlr-25462	28	4	.	.	PUNCT
ihlr-25462	28	5	see	see	VERB
ihlr-25462	28	6	international	international	ADJ
ihlr-25462	28	7	trade	trade	NOUN
ihlr-25462	28	8	and	and	CCONJ
ihlr-25462	28	9	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	28	10	:	:	PUNCT
ihlr-25462	28	11	joint	joint	ADJ
ihlr-25462	28	12	hearing	hearing	NOUN
ihlr-25462	28	13	before	before	ADP
ihlr-25462	28	14	the	the	DET
ihlr-25462	28	15	subcomm	subcomm	NOUN
ihlr-25462	28	16	.	.	PUNCT
ihlr-25462	29	1	on	on	ADP
ihlr-25462	29	2	int’l	int’l	NUM
ihlr-25462	29	3	trade	trade	NOUN
ihlr-25462	29	4	&	&	CCONJ
ihlr-25462	29	5	the	the	DET
ihlr-25462	29	6	subcomm	subcomm	NOUN
ihlr-25462	29	7	.	.	PUNCT
ihlr-25462	30	1	on	on	ADP
ihlr-25462	30	2	health	health	NOUN
ihlr-25462	30	3	care	care	NOUN
ihlr-25462	30	4	of	of	ADP
ihlr-25462	30	5	the	the	DET
ihlr-25462	30	6	s.	s.	PROPN
ihlr-25462	30	7	comm	comm	NOUN
ihlr-25462	30	8	.	.	PUNCT
ihlr-25462	31	1	on	on	ADP
ihlr-25462	31	2	fin	fin	PROPN
ihlr-25462	31	3	.	.	PUNCT
ihlr-25462	31	4	,	,	PUNCT
ihlr-25462	31	5	108th	108th	PROPN
ihlr-25462	31	6	cong	cong	NOUN
ihlr-25462	31	7	.	.	PUNCT
ihlr-25462	32	1	1	1	NUM
ihlr-25462	32	2	-	-	SYM
ihlr-25462	32	3	3	3	NUM
ihlr-25462	32	4	(	(	PUNCT
ihlr-25462	32	5	2004	2004	NUM
ihlr-25462	32	6	)	)	PUNCT
ihlr-25462	32	7	(	(	PUNCT
ihlr-25462	32	8	statement	statement	NOUN
ihlr-25462	32	9	of	of	ADP
ihlr-25462	32	10	sen	sen	PROPN
ihlr-25462	32	11	.	.	PROPN
ihlr-25462	32	12	jon	jon	PROPN
ihlr-25462	32	13	kyl	kyl	PROPN
ihlr-25462	32	14	,	,	PUNCT
ihlr-25462	32	15	chairman	chairman	NOUN
ihlr-25462	32	16	,	,	PUNCT
ihlr-25462	32	17	subcomm	subcomm	NOUN
ihlr-25462	32	18	.	.	PUNCT
ihlr-25462	33	1	on	on	ADP
ihlr-25462	33	2	health	health	NOUN
ihlr-25462	33	3	care	care	NOUN
ihlr-25462	33	4	)	)	PUNCT
ihlr-25462	33	5	.	.	PUNCT
ihlr-25462	34	1	11	11	NUM
ihlr-25462	34	2	.	.	X
ihlr-25462	35	1	see	see	VERB
ihlr-25462	35	2	generally	generally	ADV
ihlr-25462	35	3	graham	graham	PROPN
ihlr-25462	35	4	o’donnell	o’donnell	PROPN
ihlr-25462	35	5	,	,	PUNCT
ihlr-25462	35	6	the	the	DET
ihlr-25462	35	7	next	next	ADJ
ihlr-25462	35	8	step	step	NOUN
ihlr-25462	35	9	in	in	ADP
ihlr-25462	35	10	the	the	DET
ihlr-25462	35	11	battle	battle	NOUN
ihlr-25462	35	12	against	against	ADP
ihlr-25462	35	13	high	high	ADJ
ihlr-25462	35	14	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	35	15	prices	price	NOUN
ihlr-25462	35	16	:	:	PUNCT
ihlr-25462	35	17	lexmark	lexmark	NOUN
ihlr-25462	35	18	&	&	CCONJ
ihlr-25462	35	19	the	the	DET
ihlr-25462	35	20	dscsa	dscsa	PROPN
ihlr-25462	35	21	have	have	AUX
ihlr-25462	35	22	paved	pave	VERB
ihlr-25462	35	23	the	the	DET
ihlr-25462	35	24	way	way	NOUN
ihlr-25462	35	25	for	for	ADP
ihlr-25462	35	26	parallel	parallel	NOUN
ihlr-25462	35	27	,	,	PUNCT
ihlr-25462	35	28	46	46	NUM
ihlr-25462	35	29	fla	fla	PROPN
ihlr-25462	35	30	.	.	PUNCT
ihlr-25462	36	1	st	st	PROPN
ihlr-25462	36	2	.	.	PROPN
ihlr-25462	36	3	u.	u.	PROPN
ihlr-25462	36	4	l.	l.	PROPN
ihlr-25462	36	5	rev	rev	PROPN
ihlr-25462	36	6	.	.	PROPN
ihlr-25462	36	7	197	197	NUM
ihlr-25462	36	8	(	(	PUNCT
ihlr-25462	36	9	2018	2018	NUM
ihlr-25462	36	10	)	)	PUNCT
ihlr-25462	36	11	;	;	PUNCT
ihlr-25462	36	12	see	see	VERB
ihlr-25462	36	13	also	also	ADV
ihlr-25462	36	14	safe	safe	ADJ
ihlr-25462	36	15	importation	importation	NOUN
ihlr-25462	36	16	action	action	NOUN
ihlr-25462	36	17	plan	plan	NOUN
ihlr-25462	36	18	,	,	PUNCT
ihlr-25462	36	19	u.s	u.s	PROPN
ihlr-25462	36	20	.	.	PROPN
ihlr-25462	36	21	food	food	PROPN
ihlr-25462	36	22	&	&	CCONJ
ihlr-25462	36	23	drug	drug	PROPN
ihlr-25462	36	24	admin	admin	PROPN
ihlr-25462	36	25	.	.	PUNCT
ihlr-25462	37	1	(	(	PUNCT
ihlr-25462	37	2	july	july	PROPN
ihlr-25462	37	3	31	31	NUM
ihlr-25462	37	4	,	,	PUNCT
ihlr-25462	37	5	2019	2019	NUM
ihlr-25462	37	6	)	)	PUNCT
ihlr-25462	37	7	,	,	PUNCT
ihlr-25462	37	8	h	h	PROPN
ihlr-25462	37	9	t	t	X
ihlr-25462	37	10	tp:/	tp:/	X
ihlr-25462	37	11	/www.hhs.gov	/www.hhs.gov	NOUN
ihlr-25462	37	12	/	/	SYM
ihlr-25462	37	13	sites	site	NOUN
ihlr-25462	37	14	/	/	SYM
ihlr-25462	37	15	defau	defau	PROPN
ihlr-25462	37	16	lt	lt	PROPN
ihlr-25462	37	17	/	/	SYM
ihlr-25462	37	18	f	f	PROPN
ihlr-25462	37	19	iles	iles	PROPN
ihlr-25462	37	20	/	/	SYM
ihlr-25462	37	21	safe	safe	ADJ
ihlr-25462	37	22	-	-	PUNCT
ihlr-25462	37	23	importat	importat	ADJ
ihlr-25462	37	24	ion	ion	NOUN
ihlr-25462	37	25	-	-	PUNCT
ihlr-25462	37	26	act	act	NOUN
ihlr-25462	37	27	ion	ion	NOUN
ihlr-25462	37	28	-	-	PUNCT
ihlr-25462	37	29	plan	plan	NOUN
ihlr-25462	37	30	.pdf	.pdf	PUNCT
ihlr-25462	38	1	[	[	X
ihlr-25462	38	2	https://perma.cc/z4vs-dpgw	https://perma.cc/z4vs-dpgw	X
ihlr-25462	38	3	]	]	X
ihlr-25462	39	1	[	[	X
ihlr-25462	39	2	hereinafter	hereinafter	VERB
ihlr-25462	39	3	safe	safe	ADJ
ihlr-25462	39	4	importation	importation	NOUN
ihlr-25462	39	5	action	action	NOUN
ihlr-25462	39	6	plan	plan	NOUN
ihlr-25462	39	7	]	]	PUNCT
ihlr-25462	39	8	.	.	PUNCT
ihlr-25462	40	1	https://perma.cc/z4vs-dpgw	https://perma.cc/z4vs-dpgw	ADJ
ihlr-25462	40	2	2021	2021	NUM
ihlr-25462	40	3	]	]	PUNCT
ihlr-25462	40	4	a	a	DET
ihlr-25462	40	5	survey	survey	NOUN
ihlr-25462	40	6	of	of	ADP
ihlr-25462	40	7	three	three	NUM
ihlr-25462	40	8	patent	patent	NOUN
ihlr-25462	40	9	-	-	PUNCT
ihlr-25462	40	10	based	base	VERB
ihlr-25462	40	11	approaches	approach	NOUN
ihlr-25462	40	12	399	399	NUM
ihlr-25462	40	13	market	market	NOUN
ihlr-25462	40	14	exclusivity	exclusivity	NOUN
ihlr-25462	40	15	of	of	ADP
ihlr-25462	40	16	a	a	DET
ihlr-25462	40	17	particular	particular	ADJ
ihlr-25462	40	18	product	product	NOUN
ihlr-25462	40	19	.	.	PUNCT
ihlr-25462	41	1	section	section	NOUN
ihlr-25462	41	2	iii	iii	NUM
ihlr-25462	41	3	details	detail	NOUN
ihlr-25462	41	4	“	"	PUNCT
ihlr-25462	41	5	patent	patent	NOUN
ihlr-25462	41	6	thicketing	thicketing	NOUN
ihlr-25462	41	7	.	.	PUNCT
ihlr-25462	41	8	”	"	PUNCT
ihlr-25462	42	1	patent	patent	NOUN
ihlr-25462	42	2	thicketing	thicketing	NOUN
ihlr-25462	42	3	is	be	AUX
ihlr-25462	42	4	a	a	DET
ihlr-25462	42	5	nickname	nickname	NOUN
ihlr-25462	42	6	for	for	ADP
ihlr-25462	42	7	one	one	NUM
ihlr-25462	42	8	of	of	ADP
ihlr-25462	42	9	these	these	DET
ihlr-25462	42	10	practices	practice	NOUN
ihlr-25462	42	11	,	,	PUNCT
ihlr-25462	42	12	and	and	CCONJ
ihlr-25462	42	13	it	it	PRON
ihlr-25462	42	14	is	be	AUX
ihlr-25462	42	15	a	a	DET
ihlr-25462	42	16	strategy	strategy	NOUN
ihlr-25462	42	17	purportedly	purportedly	ADV
ihlr-25462	42	18	employed	employ	VERB
ihlr-25462	42	19	by	by	ADP
ihlr-25462	42	20	some	some	DET
ihlr-25462	42	21	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	42	22	manufacturers	manufacturer	NOUN
ihlr-25462	42	23	that	that	PRON
ihlr-25462	42	24	aim	aim	VERB
ihlr-25462	42	25	to	to	PART
ihlr-25462	42	26	extend	extend	VERB
ihlr-25462	42	27	the	the	DET
ihlr-25462	42	28	duration	duration	NOUN
ihlr-25462	42	29	of	of	ADP
ihlr-25462	42	30	the	the	DET
ihlr-25462	42	31	patent	patent	NOUN
ihlr-25462	42	32	“	"	PUNCT
ihlr-25462	42	33	monopoly	monopoly	NOUN
ihlr-25462	42	34	”	"	PUNCT
ihlr-25462	42	35	by	by	ADP
ihlr-25462	42	36	protecting	protect	VERB
ihlr-25462	42	37	the	the	DET
ihlr-25462	42	38	product	product	NOUN
ihlr-25462	42	39	with	with	ADP
ihlr-25462	42	40	as	as	ADV
ihlr-25462	42	41	many	many	ADJ
ihlr-25462	42	42	additional	additional	ADJ
ihlr-25462	42	43	patents	patent	NOUN
ihlr-25462	42	44	as	as	ADP
ihlr-25462	42	45	possible	possible	ADJ
ihlr-25462	42	46	,	,	PUNCT
ihlr-25462	42	47	thus	thus	ADV
ihlr-25462	42	48	creating	create	VERB
ihlr-25462	42	49	a	a	DET
ihlr-25462	42	50	so	so	ADV
ihlr-25462	42	51	-	-	PUNCT
ihlr-25462	42	52	called	call	VERB
ihlr-25462	42	53	“	"	PUNCT
ihlr-25462	42	54	thicket	thicket	NOUN
ihlr-25462	42	55	”	"	PUNCT
ihlr-25462	42	56	around	around	ADP
ihlr-25462	42	57	the	the	DET
ihlr-25462	42	58	product	product	NOUN
ihlr-25462	42	59	.	.	PUNCT
ihlr-25462	43	1	next	next	ADJ
ihlr-25462	43	2	,	,	PUNCT
ihlr-25462	43	3	section	section	NOUN
ihlr-25462	43	4	iv	iv	NUM
ihlr-25462	43	5	addresses	address	NOUN
ihlr-25462	43	6	the	the	DET
ihlr-25462	43	7	so	so	ADV
ihlr-25462	43	8	-	-	PUNCT
ihlr-25462	43	9	called	call	VERB
ihlr-25462	43	10	practice	practice	NOUN
ihlr-25462	43	11	of	of	ADP
ihlr-25462	43	12	“	"	PUNCT
ihlr-25462	43	13	product	product	NOUN
ihlr-25462	43	14	hopping	hopping	NOUN
ihlr-25462	43	15	,	,	PUNCT
ihlr-25462	43	16	”	"	PUNCT
ihlr-25462	43	17	in	in	ADP
ihlr-25462	43	18	which	which	PRON
ihlr-25462	43	19	the	the	DET
ihlr-25462	43	20	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	43	21	company	company	NOUN
ihlr-25462	43	22	allegedly	allegedly	ADV
ihlr-25462	43	23	replaces	replace	VERB
ihlr-25462	43	24	its	its	PRON
ihlr-25462	43	25	branded	brand	VERB
ihlr-25462	43	26	drugs	drug	NOUN
ihlr-25462	43	27	with	with	ADP
ihlr-25462	43	28	slightly	slightly	ADV
ihlr-25462	43	29	modified	modify	VERB
ihlr-25462	43	30	versions	version	NOUN
ihlr-25462	43	31	.	.	PUNCT
ihlr-25462	44	1	product	product	NOUN
ihlr-25462	44	2	hopping	hop	VERB
ihlr-25462	44	3	could	could	AUX
ihlr-25462	44	4	prevent	prevent	VERB
ihlr-25462	44	5	generic	generic	ADJ
ihlr-25462	44	6	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	44	7	drug	drug	NOUN
ihlr-25462	44	8	entry	entry	NOUN
ihlr-25462	44	9	because	because	SCONJ
ihlr-25462	44	10	the	the	DET
ihlr-25462	44	11	original	original	ADJ
ihlr-25462	44	12	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	44	13	drugs	drug	NOUN
ihlr-25462	44	14	must	must	AUX
ihlr-25462	44	15	be	be	AUX
ihlr-25462	44	16	on	on	ADP
ihlr-25462	44	17	the	the	DET
ihlr-25462	44	18	market	market	NOUN
ihlr-25462	44	19	for	for	ADP
ihlr-25462	44	20	regulatory	regulatory	ADJ
ihlr-25462	44	21	purposes	purpose	NOUN
ihlr-25462	44	22	.	.	PUNCT
ihlr-25462	45	1	because	because	SCONJ
ihlr-25462	45	2	product	product	NOUN
ihlr-25462	45	3	hopping	hopping	NOUN
ihlr-25462	45	4	is	be	AUX
ihlr-25462	45	5	complex	complex	ADJ
ihlr-25462	45	6	,	,	PUNCT
ihlr-25462	45	7	section	section	NOUN
ihlr-25462	45	8	iv	iv	NUM
ihlr-25462	45	9	is	be	AUX
ihlr-25462	45	10	further	far	ADV
ihlr-25462	45	11	divided	divide	VERB
ihlr-25462	45	12	into	into	ADP
ihlr-25462	45	13	two	two	NUM
ihlr-25462	45	14	subsections	subsection	NOUN
ihlr-25462	45	15	.	.	PUNCT
ihlr-25462	46	1	subsection	subsection	NOUN
ihlr-25462	46	2	a	a	DET
ihlr-25462	46	3	describes	describe	NOUN
ihlr-25462	46	4	“	"	PUNCT
ihlr-25462	46	5	hard	hard	ADJ
ihlr-25462	46	6	switches	switch	NOUN
ihlr-25462	46	7	”	"	PUNCT
ihlr-25462	46	8	–	–	PUNCT
ihlr-25462	46	9	the	the	DET
ihlr-25462	46	10	quintessential	quintessential	ADJ
ihlr-25462	46	11	product	product	NOUN
ihlr-25462	46	12	hopping	hop	VERB
ihlr-25462	46	13	scenario	scenario	NOUN
ihlr-25462	46	14	in	in	ADP
ihlr-25462	46	15	which	which	PRON
ihlr-25462	46	16	a	a	DET
ihlr-25462	46	17	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	46	18	company	company	NOUN
ihlr-25462	46	19	takes	take	VERB
ihlr-25462	46	20	the	the	DET
ihlr-25462	46	21	original	original	ADJ
ihlr-25462	46	22	drug	drug	NOUN
ihlr-25462	46	23	completely	completely	ADV
ihlr-25462	46	24	off	off	ADP
ihlr-25462	46	25	the	the	DET
ihlr-25462	46	26	market	market	NOUN
ihlr-25462	46	27	.	.	PUNCT
ihlr-25462	47	1	subsection	subsection	NOUN
ihlr-25462	47	2	b	b	PROPN
ihlr-25462	47	3	discusses	discuss	VERB
ihlr-25462	47	4	“	"	PUNCT
ihlr-25462	47	5	soft	soft	ADJ
ihlr-25462	47	6	switches	switch	NOUN
ihlr-25462	47	7	”	"	PUNCT
ihlr-25462	47	8	–	–	PUNCT
ihlr-25462	47	9	the	the	DET
ihlr-25462	47	10	less	less	ADV
ihlr-25462	47	11	forceful	forceful	ADJ
ihlr-25462	47	12	process	process	NOUN
ihlr-25462	47	13	in	in	ADP
ihlr-25462	47	14	which	which	PRON
ihlr-25462	47	15	a	a	DET
ihlr-25462	47	16	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	47	17	company	company	NOUN
ihlr-25462	47	18	disparages	disparage	VERB
ihlr-25462	47	19	the	the	DET
ihlr-25462	47	20	original	original	ADJ
ihlr-25462	47	21	form	form	NOUN
ihlr-25462	47	22	of	of	ADP
ihlr-25462	47	23	the	the	DET
ihlr-25462	47	24	drug	drug	NOUN
ihlr-25462	47	25	,	,	PUNCT
ihlr-25462	47	26	making	make	VERB
ihlr-25462	47	27	the	the	DET
ihlr-25462	47	28	generic	generic	ADJ
ihlr-25462	47	29	version	version	NOUN
ihlr-25462	47	30	more	more	ADV
ihlr-25462	47	31	difficult	difficult	ADJ
ihlr-25462	47	32	to	to	PART
ihlr-25462	47	33	obtain	obtain	VERB
ihlr-25462	47	34	.	.	PUNCT
ihlr-25462	48	1	this	this	DET
ihlr-25462	48	2	note	note	NOUN
ihlr-25462	48	3	concludes	conclude	VERB
ihlr-25462	48	4	with	with	ADP
ihlr-25462	48	5	a	a	DET
ihlr-25462	48	6	summary	summary	NOUN
ihlr-25462	48	7	about	about	ADP
ihlr-25462	48	8	the	the	DET
ihlr-25462	48	9	interplay	interplay	NOUN
ihlr-25462	48	10	between	between	ADP
ihlr-25462	48	11	patent	patent	NOUN
ihlr-25462	48	12	law	law	NOUN
ihlr-25462	48	13	and	and	CCONJ
ihlr-25462	48	14	the	the	DET
ihlr-25462	48	15	cost	cost	NOUN
ihlr-25462	48	16	of	of	ADP
ihlr-25462	48	17	prescription	prescription	NOUN
ihlr-25462	48	18	drugs	drug	NOUN
ihlr-25462	48	19	,	,	PUNCT
ihlr-25462	48	20	as	as	SCONJ
ihlr-25462	48	21	drug	drug	NOUN
ihlr-25462	48	22	pricing	pricing	NOUN
ihlr-25462	48	23	remains	remain	VERB
ihlr-25462	48	24	“	"	PUNCT
ihlr-25462	48	25	at	at	ADP
ihlr-25462	48	26	the	the	DET
ihlr-25462	48	27	forefront	forefront	NOUN
ihlr-25462	48	28	of	of	ADP
ihlr-25462	48	29	discussions	discussion	NOUN
ihlr-25462	48	30	among	among	ADP
ihlr-25462	48	31	patients	patient	NOUN
ihlr-25462	48	32	,	,	PUNCT
ihlr-25462	48	33	advocacy	advocacy	NOUN
ihlr-25462	48	34	groups	group	NOUN
ihlr-25462	48	35	,	,	PUNCT
ihlr-25462	48	36	prescribers	prescriber	NOUN
ihlr-25462	48	37	,	,	PUNCT
ihlr-25462	48	38	payers	payer	NOUN
ihlr-25462	48	39	,	,	PUNCT
ihlr-25462	48	40	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	48	41	companies	company	NOUN
ihlr-25462	48	42	,	,	PUNCT
ihlr-25462	48	43	and	and	CCONJ
ihlr-25462	48	44	policy	policy	NOUN
ihlr-25462	48	45	makers	maker	NOUN
ihlr-25462	48	46	.	.	PUNCT
ihlr-25462	49	1	”12	”12	PROPN
ihlr-25462	49	2	the	the	DET
ihlr-25462	49	3	number	number	NOUN
ihlr-25462	49	4	of	of	ADP
ihlr-25462	49	5	people	people	NOUN
ihlr-25462	49	6	interested	interested	ADJ
ihlr-25462	49	7	in	in	ADP
ihlr-25462	49	8	this	this	DET
ihlr-25462	49	9	issue	issue	NOUN
ihlr-25462	49	10	,	,	PUNCT
ihlr-25462	49	11	coupled	couple	VERB
ihlr-25462	49	12	with	with	ADP
ihlr-25462	49	13	current	current	ADJ
ihlr-25462	49	14	legislation	legislation	NOUN
ihlr-25462	49	15	targeting	target	VERB
ihlr-25462	49	16	these	these	DET
ihlr-25462	49	17	practices	practice	NOUN
ihlr-25462	49	18	,	,	PUNCT
ihlr-25462	49	19	may	may	AUX
ihlr-25462	49	20	result	result	VERB
ihlr-25462	49	21	in	in	ADP
ihlr-25462	49	22	near	near	ADJ
ihlr-25462	49	23	-	-	PUNCT
ihlr-25462	49	24	term	term	NOUN
ihlr-25462	49	25	changes	change	NOUN
ihlr-25462	49	26	to	to	ADP
ihlr-25462	49	27	drug	drug	NOUN
ihlr-25462	49	28	prices	price	NOUN
ihlr-25462	49	29	in	in	ADP
ihlr-25462	49	30	the	the	DET
ihlr-25462	49	31	u.s	u.s	PROPN
ihlr-25462	49	32	.	.	PROPN
ihlr-25462	49	33	it	it	PRON
ihlr-25462	49	34	should	should	AUX
ihlr-25462	49	35	be	be	AUX
ihlr-25462	49	36	mentioned	mention	VERB
ihlr-25462	49	37	that	that	SCONJ
ihlr-25462	49	38	many	many	ADJ
ihlr-25462	49	39	other	other	ADJ
ihlr-25462	49	40	patent	patent	NOUN
ihlr-25462	49	41	practices	practice	NOUN
ihlr-25462	49	42	exist	exist	VERB
ihlr-25462	49	43	in	in	ADP
ihlr-25462	49	44	the	the	DET
ihlr-25462	49	45	context	context	NOUN
ihlr-25462	49	46	of	of	ADP
ihlr-25462	49	47	drug	drug	NOUN
ihlr-25462	49	48	pricing	pricing	NOUN
ihlr-25462	49	49	(	(	PUNCT
ihlr-25462	49	50	e.g.	e.g.	ADV
ihlr-25462	49	51	,	,	PUNCT
ihlr-25462	49	52	sham	sham	ADJ
ihlr-25462	49	53	litigation	litigation	NOUN
ihlr-25462	49	54	,	,	PUNCT
ihlr-25462	49	55	abuse	abuse	NOUN
ihlr-25462	49	56	of	of	ADP
ihlr-25462	49	57	the	the	DET
ihlr-25462	49	58	food	food	NOUN
ihlr-25462	49	59	and	and	CCONJ
ihlr-25462	49	60	drug	drug	PROPN
ihlr-25462	49	61	administration	administration	NOUN
ihlr-25462	49	62	’s	’s	PART
ihlr-25462	49	63	risk	risk	NOUN
ihlr-25462	49	64	evaluation	evaluation	NOUN
ihlr-25462	49	65	and	and	CCONJ
ihlr-25462	49	66	mitigation	mitigation	NOUN
ihlr-25462	49	67	protocol	protocol	NOUN
ihlr-25462	49	68	,	,	PUNCT
ihlr-25462	49	69	or	or	CCONJ
ihlr-25462	49	70	abuse	abuse	NOUN
ihlr-25462	49	71	of	of	ADP
ihlr-25462	49	72	the	the	DET
ihlr-25462	49	73	food	food	NOUN
ihlr-25462	49	74	and	and	CCONJ
ihlr-25462	49	75	drug	drug	PROPN
ihlr-25462	49	76	administration	administration	NOUN
ihlr-25462	49	77	’s	’s	PART
ihlr-25462	49	78	citizen	citizen	PROPN
ihlr-25462	49	79	petition	petition	NOUN
ihlr-25462	49	80	process	process	NOUN
ihlr-25462	49	81	)	)	PUNCT
ihlr-25462	49	82	,	,	PUNCT
ihlr-25462	49	83	but	but	CCONJ
ihlr-25462	49	84	these	these	DET
ihlr-25462	49	85	issues	issue	NOUN
ihlr-25462	49	86	are	be	AUX
ihlr-25462	49	87	beyond	beyond	ADP
ihlr-25462	49	88	the	the	DET
ihlr-25462	49	89	scope	scope	NOUN
ihlr-25462	49	90	of	of	ADP
ihlr-25462	49	91	this	this	DET
ihlr-25462	49	92	note.13	note.13	PROPN
ihlr-25462	49	93	ii	ii	PROPN
ihlr-25462	49	94	.	.	PUNCT
ihlr-25462	50	1	patent	patent	NOUN
ihlr-25462	50	2	exhaustion	exhaustion	NOUN
ihlr-25462	50	3	&	&	CCONJ
ihlr-25462	50	4	drug	drug	NOUN
ihlr-25462	50	5	re	re	PROPN
ihlr-25462	50	6	-	-	NOUN
ihlr-25462	50	7	importation	importation	ADJ
ihlr-25462	50	8	a.	a.	NOUN
ihlr-25462	50	9	re	re	NOUN
ihlr-25462	50	10	-	-	NOUN
ihlr-25462	50	11	importation	importation	NOUN
ihlr-25462	50	12	of	of	ADP
ihlr-25462	50	13	lower	low	ADJ
ihlr-25462	50	14	cost	cost	NOUN
ihlr-25462	50	15	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	50	16	into	into	ADP
ihlr-25462	50	17	the	the	DET
ihlr-25462	50	18	u.s	u.s	PROPN
ihlr-25462	50	19	.	.	PROPN
ihlr-25462	50	20	from	from	ADP
ihlr-25462	50	21	canada	canada	PROPN
ihlr-25462	50	22	in	in	ADP
ihlr-25462	50	23	2003	2003	NUM
ihlr-25462	50	24	,	,	PUNCT
ihlr-25462	50	25	legislators	legislator	NOUN
ihlr-25462	50	26	made	make	VERB
ihlr-25462	50	27	changes	change	NOUN
ihlr-25462	50	28	to	to	ADP
ihlr-25462	50	29	the	the	DET
ihlr-25462	50	30	food	food	NOUN
ihlr-25462	50	31	,	,	PUNCT
ihlr-25462	50	32	drug	drug	NOUN
ihlr-25462	50	33	,	,	PUNCT
ihlr-25462	50	34	and	and	CCONJ
ihlr-25462	50	35	cosmetics	cosmetic	NOUN
ihlr-25462	50	36	act	act	NOUN
ihlr-25462	50	37	(	(	PUNCT
ihlr-25462	50	38	“	"	PUNCT
ihlr-25462	50	39	fdca	fdca	NOUN
ihlr-25462	50	40	”	"	PUNCT
ihlr-25462	50	41	)	)	PUNCT
ihlr-25462	50	42	that	that	PRON
ihlr-25462	50	43	provided	provide	VERB
ihlr-25462	50	44	the	the	DET
ihlr-25462	50	45	secretary	secretary	NOUN
ihlr-25462	50	46	of	of	ADP
ihlr-25462	50	47	hhs	hhs	PROPN
ihlr-25462	50	48	with	with	ADP
ihlr-25462	50	49	the	the	DET
ihlr-25462	50	50	legal	legal	ADJ
ihlr-25462	50	51	authority	authority	NOUN
ihlr-25462	50	52	to	to	PART
ihlr-25462	50	53	import	import	VERB
ihlr-25462	50	54	prescription	prescription	NOUN
ihlr-25462	50	55	drugs	drug	NOUN
ihlr-25462	50	56	from	from	ADP
ihlr-25462	50	57	canada.14	canada.14	NOUN
ihlr-25462	50	58	despite	despite	SCONJ
ihlr-25462	50	59	this	this	DET
ihlr-25462	50	60	law	law	NOUN
ihlr-25462	50	61	being	be	AUX
ihlr-25462	50	62	enacted	enact	VERB
ihlr-25462	50	63	over	over	ADP
ihlr-25462	50	64	a	a	DET
ihlr-25462	50	65	decade	decade	NOUN
ihlr-25462	50	66	ago	ago	ADV
ihlr-25462	50	67	,	,	PUNCT
ihlr-25462	50	68	numerous	numerous	ADJ
ihlr-25462	50	69	hurdles	hurdle	NOUN
ihlr-25462	50	70	prevented	prevent	VERB
ihlr-25462	50	71	large	large	ADJ
ihlr-25462	50	72	-	-	PUNCT
ihlr-25462	50	73	scale	scale	NOUN
ihlr-25462	50	74	re	re	NOUN
ihlr-25462	50	75	-	-	NOUN
ihlr-25462	50	76	importation	importation	NOUN
ihlr-25462	50	77	from	from	ADP
ihlr-25462	50	78	canada	canada	PROPN
ihlr-25462	50	79	,	,	PUNCT
ihlr-25462	50	80	one	one	NUM
ihlr-25462	50	81	of	of	ADP
ihlr-25462	50	82	which	which	PRON
ihlr-25462	50	83	is	be	AUX
ihlr-25462	50	84	the	the	DET
ihlr-25462	50	85	u.s	u.s	PROPN
ihlr-25462	50	86	.	.	PROPN
ihlr-25462	50	87	doctrine	doctrine	NOUN
ihlr-25462	50	88	of	of	ADP
ihlr-25462	50	89	patent	patent	NOUN
ihlr-25462	50	90	exhaustion.15	exhaustion.15	PROPN
ihlr-25462	50	91	12	12	NUM
ihlr-25462	50	92	.	.	PUNCT
ihlr-25462	51	1	o’connor	o’connor	ADV
ihlr-25462	51	2	,	,	PUNCT
ihlr-25462	51	3	supra	supra	PROPN
ihlr-25462	51	4	note	note	NOUN
ihlr-25462	51	5	6	6	NUM
ihlr-25462	51	6	.	.	NOUN
ihlr-25462	51	7	13	13	NUM
ihlr-25462	51	8	.	.	PUNCT
ihlr-25462	52	1	see	see	VERB
ihlr-25462	52	2	generally	generally	ADV
ihlr-25462	52	3	kerstin	kerstin	PROPN
ihlr-25462	52	4	noelle	noelle	PROPN
ihlr-25462	52	5	vokinger	vokinger	PROPN
ihlr-25462	52	6	et	et	PROPN
ihlr-25462	52	7	al	al	PROPN
ihlr-25462	52	8	.	.	PROPN
ihlr-25462	52	9	,	,	PUNCT
ihlr-25462	52	10	strategies	strategy	NOUN
ihlr-25462	52	11	that	that	PRON
ihlr-25462	52	12	delay	delay	VERB
ihlr-25462	52	13	market	market	NOUN
ihlr-25462	52	14	entry	entry	NOUN
ihlr-25462	52	15	of	of	ADP
ihlr-25462	52	16	generic	generic	ADJ
ihlr-25462	52	17	drugs	drug	NOUN
ihlr-25462	52	18	,	,	PUNCT
ihlr-25462	52	19	177	177	NUM
ihlr-25462	52	20	jama	jama	NOUN
ihlr-25462	52	21	internal	internal	PROPN
ihlr-25462	52	22	med	med	PROPN
ihlr-25462	52	23	.	.	PUNCT
ihlr-25462	53	1	1665	1665	NUM
ihlr-25462	53	2	(	(	PUNCT
ihlr-25462	53	3	2017	2017	NUM
ihlr-25462	53	4	)	)	PUNCT
ihlr-25462	53	5	.	.	PUNCT
ihlr-25462	54	1	14	14	NUM
ihlr-25462	54	2	.	.	PUNCT
ihlr-25462	55	1	medicare	medicare	PROPN
ihlr-25462	55	2	prescription	prescription	NOUN
ihlr-25462	55	3	drug	drug	NOUN
ihlr-25462	55	4	,	,	PUNCT
ihlr-25462	55	5	improvement	improvement	NOUN
ihlr-25462	55	6	,	,	PUNCT
ihlr-25462	55	7	and	and	CCONJ
ihlr-25462	55	8	modernization	modernization	NOUN
ihlr-25462	55	9	act	act	NOUN
ihlr-25462	55	10	of	of	ADP
ihlr-25462	55	11	2003	2003	NUM
ihlr-25462	55	12	,	,	PUNCT
ihlr-25462	55	13	pub	pub	NOUN
ihlr-25462	55	14	.	.	PUNCT
ihlr-25462	56	1	l.	l.	PROPN
ihlr-25462	56	2	no	no	INTJ
ihlr-25462	56	3	.	.	PROPN
ihlr-25462	57	1	108	108	NUM
ihlr-25462	57	2	-	-	SYM
ihlr-25462	57	3	173	173	NUM
ihlr-25462	57	4	,	,	PUNCT
ihlr-25462	57	5	117	117	NUM
ihlr-25462	57	6	stat	stat	NOUN
ihlr-25462	57	7	.	.	PUNCT
ihlr-25462	58	1	2066	2066	NUM
ihlr-25462	58	2	.	.	PUNCT
ihlr-25462	59	1	this	this	DET
ihlr-25462	59	2	public	public	ADJ
ihlr-25462	59	3	law	law	NOUN
ihlr-25462	59	4	is	be	AUX
ihlr-25462	59	5	better	well	ADV
ihlr-25462	59	6	known	know	VERB
ihlr-25462	59	7	as	as	ADP
ihlr-25462	59	8	the	the	DET
ihlr-25462	59	9	law	law	NOUN
ihlr-25462	59	10	that	that	PRON
ihlr-25462	59	11	created	create	VERB
ihlr-25462	59	12	medicare	medicare	PROPN
ihlr-25462	59	13	part	part	PROPN
ihlr-25462	59	14	d.	d.	PROPN
ihlr-25462	59	15	15	15	NUM
ihlr-25462	59	16	.	.	PUNCT
ihlr-25462	60	1	patent	patent	NOUN
ihlr-25462	60	2	rights	right	NOUN
ihlr-25462	60	3	and	and	CCONJ
ihlr-25462	60	4	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	60	5	reimportation	reimportation	NOUN
ihlr-25462	60	6	,	,	PUNCT
ihlr-25462	60	7	gen	gen	PROPN
ihlr-25462	60	8	(	(	PUNCT
ihlr-25462	60	9	nov	nov	PROPN
ihlr-25462	60	10	.	.	PROPN
ihlr-25462	60	11	1	1	NUM
ihlr-25462	60	12	,	,	PUNCT
ihlr-25462	60	13	2005	2005	NUM
ihlr-25462	60	14	)	)	PUNCT
ihlr-25462	60	15	,	,	PUNCT
ihlr-25462	60	16	https://www	https://www	PROPN
ihlr-25462	60	17	.	.	PUNCT
ihlr-25462	61	1	genengnews.com/magazine/38	genengnews.com/magazine/38	PROPN
ihlr-25462	61	2	/paten	/paten	PUNCT
ihlr-25462	61	3	t	t	PROPN
ihlr-25462	61	4	-	-	PUNCT
ihlr-25462	61	5	r	r	NOUN
ihlr-25462	61	6	igh	igh	PROPN
ihlr-25462	61	7	ts	ts	PROPN
ihlr-25462	61	8	-	-	PUNCT
ihlr-25462	61	9	and	and	CCONJ
ihlr-25462	61	10	-	-	PUNCT
ihlr-25462	61	11	pharmaceutica	pharmaceutica	NOUN
ihlr-25462	61	12	l	l	PROPN
ihlr-25462	61	13	-	-	PUNCT
ihlr-25462	61	14	r	r	NOUN
ihlr-25462	61	15	eimportat	eimportat	NOUN
ihlr-25462	61	16	ion	ion	NOUN
ihlr-25462	61	17	/	/	SYM
ihlr-25462	61	18	400	400	NUM
ihlr-25462	61	19	indiana	indiana	PROPN
ihlr-25462	61	20	health	health	PROPN
ihlr-25462	61	21	law	law	NOUN
ihlr-25462	61	22	review	review	NOUN
ihlr-25462	62	1	[	[	X
ihlr-25462	62	2	vol	vol	NOUN
ihlr-25462	62	3	.	.	PUNCT
ihlr-25462	62	4	18:397	18:397	NUM
ihlr-25462	62	5	under	under	ADP
ihlr-25462	62	6	the	the	DET
ihlr-25462	62	7	doctrine	doctrine	NOUN
ihlr-25462	62	8	of	of	ADP
ihlr-25462	62	9	patent	patent	NOUN
ihlr-25462	62	10	exhaustion	exhaustion	NOUN
ihlr-25462	62	11	,	,	PUNCT
ihlr-25462	62	12	when	when	SCONJ
ihlr-25462	62	13	a	a	DET
ihlr-25462	62	14	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	62	15	manufacturer	manufacturer	NOUN
ihlr-25462	62	16	or	or	CCONJ
ihlr-25462	62	17	licensee	licensee	NOUN
ihlr-25462	62	18	distributes	distribute	VERB
ihlr-25462	62	19	patented	patented	ADJ
ihlr-25462	62	20	medicines	medicine	NOUN
ihlr-25462	62	21	within	within	ADP
ihlr-25462	62	22	the	the	DET
ihlr-25462	62	23	u.s	u.s	PROPN
ihlr-25462	62	24	.	.	PROPN
ihlr-25462	62	25	,	,	PUNCT
ihlr-25462	62	26	the	the	DET
ihlr-25462	62	27	patent	patent	NOUN
ihlr-25462	62	28	rights	right	NOUN
ihlr-25462	62	29	with	with	ADP
ihlr-25462	62	30	respect	respect	NOUN
ihlr-25462	62	31	to	to	ADP
ihlr-25462	62	32	these	these	DET
ihlr-25462	62	33	drugs	drug	NOUN
ihlr-25462	62	34	are	be	AUX
ihlr-25462	62	35	effectively	effectively	ADV
ihlr-25462	62	36	terminated,16	terminated,16	ADJ
ihlr-25462	62	37	and	and	CCONJ
ihlr-25462	62	38	the	the	DET
ihlr-25462	62	39	purchaser	purchaser	NOUN
ihlr-25462	62	40	and	and	CCONJ
ihlr-25462	62	41	all	all	DET
ihlr-25462	62	42	subsequent	subsequent	ADJ
ihlr-25462	62	43	owners	owner	NOUN
ihlr-25462	62	44	are	be	AUX
ihlr-25462	62	45	free	free	ADJ
ihlr-25462	62	46	to	to	PART
ihlr-25462	62	47	use	use	VERB
ihlr-25462	62	48	or	or	CCONJ
ihlr-25462	62	49	resell	resell	VERB
ihlr-25462	62	50	the	the	DET
ihlr-25462	62	51	product	product	NOUN
ihlr-25462	62	52	just	just	ADV
ihlr-25462	62	53	like	like	ADP
ihlr-25462	62	54	any	any	DET
ihlr-25462	62	55	other	other	ADJ
ihlr-25462	62	56	item	item	NOUN
ihlr-25462	62	57	of	of	ADP
ihlr-25462	62	58	personal	personal	ADJ
ihlr-25462	62	59	property	property	NOUN
ihlr-25462	62	60	without	without	ADP
ihlr-25462	62	61	fear	fear	NOUN
ihlr-25462	62	62	of	of	ADP
ihlr-25462	62	63	an	an	DET
ihlr-25462	62	64	infringement	infringement	NOUN
ihlr-25462	62	65	lawsuit.17	lawsuit.17	ADV
ihlr-25462	62	66	however	however	ADV
ihlr-25462	62	67	,	,	PUNCT
ihlr-25462	62	68	the	the	DET
ihlr-25462	62	69	law	law	NOUN
ihlr-25462	62	70	has	have	AUX
ihlr-25462	62	71	historically	historically	ADV
ihlr-25462	62	72	been	be	AUX
ihlr-25462	62	73	unclear	unclear	ADJ
ihlr-25462	62	74	as	as	ADP
ihlr-25462	62	75	to	to	ADP
ihlr-25462	62	76	how	how	SCONJ
ihlr-25462	62	77	this	this	PRON
ihlr-25462	62	78	applies	apply	VERB
ihlr-25462	62	79	to	to	ADP
ihlr-25462	62	80	international	international	ADJ
ihlr-25462	62	81	patent	patent	NOUN
ihlr-25462	62	82	exhaustion	exhaustion	NOUN
ihlr-25462	62	83	.	.	PUNCT
ihlr-25462	63	1	this	this	PRON
ihlr-25462	63	2	means	mean	VERB
ihlr-25462	63	3	that	that	SCONJ
ihlr-25462	63	4	,	,	PUNCT
ihlr-25462	63	5	in	in	ADP
ihlr-25462	63	6	the	the	DET
ihlr-25462	63	7	past	past	NOUN
ihlr-25462	63	8	,	,	PUNCT
ihlr-25462	63	9	authorized	authorize	VERB
ihlr-25462	63	10	sales	sale	NOUN
ihlr-25462	63	11	and	and	CCONJ
ihlr-25462	63	12	the	the	DET
ihlr-25462	63	13	corresponding	corresponding	ADJ
ihlr-25462	63	14	distribution	distribution	NOUN
ihlr-25462	63	15	of	of	ADP
ihlr-25462	63	16	patented	patent	VERB
ihlr-25462	63	17	medicines	medicine	NOUN
ihlr-25462	63	18	by	by	ADP
ihlr-25462	63	19	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	63	20	manufacturers	manufacturer	NOUN
ihlr-25462	63	21	to	to	ADP
ihlr-25462	63	22	countries	country	NOUN
ihlr-25462	63	23	outside	outside	ADP
ihlr-25462	63	24	the	the	DET
ihlr-25462	63	25	u.s	u.s	PROPN
ihlr-25462	63	26	.	.	PROPN
ihlr-25462	63	27	(	(	PUNCT
ihlr-25462	63	28	e.g.	e.g.	ADV
ihlr-25462	63	29	,	,	PUNCT
ihlr-25462	63	30	direct	direct	ADJ
ihlr-25462	63	31	sales	sale	NOUN
ihlr-25462	63	32	of	of	ADP
ihlr-25462	63	33	a	a	DET
ihlr-25462	63	34	drug	drug	NOUN
ihlr-25462	63	35	to	to	ADP
ihlr-25462	63	36	canada	canada	PROPN
ihlr-25462	63	37	)	)	PUNCT
ihlr-25462	63	38	would	would	AUX
ihlr-25462	63	39	not	not	PART
ihlr-25462	63	40	terminate	terminate	VERB
ihlr-25462	63	41	u.s	u.s	PROPN
ihlr-25462	63	42	.	.	PROPN
ihlr-25462	63	43	patent	patent	NOUN
ihlr-25462	63	44	rights	right	NOUN
ihlr-25462	63	45	to	to	ADP
ihlr-25462	63	46	that	that	DET
ihlr-25462	63	47	drug	drug	NOUN
ihlr-25462	63	48	;	;	PUNCT
ihlr-25462	63	49	or	or	CCONJ
ihlr-25462	63	50	,	,	PUNCT
ihlr-25462	63	51	at	at	ADP
ihlr-25462	63	52	least	least	ADJ
ihlr-25462	63	53	,	,	PUNCT
ihlr-25462	63	54	the	the	DET
ihlr-25462	63	55	law	law	NOUN
ihlr-25462	63	56	has	have	AUX
ihlr-25462	63	57	historically	historically	ADV
ihlr-25462	63	58	been	be	AUX
ihlr-25462	63	59	unclear	unclear	ADJ
ihlr-25462	63	60	on	on	ADP
ihlr-25462	63	61	this	this	DET
ihlr-25462	63	62	point.18	point.18	NOUN
ihlr-25462	63	63	therefore	therefore	ADV
ihlr-25462	63	64	,	,	PUNCT
ihlr-25462	63	65	most	most	ADJ
ihlr-25462	63	66	people	people	NOUN
ihlr-25462	63	67	believed	believe	VERB
ihlr-25462	63	68	that	that	SCONJ
ihlr-25462	63	69	re	re	NOUN
ihlr-25462	63	70	-	-	NOUN
ihlr-25462	63	71	importation	importation	NOUN
ihlr-25462	63	72	of	of	ADP
ihlr-25462	63	73	medicine	medicine	NOUN
ihlr-25462	63	74	initially	initially	ADV
ihlr-25462	63	75	sold	sell	VERB
ihlr-25462	63	76	or	or	CCONJ
ihlr-25462	63	77	distributed	distribute	VERB
ihlr-25462	63	78	to	to	ADP
ihlr-25462	63	79	a	a	DET
ihlr-25462	63	80	foreign	foreign	ADJ
ihlr-25462	63	81	country	country	NOUN
ihlr-25462	63	82	,	,	PUNCT
ihlr-25462	63	83	and	and	CCONJ
ihlr-25462	63	84	then	then	ADV
ihlr-25462	63	85	re	re	VERB
ihlr-25462	63	86	-	-	VERB
ihlr-25462	63	87	imported	import	VERB
ihlr-25462	63	88	back	back	ADV
ihlr-25462	63	89	into	into	ADP
ihlr-25462	63	90	the	the	DET
ihlr-25462	63	91	u.s	u.s	PROPN
ihlr-25462	63	92	.	.	PROPN
ihlr-25462	63	93	,	,	PUNCT
ihlr-25462	63	94	would	would	AUX
ihlr-25462	63	95	be	be	AUX
ihlr-25462	63	96	considered	consider	VERB
ihlr-25462	63	97	an	an	DET
ihlr-25462	63	98	act	act	NOUN
ihlr-25462	63	99	of	of	ADP
ihlr-25462	63	100	patent	patent	NOUN
ihlr-25462	63	101	infringement.19	infringement.19	NOUN
ihlr-25462	63	102	this	this	DET
ihlr-25462	63	103	rule	rule	NOUN
ihlr-25462	63	104	is	be	AUX
ihlr-25462	63	105	important	important	ADJ
ihlr-25462	63	106	to	to	ADP
ihlr-25462	63	107	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	63	108	re	re	NOUN
ihlr-25462	63	109	-	-	NOUN
ihlr-25462	63	110	importation	importation	NOUN
ihlr-25462	63	111	because	because	SCONJ
ihlr-25462	63	112	prices	price	NOUN
ihlr-25462	63	113	are	be	AUX
ihlr-25462	63	114	lower	low	ADJ
ihlr-25462	63	115	in	in	ADP
ihlr-25462	63	116	canada	canada	PROPN
ihlr-25462	63	117	and	and	CCONJ
ihlr-25462	63	118	many	many	ADJ
ihlr-25462	63	119	other	other	ADJ
ihlr-25462	63	120	foreign	foreign	ADJ
ihlr-25462	63	121	countries	country	NOUN
ihlr-25462	63	122	than	than	SCONJ
ihlr-25462	63	123	they	they	PRON
ihlr-25462	63	124	are	be	AUX
ihlr-25462	63	125	in	in	ADP
ihlr-25462	63	126	the	the	DET
ihlr-25462	63	127	u.s.20	u.s.20	NOUN
ihlr-25462	63	128	one	one	NUM
ihlr-25462	63	129	reason	reason	NOUN
ihlr-25462	63	130	for	for	ADP
ihlr-25462	63	131	this	this	PRON
ihlr-25462	63	132	is	be	AUX
ihlr-25462	63	133	that	that	SCONJ
ihlr-25462	63	134	some	some	DET
ihlr-25462	63	135	governments	government	NOUN
ihlr-25462	63	136	(	(	PUNCT
ihlr-25462	63	137	e.g.	e.g.	ADV
ihlr-25462	63	138	,	,	PUNCT
ihlr-25462	63	139	canada	canada	PROPN
ihlr-25462	63	140	)	)	PUNCT
ihlr-25462	63	141	“	"	PUNCT
ihlr-25462	63	142	are	be	AUX
ihlr-25462	63	143	the	the	DET
ihlr-25462	63	144	primary	primary	ADJ
ihlr-25462	63	145	or	or	CCONJ
ihlr-25462	63	146	only	only	ADV
ihlr-25462	63	147	payer	payer	NOUN
ihlr-25462	63	148	of	of	ADP
ihlr-25462	63	149	health	health	NOUN
ihlr-25462	63	150	care	care	NOUN
ihlr-25462	63	151	and	and	CCONJ
ihlr-25462	63	152	in	in	ADP
ihlr-25462	63	153	effect	effect	NOUN
ihlr-25462	63	154	[	[	X
ihlr-25462	63	155	can	can	AUX
ihlr-25462	63	156	]	]	PUNCT
ihlr-25462	63	157	dictate	dictate	VERB
ihlr-25462	63	158	the	the	DET
ihlr-25462	63	159	prices	price	NOUN
ihlr-25462	63	160	of	of	ADP
ihlr-25462	63	161	medicines	medicine	NOUN
ihlr-25462	63	162	as	as	ADP
ihlr-25462	63	163	a	a	DET
ihlr-25462	63	164	condition	condition	NOUN
ihlr-25462	63	165	of	of	ADP
ihlr-25462	63	166	market	market	NOUN
ihlr-25462	63	167	access	access	NOUN
ihlr-25462	63	168	.	.	PUNCT
ihlr-25462	64	1	”21	”21	PUNCT
ihlr-25462	64	2	therefore	therefore	ADV
ihlr-25462	64	3	,	,	PUNCT
ihlr-25462	64	4	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	64	5	companies	company	NOUN
ihlr-25462	64	6	wanting	want	VERB
ihlr-25462	64	7	to	to	PART
ihlr-25462	64	8	make	make	VERB
ihlr-25462	64	9	their	their	PRON
ihlr-25462	64	10	products	product	NOUN
ihlr-25462	64	11	available	available	ADJ
ihlr-25462	64	12	in	in	ADP
ihlr-25462	64	13	canada	canada	PROPN
ihlr-25462	64	14	may	may	AUX
ihlr-25462	64	15	be	be	AUX
ihlr-25462	64	16	forced	force	VERB
ihlr-25462	64	17	to	to	PART
ihlr-25462	64	18	sell	sell	VERB
ihlr-25462	64	19	their	their	PRON
ihlr-25462	64	20	product	product	NOUN
ihlr-25462	64	21	at	at	ADP
ihlr-25462	64	22	a	a	DET
ihlr-25462	64	23	lower	low	ADJ
ihlr-25462	64	24	price	price	NOUN
ihlr-25462	64	25	in	in	ADP
ihlr-25462	64	26	canada	canada	PROPN
ihlr-25462	64	27	than	than	ADP
ihlr-25462	64	28	in	in	ADP
ihlr-25462	64	29	the	the	DET
ihlr-25462	64	30	u.s.22	u.s.22	NOUN
ihlr-25462	64	31	in	in	ADP
ihlr-25462	64	32	contrast	contrast	NOUN
ihlr-25462	64	33	,	,	PUNCT
ihlr-25462	64	34	the	the	DET
ihlr-25462	64	35	u.s	u.s	PROPN
ihlr-25462	64	36	.	.	PROPN
ihlr-25462	64	37	does	do	AUX
ihlr-25462	64	38	not	not	PART
ihlr-25462	64	39	participate	participate	VERB
ihlr-25462	64	40	in	in	ADP
ihlr-25462	64	41	direct	direct	ADJ
ihlr-25462	64	42	regulation	regulation	NOUN
ihlr-25462	64	43	of	of	ADP
ihlr-25462	64	44	the	the	DET
ihlr-25462	64	45	prices	price	NOUN
ihlr-25462	64	46	that	that	SCONJ
ihlr-25462	64	47	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	64	48	manufacturers	manufacturer	NOUN
ihlr-25462	64	49	charge	charge	VERB
ihlr-25462	64	50	for	for	ADP
ihlr-25462	64	51	their	their	PRON
ihlr-25462	64	52	products	product	NOUN
ihlr-25462	64	53	,	,	PUNCT
ihlr-25462	64	54	and	and	CCONJ
ihlr-25462	64	55	the	the	DET
ihlr-25462	64	56	list	list	NOUN
ihlr-25462	64	57	price	price	NOUN
ihlr-25462	64	58	in	in	ADP
ihlr-25462	64	59	the	the	DET
ihlr-25462	64	60	u.s	u.s	PROPN
ihlr-25462	64	61	.	.	PROPN
ihlr-25462	64	62	is	be	AUX
ihlr-25462	64	63	often	often	ADV
ihlr-25462	64	64	higher	high	ADJ
ihlr-25462	64	65	than	than	ADP
ihlr-25462	64	66	in	in	ADP
ihlr-25462	64	67	other	other	ADJ
ihlr-25462	64	68	industrialized	industrialize	VERB
ihlr-25462	64	69	nations	nation	NOUN
ihlr-25462	64	70	,	,	PUNCT
ihlr-25462	64	71	even	even	ADV
ihlr-25462	64	72	though	though	SCONJ
ihlr-25462	64	73	the	the	DET
ihlr-25462	64	74	actual	actual	ADJ
ihlr-25462	64	75	price	price	NOUN
ihlr-25462	64	76	to	to	ADP
ihlr-25462	64	77	the	the	DET
ihlr-25462	64	78	consumer	consumer	NOUN
ihlr-25462	64	79	often	often	ADV
ihlr-25462	64	80	includes	include	VERB
ihlr-25462	64	81	discounts	discount	NOUN
ihlr-25462	64	82	,	,	PUNCT
ihlr-25462	64	83	savings	saving	NOUN
ihlr-25462	64	84	programs	program	NOUN
ihlr-25462	64	85	from	from	ADP
ihlr-25462	64	86	the	the	DET
ihlr-25462	64	87	manufacturer	manufacturer	NOUN
ihlr-25462	64	88	,	,	PUNCT
ihlr-25462	64	89	and	and	CCONJ
ihlr-25462	64	90	negotiated	negotiate	VERB
ihlr-25462	64	91	out	out	ADP
ihlr-25462	64	92	-	-	PUNCT
ihlr-25462	64	93	of	of	ADP
ihlr-25462	64	94	-	-	PUNCT
ihlr-25462	64	95	pocket	pocket	NOUN
ihlr-25462	64	96	costs	cost	NOUN
ihlr-25462	64	97	from	from	ADP
ihlr-25462	64	98	the	the	DET
ihlr-25462	64	99	consumer	consumer	NOUN
ihlr-25462	64	100	’s	’s	PART
ihlr-25462	64	101	insurer	insurer	NOUN
ihlr-25462	64	102	or	or	CCONJ
ihlr-25462	64	103	pharmacy	pharmacy	NOUN
ihlr-25462	64	104	benefit	benefit	NOUN
ihlr-25462	64	105	manager.23	manager.23	PROPN
ihlr-25462	65	1	[	[	X
ihlr-25462	65	2	https://perma.cc/8esk-g6ul	https://perma.cc/8esk-g6ul	X
ihlr-25462	65	3	]	]	X
ihlr-25462	65	4	.	.	PUNCT
ihlr-25462	66	1	16	16	NUM
ihlr-25462	66	2	.	.	PUNCT
ihlr-25462	67	1	i	i	PRON
ihlr-25462	67	2	d.	d.	PROPN
ihlr-25462	67	3	17	17	NUM
ihlr-25462	67	4	.	.	PUNCT
ihlr-25462	68	1	impression	impression	NOUN
ihlr-25462	68	2	prods	prod	VERB
ihlr-25462	68	3	.	.	PUNCT
ihlr-25462	68	4	,	,	PUNCT
ihlr-25462	68	5	inc	inc	PROPN
ihlr-25462	68	6	.	.	PROPN
ihlr-25462	69	1	v.	v.	ADP
ihlr-25462	69	2	lexmark	lexmark	PROPN
ihlr-25462	69	3	int’l	int’l	NUM
ihlr-25462	69	4	,	,	PUNCT
ihlr-25462	69	5	inc	inc	PROPN
ihlr-25462	69	6	.	.	PROPN
ihlr-25462	69	7	,	,	PUNCT
ihlr-25462	69	8	137	137	NUM
ihlr-25462	69	9	s.	s.	PROPN
ihlr-25462	69	10	ct	ct	PROPN
ihlr-25462	69	11	.	.	PROPN
ihlr-25462	69	12	1523	1523	NUM
ihlr-25462	69	13	,	,	PUNCT
ihlr-25462	69	14	1535	1535	NUM
ihlr-25462	69	15	(	(	PUNCT
ihlr-25462	69	16	2017	2017	NUM
ihlr-25462	69	17	)	)	PUNCT
ihlr-25462	69	18	.	.	PUNCT
ihlr-25462	70	1	18	18	NUM
ihlr-25462	70	2	.	.	PUNCT
ihlr-25462	70	3	patent	patent	NOUN
ihlr-25462	70	4	rights	right	NOUN
ihlr-25462	70	5	and	and	CCONJ
ihlr-25462	70	6	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	70	7	reimportation	reimportation	NOUN
ihlr-25462	70	8	,	,	PUNCT
ihlr-25462	70	9	supra	supra	PROPN
ihlr-25462	70	10	note	note	PROPN
ihlr-25462	70	11	15	15	NUM
ihlr-25462	70	12	;	;	PUNCT
ihlr-25462	70	13	see	see	VERB
ihlr-25462	70	14	also	also	ADV
ihlr-25462	70	15	jazz	jazz	NOUN
ihlr-25462	70	16	photo	photo	PROPN
ihlr-25462	70	17	corp	corp	PROPN
ihlr-25462	70	18	.	.	PROPN
ihlr-25462	71	1	v.	v.	ADP
ihlr-25462	71	2	int’l	int’l	NUM
ihlr-25462	71	3	trade	trade	NOUN
ihlr-25462	71	4	comm’n	comm’n	NOUN
ihlr-25462	71	5	,	,	PUNCT
ihlr-25462	71	6	264	264	NUM
ihlr-25462	71	7	f.3d	f.3d	NUM
ihlr-25462	71	8	1094	1094	NUM
ihlr-25462	71	9	(	(	PUNCT
ihlr-25462	71	10	d.c	d.c	PROPN
ihlr-25462	71	11	.	.	PROPN
ihlr-25462	71	12	cir	cir	PROPN
ihlr-25462	71	13	.	.	PROPN
ihlr-25462	71	14	2001	2001	NUM
ihlr-25462	71	15	)	)	PUNCT
ihlr-25462	72	1	(	(	PUNCT
ihlr-25462	72	2	holding	hold	VERB
ihlr-25462	72	3	that	that	SCONJ
ihlr-25462	72	4	a	a	DET
ihlr-25462	72	5	patentee	patentee	NOUN
ihlr-25462	72	6	’s	’s	PART
ihlr-25462	72	7	decision	decision	NOUN
ihlr-25462	72	8	to	to	PART
ihlr-25462	72	9	sell	sell	VERB
ihlr-25462	72	10	a	a	DET
ihlr-25462	72	11	product	product	NOUN
ihlr-25462	72	12	abroad	abroad	ADV
ihlr-25462	72	13	did	do	AUX
ihlr-25462	72	14	not	not	PART
ihlr-25462	72	15	terminate	terminate	VERB
ihlr-25462	72	16	its	its	PRON
ihlr-25462	72	17	ability	ability	NOUN
ihlr-25462	72	18	to	to	PART
ihlr-25462	72	19	bring	bring	VERB
ihlr-25462	72	20	an	an	DET
ihlr-25462	72	21	infringement	infringement	NOUN
ihlr-25462	72	22	suit	suit	NOUN
ihlr-25462	72	23	against	against	ADP
ihlr-25462	72	24	the	the	DET
ihlr-25462	72	25	buyer	buyer	NOUN
ihlr-25462	72	26	that	that	PRON
ihlr-25462	72	27	imported	import	VERB
ihlr-25462	72	28	the	the	DET
ihlr-25462	72	29	article	article	NOUN
ihlr-25462	72	30	and	and	CCONJ
ihlr-25462	72	31	sold	sell	VERB
ihlr-25462	72	32	it	it	PRON
ihlr-25462	72	33	in	in	ADP
ihlr-25462	72	34	the	the	DET
ihlr-25462	72	35	u.s	u.s	PROPN
ihlr-25462	72	36	.	.	PROPN
ihlr-25462	72	37	)	)	PUNCT
ihlr-25462	72	38	;	;	PUNCT
ihlr-25462	72	39	quanta	quanta	PROPN
ihlr-25462	72	40	computer	computer	PROPN
ihlr-25462	72	41	,	,	PUNCT
ihlr-25462	72	42	inc	inc	PROPN
ihlr-25462	72	43	.	.	PROPN
ihlr-25462	72	44	v.	v.	ADP
ihlr-25462	72	45	lg	lg	NOUN
ihlr-25462	72	46	elecs	elec	NOUN
ihlr-25462	72	47	.	.	PUNCT
ihlr-25462	72	48	,	,	PUNCT
ihlr-25462	72	49	inc	inc	PROPN
ihlr-25462	72	50	.	.	PROPN
ihlr-25462	72	51	,	,	PUNCT
ihlr-25462	72	52	128	128	NUM
ihlr-25462	72	53	s.	s.	PROPN
ihlr-25462	72	54	ct	ct	PROPN
ihlr-25462	72	55	.	.	PROPN
ihlr-25462	72	56	2109	2109	NUM
ihlr-25462	72	57	,	,	PUNCT
ihlr-25462	72	58	2122	2122	NUM
ihlr-25462	72	59	(	(	PUNCT
ihlr-25462	72	60	2008	2008	NUM
ihlr-25462	72	61	)	)	PUNCT
ihlr-25462	72	62	(	(	PUNCT
ihlr-25462	72	63	holding	hold	VERB
ihlr-25462	72	64	that	that	SCONJ
ihlr-25462	72	65	the	the	DET
ihlr-25462	72	66	patentee	patentee	NOUN
ihlr-25462	72	67	could	could	AUX
ihlr-25462	72	68	not	not	PART
ihlr-25462	72	69	bring	bring	VERB
ihlr-25462	72	70	an	an	DET
ihlr-25462	72	71	infringement	infringement	NOUN
ihlr-25462	72	72	suit	suit	NOUN
ihlr-25462	72	73	because	because	SCONJ
ihlr-25462	72	74	the	the	DET
ihlr-25462	72	75	“	"	PUNCT
ihlr-25462	72	76	authorized	authorize	VERB
ihlr-25462	72	77	sale	sale	NOUN
ihlr-25462	72	78	.	.	PUNCT
ihlr-25462	72	79	.	.	PUNCT
ihlr-25462	73	1	.	.	PUNCT
ihlr-25462	74	1	took	take	VERB
ihlr-25462	74	2	its	its	PRON
ihlr-25462	74	3	products	product	NOUN
ihlr-25462	74	4	outside	outside	ADP
ihlr-25462	74	5	of	of	ADP
ihlr-25462	74	6	the	the	DET
ihlr-25462	74	7	patent	patent	NOUN
ihlr-25462	74	8	monopoly	monopoly	NOUN
ihlr-25462	74	9	”	"	PUNCT
ihlr-25462	74	10	)	)	PUNCT
ihlr-25462	74	11	.	.	PUNCT
ihlr-25462	75	1	19	19	NUM
ihlr-25462	75	2	.	.	NOUN
ihlr-25462	75	3	35	35	NUM
ihlr-25462	75	4	u.s.c	u.s.c	NOUN
ihlr-25462	75	5	.	.	PUNCT
ihlr-25462	76	1	§	§	PROPN
ihlr-25462	76	2	271(a	271(a	PROPN
ihlr-25462	76	3	)	)	PUNCT
ihlr-25462	76	4	(	(	PUNCT
ihlr-25462	76	5	2020	2020	NUM
ihlr-25462	76	6	)	)	PUNCT
ihlr-25462	76	7	(	(	PUNCT
ihlr-25462	76	8	“	"	PUNCT
ihlr-25462	76	9	except	except	SCONJ
ihlr-25462	76	10	as	as	ADV
ihlr-25462	76	11	otherwise	otherwise	ADV
ihlr-25462	76	12	provided	provide	VERB
ihlr-25462	76	13	in	in	ADP
ihlr-25462	76	14	this	this	DET
ihlr-25462	76	15	title	title	NOUN
ihlr-25462	76	16	,	,	PUNCT
ihlr-25462	76	17	whoever	whoever	PRON
ihlr-25462	76	18	without	without	ADP
ihlr-25462	76	19	authority	authority	NOUN
ihlr-25462	76	20	makes	make	VERB
ihlr-25462	76	21	,	,	PUNCT
ihlr-25462	76	22	uses	use	NOUN
ihlr-25462	76	23	,	,	PUNCT
ihlr-25462	76	24	offers	offer	VERB
ihlr-25462	76	25	to	to	PART
ihlr-25462	76	26	sell	sell	VERB
ihlr-25462	76	27	,	,	PUNCT
ihlr-25462	76	28	or	or	CCONJ
ihlr-25462	76	29	sells	sell	VERB
ihlr-25462	76	30	any	any	DET
ihlr-25462	76	31	patented	patented	ADJ
ihlr-25462	76	32	invention	invention	NOUN
ihlr-25462	76	33	,	,	PUNCT
ihlr-25462	76	34	within	within	ADP
ihlr-25462	76	35	the	the	DET
ihlr-25462	76	36	[	[	X
ihlr-25462	76	37	u.s	u.s	PROPN
ihlr-25462	76	38	]	]	X
ihlr-25462	76	39	.	.	PUNCT
ihlr-25462	77	1	or	or	CCONJ
ihlr-25462	77	2	imports	import	NOUN
ihlr-25462	77	3	into	into	ADP
ihlr-25462	77	4	the	the	DET
ihlr-25462	77	5	[	[	X
ihlr-25462	77	6	u.s	u.s	PROPN
ihlr-25462	77	7	]	]	X
ihlr-25462	77	8	.	.	PUNCT
ihlr-25462	78	1	any	any	DET
ihlr-25462	78	2	patented	patented	ADJ
ihlr-25462	78	3	invention	invention	NOUN
ihlr-25462	78	4	during	during	ADP
ihlr-25462	78	5	the	the	DET
ihlr-25462	78	6	term	term	NOUN
ihlr-25462	78	7	of	of	ADP
ihlr-25462	78	8	the	the	DET
ihlr-25462	78	9	patent	patent	NOUN
ihlr-25462	78	10	therefor	therefor	ADV
ihlr-25462	78	11	,	,	PUNCT
ihlr-25462	78	12	infringes	infringe	VERB
ihlr-25462	78	13	the	the	DET
ihlr-25462	78	14	patent	patent	NOUN
ihlr-25462	78	15	.	.	PUNCT
ihlr-25462	78	16	”	"	PUNCT
ihlr-25462	78	17	)	)	PUNCT
ihlr-25462	78	18	.	.	PUNCT
ihlr-25462	79	1	20	20	NUM
ihlr-25462	79	2	.	.	PUNCT
ihlr-25462	80	1	see	see	VERB
ihlr-25462	80	2	panos	panos	PROPN
ihlr-25462	80	3	kanavos	kanavos	NOUN
ihlr-25462	80	4	et	et	PROPN
ihlr-25462	80	5	al	al	PROPN
ihlr-25462	80	6	.	.	PROPN
ihlr-25462	80	7	,	,	PUNCT
ihlr-25462	80	8	higher	high	ADJ
ihlr-25462	80	9	us	we	PRON
ihlr-25462	80	10	branded	brand	VERB
ihlr-25462	80	11	drug	drug	NOUN
ihlr-25462	80	12	prices	price	NOUN
ihlr-25462	80	13	and	and	CCONJ
ihlr-25462	80	14	spending	spending	NOUN
ihlr-25462	80	15	compared	compare	VERB
ihlr-25462	80	16	to	to	ADP
ihlr-25462	80	17	other	other	ADJ
ihlr-25462	80	18	countries	country	NOUN
ihlr-25462	80	19	may	may	AUX
ihlr-25462	80	20	stem	stem	VERB
ihlr-25462	80	21	partly	partly	ADV
ihlr-25462	80	22	from	from	ADP
ihlr-25462	80	23	quick	quick	ADJ
ihlr-25462	80	24	uptake	uptake	NOUN
ihlr-25462	80	25	of	of	ADP
ihlr-25462	80	26	new	new	ADJ
ihlr-25462	80	27	drugs	drug	NOUN
ihlr-25462	80	28	,	,	PUNCT
ihlr-25462	80	29	32	32	NUM
ihlr-25462	80	30	health	health	NOUN
ihlr-25462	80	31	aff	aff	NOUN
ihlr-25462	80	32	.	.	PUNCT
ihlr-25462	81	1	753	753	NUM
ihlr-25462	81	2	(	(	PUNCT
ihlr-25462	81	3	2013	2013	NUM
ihlr-25462	81	4	)	)	PUNCT
ihlr-25462	81	5	.	.	PUNCT
ihlr-25462	82	1	21	21	NUM
ihlr-25462	82	2	.	.	PUNCT
ihlr-25462	83	1	kevin	kevin	PROPN
ihlr-25462	83	2	haninger	haninger	PROPN
ihlr-25462	83	3	,	,	PUNCT
ihlr-25462	83	4	setting	set	VERB
ihlr-25462	83	5	the	the	DET
ihlr-25462	83	6	record	record	NOUN
ihlr-25462	83	7	straight	straight	ADV
ihlr-25462	83	8	on	on	ADP
ihlr-25462	83	9	international	international	ADJ
ihlr-25462	83	10	reference	reference	NOUN
ihlr-25462	83	11	pricing	pricing	NOUN
ihlr-25462	83	12	,	,	PUNCT
ihlr-25462	83	13	catalyst	catalyst	NOUN
ihlr-25462	83	14	(	(	PUNCT
ihlr-25462	83	15	july	july	PROPN
ihlr-25462	83	16	16	16	NUM
ihlr-25462	83	17	,	,	PUNCT
ihlr-25462	83	18	2019	2019	NUM
ihlr-25462	83	19	)	)	PUNCT
ihlr-25462	83	20	,	,	PUNCT
ihlr-25462	83	21	https://catalyst.phrma.org/setting-the-record-straight-on-internationalreference-pricing	https://catalyst.phrma.org/setting-the-record-straight-on-internationalreference-price	VERB
ihlr-25462	83	22	[	[	X
ihlr-25462	83	23	https://perma.cc/mlx7-gjbh	https://perma.cc/mlx7-gjbh	PROPN
ihlr-25462	83	24	]	]	PUNCT
ihlr-25462	83	25	.	.	PUNCT
ihlr-25462	84	1	22	22	NUM
ihlr-25462	84	2	.	.	PUNCT
ihlr-25462	85	1	i	i	PRON
ihlr-25462	85	2	d.	d.	PROPN
ihlr-25462	85	3	23	23	NUM
ihlr-25462	85	4	.	.	PUNCT
ihlr-25462	86	1	topher	topher	PROPN
ihlr-25462	86	2	spiro	spiro	PROPN
ihlr-25462	86	3	et	et	PROPN
ihlr-25462	86	4	al	al	PROPN
ihlr-25462	86	5	.	.	PROPN
ihlr-25462	86	6	,	,	PUNCT
ihlr-25462	86	7	enough	enough	ADJ
ihlr-25462	86	8	is	be	AUX
ihlr-25462	86	9	enough	enough	ADJ
ihlr-25462	86	10	;	;	PUNCT
ihlr-25462	86	11	the	the	DET
ihlr-25462	86	12	time	time	NOUN
ihlr-25462	86	13	has	have	AUX
ihlr-25462	86	14	come	come	VERB
ihlr-25462	86	15	to	to	PART
ihlr-25462	86	16	address	address	VERB
ihlr-25462	86	17	sky	sky	NOUN
ihlr-25462	86	18	-	-	PUNCT
ihlr-25462	86	19	high	high	ADJ
ihlr-25462	86	20	drug	drug	NOUN
ihlr-25462	86	21	prices	price	NOUN
ihlr-25462	86	22	,	,	PUNCT
ihlr-25462	86	23	ctr	ctr	PROPN
ihlr-25462	86	24	.	.	PROPN
ihlr-25462	87	1	for	for	ADP
ihlr-25462	87	2	am	am	PROPN
ihlr-25462	87	3	.	.	PUNCT
ihlr-25462	87	4	progress	progress	NOUN
ihlr-25462	87	5	(	(	PUNCT
ihlr-25462	87	6	sept	sept	PROPN
ihlr-25462	87	7	.	.	PROPN
ihlr-25462	87	8	18	18	NUM
ihlr-25462	87	9	,	,	PUNCT
ihlr-25462	87	10	2015	2015	NUM
ihlr-25462	87	11	)	)	PUNCT
ihlr-25462	87	12	,	,	PUNCT
ihlr-25462	87	13	https://www.americanprogress.org/issues/	https://www.americanprogress.org/issues/	PROPN
ihlr-25462	87	14	2021	2021	NUM
ihlr-25462	87	15	]	]	PUNCT
ihlr-25462	87	16	a	a	DET
ihlr-25462	87	17	survey	survey	NOUN
ihlr-25462	87	18	of	of	ADP
ihlr-25462	87	19	three	three	NUM
ihlr-25462	87	20	patent	patent	NOUN
ihlr-25462	87	21	-	-	PUNCT
ihlr-25462	87	22	based	base	VERB
ihlr-25462	87	23	approaches	approach	NOUN
ihlr-25462	87	24	401	401	NUM
ihlr-25462	87	25	canada	canada	PROPN
ihlr-25462	87	26	sets	set	VERB
ihlr-25462	87	27	its	its	PRON
ihlr-25462	87	28	prices	price	NOUN
ihlr-25462	87	29	for	for	ADP
ihlr-25462	87	30	patented	patented	ADJ
ihlr-25462	87	31	medicines	medicine	NOUN
ihlr-25462	87	32	at	at	ADP
ihlr-25462	87	33	the	the	DET
ihlr-25462	87	34	federal	federal	ADJ
ihlr-25462	87	35	level	level	NOUN
ihlr-25462	87	36	through	through	ADP
ihlr-25462	87	37	a	a	DET
ihlr-25462	87	38	quasi	quasi	ADJ
ihlr-25462	87	39	-	-	ADJ
ihlr-25462	87	40	judicial	judicial	ADJ
ihlr-25462	87	41	agency	agency	NOUN
ihlr-25462	87	42	called	call	VERB
ihlr-25462	87	43	the	the	DET
ihlr-25462	87	44	patented	patent	VERB
ihlr-25462	87	45	medicine	medicine	NOUN
ihlr-25462	87	46	prices	price	NOUN
ihlr-25462	87	47	review	review	VERB
ihlr-25462	87	48	board	board	NOUN
ihlr-25462	87	49	(	(	PUNCT
ihlr-25462	87	50	“	"	PUNCT
ihlr-25462	87	51	pmprb”).24	pmprb”).24	AUX
ihlr-25462	87	52	the	the	DET
ihlr-25462	87	53	pmprb	pmprb	NOUN
ihlr-25462	87	54	also	also	ADV
ihlr-25462	87	55	places	place	VERB
ihlr-25462	87	56	price	price	NOUN
ihlr-25462	87	57	caps	cap	NOUN
ihlr-25462	87	58	after	after	SCONJ
ihlr-25462	87	59	a	a	DET
ihlr-25462	87	60	prescription	prescription	NOUN
ihlr-25462	87	61	drug	drug	NOUN
ihlr-25462	87	62	appears	appear	VERB
ihlr-25462	87	63	on	on	ADP
ihlr-25462	87	64	the	the	DET
ihlr-25462	87	65	canadian	canadian	ADJ
ihlr-25462	87	66	market	market	NOUN
ihlr-25462	87	67	.	.	PUNCT
ihlr-25462	88	1	the	the	DET
ihlr-25462	88	2	price	price	NOUN
ihlr-25462	88	3	charged	charge	VERB
ihlr-25462	88	4	each	each	DET
ihlr-25462	88	5	successive	successive	ADJ
ihlr-25462	88	6	year	year	NOUN
ihlr-25462	88	7	can	can	AUX
ihlr-25462	88	8	rise	rise	VERB
ihlr-25462	88	9	only	only	ADV
ihlr-25462	88	10	with	with	ADP
ihlr-25462	88	11	the	the	DET
ihlr-25462	88	12	rate	rate	NOUN
ihlr-25462	88	13	of	of	ADP
ihlr-25462	88	14	inflation.25	inflation.25	NOUN
ihlr-25462	88	15	however	however	ADV
ihlr-25462	88	16	,	,	PUNCT
ihlr-25462	88	17	to	to	PART
ihlr-25462	88	18	paint	paint	VERB
ihlr-25462	88	19	a	a	DET
ihlr-25462	88	20	fair	fair	ADJ
ihlr-25462	88	21	picture	picture	NOUN
ihlr-25462	88	22	of	of	ADP
ihlr-25462	88	23	this	this	DET
ihlr-25462	88	24	process	process	NOUN
ihlr-25462	88	25	,	,	PUNCT
ihlr-25462	88	26	canadians	canadian	NOUN
ihlr-25462	88	27	generally	generally	ADV
ihlr-25462	88	28	have	have	VERB
ihlr-25462	88	29	less	less	ADJ
ihlr-25462	88	30	access	access	NOUN
ihlr-25462	88	31	to	to	ADP
ihlr-25462	88	32	patented	patent	VERB
ihlr-25462	88	33	medicines.26	medicines.26	NOUN
ihlr-25462	88	34	in	in	ADP
ihlr-25462	88	35	addition	addition	NOUN
ihlr-25462	88	36	to	to	ADP
ihlr-25462	88	37	patent	patent	NOUN
ihlr-25462	88	38	exhaustion	exhaustion	NOUN
ihlr-25462	88	39	concerns	concern	NOUN
ihlr-25462	88	40	,	,	PUNCT
ihlr-25462	88	41	the	the	DET
ihlr-25462	88	42	passage	passage	NOUN
ihlr-25462	88	43	of	of	ADP
ihlr-25462	88	44	drug	drug	NOUN
ihlr-25462	88	45	importation	importation	NOUN
ihlr-25462	88	46	legislation	legislation	NOUN
ihlr-25462	88	47	in	in	ADP
ihlr-25462	88	48	2003	2003	NUM
ihlr-25462	88	49	has	have	AUX
ihlr-25462	88	50	been	be	AUX
ihlr-25462	88	51	further	far	ADV
ihlr-25462	88	52	hindered	hinder	VERB
ihlr-25462	88	53	by	by	ADP
ihlr-25462	88	54	complex	complex	ADJ
ihlr-25462	88	55	legal	legal	ADJ
ihlr-25462	88	56	,	,	PUNCT
ihlr-25462	88	57	regulatory	regulatory	ADJ
ihlr-25462	88	58	,	,	PUNCT
ihlr-25462	88	59	and	and	CCONJ
ihlr-25462	88	60	safety	safety	PROPN
ihlr-25462	88	61	concerns.27	concerns.27	PROPN
ihlr-25462	88	62	also	also	ADV
ihlr-25462	88	63	,	,	PUNCT
ihlr-25462	88	64	there	there	PRON
ihlr-25462	88	65	have	have	AUX
ihlr-25462	88	66	been	be	AUX
ihlr-25462	88	67	numerous	numerous	ADJ
ihlr-25462	88	68	failed	fail	VERB
ihlr-25462	88	69	attempts	attempt	NOUN
ihlr-25462	88	70	to	to	PART
ihlr-25462	88	71	implement	implement	VERB
ihlr-25462	88	72	importation.28	importation.28	NOUN
ihlr-25462	88	73	however	however	ADV
ihlr-25462	88	74	,	,	PUNCT
ihlr-25462	88	75	on	on	ADP
ihlr-25462	88	76	july	july	PROPN
ihlr-25462	88	77	31	31	NUM
ihlr-25462	88	78	,	,	PUNCT
ihlr-25462	88	79	2019	2019	NUM
ihlr-25462	88	80	,	,	PUNCT
ihlr-25462	88	81	hhs	hhs	PROPN
ihlr-25462	88	82	and	and	CCONJ
ihlr-25462	88	83	u.s	u.s	PROPN
ihlr-25462	88	84	.	.	PROPN
ihlr-25462	88	85	food	food	PROPN
ihlr-25462	88	86	and	and	CCONJ
ihlr-25462	88	87	drug	drug	PROPN
ihlr-25462	88	88	administration	administration	NOUN
ihlr-25462	88	89	(	(	PUNCT
ihlr-25462	88	90	“	"	PUNCT
ihlr-25462	88	91	fda	fda	PROPN
ihlr-25462	88	92	”	"	PUNCT
ihlr-25462	88	93	)	)	PUNCT
ihlr-25462	88	94	issued	issue	VERB
ihlr-25462	88	95	a	a	DET
ihlr-25462	88	96	federal	federal	ADJ
ihlr-25462	88	97	“	"	PUNCT
ihlr-25462	88	98	safe	safe	ADJ
ihlr-25462	88	99	importation	importation	NOUN
ihlr-25462	88	100	action	action	NOUN
ihlr-25462	88	101	plan	plan	NOUN
ihlr-25462	88	102	,	,	PUNCT
ihlr-25462	88	103	”	"	PUNCT
ihlr-25462	88	104	proposing	propose	VERB
ihlr-25462	88	105	two	two	NUM
ihlr-25462	88	106	pathways	pathway	NOUN
ihlr-25462	88	107	to	to	PART
ihlr-25462	88	108	allow	allow	VERB
ihlr-25462	88	109	for	for	ADP
ihlr-25462	88	110	the	the	DET
ihlr-25462	88	111	importation	importation	NOUN
ihlr-25462	88	112	of	of	ADP
ihlr-25462	88	113	drugs	drug	NOUN
ihlr-25462	88	114	from	from	ADP
ihlr-25462	88	115	canada.29	canada.29	NOUN
ihlr-25462	88	116	with	with	ADP
ihlr-25462	88	117	the	the	DET
ihlr-25462	88	118	proper	proper	ADJ
ihlr-25462	88	119	framework	framework	NOUN
ihlr-25462	88	120	for	for	ADP
ihlr-25462	88	121	drug	drug	NOUN
ihlr-25462	88	122	safety	safety	NOUN
ihlr-25462	88	123	assurances,30	assurances,30	VERB
ihlr-25462	88	124	legislative	legislative	ADJ
ihlr-25462	88	125	support	support	NOUN
ihlr-25462	88	126	from	from	ADP
ihlr-25462	88	127	individual	individual	ADJ
ihlr-25462	88	128	states,31	states,31	NOUN
ihlr-25462	88	129	and	and	CCONJ
ihlr-25462	88	130	the	the	DET
ihlr-25462	88	131	recent	recent	ADJ
ihlr-25462	88	132	u.s	u.s	PROPN
ihlr-25462	88	133	.	.	PROPN
ihlr-25462	88	134	supreme	supreme	PROPN
ihlr-25462	88	135	court	court	PROPN
ihlr-25462	88	136	decision	decision	NOUN
ihlr-25462	88	137	regarding	regard	VERB
ihlr-25462	88	138	international	international	ADJ
ihlr-25462	88	139	patent	patent	NOUN
ihlr-25462	88	140	exhaustion,32	exhaustion,32	VERB
ihlr-25462	88	141	the	the	DET
ihlr-25462	88	142	necessary	necessary	ADJ
ihlr-25462	88	143	logistics	logistic	NOUN
ihlr-25462	88	144	of	of	ADP
ihlr-25462	88	145	parallel	parallel	ADJ
ihlr-25462	88	146	importation	importation	NOUN
ihlr-25462	88	147	are	be	AUX
ihlr-25462	88	148	increasing	increase	VERB
ihlr-25462	88	149	in	in	ADP
ihlr-25462	88	150	probability	probability	NOUN
ihlr-25462	88	151	.	.	PUNCT
ihlr-25462	89	1	healthcare	healthcare	PROPN
ihlr-25462	89	2	/	/	SYM
ihlr-25462	89	3	report/2015/09/18/121153	report/2015/09/18/121153	PROPN
ihlr-25462	89	4	/	/	SYM
ihlr-25462	89	5	enough	enough	ADJ
ihlr-25462	89	6	-	-	PUNCT
ihlr-25462	89	7	is	be	AUX
ihlr-25462	89	8	-	-	PUNCT
ihlr-25462	89	9	enough/	enough/	PROPN
ihlr-25462	89	10	[	[	X
ihlr-25462	89	11	https://perma.cc/884m-yqwk	https://perma.cc/884m-yqwk	X
ihlr-25462	89	12	]	]	X
ihlr-25462	89	13	.	.	PUNCT
ihlr-25462	90	1	24	24	NUM
ihlr-25462	90	2	.	.	PUNCT
ihlr-25462	91	1	patented	patent	VERB
ihlr-25462	91	2	medicines	medicine	NOUN
ihlr-25462	91	3	prices	price	NOUN
ihlr-25462	91	4	review	review	VERB
ihlr-25462	91	5	board	board	NOUN
ihlr-25462	91	6	,	,	PUNCT
ihlr-25462	91	7	gov’t	gov’t	X
ihlr-25462	91	8	can	can	AUX
ihlr-25462	91	9	.	.	PUNCT
ihlr-25462	91	10	,	,	PUNCT
ihlr-25462	91	11	https://www.canada.ca/	https://www.canada.ca/	PROPN
ihlr-25462	91	12	en	en	X
ihlr-25462	91	13	/	/	SYM
ihlr-25462	91	14	patented	patent	VERB
ihlr-25462	91	15	-	-	PUNCT
ihlr-25462	91	16	medicine	medicine	NOUN
ihlr-25462	91	17	-	-	PUNCT
ihlr-25462	91	18	prices	price	NOUN
ihlr-25462	91	19	-	-	PUNCT
ihlr-25462	91	20	review.html	review.html	NOUN
ihlr-25462	91	21	[	[	X
ihlr-25462	91	22	https://perma.cc/r5ql-gkya	https://perma.cc/r5ql-gkya	NOUN
ihlr-25462	91	23	]	]	X
ihlr-25462	91	24	(	(	PUNCT
ihlr-25462	91	25	last	last	ADV
ihlr-25462	91	26	visited	visit	VERB
ihlr-25462	91	27	mar	mar	PROPN
ihlr-25462	91	28	.	.	PROPN
ihlr-25462	91	29	14	14	NUM
ihlr-25462	91	30	,	,	PUNCT
ihlr-25462	91	31	2021	2021	NUM
ihlr-25462	91	32	)	)	PUNCT
ihlr-25462	91	33	.	.	PUNCT
ihlr-25462	92	1	25	25	NUM
ihlr-25462	92	2	.	.	PUNCT
ihlr-25462	92	3	patented	patent	VERB
ihlr-25462	92	4	meds	med	NOUN
ihlr-25462	92	5	.	.	PUNCT
ihlr-25462	93	1	prices	price	NOUN
ihlr-25462	93	2	review	review	VERB
ihlr-25462	93	3	bd	bd	PROPN
ihlr-25462	93	4	.	.	PROPN
ihlr-25462	93	5	,	,	PUNCT
ihlr-25462	93	6	gov’t	gov’t	NOUN
ihlr-25462	93	7	of	of	ADP
ihlr-25462	93	8	can	can	AUX
ihlr-25462	93	9	.	.	PUNCT
ihlr-25462	93	10	,	,	PUNCT
ihlr-25462	93	11	compendium	compendium	NOUN
ihlr-25462	93	12	of	of	ADP
ihlr-25462	93	13	policies	policy	NOUN
ihlr-25462	93	14	,	,	PUNCT
ihlr-25462	93	15	guidelines	guideline	NOUN
ihlr-25462	93	16	and	and	CCONJ
ihlr-25462	93	17	procedures	procedure	NOUN
ihlr-25462	93	18	45	45	NUM
ihlr-25462	93	19	(	(	PUNCT
ihlr-25462	93	20	2017	2017	NUM
ihlr-25462	93	21	)	)	PUNCT
ihlr-25462	93	22	,	,	PUNCT
ihlr-25462	93	23	http://www.pmprb-cepmb.gc.ca/view.asp?ccid=492	http://www.pmprb-cepmb.gc.ca/view.asp?ccid=492	PROPN
ihlr-25462	93	24	#	#	NOUN
ihlr-25462	93	25	1645	1645	NUM
ihlr-25462	93	26	[	[	X
ihlr-25462	93	27	https://perma.cc/h6dp-6k9j#1645	https://perma.cc/h6dp-6k9j#1645	NOUN
ihlr-25462	93	28	]	]	X
ihlr-25462	93	29	(	(	PUNCT
ihlr-25462	93	30	stating	state	VERB
ihlr-25462	93	31	that	that	SCONJ
ihlr-25462	93	32	the	the	DET
ihlr-25462	93	33	price	price	NOUN
ihlr-25462	93	34	of	of	ADP
ihlr-25462	93	35	an	an	DET
ihlr-25462	93	36	existing	exist	VERB
ihlr-25462	93	37	patenting	patenting	NOUN
ihlr-25462	93	38	drug	drug	NOUN
ihlr-25462	93	39	can	can	AUX
ihlr-25462	93	40	not	not	PART
ihlr-25462	93	41	increase	increase	VERB
ihlr-25462	93	42	by	by	ADP
ihlr-25462	93	43	more	more	ADJ
ihlr-25462	93	44	than	than	ADP
ihlr-25462	93	45	the	the	DET
ihlr-25462	93	46	consumer	consumer	NOUN
ihlr-25462	93	47	price	price	NOUN
ihlr-25462	93	48	index	index	NOUN
ihlr-25462	93	49	)	)	PUNCT
ihlr-25462	93	50	.	.	PUNCT
ihlr-25462	94	1	26	26	NUM
ihlr-25462	94	2	.	.	X
ihlr-25462	95	1	brad	brad	PROPN
ihlr-25462	95	2	millson	millson	PROPN
ihlr-25462	95	3	et	et	PROPN
ihlr-25462	95	4	al	al	PROPN
ihlr-25462	95	5	.	.	PROPN
ihlr-25462	95	6	,	,	PUNCT
ihlr-25462	95	7	innovative	innovative	ADJ
ihlr-25462	95	8	meds	med	NOUN
ihlr-25462	95	9	.	.	PUNCT
ihlr-25462	96	1	can	can	AUX
ihlr-25462	96	2	.	.	PUNCT
ihlr-25462	96	3	,	,	PUNCT
ihlr-25462	96	4	access	access	NOUN
ihlr-25462	96	5	to	to	ADP
ihlr-25462	96	6	new	new	ADJ
ihlr-25462	96	7	medicines	medicine	NOUN
ihlr-25462	96	8	in	in	ADP
ihlr-25462	96	9	public	public	ADJ
ihlr-25462	96	10	drug	drug	NOUN
ihlr-25462	96	11	plans	plan	NOUN
ihlr-25462	96	12	:	:	PUNCT
ihlr-25462	96	13	canada	canada	PROPN
ihlr-25462	96	14	and	and	CCONJ
ihlr-25462	96	15	comparable	comparable	ADJ
ihlr-25462	96	16	countries	country	NOUN
ihlr-25462	96	17	23	23	NUM
ihlr-25462	96	18	(	(	PUNCT
ihlr-25462	96	19	2016	2016	NUM
ihlr-25462	96	20	)	)	PUNCT
ihlr-25462	96	21	,	,	PUNCT
ihlr-25462	96	22	http://innovativemedicines	http://innovativemedicines	X
ihlr-25462	96	23	.	.	PUNCT
ihlr-25462	97	1	ca	can	AUX
ihlr-25462	97	2	/	/	SYM
ihlr-25462	97	3	wp	wp	NOUN
ihlr-25462	97	4	-	-	PUNCT
ihlr-25462	97	5	content	content	NOUN
ihlr-25462	97	6	/	/	SYM
ihlr-25462	97	7	uploads/2016/05/20160524_access_to_medicines_report_en_web.pdf	uploads/2016/05/20160524_access_to_medicines_report_en_web.pdf	NOUN
ihlr-25462	98	1	[	[	X
ihlr-25462	98	2	https://perma.cc/u6mv-z9rq	https://perma.cc/u6mv-z9rq	NOUN
ihlr-25462	98	3	]	]	X
ihlr-25462	98	4	.	.	PUNCT
ihlr-25462	99	1	in	in	ADP
ihlr-25462	99	2	a	a	DET
ihlr-25462	99	3	2016	2016	NUM
ihlr-25462	99	4	report	report	NOUN
ihlr-25462	99	5	by	by	ADP
ihlr-25462	99	6	innovative	innovative	ADJ
ihlr-25462	99	7	medicines	medicine	NOUN
ihlr-25462	99	8	canada	canada	PROPN
ihlr-25462	99	9	,	,	PUNCT
ihlr-25462	99	10	comparing	compare	VERB
ihlr-25462	99	11	canada	canada	PROPN
ihlr-25462	99	12	to	to	ADP
ihlr-25462	99	13	the	the	DET
ihlr-25462	99	14	twenty	twenty	NUM
ihlr-25462	99	15	highest	high	ADJ
ihlr-25462	99	16	gdp	gdp	NOUN
ihlr-25462	99	17	nations	nation	NOUN
ihlr-25462	99	18	,	,	PUNCT
ihlr-25462	99	19	canada	canada	PROPN
ihlr-25462	99	20	ranked	rank	VERB
ihlr-25462	99	21	eighteen	eighteen	NUM
ihlr-25462	99	22	out	out	ADP
ihlr-25462	99	23	of	of	ADP
ihlr-25462	99	24	twenty	twenty	NUM
ihlr-25462	99	25	,	,	PUNCT
ihlr-25462	99	26	with	with	ADP
ihlr-25462	99	27	only	only	ADV
ihlr-25462	99	28	37	37	NUM
ihlr-25462	99	29	%	%	NOUN
ihlr-25462	99	30	of	of	ADP
ihlr-25462	99	31	new	new	ADJ
ihlr-25462	99	32	medicines	medicine	NOUN
ihlr-25462	99	33	being	be	AUX
ihlr-25462	99	34	reimbursed	reimburse	VERB
ihlr-25462	99	35	across	across	ADP
ihlr-25462	99	36	the	the	DET
ihlr-25462	99	37	country	country	NOUN
ihlr-25462	99	38	.	.	PUNCT
ihlr-25462	100	1	i	i	PRON
ihlr-25462	100	2	d.	d.	PROPN
ihlr-25462	100	3	at	at	ADP
ihlr-25462	100	4	5	5	NUM
ihlr-25462	100	5	.	.	PUNCT
ihlr-25462	101	1	canada	canada	PROPN
ihlr-25462	101	2	also	also	ADV
ihlr-25462	101	3	ranked	rank	VERB
ihlr-25462	101	4	low	low	ADJ
ihlr-25462	101	5	for	for	ADP
ihlr-25462	101	6	the	the	DET
ihlr-25462	101	7	length	length	NOUN
ihlr-25462	101	8	of	of	ADP
ihlr-25462	101	9	time	time	NOUN
ihlr-25462	101	10	before	before	SCONJ
ihlr-25462	101	11	reimbursement	reimbursement	NOUN
ihlr-25462	101	12	was	be	AUX
ihlr-25462	101	13	granted	grant	VERB
ihlr-25462	101	14	in	in	ADP
ihlr-25462	101	15	public	public	ADJ
ihlr-25462	101	16	drug	drug	NOUN
ihlr-25462	101	17	plans	plan	NOUN
ihlr-25462	101	18	,	,	PUNCT
ihlr-25462	101	19	taking	take	VERB
ihlr-25462	101	20	on	on	ADP
ihlr-25462	101	21	average	average	ADJ
ihlr-25462	101	22	449	449	NUM
ihlr-25462	101	23	days	day	NOUN
ihlr-25462	101	24	from	from	ADP
ihlr-25462	101	25	new	new	ADJ
ihlr-25462	101	26	drug	drug	NOUN
ihlr-25462	101	27	approval	approval	NOUN
ihlr-25462	101	28	to	to	PART
ihlr-25462	101	29	reimbursement	reimbursement	NOUN
ihlr-25462	101	30	.	.	PUNCT
ihlr-25462	102	1	i	i	PRON
ihlr-25462	102	2	d.	d.	PROPN
ihlr-25462	102	3	at	at	ADP
ihlr-25462	102	4	6	6	NUM
ihlr-25462	102	5	.	.	NOUN
ihlr-25462	102	6	27	27	NUM
ihlr-25462	102	7	.	.	PUNCT
ihlr-25462	103	1	see	see	VERB
ihlr-25462	103	2	,	,	PUNCT
ihlr-25462	103	3	e.g.	e.g.	ADV
ihlr-25462	103	4	,	,	PUNCT
ihlr-25462	103	5	monali	monali	PROPN
ihlr-25462	103	6	bhosle	bhosle	PROPN
ihlr-25462	103	7	&	&	CCONJ
ihlr-25462	103	8	rajesh	rajesh	PROPN
ihlr-25462	103	9	balkrishnan	balkrishnan	PROPN
ihlr-25462	103	10	,	,	PUNCT
ihlr-25462	103	11	drug	drug	NOUN
ihlr-25462	103	12	reimportation	reimportation	NOUN
ihlr-25462	103	13	practices	practice	NOUN
ihlr-25462	103	14	in	in	ADP
ihlr-25462	103	15	the	the	DET
ihlr-25462	103	16	united	united	PROPN
ihlr-25462	103	17	states	states	PROPN
ihlr-25462	103	18	,	,	PUNCT
ihlr-25462	103	19	3	3	NUM
ihlr-25462	103	20	therapeutics	therapeutic	NOUN
ihlr-25462	103	21	&	&	CCONJ
ihlr-25462	103	22	clinical	clinical	ADJ
ihlr-25462	103	23	risk	risk	NOUN
ihlr-25462	103	24	mgmt	mgmt	NOUN
ihlr-25462	103	25	.	.	PUNCT
ihlr-25462	104	1	41	41	NUM
ihlr-25462	104	2	(	(	PUNCT
ihlr-25462	104	3	2007	2007	NUM
ihlr-25462	104	4	)	)	PUNCT
ihlr-25462	104	5	.	.	PUNCT
ihlr-25462	105	1	28	28	NUM
ihlr-25462	105	2	.	.	PUNCT
ihlr-25462	106	1	see	see	VERB
ihlr-25462	106	2	,	,	PUNCT
ihlr-25462	106	3	e.g.	e.g.	ADV
ihlr-25462	106	4	,	,	PUNCT
ihlr-25462	106	5	i	i	PRON
ihlr-25462	106	6	d.	d.	PROPN
ihlr-25462	106	7	29	29	NUM
ihlr-25462	106	8	.	.	PUNCT
ihlr-25462	107	1	safe	safe	ADJ
ihlr-25462	107	2	importation	importation	NOUN
ihlr-25462	107	3	action	action	NOUN
ihlr-25462	107	4	plan	plan	NOUN
ihlr-25462	107	5	,	,	PUNCT
ihlr-25462	107	6	supra	supra	PROPN
ihlr-25462	107	7	note	note	NOUN
ihlr-25462	107	8	11	11	NUM
ihlr-25462	107	9	.	.	SYM
ihlr-25462	107	10	30	30	NUM
ihlr-25462	107	11	.	.	PUNCT
ihlr-25462	108	1	see	see	VERB
ihlr-25462	108	2	o’donnell	o’donnell	PROPN
ihlr-25462	108	3	,	,	PUNCT
ihlr-25462	108	4	supra	supra	PROPN
ihlr-25462	108	5	note	note	PROPN
ihlr-25462	108	6	11	11	NUM
ihlr-25462	108	7	(	(	PUNCT
ihlr-25462	108	8	discussing	discuss	VERB
ihlr-25462	108	9	the	the	DET
ihlr-25462	108	10	necessary	necessary	ADJ
ihlr-25462	108	11	safety	safety	NOUN
ihlr-25462	108	12	frameworks	framework	NOUN
ihlr-25462	108	13	for	for	ADP
ihlr-25462	108	14	safe	safe	ADJ
ihlr-25462	108	15	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	108	16	drug	drug	NOUN
ihlr-25462	108	17	importation	importation	NOUN
ihlr-25462	108	18	)	)	PUNCT
ihlr-25462	108	19	.	.	PUNCT
ihlr-25462	109	1	31	31	NUM
ihlr-25462	109	2	.	.	PUNCT
ihlr-25462	109	3	steven	steven	PROPN
ihlr-25462	109	4	findlay	findlay	PROPN
ihlr-25462	109	5	,	,	PUNCT
ihlr-25462	109	6	states	state	NOUN
ihlr-25462	109	7	pass	pass	VERB
ihlr-25462	109	8	record	record	NOUN
ihlr-25462	109	9	number	number	NOUN
ihlr-25462	109	10	of	of	ADP
ihlr-25462	109	11	laws	law	NOUN
ihlr-25462	109	12	to	to	PART
ihlr-25462	109	13	reel	reel	VERB
ihlr-25462	109	14	in	in	ADP
ihlr-25462	109	15	drug	drug	NOUN
ihlr-25462	109	16	prices	price	NOUN
ihlr-25462	109	17	,	,	PUNCT
ihlr-25462	109	18	kaiser	kaiser	PROPN
ihlr-25462	109	19	health	health	PROPN
ihlr-25462	109	20	news	news	PROPN
ihlr-25462	109	21	(	(	PUNCT
ihlr-25462	109	22	sept	sept	PROPN
ihlr-25462	109	23	.	.	PROPN
ihlr-25462	109	24	9	9	NUM
ihlr-25462	109	25	,	,	PUNCT
ihlr-25462	109	26	2019	2019	NUM
ihlr-25462	109	27	)	)	PUNCT
ihlr-25462	109	28	,	,	PUNCT
ihlr-25462	109	29	https://khn.org/news/states-pass-record-number-of-laws-to-reel-indrug-prices/	https://khn.org/news/states-pass-record-number-of-laws-to-reel-indrug-prices/	ADV
ihlr-25462	109	30	[	[	X
ihlr-25462	109	31	https://perma.cc/q7ps-t92e	https://perma.cc/q7ps-t92e	X
ihlr-25462	109	32	]	]	X
ihlr-25462	109	33	(	(	PUNCT
ihlr-25462	109	34	stating	state	VERB
ihlr-25462	109	35	that	that	SCONJ
ihlr-25462	109	36	four	four	NUM
ihlr-25462	109	37	states	state	NOUN
ihlr-25462	109	38	–	–	PUNCT
ihlr-25462	109	39	colorado	colorado	PROPN
ihlr-25462	109	40	,	,	PUNCT
ihlr-25462	109	41	florida	florida	PROPN
ihlr-25462	109	42	,	,	PUNCT
ihlr-25462	109	43	maine	maine	PROPN
ihlr-25462	109	44	,	,	PUNCT
ihlr-25462	109	45	and	and	CCONJ
ihlr-25462	109	46	vermont	vermont	PROPN
ihlr-25462	109	47	–	–	PUNCT
ihlr-25462	109	48	established	establish	VERB
ihlr-25462	109	49	protocols	protocol	NOUN
ihlr-25462	109	50	in	in	ADP
ihlr-25462	109	51	2019	2019	NUM
ihlr-25462	109	52	to	to	PART
ihlr-25462	109	53	begin	begin	VERB
ihlr-25462	109	54	the	the	DET
ihlr-25462	109	55	process	process	NOUN
ihlr-25462	109	56	of	of	ADP
ihlr-25462	109	57	importing	import	VERB
ihlr-25462	109	58	prescription	prescription	NOUN
ihlr-25462	109	59	drugs	drug	NOUN
ihlr-25462	109	60	from	from	ADP
ihlr-25462	109	61	canada	canada	PROPN
ihlr-25462	109	62	)	)	PUNCT
ihlr-25462	109	63	.	.	PUNCT
ihlr-25462	110	1	32	32	NUM
ihlr-25462	110	2	.	.	PUNCT
ihlr-25462	111	1	see	see	VERB
ihlr-25462	111	2	impression	impression	NOUN
ihlr-25462	111	3	prods	prod	NOUN
ihlr-25462	111	4	.	.	PUNCT
ihlr-25462	111	5	,	,	PUNCT
ihlr-25462	111	6	inc	inc	PROPN
ihlr-25462	111	7	.	.	PROPN
ihlr-25462	112	1	v.	v.	ADP
ihlr-25462	112	2	lexmark	lexmark	PROPN
ihlr-25462	112	3	int’l	int’l	NUM
ihlr-25462	112	4	,	,	PUNCT
ihlr-25462	112	5	inc	inc	PROPN
ihlr-25462	112	6	.	.	PROPN
ihlr-25462	112	7	,	,	PUNCT
ihlr-25462	112	8	137	137	NUM
ihlr-25462	112	9	s.	s.	PROPN
ihlr-25462	112	10	ct	ct	PROPN
ihlr-25462	112	11	.	.	PROPN
ihlr-25462	112	12	1523	1523	NUM
ihlr-25462	112	13	(	(	PUNCT
ihlr-25462	112	14	2017	2017	NUM
ihlr-25462	112	15	)	)	PUNCT
ihlr-25462	112	16	.	.	PUNCT
ihlr-25462	113	1	https://perma.cc/q7ps-t92e	https://perma.cc/q7ps-t92e	NOUN
ihlr-25462	113	2	402	402	NUM
ihlr-25462	113	3	indiana	indiana	PROPN
ihlr-25462	113	4	health	health	PROPN
ihlr-25462	113	5	law	law	PROPN
ihlr-25462	113	6	review	review	NOUN
ihlr-25462	114	1	[	[	X
ihlr-25462	114	2	vol	vol	NOUN
ihlr-25462	114	3	.	.	PROPN
ihlr-25462	114	4	18:397	18:397	NUM
ihlr-25462	114	5	b.	b.	PROPN
ihlr-25462	114	6	international	international	PROPN
ihlr-25462	114	7	patent	patent	NOUN
ihlr-25462	114	8	exhaustion	exhaustion	NOUN
ihlr-25462	114	9	&	&	CCONJ
ihlr-25462	114	10	the	the	DET
ihlr-25462	114	11	lexmark	lexmark	NOUN
ihlr-25462	114	12	decision	decision	NOUN
ihlr-25462	114	13	prior	prior	ADV
ihlr-25462	114	14	to	to	ADP
ihlr-25462	114	15	the	the	DET
ihlr-25462	114	16	lexmark	lexmark	NOUN
ihlr-25462	114	17	decision	decision	NOUN
ihlr-25462	114	18	,	,	PUNCT
ihlr-25462	114	19	even	even	ADV
ihlr-25462	114	20	if	if	SCONJ
ihlr-25462	114	21	the	the	DET
ihlr-25462	114	22	u.s	u.s	PROPN
ihlr-25462	114	23	.	.	PROPN
ihlr-25462	114	24	promulgated	promulgate	VERB
ihlr-25462	114	25	legislation	legislation	NOUN
ihlr-25462	114	26	that	that	PRON
ihlr-25462	114	27	allowed	allow	VERB
ihlr-25462	114	28	for	for	ADP
ihlr-25462	114	29	parallel	parallel	ADJ
ihlr-25462	114	30	drug	drug	NOUN
ihlr-25462	114	31	importation	importation	NOUN
ihlr-25462	114	32	,	,	PUNCT
ihlr-25462	114	33	the	the	DET
ihlr-25462	114	34	doctrine	doctrine	NOUN
ihlr-25462	114	35	of	of	ADP
ihlr-25462	114	36	patent	patent	NOUN
ihlr-25462	114	37	exhaustion	exhaustion	NOUN
ihlr-25462	114	38	would	would	AUX
ihlr-25462	114	39	have	have	AUX
ihlr-25462	114	40	precluded	preclude	VERB
ihlr-25462	114	41	the	the	DET
ihlr-25462	114	42	sale	sale	NOUN
ihlr-25462	114	43	of	of	ADP
ihlr-25462	114	44	these	these	DET
ihlr-25462	114	45	imported	import	VERB
ihlr-25462	114	46	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	114	47	drugs	drug	NOUN
ihlr-25462	114	48	in	in	ADP
ihlr-25462	114	49	the	the	DET
ihlr-25462	114	50	u.s.33	u.s.33	NOUN
ihlr-25462	114	51	the	the	DET
ihlr-25462	114	52	facts	fact	NOUN
ihlr-25462	114	53	and	and	CCONJ
ihlr-25462	114	54	issues	issue	NOUN
ihlr-25462	114	55	decided	decide	VERB
ihlr-25462	114	56	in	in	ADP
ihlr-25462	114	57	lexmark	lexmark	NOUN
ihlr-25462	114	58	are	be	AUX
ihlr-25462	114	59	thus	thus	ADV
ihlr-25462	114	60	instructive	instructive	ADJ
ihlr-25462	114	61	as	as	ADP
ihlr-25462	114	62	to	to	ADP
ihlr-25462	114	63	how	how	SCONJ
ihlr-25462	114	64	re	re	VERB
ihlr-25462	114	65	-	-	NOUN
ihlr-25462	114	66	importation	importation	ADJ
ihlr-25462	114	67	questions	question	NOUN
ihlr-25462	114	68	may	may	AUX
ihlr-25462	114	69	be	be	AUX
ihlr-25462	114	70	resolved	resolve	VERB
ihlr-25462	114	71	legally	legally	ADV
ihlr-25462	114	72	going	go	VERB
ihlr-25462	114	73	forward	forward	ADV
ihlr-25462	114	74	.	.	PUNCT
ihlr-25462	115	1	lexmark	lexmark	PROPN
ihlr-25462	115	2	international	international	PROPN
ihlr-25462	115	3	,	,	PUNCT
ihlr-25462	115	4	inc	inc	PROPN
ihlr-25462	115	5	.	.	PROPN
ihlr-25462	115	6	(	(	PUNCT
ihlr-25462	115	7	“	"	PUNCT
ihlr-25462	115	8	lexmark	lexmark	ADJ
ihlr-25462	115	9	international	international	NOUN
ihlr-25462	115	10	”	"	PUNCT
ihlr-25462	115	11	)	)	PUNCT
ihlr-25462	115	12	designed	design	VERB
ihlr-25462	115	13	,	,	PUNCT
ihlr-25462	115	14	manufactured	manufacture	VERB
ihlr-25462	115	15	,	,	PUNCT
ihlr-25462	115	16	and	and	CCONJ
ihlr-25462	115	17	sold	sell	VERB
ihlr-25462	115	18	toner	toner	NOUN
ihlr-25462	115	19	cartridges	cartridge	NOUN
ihlr-25462	115	20	to	to	ADP
ihlr-25462	115	21	customers	customer	NOUN
ihlr-25462	115	22	in	in	ADP
ihlr-25462	115	23	the	the	DET
ihlr-25462	115	24	u.s	u.s	PROPN
ihlr-25462	115	25	.	.	PROPN
ihlr-25462	115	26	and	and	CCONJ
ihlr-25462	115	27	globally.34	globally.34	PROPN
ihlr-25462	115	28	lexmark	lexmark	NOUN
ihlr-25462	115	29	international	international	PROPN
ihlr-25462	115	30	owned	own	VERB
ihlr-25462	115	31	several	several	ADJ
ihlr-25462	115	32	patents	patent	NOUN
ihlr-25462	115	33	that	that	PRON
ihlr-25462	115	34	covered	cover	VERB
ihlr-25462	115	35	components	component	NOUN
ihlr-25462	115	36	of	of	ADP
ihlr-25462	115	37	their	their	PRON
ihlr-25462	115	38	print	print	NOUN
ihlr-25462	115	39	cartridges	cartridge	NOUN
ihlr-25462	115	40	and	and	CCONJ
ihlr-25462	115	41	the	the	DET
ihlr-25462	115	42	manner	manner	NOUN
ihlr-25462	115	43	in	in	ADP
ihlr-25462	115	44	which	which	PRON
ihlr-25462	115	45	they	they	PRON
ihlr-25462	115	46	were	be	AUX
ihlr-25462	115	47	used.35	used.35	NOUN
ihlr-25462	115	48	when	when	SCONJ
ihlr-25462	115	49	toner	toner	NOUN
ihlr-25462	115	50	cartridges	cartridge	NOUN
ihlr-25462	115	51	ran	run	VERB
ihlr-25462	115	52	out	out	ADP
ihlr-25462	115	53	of	of	ADP
ihlr-25462	115	54	toner	toner	NOUN
ihlr-25462	115	55	,	,	PUNCT
ihlr-25462	115	56	they	they	PRON
ihlr-25462	115	57	could	could	AUX
ihlr-25462	115	58	be	be	AUX
ihlr-25462	115	59	refilled	refill	VERB
ihlr-25462	115	60	and	and	CCONJ
ihlr-25462	115	61	reused	reuse	VERB
ihlr-25462	115	62	again.36	again.36	NOUN
ihlr-25462	115	63	however	however	ADV
ihlr-25462	115	64	,	,	PUNCT
ihlr-25462	115	65	this	this	PRON
ihlr-25462	115	66	created	create	VERB
ihlr-25462	115	67	an	an	DET
ihlr-25462	115	68	opportunity	opportunity	NOUN
ihlr-25462	115	69	for	for	ADP
ihlr-25462	115	70	other	other	ADJ
ihlr-25462	115	71	companies	company	NOUN
ihlr-25462	115	72	–	–	PUNCT
ihlr-25462	115	73	known	know	VERB
ihlr-25462	115	74	as	as	ADP
ihlr-25462	115	75	remanufacturers	remanufacturer	NOUN
ihlr-25462	115	76	–	–	PUNCT
ihlr-25462	115	77	to	to	PART
ihlr-25462	115	78	acquire	acquire	VERB
ihlr-25462	115	79	empty	empty	ADJ
ihlr-25462	115	80	lexmark	lexmark	ADJ
ihlr-25462	115	81	international	international	ADJ
ihlr-25462	115	82	cartridges	cartridge	NOUN
ihlr-25462	115	83	from	from	ADP
ihlr-25462	115	84	purchasers	purchaser	NOUN
ihlr-25462	115	85	in	in	ADP
ihlr-25462	115	86	the	the	DET
ihlr-25462	115	87	u.s	u.s	PROPN
ihlr-25462	115	88	.	.	PROPN
ihlr-25462	115	89	and	and	CCONJ
ihlr-25462	115	90	abroad	abroad	ADV
ihlr-25462	115	91	,	,	PUNCT
ihlr-25462	115	92	refill	refill	VERB
ihlr-25462	115	93	them	they	PRON
ihlr-25462	115	94	with	with	ADP
ihlr-25462	115	95	toner	toner	NOUN
ihlr-25462	115	96	,	,	PUNCT
ihlr-25462	115	97	and	and	CCONJ
ihlr-25462	115	98	then	then	ADV
ihlr-25462	115	99	resell	resell	VERB
ihlr-25462	115	100	them	they	PRON
ihlr-25462	115	101	at	at	ADP
ihlr-25462	115	102	a	a	DET
ihlr-25462	115	103	lower	low	ADJ
ihlr-25462	115	104	price	price	NOUN
ihlr-25462	115	105	than	than	SCONJ
ihlr-25462	115	106	the	the	DET
ihlr-25462	115	107	ones	one	NOUN
ihlr-25462	115	108	lexmark	lexmark	VERB
ihlr-25462	115	109	international	international	ADJ
ihlr-25462	115	110	put	put	VERB
ihlr-25462	115	111	on	on	ADP
ihlr-25462	115	112	shelves.37	shelves.37	VERB
ihlr-25462	115	113	in	in	ADP
ihlr-25462	115	114	an	an	DET
ihlr-25462	115	115	attempt	attempt	NOUN
ihlr-25462	115	116	to	to	PART
ihlr-25462	115	117	combat	combat	VERB
ihlr-25462	115	118	this	this	DET
ihlr-25462	115	119	problem	problem	NOUN
ihlr-25462	115	120	,	,	PUNCT
ihlr-25462	115	121	lexmark	lexmark	ADJ
ihlr-25462	115	122	international	international	PROPN
ihlr-25462	115	123	structured	structure	VERB
ihlr-25462	115	124	its	its	PRON
ihlr-25462	115	125	sales	sale	NOUN
ihlr-25462	115	126	in	in	ADP
ihlr-25462	115	127	a	a	DET
ihlr-25462	115	128	way	way	NOUN
ihlr-25462	115	129	that	that	PRON
ihlr-25462	115	130	encouraged	encourage	VERB
ihlr-25462	115	131	customers	customer	NOUN
ihlr-25462	115	132	to	to	PART
ihlr-25462	115	133	return	return	VERB
ihlr-25462	115	134	their	their	PRON
ihlr-25462	115	135	empty	empty	ADJ
ihlr-25462	115	136	cartridges	cartridge	NOUN
ihlr-25462	115	137	back	back	ADV
ihlr-25462	115	138	to	to	ADP
ihlr-25462	115	139	them.38	them.38	PROPN
ihlr-25462	115	140	one	one	NUM
ihlr-25462	115	141	means	mean	NOUN
ihlr-25462	115	142	by	by	ADP
ihlr-25462	115	143	which	which	PRON
ihlr-25462	115	144	lexmark	lexmark	NOUN
ihlr-25462	115	145	international	international	PROPN
ihlr-25462	115	146	attempted	attempt	VERB
ihlr-25462	115	147	to	to	PART
ihlr-25462	115	148	do	do	VERB
ihlr-25462	115	149	this	this	PRON
ihlr-25462	115	150	was	be	AUX
ihlr-25462	115	151	to	to	PART
ihlr-25462	115	152	incentivize	incentivize	VERB
ihlr-25462	115	153	its	its	PRON
ihlr-25462	115	154	customers	customer	NOUN
ihlr-25462	115	155	to	to	PART
ihlr-25462	115	156	purchase	purchase	VERB
ihlr-25462	115	157	a	a	DET
ihlr-25462	115	158	cartridge	cartridge	NOUN
ihlr-25462	115	159	at	at	ADP
ihlr-25462	115	160	a	a	DET
ihlr-25462	115	161	discount	discount	NOUN
ihlr-25462	115	162	through	through	ADP
ihlr-25462	115	163	a	a	DET
ihlr-25462	115	164	“	"	PUNCT
ihlr-25462	115	165	return	return	NOUN
ihlr-25462	115	166	program	program	NOUN
ihlr-25462	115	167	.	.	PUNCT
ihlr-25462	116	1	”39	”39	PROPN
ihlr-25462	116	2	a	a	DET
ihlr-25462	116	3	customer	customer	NOUN
ihlr-25462	116	4	who	who	PRON
ihlr-25462	116	5	bought	buy	VERB
ihlr-25462	116	6	a	a	DET
ihlr-25462	116	7	cartridge	cartridge	NOUN
ihlr-25462	116	8	through	through	ADP
ihlr-25462	116	9	this	this	DET
ihlr-25462	116	10	program	program	NOUN
ihlr-25462	116	11	still	still	ADV
ihlr-25462	116	12	owned	own	VERB
ihlr-25462	116	13	the	the	DET
ihlr-25462	116	14	cartridge	cartridge	NOUN
ihlr-25462	116	15	,	,	PUNCT
ihlr-25462	116	16	but	but	CCONJ
ihlr-25462	116	17	,	,	PUNCT
ihlr-25462	116	18	“	"	PUNCT
ihlr-25462	116	19	in	in	ADP
ihlr-25462	116	20	exchange	exchange	NOUN
ihlr-25462	116	21	for	for	ADP
ihlr-25462	116	22	the	the	DET
ihlr-25462	116	23	lower	low	ADJ
ihlr-25462	116	24	price	price	NOUN
ihlr-25462	116	25	,	,	PUNCT
ihlr-25462	116	26	sign[ed	sign[ed	PROPN
ihlr-25462	116	27	]	]	X
ihlr-25462	116	28	a	a	DET
ihlr-25462	116	29	contract	contract	NOUN
ihlr-25462	116	30	agreeing	agree	VERB
ihlr-25462	116	31	to	to	PART
ihlr-25462	116	32	use	use	VERB
ihlr-25462	116	33	it	it	PRON
ihlr-25462	116	34	only	only	ADV
ihlr-25462	116	35	once	once	ADV
ihlr-25462	116	36	and	and	CCONJ
ihlr-25462	116	37	to	to	PART
ihlr-25462	116	38	refrain	refrain	VERB
ihlr-25462	116	39	from	from	ADP
ihlr-25462	116	40	transferring	transfer	VERB
ihlr-25462	116	41	the	the	DET
ihlr-25462	116	42	empty	empty	ADJ
ihlr-25462	116	43	cartridge	cartridge	NOUN
ihlr-25462	116	44	to	to	ADP
ihlr-25462	116	45	anyone	anyone	PRON
ihlr-25462	116	46	but	but	CCONJ
ihlr-25462	116	47	lexmark	lexmark	VERB
ihlr-25462	116	48	[	[	PUNCT
ihlr-25462	116	49	international].”40	international].”40	VERB
ihlr-25462	116	50	further	far	ADV
ihlr-25462	116	51	,	,	PUNCT
ihlr-25462	116	52	lexmark	lexmark	ADJ
ihlr-25462	116	53	international	international	ADJ
ihlr-25462	116	54	“	"	PUNCT
ihlr-25462	116	55	install[ed	install[ed	PROPN
ihlr-25462	116	56	]	]	PUNCT
ihlr-25462	116	57	a	a	DET
ihlr-25462	116	58	microchip	microchip	NOUN
ihlr-25462	116	59	on	on	ADP
ihlr-25462	116	60	each	each	DET
ihlr-25462	116	61	return	return	NOUN
ihlr-25462	116	62	program	program	NOUN
ihlr-25462	116	63	cartridge	cartridge	NOUN
ihlr-25462	116	64	”	"	PUNCT
ihlr-25462	116	65	that	that	PRON
ihlr-25462	116	66	would	would	AUX
ihlr-25462	116	67	further	far	ADV
ihlr-25462	116	68	dissuade	dissuade	VERB
ihlr-25462	116	69	customers	customer	NOUN
ihlr-25462	116	70	to	to	PART
ihlr-25462	116	71	reuse	reuse	VERB
ihlr-25462	116	72	them.41	them.41	NOUN
ihlr-25462	116	73	despite	despite	SCONJ
ihlr-25462	116	74	these	these	DET
ihlr-25462	116	75	efforts	effort	NOUN
ihlr-25462	116	76	,	,	PUNCT
ihlr-25462	116	77	however	however	ADV
ihlr-25462	116	78	,	,	PUNCT
ihlr-25462	116	79	remanufacturers	remanufacturer	NOUN
ihlr-25462	116	80	continued	continue	VERB
ihlr-25462	116	81	to	to	PART
ihlr-25462	116	82	successfully	successfully	ADV
ihlr-25462	116	83	buy	buy	VERB
ihlr-25462	116	84	and	and	CCONJ
ihlr-25462	116	85	refill	refill	NOUN
ihlr-25462	116	86	lexmark	lexmark	NOUN
ihlr-25462	116	87	international	international	ADJ
ihlr-25462	116	88	cartridges	cartridge	NOUN
ihlr-25462	116	89	,	,	PUNCT
ihlr-25462	116	90	albeit	albeit	SCONJ
ihlr-25462	116	91	more	more	ADJ
ihlr-25462	116	92	creatively.42	creatively.42	NOUN
ihlr-25462	116	93	one	one	NUM
ihlr-25462	116	94	issue	issue	NOUN
ihlr-25462	116	95	was	be	AUX
ihlr-25462	116	96	that	that	SCONJ
ihlr-25462	116	97	the	the	DET
ihlr-25462	116	98	company	company	NOUN
ihlr-25462	116	99	’s	’s	PART
ihlr-25462	116	100	“	"	PUNCT
ihlr-25462	116	101	contractual	contractual	ADJ
ihlr-25462	116	102	single	single	ADJ
ihlr-25462	116	103	-	-	PUNCT
ihlr-25462	116	104	use	use	NOUN
ihlr-25462	116	105	/	/	SYM
ihlr-25462	116	106	no	no	DET
ihlr-25462	116	107	-	-	PUNCT
ihlr-25462	116	108	resale	resale	NOUN
ihlr-25462	116	109	agreements	agreement	NOUN
ihlr-25462	116	110	were	be	AUX
ihlr-25462	116	111	with	with	ADP
ihlr-25462	116	112	the	the	DET
ihlr-25462	116	113	initial	initial	ADJ
ihlr-25462	116	114	customers	customer	NOUN
ihlr-25462	116	115	,	,	PUNCT
ihlr-25462	116	116	not	not	PART
ihlr-25462	116	117	with	with	ADP
ihlr-25462	116	118	downstream	downstream	ADJ
ihlr-25462	116	119	purchasers	purchaser	NOUN
ihlr-25462	116	120	like	like	ADP
ihlr-25462	116	121	remanufacturers	remanufacturer	NOUN
ihlr-25462	116	122	.	.	PUNCT
ihlr-25462	117	1	”43	”43	PROPN
ihlr-25462	117	2	the	the	DET
ihlr-25462	117	3	lexmark	lexmark	NOUN
ihlr-25462	117	4	decision	decision	NOUN
ihlr-25462	117	5	thus	thus	ADV
ihlr-25462	117	6	presented	present	VERB
ihlr-25462	117	7	one	one	NUM
ihlr-25462	117	8	major	major	ADJ
ihlr-25462	117	9	question	question	NOUN
ihlr-25462	117	10	about	about	ADP
ihlr-25462	117	11	the	the	DET
ihlr-25462	117	12	scope	scope	NOUN
ihlr-25462	117	13	of	of	ADP
ihlr-25462	117	14	the	the	DET
ihlr-25462	117	15	patent	patent	NOUN
ihlr-25462	117	16	exhaustion	exhaustion	NOUN
ihlr-25462	117	17	doctrine	doctrine	NOUN
ihlr-25462	117	18	that	that	PRON
ihlr-25462	117	19	will	will	AUX
ihlr-25462	117	20	become	become	VERB
ihlr-25462	117	21	important	important	ADJ
ihlr-25462	117	22	to	to	ADP
ihlr-25462	117	23	this	this	DET
ihlr-25462	117	24	note	note	NOUN
ihlr-25462	117	25	’s	’s	PART
ihlr-25462	117	26	discussion	discussion	NOUN
ihlr-25462	117	27	of	of	ADP
ihlr-25462	117	28	the	the	DET
ihlr-25462	117	29	re	re	NOUN
ihlr-25462	117	30	-	-	NOUN
ihlr-25462	117	31	importation	importation	NOUN
ihlr-25462	117	32	of	of	ADP
ihlr-25462	117	33	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	117	34	later	later	ADV
ihlr-25462	117	35	:	:	PUNCT
ihlr-25462	117	36	whether	whether	SCONJ
ihlr-25462	117	37	patent	patent	NOUN
ihlr-25462	117	38	rights	right	NOUN
ihlr-25462	117	39	33	33	NUM
ihlr-25462	117	40	.	.	PUNCT
ihlr-25462	118	1	see	see	VERB
ihlr-25462	118	2	generally	generally	ADV
ihlr-25462	118	3	jazz	jazz	PROPN
ihlr-25462	118	4	photo	photo	PROPN
ihlr-25462	118	5	corp	corp	PROPN
ihlr-25462	118	6	.	.	PROPN
ihlr-25462	119	1	v.	v.	ADP
ihlr-25462	119	2	int’l	int’l	NUM
ihlr-25462	119	3	trade	trade	NOUN
ihlr-25462	119	4	comm’n	comm’n	NOUN
ihlr-25462	119	5	,	,	PUNCT
ihlr-25462	119	6	264	264	NUM
ihlr-25462	119	7	f.3d	f.3d	NUM
ihlr-25462	119	8	1094	1094	NUM
ihlr-25462	119	9	(	(	PUNCT
ihlr-25462	119	10	d.c	d.c	PROPN
ihlr-25462	119	11	.	.	PROPN
ihlr-25462	119	12	cir	cir	PROPN
ihlr-25462	119	13	.	.	PROPN
ihlr-25462	119	14	2001	2001	NUM
ihlr-25462	119	15	)	)	PUNCT
ihlr-25462	119	16	;	;	PUNCT
ihlr-25462	119	17	see	see	VERB
ihlr-25462	119	18	generally	generally	ADV
ihlr-25462	119	19	quanta	quanta	PROPN
ihlr-25462	119	20	computer	computer	PROPN
ihlr-25462	119	21	,	,	PUNCT
ihlr-25462	119	22	inc	inc	PROPN
ihlr-25462	119	23	.	.	PROPN
ihlr-25462	120	1	v.	v.	ADP
ihlr-25462	120	2	lg	lg	NOUN
ihlr-25462	120	3	elecs	elec	NOUN
ihlr-25462	120	4	.	.	PUNCT
ihlr-25462	120	5	,	,	PUNCT
ihlr-25462	120	6	inc	inc	PROPN
ihlr-25462	120	7	.	.	PROPN
ihlr-25462	120	8	,	,	PUNCT
ihlr-25462	120	9	128	128	NUM
ihlr-25462	120	10	s.	s.	PROPN
ihlr-25462	120	11	ct	ct	PROPN
ihlr-25462	120	12	.	.	PUNCT
ihlr-25462	120	13	2109	2109	NUM
ihlr-25462	120	14	(	(	PUNCT
ihlr-25462	120	15	2008	2008	NUM
ihlr-25462	120	16	)	)	PUNCT
ihlr-25462	120	17	.	.	PUNCT
ihlr-25462	121	1	both	both	PRON
ihlr-25462	121	2	seemed	seem	VERB
ihlr-25462	121	3	to	to	PART
ihlr-25462	121	4	imply	imply	VERB
ihlr-25462	121	5	that	that	SCONJ
ihlr-25462	121	6	u.s	u.s	PROPN
ihlr-25462	121	7	.	.	PROPN
ihlr-25462	121	8	patent	patent	NOUN
ihlr-25462	121	9	rights	right	NOUN
ihlr-25462	121	10	were	be	AUX
ihlr-25462	121	11	not	not	PART
ihlr-25462	121	12	extinguished	extinguish	VERB
ihlr-25462	121	13	by	by	ADP
ihlr-25462	121	14	an	an	DET
ihlr-25462	121	15	international	international	ADJ
ihlr-25462	121	16	sale	sale	NOUN
ihlr-25462	121	17	.	.	PUNCT
ihlr-25462	122	1	34	34	NUM
ihlr-25462	122	2	.	.	PUNCT
ihlr-25462	123	1	impression	impression	NOUN
ihlr-25462	123	2	prods	prod	VERB
ihlr-25462	123	3	.	.	PUNCT
ihlr-25462	123	4	,	,	PUNCT
ihlr-25462	123	5	inc	inc	PROPN
ihlr-25462	123	6	.	.	PROPN
ihlr-25462	123	7	,	,	PUNCT
ihlr-25462	123	8	137	137	NUM
ihlr-25462	123	9	s.	s.	PROPN
ihlr-25462	123	10	ct	ct	PROPN
ihlr-25462	123	11	.	.	PUNCT
ihlr-25462	124	1	at	at	ADP
ihlr-25462	124	2	1529	1529	NUM
ihlr-25462	124	3	.	.	PUNCT
ihlr-25462	125	1	35	35	NUM
ihlr-25462	125	2	.	.	PUNCT
ihlr-25462	126	1	i	i	PRON
ihlr-25462	126	2	d.	d.	PROPN
ihlr-25462	126	3	36	36	NUM
ihlr-25462	126	4	.	.	PUNCT
ihlr-25462	127	1	i	i	PRON
ihlr-25462	127	2	d.	d.	PROPN
ihlr-25462	127	3	37	37	NUM
ihlr-25462	127	4	.	.	PUNCT
ihlr-25462	128	1	i	i	PRON
ihlr-25462	128	2	d.	d.	PROPN
ihlr-25462	128	3	38	38	NUM
ihlr-25462	128	4	.	.	PUNCT
ihlr-25462	129	1	i	i	PRON
ihlr-25462	129	2	d.	d.	PROPN
ihlr-25462	129	3	39	39	NUM
ihlr-25462	129	4	.	.	PUNCT
ihlr-25462	130	1	i	i	PRON
ihlr-25462	130	2	d.	d.	PROPN
ihlr-25462	130	3	at	at	ADP
ihlr-25462	130	4	1529	1529	NUM
ihlr-25462	130	5	-	-	SYM
ihlr-25462	130	6	30	30	NUM
ihlr-25462	130	7	.	.	PUNCT
ihlr-25462	131	1	40	40	NUM
ihlr-25462	131	2	.	.	PUNCT
ihlr-25462	132	1	i	i	PRON
ihlr-25462	132	2	d.	d.	PROPN
ihlr-25462	132	3	at	at	ADP
ihlr-25462	132	4	1530	1530	NUM
ihlr-25462	132	5	.	.	PUNCT
ihlr-25462	133	1	41	41	NUM
ihlr-25462	133	2	.	.	PUNCT
ihlr-25462	134	1	i	i	PRON
ihlr-25462	134	2	d.	d.	PROPN
ihlr-25462	134	3	42	42	NUM
ihlr-25462	134	4	.	.	PUNCT
ihlr-25462	135	1	i	i	PRON
ihlr-25462	135	2	d.	d.	PROPN
ihlr-25462	135	3	43	43	NUM
ihlr-25462	135	4	.	.	PUNCT
ihlr-25462	136	1	i	i	PRON
ihlr-25462	136	2	d.	d.	PROPN
ihlr-25462	136	3	2021	2021	NUM
ihlr-25462	136	4	]	]	PUNCT
ihlr-25462	137	1	a	a	DET
ihlr-25462	137	2	survey	survey	NOUN
ihlr-25462	137	3	of	of	ADP
ihlr-25462	137	4	three	three	NUM
ihlr-25462	137	5	patent	patent	NOUN
ihlr-25462	137	6	-	-	PUNCT
ihlr-25462	137	7	based	base	VERB
ihlr-25462	137	8	approaches	approach	NOUN
ihlr-25462	137	9	403	403	NUM
ihlr-25462	137	10	are	be	AUX
ihlr-25462	137	11	exhausted	exhaust	VERB
ihlr-25462	137	12	when	when	SCONJ
ihlr-25462	137	13	a	a	DET
ihlr-25462	137	14	patent	patent	NOUN
ihlr-25462	137	15	owner	owner	NOUN
ihlr-25462	137	16	sells	sell	VERB
ihlr-25462	137	17	its	its	PRON
ihlr-25462	137	18	product	product	NOUN
ihlr-25462	137	19	outside	outside	ADP
ihlr-25462	137	20	of	of	ADP
ihlr-25462	137	21	the	the	DET
ihlr-25462	137	22	u.s.44	u.s.44	NOUN
ihlr-25462	137	23	the	the	DET
ihlr-25462	137	24	u.s	u.s	PROPN
ihlr-25462	137	25	.	.	PROPN
ihlr-25462	137	26	supreme	supreme	PROPN
ihlr-25462	137	27	court	court	PROPN
ihlr-25462	137	28	concluded	conclude	VERB
ihlr-25462	137	29	that	that	SCONJ
ihlr-25462	137	30	a	a	DET
ihlr-25462	137	31	patentee	patentee	NOUN
ihlr-25462	137	32	’s	’s	PART
ihlr-25462	137	33	decision	decision	NOUN
ihlr-25462	137	34	to	to	PART
ihlr-25462	137	35	sell	sell	VERB
ihlr-25462	137	36	a	a	DET
ihlr-25462	137	37	product	product	NOUN
ihlr-25462	137	38	“	"	PUNCT
ihlr-25462	137	39	exhausts	exhaust	VERB
ihlr-25462	137	40	all	all	PRON
ihlr-25462	137	41	of	of	ADP
ihlr-25462	137	42	its	its	PRON
ihlr-25462	137	43	patent	patent	NOUN
ihlr-25462	137	44	rights	right	NOUN
ihlr-25462	137	45	in	in	ADP
ihlr-25462	137	46	that	that	DET
ihlr-25462	137	47	item	item	NOUN
ihlr-25462	137	48	,	,	PUNCT
ihlr-25462	137	49	regardless	regardless	ADV
ihlr-25462	137	50	of	of	ADP
ihlr-25462	137	51	any	any	DET
ihlr-25462	137	52	restrictions	restriction	NOUN
ihlr-25462	137	53	the	the	DET
ihlr-25462	137	54	patentee	patentee	NOUN
ihlr-25462	137	55	purports	purport	NOUN
ihlr-25462	137	56	to	to	PART
ihlr-25462	137	57	impose	impose	VERB
ihlr-25462	137	58	”	"	PUNCT
ihlr-25462	137	59	on	on	ADP
ihlr-25462	137	60	the	the	DET
ihlr-25462	137	61	location	location	NOUN
ihlr-25462	137	62	of	of	ADP
ihlr-25462	137	63	the	the	DET
ihlr-25462	137	64	sale	sale	NOUN
ihlr-25462	137	65	,	,	PUNCT
ihlr-25462	137	66	meaning	mean	VERB
ihlr-25462	137	67	that	that	SCONJ
ihlr-25462	137	68	the	the	DET
ihlr-25462	137	69	patent	patent	NOUN
ihlr-25462	137	70	owner	owner	NOUN
ihlr-25462	137	71	may	may	AUX
ihlr-25462	137	72	not	not	PART
ihlr-25462	137	73	use	use	VERB
ihlr-25462	137	74	patent	patent	NOUN
ihlr-25462	137	75	law	law	NOUN
ihlr-25462	137	76	to	to	PART
ihlr-25462	137	77	follow	follow	VERB
ihlr-25462	137	78	the	the	DET
ihlr-25462	137	79	product	product	NOUN
ihlr-25462	137	80	down	down	ADP
ihlr-25462	137	81	the	the	DET
ihlr-25462	137	82	stream	stream	NOUN
ihlr-25462	137	83	of	of	ADP
ihlr-25462	137	84	commerce	commerce	NOUN
ihlr-25462	137	85	and	and	CCONJ
ihlr-25462	137	86	sue	sue	VERB
ihlr-25462	137	87	subsequent	subsequent	ADJ
ihlr-25462	137	88	purchasers	purchaser	NOUN
ihlr-25462	137	89	for	for	ADP
ihlr-25462	137	90	patent	patent	NOUN
ihlr-25462	137	91	infringement.45	infringement.45	VERB
ihlr-25462	137	92	importantly	importantly	ADV
ihlr-25462	137	93	,	,	PUNCT
ihlr-25462	137	94	the	the	DET
ihlr-25462	137	95	u.s	u.s	PROPN
ihlr-25462	137	96	.	.	PROPN
ihlr-25462	137	97	supreme	supreme	PROPN
ihlr-25462	137	98	court	court	PROPN
ihlr-25462	137	99	noted	note	VERB
ihlr-25462	137	100	that	that	SCONJ
ihlr-25462	137	101	“	"	PUNCT
ihlr-25462	137	102	even	even	ADV
ihlr-25462	137	103	if	if	SCONJ
ihlr-25462	137	104	the	the	DET
ihlr-25462	137	105	restrictions	restriction	NOUN
ihlr-25462	137	106	in	in	ADP
ihlr-25462	137	107	[	[	PUNCT
ihlr-25462	137	108	lexmark	lexmark	NOUN
ihlr-25462	137	109	international	international	PROPN
ihlr-25462	137	110	’s	’s	X
ihlr-25462	137	111	]	]	PUNCT
ihlr-25462	137	112	contracts	contract	NOUN
ihlr-25462	137	113	with	with	ADP
ihlr-25462	137	114	its	its	PRON
ihlr-25462	137	115	customers	customer	NOUN
ihlr-25462	137	116	were	be	AUX
ihlr-25462	137	117	clear	clear	ADJ
ihlr-25462	137	118	and	and	CCONJ
ihlr-25462	137	119	enforceable	enforceable	ADJ
ihlr-25462	137	120	under	under	ADP
ihlr-25462	137	121	contract	contract	NOUN
ihlr-25462	137	122	law	law	NOUN
ihlr-25462	137	123	,	,	PUNCT
ihlr-25462	137	124	they	they	PRON
ihlr-25462	137	125	do	do	AUX
ihlr-25462	137	126	not	not	PART
ihlr-25462	137	127	entitle	entitle	VERB
ihlr-25462	137	128	lexmark	lexmark	NOUN
ihlr-25462	137	129	[	[	X
ihlr-25462	137	130	international	international	ADJ
ihlr-25462	137	131	]	]	PUNCT
ihlr-25462	137	132	to	to	PART
ihlr-25462	137	133	retain	retain	VERB
ihlr-25462	137	134	patent	patent	NOUN
ihlr-25462	137	135	rights	right	NOUN
ihlr-25462	137	136	in	in	ADP
ihlr-25462	137	137	an	an	DET
ihlr-25462	137	138	item	item	NOUN
ihlr-25462	137	139	that	that	PRON
ihlr-25462	137	140	it	it	PRON
ihlr-25462	137	141	has	have	AUX
ihlr-25462	137	142	elected	elect	VERB
ihlr-25462	137	143	to	to	PART
ihlr-25462	137	144	sell	sell	VERB
ihlr-25462	137	145	.	.	PUNCT
ihlr-25462	138	1	”46	”46	ADJ
ihlr-25462	138	2	c.	c.	PROPN
ihlr-25462	139	1	how	how	SCONJ
ihlr-25462	139	2	patent	patent	NOUN
ihlr-25462	139	3	exhaustion	exhaustion	NOUN
ihlr-25462	139	4	can	can	AUX
ihlr-25462	139	5	affect	affect	VERB
ihlr-25462	139	6	the	the	DET
ihlr-25462	139	7	market	market	NOUN
ihlr-25462	139	8	prices	price	NOUN
ihlr-25462	139	9	of	of	ADP
ihlr-25462	139	10	prescription	prescription	NOUN
ihlr-25462	139	11	drugs	drug	NOUN
ihlr-25462	139	12	to	to	PART
ihlr-25462	139	13	illustrate	illustrate	VERB
ihlr-25462	139	14	what	what	PRON
ihlr-25462	139	15	could	could	AUX
ihlr-25462	139	16	happen	happen	VERB
ihlr-25462	139	17	with	with	ADP
ihlr-25462	139	18	the	the	DET
ihlr-25462	139	19	doctrine	doctrine	NOUN
ihlr-25462	139	20	of	of	ADP
ihlr-25462	139	21	patent	patent	NOUN
ihlr-25462	139	22	exhaustion	exhaustion	NOUN
ihlr-25462	139	23	and	and	CCONJ
ihlr-25462	139	24	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	139	25	drug	drug	NOUN
ihlr-25462	139	26	prices	price	NOUN
ihlr-25462	139	27	,	,	PUNCT
ihlr-25462	139	28	it	it	PRON
ihlr-25462	139	29	may	may	AUX
ihlr-25462	139	30	be	be	AUX
ihlr-25462	139	31	useful	useful	ADJ
ihlr-25462	139	32	to	to	PART
ihlr-25462	139	33	study	study	VERB
ihlr-25462	139	34	how	how	SCONJ
ihlr-25462	139	35	a	a	DET
ihlr-25462	139	36	ruling	ruling	NOUN
ihlr-25462	139	37	by	by	ADP
ihlr-25462	139	38	the	the	DET
ihlr-25462	139	39	u.s	u.s	PROPN
ihlr-25462	139	40	.	.	PROPN
ihlr-25462	139	41	supreme	supreme	PROPN
ihlr-25462	139	42	court	court	PROPN
ihlr-25462	139	43	on	on	ADP
ihlr-25462	139	44	a	a	DET
ihlr-25462	139	45	similar	similar	ADJ
ihlr-25462	139	46	intellectual	intellectual	ADJ
ihlr-25462	139	47	property	property	NOUN
ihlr-25462	139	48	doctrine	doctrine	NOUN
ihlr-25462	139	49	,	,	PUNCT
ihlr-25462	139	50	the	the	DET
ihlr-25462	139	51	“	"	PUNCT
ihlr-25462	139	52	first	first	ADJ
ihlr-25462	139	53	sale	sale	NOUN
ihlr-25462	139	54	”	"	PUNCT
ihlr-25462	139	55	doctrine	doctrine	NOUN
ihlr-25462	139	56	of	of	ADP
ihlr-25462	139	57	copyright	copyright	NOUN
ihlr-25462	139	58	law	law	NOUN
ihlr-25462	139	59	,	,	PUNCT
ihlr-25462	139	60	influenced	influence	VERB
ihlr-25462	139	61	the	the	DET
ihlr-25462	139	62	prices	price	NOUN
ihlr-25462	139	63	of	of	ADP
ihlr-25462	139	64	textbooks	textbook	NOUN
ihlr-25462	139	65	sold	sell	VERB
ihlr-25462	139	66	internationally	internationally	ADV
ihlr-25462	139	67	.	.	PUNCT
ihlr-25462	140	1	in	in	ADP
ihlr-25462	140	2	2013	2013	NUM
ihlr-25462	140	3	,	,	PUNCT
ihlr-25462	140	4	a	a	DET
ihlr-25462	140	5	lawsuit	lawsuit	NOUN
ihlr-25462	140	6	between	between	ADP
ihlr-25462	140	7	a	a	DET
ihlr-25462	140	8	major	major	ADJ
ihlr-25462	140	9	book	book	NOUN
ihlr-25462	140	10	publisher	publisher	NOUN
ihlr-25462	140	11	and	and	CCONJ
ihlr-25462	140	12	a	a	DET
ihlr-25462	140	13	u.s	u.s	PROPN
ihlr-25462	140	14	.	.	PROPN
ihlr-25462	140	15	college	college	NOUN
ihlr-25462	140	16	student	student	NOUN
ihlr-25462	140	17	ensued	ensue	VERB
ihlr-25462	140	18	after	after	SCONJ
ihlr-25462	140	19	the	the	DET
ihlr-25462	140	20	student	student	NOUN
ihlr-25462	140	21	imported	import	VERB
ihlr-25462	140	22	and	and	CCONJ
ihlr-25462	140	23	resold	resold	ADJ
ihlr-25462	140	24	textbooks	textbook	NOUN
ihlr-25462	140	25	in	in	ADP
ihlr-25462	140	26	the	the	DET
ihlr-25462	140	27	u.s	u.s	PROPN
ihlr-25462	140	28	.	.	PROPN
ihlr-25462	140	29	that	that	PRON
ihlr-25462	140	30	had	have	AUX
ihlr-25462	140	31	been	be	AUX
ihlr-25462	140	32	priced	price	VERB
ihlr-25462	140	33	lower	low	ADJ
ihlr-25462	140	34	abroad.47	abroad.47	ADJ
ihlr-25462	140	35	when	when	SCONJ
ihlr-25462	140	36	kirtsaeng	kirtsaeng	PROPN
ihlr-25462	140	37	,	,	PUNCT
ihlr-25462	140	38	the	the	DET
ihlr-25462	140	39	petitioner	petitioner	NOUN
ihlr-25462	140	40	and	and	CCONJ
ihlr-25462	140	41	a	a	DET
ihlr-25462	140	42	college	college	NOUN
ihlr-25462	140	43	student	student	NOUN
ihlr-25462	140	44	,	,	PUNCT
ihlr-25462	140	45	moved	move	VERB
ihlr-25462	140	46	from	from	ADP
ihlr-25462	140	47	thailand	thailand	PROPN
ihlr-25462	140	48	to	to	ADP
ihlr-25462	140	49	the	the	DET
ihlr-25462	140	50	u.s	u.s	PROPN
ihlr-25462	140	51	.	.	PROPN
ihlr-25462	140	52	to	to	PART
ihlr-25462	140	53	study	study	VERB
ihlr-25462	140	54	mathematics	mathematic	NOUN
ihlr-25462	140	55	at	at	ADP
ihlr-25462	140	56	cornell	cornell	PROPN
ihlr-25462	140	57	university	university	PROPN
ihlr-25462	140	58	,	,	PUNCT
ihlr-25462	140	59	“	"	PUNCT
ihlr-25462	140	60	he	he	PRON
ihlr-25462	140	61	asked	ask	VERB
ihlr-25462	140	62	friends	friend	NOUN
ihlr-25462	140	63	and	and	CCONJ
ihlr-25462	140	64	family	family	NOUN
ihlr-25462	140	65	to	to	PART
ihlr-25462	140	66	buy	buy	VERB
ihlr-25462	140	67	foreign	foreign	ADJ
ihlr-25462	140	68	edition	edition	NOUN
ihlr-25462	140	69	english	english	PROPN
ihlr-25462	140	70	-	-	PUNCT
ihlr-25462	140	71	language	language	NOUN
ihlr-25462	140	72	textbooks	textbook	NOUN
ihlr-25462	140	73	in	in	ADP
ihlr-25462	140	74	thai	thai	ADJ
ihlr-25462	140	75	bookshops	bookshop	NOUN
ihlr-25462	140	76	,	,	PUNCT
ihlr-25462	140	77	where	where	SCONJ
ihlr-25462	140	78	they	they	PRON
ihlr-25462	140	79	[	[	X
ihlr-25462	140	80	were	be	AUX
ihlr-25462	140	81	]	]	PUNCT
ihlr-25462	140	82	sold	sell	VERB
ihlr-25462	140	83	at	at	ADP
ihlr-25462	140	84	low	low	ADJ
ihlr-25462	140	85	prices	price	NOUN
ihlr-25462	140	86	,	,	PUNCT
ihlr-25462	140	87	and	and	CCONJ
ihlr-25462	140	88	to	to	PART
ihlr-25462	140	89	mail	mail	VERB
ihlr-25462	140	90	them	they	PRON
ihlr-25462	140	91	to	to	ADP
ihlr-25462	140	92	him	he	PRON
ihlr-25462	140	93	in	in	ADP
ihlr-25462	140	94	the	the	PRON
ihlr-25462	140	95	[	[	X
ihlr-25462	140	96	u.s.].”48	u.s.].”48	X
ihlr-25462	140	97	he	he	PRON
ihlr-25462	140	98	then	then	ADV
ihlr-25462	140	99	sold	sell	VERB
ihlr-25462	140	100	the	the	DET
ihlr-25462	140	101	books	book	NOUN
ihlr-25462	140	102	for	for	ADP
ihlr-25462	140	103	a	a	DET
ihlr-25462	140	104	profit	profit	NOUN
ihlr-25462	140	105	in	in	ADP
ihlr-25462	140	106	the	the	DET
ihlr-25462	140	107	u.s	u.s	PROPN
ihlr-25462	140	108	.	.	PROPN
ihlr-25462	140	109	and	and	CCONJ
ihlr-25462	140	110	reimbursed	reimburse	VERB
ihlr-25462	140	111	his	his	PRON
ihlr-25462	140	112	family	family	NOUN
ihlr-25462	140	113	and	and	CCONJ
ihlr-25462	140	114	friends.49	friends.49	NOUN
ihlr-25462	140	115	under	under	ADP
ihlr-25462	140	116	the	the	DET
ihlr-25462	140	117	first	first	ADJ
ihlr-25462	140	118	sale	sale	NOUN
ihlr-25462	140	119	doctrine	doctrine	NOUN
ihlr-25462	140	120	of	of	ADP
ihlr-25462	140	121	copyright	copyright	NOUN
ihlr-25462	140	122	law	law	NOUN
ihlr-25462	140	123	,	,	PUNCT
ihlr-25462	140	124	when	when	SCONJ
ihlr-25462	140	125	a	a	DET
ihlr-25462	140	126	copyright	copyright	NOUN
ihlr-25462	140	127	owner	owner	NOUN
ihlr-25462	140	128	sells	sell	VERB
ihlr-25462	140	129	a	a	DET
ihlr-25462	140	130	lawfully	lawfully	ADV
ihlr-25462	140	131	made	make	VERB
ihlr-25462	140	132	copy	copy	NOUN
ihlr-25462	140	133	of	of	ADP
ihlr-25462	140	134	its	its	PRON
ihlr-25462	140	135	work	work	NOUN
ihlr-25462	140	136	,	,	PUNCT
ihlr-25462	140	137	it	it	PRON
ihlr-25462	140	138	loses	lose	VERB
ihlr-25462	140	139	the	the	DET
ihlr-25462	140	140	power	power	NOUN
ihlr-25462	140	141	to	to	PART
ihlr-25462	140	142	restrict	restrict	VERB
ihlr-25462	140	143	the	the	DET
ihlr-25462	140	144	purchaser	purchaser	NOUN
ihlr-25462	140	145	’s	’s	PART
ihlr-25462	140	146	freedom	freedom	NOUN
ihlr-25462	140	147	“	"	PUNCT
ihlr-25462	140	148	to	to	PART
ihlr-25462	140	149	sell	sell	VERB
ihlr-25462	140	150	or	or	CCONJ
ihlr-25462	140	151	otherwise	otherwise	ADV
ihlr-25462	140	152	dispose	dispose	VERB
ihlr-25462	140	153	of	of	ADP
ihlr-25462	140	154	.	.	PUNCT
ihlr-25462	140	155	.	.	PUNCT
ihlr-25462	140	156	.	.	PUNCT
ihlr-25462	141	1	that	that	PRON
ihlr-25462	141	2	copy	copy	NOUN
ihlr-25462	141	3	.	.	PUNCT
ihlr-25462	142	1	”50	”50	PROPN
ihlr-25462	142	2	however	however	ADV
ihlr-25462	142	3	,	,	PUNCT
ihlr-25462	142	4	like	like	ADP
ihlr-25462	142	5	lexmark	lexmark	NOUN
ihlr-25462	142	6	,	,	PUNCT
ihlr-25462	142	7	prior	prior	ADV
ihlr-25462	142	8	to	to	ADP
ihlr-25462	142	9	kirtsaeng	kirtsaeng	PROPN
ihlr-25462	142	10	,	,	PUNCT
ihlr-25462	142	11	the	the	DET
ihlr-25462	142	12	court	court	NOUN
ihlr-25462	142	13	had	have	AUX
ihlr-25462	142	14	not	not	PART
ihlr-25462	142	15	ruled	rule	VERB
ihlr-25462	142	16	on	on	ADP
ihlr-25462	142	17	whether	whether	SCONJ
ihlr-25462	142	18	this	this	DET
ihlr-25462	142	19	doctrine	doctrine	NOUN
ihlr-25462	142	20	applied	apply	VERB
ihlr-25462	142	21	to	to	ADP
ihlr-25462	142	22	the	the	DET
ihlr-25462	142	23	sale	sale	NOUN
ihlr-25462	142	24	of	of	ADP
ihlr-25462	142	25	works	work	NOUN
ihlr-25462	142	26	made	make	VERB
ihlr-25462	142	27	and	and	CCONJ
ihlr-25462	142	28	sold	sell	VERB
ihlr-25462	142	29	abroad.51	abroad.51	PROPN
ihlr-25462	142	30	the	the	DET
ihlr-25462	142	31	u.s	u.s	PROPN
ihlr-25462	142	32	.	.	PROPN
ihlr-25462	142	33	supreme	supreme	PROPN
ihlr-25462	142	34	court	court	PROPN
ihlr-25462	142	35	granted	grant	VERB
ihlr-25462	142	36	kirtsaeng	kirtsaeng	PROPN
ihlr-25462	142	37	’s	’s	PART
ihlr-25462	142	38	petition	petition	NOUN
ihlr-25462	142	39	for	for	ADP
ihlr-25462	142	40	certiorari	certiorari	NOUN
ihlr-25462	142	41	and	and	CCONJ
ihlr-25462	142	42	held	hold	VERB
ihlr-25462	142	43	that	that	SCONJ
ihlr-25462	142	44	the	the	DET
ihlr-25462	142	45	first	first	ADJ
ihlr-25462	142	46	sale	sale	NOUN
ihlr-25462	142	47	doctrine	doctrine	NOUN
ihlr-25462	142	48	applies	apply	VERB
ihlr-25462	142	49	to	to	ADP
ihlr-25462	142	50	copies	copy	NOUN
ihlr-25462	142	51	of	of	ADP
ihlr-25462	142	52	a	a	DET
ihlr-25462	142	53	copyrighted	copyright	VERB
ihlr-25462	142	54	work	work	NOUN
ihlr-25462	142	55	lawfully	lawfully	ADV
ihlr-25462	142	56	made	make	VERB
ihlr-25462	142	57	abroad.52	abroad.52	PROPN
ihlr-25462	142	58	the	the	DET
ihlr-25462	142	59	u.s	u.s	PROPN
ihlr-25462	142	60	.	.	PROPN
ihlr-25462	142	61	supreme	supreme	PROPN
ihlr-25462	142	62	court	court	PROPN
ihlr-25462	142	63	in	in	ADP
ihlr-25462	142	64	kirtsaeng	kirtsaeng	PROPN
ihlr-25462	142	65	stated	state	VERB
ihlr-25462	142	66	that	that	SCONJ
ihlr-25462	142	67	what	what	PRON
ihlr-25462	142	68	tipped	tip	VERB
ihlr-25462	142	69	the	the	DET
ihlr-25462	142	70	scales	scale	NOUN
ihlr-25462	142	71	toward	toward	ADP
ihlr-25462	142	72	a	a	DET
ihlr-25462	142	73	global	global	ADJ
ihlr-25462	142	74	exhaustion	exhaustion	NOUN
ihlr-25462	142	75	policy	policy	NOUN
ihlr-25462	142	76	was	be	AUX
ihlr-25462	142	77	the	the	DET
ihlr-25462	142	78	fact	fact	NOUN
ihlr-25462	142	79	that	that	SCONJ
ihlr-25462	142	80	the	the	DET
ihlr-25462	142	81	first	first	ADJ
ihlr-25462	142	82	sale	sale	NOUN
ihlr-25462	142	83	doctrine	doctrine	NOUN
ihlr-25462	142	84	44	44	NUM
ihlr-25462	142	85	.	.	PUNCT
ihlr-25462	143	1	i	i	PRON
ihlr-25462	143	2	d.	d.	PROPN
ihlr-25462	143	3	at	at	ADP
ihlr-25462	143	4	1529	1529	NUM
ihlr-25462	143	5	.	.	PUNCT
ihlr-25462	144	1	45	45	NUM
ihlr-25462	144	2	.	.	PUNCT
ihlr-25462	145	1	i	i	PRON
ihlr-25462	145	2	d.	d.	PROPN
ihlr-25462	145	3	at	at	ADP
ihlr-25462	145	4	1535	1535	NUM
ihlr-25462	145	5	46	46	NUM
ihlr-25462	145	6	.	.	PUNCT
ihlr-25462	146	1	i	i	PRON
ihlr-25462	146	2	d.	d.	PROPN
ihlr-25462	146	3	at	at	ADP
ihlr-25462	146	4	1526	1526	NUM
ihlr-25462	146	5	.	.	PUNCT
ihlr-25462	147	1	47	47	NUM
ihlr-25462	147	2	.	.	PUNCT
ihlr-25462	148	1	see	see	VERB
ihlr-25462	148	2	kirtsaeng	kirtsaeng	PROPN
ihlr-25462	148	3	v.	v.	PROPN
ihlr-25462	148	4	john	john	PROPN
ihlr-25462	148	5	wiley	wiley	PROPN
ihlr-25462	148	6	&	&	CCONJ
ihlr-25462	148	7	sons	sons	PROPN
ihlr-25462	148	8	,	,	PUNCT
ihlr-25462	148	9	inc	inc	PROPN
ihlr-25462	148	10	.	.	PROPN
ihlr-25462	148	11	,	,	PUNCT
ihlr-25462	148	12	133	133	NUM
ihlr-25462	148	13	s.	s.	PROPN
ihlr-25462	148	14	ct	ct	PROPN
ihlr-25462	148	15	.	.	PROPN
ihlr-25462	148	16	1351	1351	NUM
ihlr-25462	148	17	(	(	PUNCT
ihlr-25462	148	18	2013	2013	NUM
ihlr-25462	148	19	)	)	PUNCT
ihlr-25462	148	20	.	.	PUNCT
ihlr-25462	149	1	48	48	NUM
ihlr-25462	149	2	.	.	PUNCT
ihlr-25462	150	1	i	i	PRON
ihlr-25462	150	2	d.	d.	PROPN
ihlr-25462	150	3	at	at	ADP
ihlr-25462	150	4	1356	1356	NUM
ihlr-25462	150	5	.	.	PUNCT
ihlr-25462	151	1	49	49	NUM
ihlr-25462	151	2	.	.	PUNCT
ihlr-25462	152	1	i	i	PRON
ihlr-25462	152	2	d.	d.	PROPN
ihlr-25462	152	3	50	50	NUM
ihlr-25462	152	4	.	.	PUNCT
ihlr-25462	152	5	17	17	NUM
ihlr-25462	152	6	u.s.c	u.s.c	ADJ
ihlr-25462	152	7	.	.	PUNCT
ihlr-25462	153	1	§	§	PROPN
ihlr-25462	153	2	109(a	109(a	PROPN
ihlr-25462	153	3	)	)	PUNCT
ihlr-25462	153	4	(	(	PUNCT
ihlr-25462	153	5	2020	2020	NUM
ihlr-25462	153	6	)	)	PUNCT
ihlr-25462	153	7	.	.	PUNCT
ihlr-25462	154	1	51	51	NUM
ihlr-25462	154	2	.	.	PUNCT
ihlr-25462	155	1	impression	impression	NOUN
ihlr-25462	155	2	prods	prod	VERB
ihlr-25462	155	3	.	.	PUNCT
ihlr-25462	156	1	v.	v.	ADP
ihlr-25462	156	2	lexmark	lexmark	NOUN
ihlr-25462	156	3	int’l	int’l	NUM
ihlr-25462	156	4	,	,	PUNCT
ihlr-25462	156	5	inc	inc	PROPN
ihlr-25462	156	6	.	.	PROPN
ihlr-25462	156	7	,	,	PUNCT
ihlr-25462	156	8	137	137	NUM
ihlr-25462	156	9	u.s	u.s	PROPN
ihlr-25462	156	10	.	.	PROPN
ihlr-25462	156	11	1523	1523	NUM
ihlr-25462	156	12	,	,	PUNCT
ihlr-25462	156	13	1527	1527	NUM
ihlr-25462	156	14	(	(	PUNCT
ihlr-25462	156	15	2017	2017	NUM
ihlr-25462	156	16	)	)	PUNCT
ihlr-25462	156	17	.	.	PUNCT
ihlr-25462	157	1	52	52	NUM
ihlr-25462	157	2	.	.	PUNCT
ihlr-25462	158	1	kirtsaeng	kirtsaeng	NOUN
ihlr-25462	158	2	,	,	PUNCT
ihlr-25462	158	3	133	133	NUM
ihlr-25462	158	4	s.	s.	PROPN
ihlr-25462	158	5	ct	ct	PROPN
ihlr-25462	158	6	.	.	PUNCT
ihlr-25462	159	1	at	at	ADP
ihlr-25462	159	2	1351	1351	NUM
ihlr-25462	159	3	.	.	PUNCT
ihlr-25462	160	1	404	404	NUM
ihlr-25462	160	2	indiana	indiana	PROPN
ihlr-25462	160	3	health	health	PROPN
ihlr-25462	160	4	law	law	PROPN
ihlr-25462	160	5	review	review	NOUN
ihlr-25462	161	1	[	[	X
ihlr-25462	161	2	vol	vol	NOUN
ihlr-25462	161	3	.	.	PUNCT
ihlr-25462	161	4	18:397	18:397	NUM
ihlr-25462	161	5	originated	originate	VERB
ihlr-25462	161	6	in	in	ADP
ihlr-25462	161	7	“	"	PUNCT
ihlr-25462	161	8	the	the	DET
ihlr-25462	161	9	common	common	ADJ
ihlr-25462	161	10	law	law	NOUN
ihlr-25462	161	11	’s	’s	PART
ihlr-25462	161	12	refusal	refusal	NOUN
ihlr-25462	161	13	to	to	PART
ihlr-25462	161	14	permit	permit	VERB
ihlr-25462	161	15	restraints	restraint	NOUN
ihlr-25462	161	16	on	on	ADP
ihlr-25462	161	17	alienation	alienation	NOUN
ihlr-25462	161	18	of	of	ADP
ihlr-25462	161	19	chattels	chattel	NOUN
ihlr-25462	161	20	.	.	PUNCT
ihlr-25462	162	1	”53	”53	ADV
ihlr-25462	162	2	the	the	DET
ihlr-25462	162	3	court	court	NOUN
ihlr-25462	162	4	expressly	expressly	ADV
ihlr-25462	162	5	acknowledged	acknowledge	VERB
ihlr-25462	162	6	that	that	SCONJ
ihlr-25462	162	7	its	its	PRON
ihlr-25462	162	8	decision	decision	NOUN
ihlr-25462	162	9	was	be	AUX
ihlr-25462	162	10	likely	likely	ADJ
ihlr-25462	162	11	to	to	PART
ihlr-25462	162	12	impact	impact	VERB
ihlr-25462	162	13	prices	price	NOUN
ihlr-25462	162	14	,	,	PUNCT
ihlr-25462	162	15	noting	note	VERB
ihlr-25462	162	16	that	that	SCONJ
ihlr-25462	162	17	“	"	PUNCT
ihlr-25462	162	18	[	[	X
ihlr-25462	162	19	a	a	X
ihlr-25462	162	20	]	]	X
ihlr-25462	162	21	publisher	publisher	NOUN
ihlr-25462	162	22	may	may	AUX
ihlr-25462	162	23	find	find	VERB
ihlr-25462	162	24	it	it	PRON
ihlr-25462	162	25	more	more	ADV
ihlr-25462	162	26	difficult	difficult	ADJ
ihlr-25462	162	27	to	to	PART
ihlr-25462	162	28	charge	charge	VERB
ihlr-25462	162	29	different	different	ADJ
ihlr-25462	162	30	prices	price	NOUN
ihlr-25462	162	31	for	for	ADP
ihlr-25462	162	32	the	the	DET
ihlr-25462	162	33	same	same	ADJ
ihlr-25462	162	34	book	book	NOUN
ihlr-25462	162	35	in	in	ADP
ihlr-25462	162	36	different	different	ADJ
ihlr-25462	162	37	geographic	geographic	ADJ
ihlr-25462	162	38	markets	market	NOUN
ihlr-25462	162	39	”	"	PUNCT
ihlr-25462	162	40	but	but	CCONJ
ihlr-25462	162	41	also	also	ADV
ihlr-25462	162	42	that	that	SCONJ
ihlr-25462	162	43	they	they	PRON
ihlr-25462	162	44	could	could	AUX
ihlr-25462	162	45	“	"	PUNCT
ihlr-25462	162	46	find	find	VERB
ihlr-25462	162	47	no	no	DET
ihlr-25462	162	48	basic	basic	ADJ
ihlr-25462	162	49	principle	principle	NOUN
ihlr-25462	162	50	of	of	ADP
ihlr-25462	162	51	copyright	copyright	NOUN
ihlr-25462	162	52	law	law	NOUN
ihlr-25462	162	53	that	that	PRON
ihlr-25462	162	54	suggests	suggest	VERB
ihlr-25462	162	55	publishers	publisher	NOUN
ihlr-25462	162	56	are	be	AUX
ihlr-25462	162	57	especially	especially	ADV
ihlr-25462	162	58	entitled	entitle	VERB
ihlr-25462	162	59	to	to	ADP
ihlr-25462	162	60	such	such	ADJ
ihlr-25462	162	61	rights	right	NOUN
ihlr-25462	162	62	.	.	PUNCT
ihlr-25462	163	1	”54	”54	PROPN
ihlr-25462	163	2	notably	notably	ADV
ihlr-25462	163	3	,	,	PUNCT
ihlr-25462	163	4	justice	justice	PROPN
ihlr-25462	163	5	ruth	ruth	PROPN
ihlr-25462	163	6	bader	bader	PROPN
ihlr-25462	163	7	ginsburg	ginsburg	PROPN
ihlr-25462	163	8	dissented	dissent	VERB
ihlr-25462	163	9	in	in	ADP
ihlr-25462	163	10	both	both	CCONJ
ihlr-25462	163	11	the	the	DET
ihlr-25462	163	12	lexmark	lexmark	NOUN
ihlr-25462	163	13	and	and	CCONJ
ihlr-25462	163	14	kirtsaeng	kirtsaeng	NOUN
ihlr-25462	163	15	decisions	decision	NOUN
ihlr-25462	163	16	.	.	PUNCT
ihlr-25462	164	1	as	as	SCONJ
ihlr-25462	164	2	the	the	DET
ihlr-25462	164	3	protections	protection	NOUN
ihlr-25462	164	4	of	of	ADP
ihlr-25462	164	5	the	the	DET
ihlr-25462	164	6	patent	patent	NOUN
ihlr-25462	164	7	act	act	NOUN
ihlr-25462	164	8	have	have	VERB
ihlr-25462	164	9	no	no	DET
ihlr-25462	164	10	extraterritorial	extraterritorial	ADJ
ihlr-25462	164	11	effect	effect	NOUN
ihlr-25462	164	12	,	,	PUNCT
ihlr-25462	164	13	justice	justice	NOUN
ihlr-25462	164	14	ginsburg	ginsburg	PROPN
ihlr-25462	164	15	argued	argue	VERB
ihlr-25462	164	16	that	that	SCONJ
ihlr-25462	164	17	“	"	PUNCT
ihlr-25462	164	18	it	it	PRON
ihlr-25462	164	19	makes	make	VERB
ihlr-25462	164	20	little	little	ADJ
ihlr-25462	164	21	sense	sense	NOUN
ihlr-25462	164	22	to	to	PART
ihlr-25462	164	23	say	say	VERB
ihlr-25462	164	24	that	that	SCONJ
ihlr-25462	164	25	such	such	DET
ihlr-25462	164	26	a	a	DET
ihlr-25462	164	27	sale	sale	NOUN
ihlr-25462	164	28	exhausts	exhaust	VERB
ihlr-25462	164	29	an	an	DET
ihlr-25462	164	30	inventor	inventor	NOUN
ihlr-25462	164	31	’s	’s	PART
ihlr-25462	164	32	u.s	u.s	PROPN
ihlr-25462	164	33	.	.	PROPN
ihlr-25462	164	34	patent	patent	NOUN
ihlr-25462	164	35	rights	right	NOUN
ihlr-25462	164	36	.	.	PUNCT
ihlr-25462	165	1	”55	”55	PROPN
ihlr-25462	165	2	this	this	PRON
ihlr-25462	165	3	echoed	echo	VERB
ihlr-25462	165	4	the	the	DET
ihlr-25462	165	5	same	same	ADJ
ihlr-25462	165	6	position	position	NOUN
ihlr-25462	165	7	that	that	PRON
ihlr-25462	165	8	justice	justice	NOUN
ihlr-25462	165	9	ginsburg	ginsburg	PROPN
ihlr-25462	165	10	took	take	VERB
ihlr-25462	165	11	when	when	SCONJ
ihlr-25462	165	12	dissenting	dissent	VERB
ihlr-25462	165	13	in	in	ADP
ihlr-25462	165	14	kirtsaeng	kirtsaeng	NOUN
ihlr-25462	165	15	,	,	PUNCT
ihlr-25462	165	16	where	where	SCONJ
ihlr-25462	165	17	she	she	PRON
ihlr-25462	165	18	argued	argue	VERB
ihlr-25462	165	19	that	that	SCONJ
ihlr-25462	165	20	a	a	DET
ihlr-25462	165	21	foreign	foreign	ADJ
ihlr-25462	165	22	sale	sale	NOUN
ihlr-25462	165	23	should	should	AUX
ihlr-25462	165	24	not	not	PART
ihlr-25462	165	25	exhaust	exhaust	VERB
ihlr-25462	165	26	u.s	u.s	PROPN
ihlr-25462	165	27	.	.	PROPN
ihlr-25462	165	28	copyright	copyright	NOUN
ihlr-25462	165	29	protections.56	protections.56	NOUN
ihlr-25462	165	30	regardless	regardless	ADV
ihlr-25462	165	31	,	,	PUNCT
ihlr-25462	165	32	most	most	ADJ
ihlr-25462	165	33	economists	economist	NOUN
ihlr-25462	165	34	believe	believe	VERB
ihlr-25462	165	35	that	that	SCONJ
ihlr-25462	165	36	parallel	parallel	ADJ
ihlr-25462	165	37	importation	importation	NOUN
ihlr-25462	165	38	will	will	AUX
ihlr-25462	165	39	result	result	VERB
ihlr-25462	165	40	in	in	ADP
ihlr-25462	165	41	more	more	ADJ
ihlr-25462	165	42	uniform	uniform	ADJ
ihlr-25462	165	43	pricing	pricing	NOUN
ihlr-25462	165	44	:	:	PUNCT
ihlr-25462	165	45	namely	namely	ADV
ihlr-25462	165	46	,	,	PUNCT
ihlr-25462	165	47	lower	low	ADJ
ihlr-25462	165	48	u.s	u.s	PROPN
ihlr-25462	165	49	.	.	PROPN
ihlr-25462	165	50	prices	price	NOUN
ihlr-25462	165	51	and	and	CCONJ
ihlr-25462	165	52	higher	high	ADJ
ihlr-25462	165	53	prices	price	NOUN
ihlr-25462	165	54	abroad.57	abroad.57	PROPN
ihlr-25462	165	55	in	in	ADP
ihlr-25462	165	56	its	its	PRON
ihlr-25462	165	57	best	good	ADJ
ihlr-25462	165	58	-	-	PUNCT
ihlr-25462	165	59	case	case	NOUN
ihlr-25462	165	60	scenario	scenario	NOUN
ihlr-25462	165	61	,	,	PUNCT
ihlr-25462	165	62	the	the	DET
ihlr-25462	165	63	establishment	establishment	NOUN
ihlr-25462	165	64	of	of	ADP
ihlr-25462	165	65	international	international	ADJ
ihlr-25462	165	66	exhaustion	exhaustion	NOUN
ihlr-25462	165	67	will	will	AUX
ihlr-25462	165	68	align	align	VERB
ihlr-25462	165	69	u.s	u.s	PROPN
ihlr-25462	165	70	.	.	PROPN
ihlr-25462	165	71	patent	patent	NOUN
ihlr-25462	165	72	law	law	NOUN
ihlr-25462	165	73	with	with	ADP
ihlr-25462	165	74	free	free	ADJ
ihlr-25462	165	75	trade	trade	NOUN
ihlr-25462	165	76	principles	principle	NOUN
ihlr-25462	165	77	,	,	PUNCT
ihlr-25462	165	78	decreasing	decrease	VERB
ihlr-25462	165	79	international	international	ADJ
ihlr-25462	165	80	price	price	NOUN
ihlr-25462	165	81	discrimination.58	discrimination.58	NOUN
ihlr-25462	165	82	notably	notably	ADV
ihlr-25462	165	83	,	,	PUNCT
ihlr-25462	165	84	there	there	PRON
ihlr-25462	165	85	is	be	VERB
ihlr-25462	165	86	no	no	DET
ihlr-25462	165	87	uniform	uniform	ADJ
ihlr-25462	165	88	agreement	agreement	NOUN
ihlr-25462	165	89	on	on	ADP
ihlr-25462	165	90	this	this	DET
ihlr-25462	165	91	point	point	NOUN
ihlr-25462	165	92	.	.	PUNCT
ihlr-25462	166	1	the	the	DET
ihlr-25462	166	2	fact	fact	NOUN
ihlr-25462	166	3	that	that	SCONJ
ihlr-25462	166	4	mandatory	mandatory	ADJ
ihlr-25462	166	5	exhaustion	exhaustion	NOUN
ihlr-25462	166	6	will	will	AUX
ihlr-25462	166	7	benefit	benefit	VERB
ihlr-25462	166	8	u.s	u.s	PROPN
ihlr-25462	166	9	.	.	PROPN
ihlr-25462	166	10	consumers	consumer	NOUN
ihlr-25462	166	11	’	'	PUNCT
ihlr-25462	166	12	pocketbooks	pocketbook	NOUN
ihlr-25462	166	13	does	do	AUX
ihlr-25462	166	14	not	not	PART
ihlr-25462	166	15	mean	mean	VERB
ihlr-25462	166	16	that	that	SCONJ
ihlr-25462	166	17	mandatory	mandatory	ADJ
ihlr-25462	166	18	exhaustion	exhaustion	NOUN
ihlr-25462	166	19	will	will	AUX
ihlr-25462	166	20	increase	increase	VERB
ihlr-25462	166	21	u.s	u.s	PROPN
ihlr-25462	166	22	.	.	PROPN
ihlr-25462	166	23	citizens	citizen	NOUN
ihlr-25462	166	24	’	’	PART
ihlr-25462	166	25	welfare	welfare	NOUN
ihlr-25462	166	26	overall.59	overall.59	VERB
ihlr-25462	166	27	it	it	PRON
ihlr-25462	166	28	is	be	AUX
ihlr-25462	166	29	not	not	PART
ihlr-25462	166	30	yet	yet	ADV
ihlr-25462	166	31	clear	clear	ADJ
ihlr-25462	166	32	whether	whether	SCONJ
ihlr-25462	166	33	the	the	DET
ihlr-25462	166	34	advantages	advantage	NOUN
ihlr-25462	166	35	to	to	ADP
ihlr-25462	166	36	u.s	u.s	PROPN
ihlr-25462	166	37	.	.	PROPN
ihlr-25462	166	38	customers	customer	NOUN
ihlr-25462	166	39	will	will	AUX
ihlr-25462	166	40	outweigh	outweigh	VERB
ihlr-25462	166	41	the	the	DET
ihlr-25462	166	42	losses	loss	NOUN
ihlr-25462	166	43	to	to	ADP
ihlr-25462	166	44	u.s	u.s	PROPN
ihlr-25462	166	45	.	.	PROPN
ihlr-25462	166	46	patent	patent	NOUN
ihlr-25462	166	47	holders	holder	NOUN
ihlr-25462	166	48	and	and	CCONJ
ihlr-25462	166	49	how	how	SCONJ
ihlr-25462	166	50	that	that	PRON
ihlr-25462	166	51	will	will	AUX
ihlr-25462	166	52	affect	affect	VERB
ihlr-25462	166	53	the	the	DET
ihlr-25462	166	54	industry	industry	NOUN
ihlr-25462	166	55	long	long	ADV
ihlr-25462	166	56	-	-	PUNCT
ihlr-25462	166	57	term.60	term.60	NOUN
ihlr-25462	166	58	in	in	ADP
ihlr-25462	166	59	fact	fact	NOUN
ihlr-25462	166	60	,	,	PUNCT
ihlr-25462	166	61	a	a	DET
ihlr-25462	166	62	law	law	NOUN
ihlr-25462	166	63	school	school	NOUN
ihlr-25462	166	64	professor	professor	NOUN
ihlr-25462	166	65	at	at	ADP
ihlr-25462	166	66	the	the	DET
ihlr-25462	166	67	university	university	PROPN
ihlr-25462	166	68	of	of	ADP
ihlr-25462	166	69	pennsylvania	pennsylvania	PROPN
ihlr-25462	166	70	argued	argue	VERB
ihlr-25462	166	71	against	against	ADP
ihlr-25462	166	72	the	the	DET
ihlr-25462	166	73	u.s	u.s	PROPN
ihlr-25462	166	74	.	.	PROPN
ihlr-25462	166	75	supreme	supreme	PROPN
ihlr-25462	166	76	court	court	PROPN
ihlr-25462	166	77	’s	’s	PART
ihlr-25462	166	78	patent	patent	NOUN
ihlr-25462	166	79	exhaustion	exhaustion	NOUN
ihlr-25462	166	80	rule	rule	NOUN
ihlr-25462	166	81	,	,	PUNCT
ihlr-25462	166	82	calling	call	VERB
ihlr-25462	166	83	it	it	PRON
ihlr-25462	166	84	“	"	PUNCT
ihlr-25462	166	85	draconian	draconian	ADJ
ihlr-25462	166	86	”	"	PUNCT
ihlr-25462	166	87	and	and	CCONJ
ihlr-25462	166	88	“	"	PUNCT
ihlr-25462	166	89	indifferent	indifferent	ADJ
ihlr-25462	166	90	to	to	ADP
ihlr-25462	166	91	effects	effect	NOUN
ihlr-25462	166	92	on	on	ADP
ihlr-25462	166	93	innovation	innovation	NOUN
ihlr-25462	166	94	”	"	PUNCT
ihlr-25462	166	95	because	because	SCONJ
ihlr-25462	166	96	“	"	PUNCT
ihlr-25462	166	97	[	[	X
ihlr-25462	166	98	n]o	n]o	NOUN
ihlr-25462	166	99	further	further	ADJ
ihlr-25462	166	100	inquiry	inquiry	NOUN
ihlr-25462	166	101	is	be	AUX
ihlr-25462	166	102	made	make	VERB
ihlr-25462	166	103	into	into	ADP
ihlr-25462	166	104	the	the	DET
ihlr-25462	166	105	patentee	patentee	NOUN
ihlr-25462	166	106	’s	’s	PART
ihlr-25462	166	107	market	market	NOUN
ihlr-25462	166	108	power	power	NOUN
ihlr-25462	166	109	,	,	PUNCT
ihlr-25462	166	110	[	[	X
ihlr-25462	166	111	anti	anti	ADJ
ihlr-25462	166	112	-	-	ADJ
ihlr-25462	166	113	competitive	competitive	ADJ
ihlr-25462	166	114	]	]	PUNCT
ihlr-25462	166	115	effects	effect	NOUN
ihlr-25462	166	116	,	,	PUNCT
ihlr-25462	166	117	or	or	CCONJ
ihlr-25462	166	118	other	other	ADJ
ihlr-25462	166	119	types	type	NOUN
ihlr-25462	166	120	of	of	ADP
ihlr-25462	166	121	harms	harm	NOUN
ihlr-25462	166	122	,	,	PUNCT
ihlr-25462	166	123	whether	whether	SCONJ
ihlr-25462	166	124	enforcement	enforcement	NOUN
ihlr-25462	166	125	of	of	ADP
ihlr-25462	166	126	the	the	DET
ihlr-25462	166	127	condition	condition	NOUN
ihlr-25462	166	128	is	be	AUX
ihlr-25462	166	129	socially	socially	ADV
ihlr-25462	166	130	costly	costly	ADJ
ihlr-25462	166	131	or	or	CCONJ
ihlr-25462	166	132	valuable	valuable	ADJ
ihlr-25462	166	133	,	,	PUNCT
ihlr-25462	166	134	or	or	CCONJ
ihlr-25462	166	135	has	have	VERB
ihlr-25462	166	136	a	a	DET
ihlr-25462	166	137	positive	positive	ADJ
ihlr-25462	166	138	or	or	CCONJ
ihlr-25462	166	139	negative	negative	ADJ
ihlr-25462	166	140	impact	impact	NOUN
ihlr-25462	166	141	on	on	ADP
ihlr-25462	166	142	innovation	innovation	NOUN
ihlr-25462	166	143	.	.	PUNCT
ihlr-25462	167	1	”61	”61	NOUN
ihlr-25462	167	2	53	53	NUM
ihlr-25462	167	3	.	.	PUNCT
ihlr-25462	168	1	i	i	PRON
ihlr-25462	168	2	d.	d.	PROPN
ihlr-25462	168	3	at	at	ADP
ihlr-25462	168	4	1363	1363	NUM
ihlr-25462	168	5	.	.	PUNCT
ihlr-25462	169	1	54	54	NUM
ihlr-25462	169	2	.	.	PUNCT
ihlr-25462	170	1	i	i	PRON
ihlr-25462	170	2	d.	d.	PROPN
ihlr-25462	170	3	at	at	ADP
ihlr-25462	170	4	1370	1370	NUM
ihlr-25462	170	5	.	.	PUNCT
ihlr-25462	171	1	55	55	NUM
ihlr-25462	171	2	.	.	PUNCT
ihlr-25462	172	1	impression	impression	NOUN
ihlr-25462	172	2	prods	prod	VERB
ihlr-25462	172	3	,	,	PUNCT
ihlr-25462	172	4	137	137	NUM
ihlr-25462	172	5	u.s	u.s	PROPN
ihlr-25462	172	6	.	.	PROPN
ihlr-25462	172	7	at	at	ADP
ihlr-25462	172	8	1539	1539	NUM
ihlr-25462	172	9	.	.	PUNCT
ihlr-25462	173	1	56	56	NUM
ihlr-25462	173	2	.	.	X
ihlr-25462	173	3	kirtsaeng	kirtsaeng	NOUN
ihlr-25462	173	4	,	,	PUNCT
ihlr-25462	173	5	133	133	NUM
ihlr-25462	173	6	s.	s.	PROPN
ihlr-25462	173	7	ct	ct	PROPN
ihlr-25462	173	8	.	.	PUNCT
ihlr-25462	174	1	at	at	ADP
ihlr-25462	174	2	1373	1373	NUM
ihlr-25462	174	3	.	.	PUNCT
ihlr-25462	175	1	57	57	NUM
ihlr-25462	175	2	.	.	PUNCT
ihlr-25462	175	3	daniel	daniel	PROPN
ihlr-25462	175	4	j.	j.	PROPN
ihlr-25462	175	5	hemel	hemel	PROPN
ihlr-25462	175	6	&	&	CCONJ
ihlr-25462	175	7	lisa	lisa	PROPN
ihlr-25462	175	8	larrimore	larrimore	PROPN
ihlr-25462	175	9	ouellette	ouellette	PROPN
ihlr-25462	175	10	,	,	PUNCT
ihlr-25462	175	11	trade	trade	NOUN
ihlr-25462	175	12	and	and	CCONJ
ihlr-25462	175	13	tradeoffs	tradeoff	NOUN
ihlr-25462	175	14	:	:	PUNCT
ihlr-25462	175	15	the	the	DET
ihlr-25462	175	16	case	case	NOUN
ihlr-25462	175	17	of	of	ADP
ihlr-25462	175	18	international	international	ADJ
ihlr-25462	175	19	patent	patent	NOUN
ihlr-25462	175	20	exhaustion	exhaustion	NOUN
ihlr-25462	175	21	,	,	PUNCT
ihlr-25462	175	22	116	116	NUM
ihlr-25462	175	23	colum	colum	NOUN
ihlr-25462	175	24	.	.	PUNCT
ihlr-25462	176	1	l.	l.	PROPN
ihlr-25462	176	2	rev	rev	PROPN
ihlr-25462	176	3	.	.	PROPN
ihlr-25462	176	4	17	17	NUM
ihlr-25462	176	5	,	,	PUNCT
ihlr-25462	176	6	24	24	NUM
ihlr-25462	176	7	-	-	SYM
ihlr-25462	176	8	26	26	NUM
ihlr-25462	176	9	(	(	PUNCT
ihlr-25462	176	10	2016	2016	NUM
ihlr-25462	176	11	)	)	PUNCT
ihlr-25462	176	12	.	.	PUNCT
ihlr-25462	177	1	58	58	NUM
ihlr-25462	177	2	.	.	PUNCT
ihlr-25462	178	1	sarah	sarah	PROPN
ihlr-25462	178	2	r.	r.	PROPN
ihlr-25462	178	3	wasserman	wasserman	PROPN
ihlr-25462	178	4	rajec	rajec	PROPN
ihlr-25462	178	5	,	,	PUNCT
ihlr-25462	178	6	impression	impression	NOUN
ihlr-25462	178	7	products	product	NOUN
ihlr-25462	178	8	,	,	PUNCT
ihlr-25462	178	9	inc	inc	PROPN
ihlr-25462	178	10	.	.	PROPN
ihlr-25462	179	1	v.	v.	PROPN
ihlr-25462	179	2	lexmark	lexmark	PROPN
ihlr-25462	179	3	inc	inc	PROPN
ihlr-25462	179	4	.	.	PROPN
ihlr-25462	179	5	:	:	PUNCT
ihlr-25462	180	1	will	will	AUX
ihlr-25462	180	2	international	international	ADJ
ihlr-25462	180	3	patent	patent	NOUN
ihlr-25462	180	4	exhaustion	exhaustion	NOUN
ihlr-25462	180	5	bring	bring	VERB
ihlr-25462	180	6	free	free	ADJ
ihlr-25462	180	7	trade	trade	NOUN
ihlr-25462	180	8	in	in	ADP
ihlr-25462	180	9	patented	patented	ADJ
ihlr-25462	180	10	goods	good	NOUN
ihlr-25462	180	11	,	,	PUNCT
ihlr-25462	180	12	patently	patently	ADV
ihlr-25462	180	13	-	-	PUNCT
ihlr-25462	180	14	o	o	X
ihlr-25462	180	15	(	(	PUNCT
ihlr-25462	180	16	june	june	PROPN
ihlr-25462	180	17	1	1	NUM
ihlr-25462	180	18	,	,	PUNCT
ihlr-25462	180	19	2017	2017	NUM
ihlr-25462	180	20	)	)	PUNCT
ihlr-25462	180	21	,	,	PUNCT
ihlr-25462	180	22	h	h	PROPN
ihlr-25462	180	23	t	t	PROPN
ihlr-25462	180	24	tps:/	tps:/	PROPN
ihlr-25462	180	25	/paten	/paten	PUNCT
ihlr-25462	180	26	tlyo.com/paten	tlyo.com/paten	ADV
ihlr-25462	180	27	t/201	t/201	VERB
ihlr-25462	180	28	7	7	NUM
ihlr-25462	180	29	/0	/0	NOUN
ihlr-25462	180	30	6	6	NUM
ihlr-25462	180	31	/impression	/impression	NOUN
ihlr-25462	180	32	-	-	PUNCT
ihlr-25462	180	33	in	in	ADP
ihlr-25462	180	34	ternational	ternational	ADJ
ihlr-25462	180	35	-	-	PUNCT
ihlr-25462	180	36	exhaust	exhaust	NOUN
ihlr-25462	180	37	ion	ion	NOUN
ihlr-25462	180	38	.h	.h	NOUN
ihlr-25462	181	1	tml	tml	PROPN
ihlr-25462	182	1	https://perma.cc/b3jx-xdkx	https://perma.cc/b3jx-xdkx	PROPN
ihlr-25462	182	2	]	]	PUNCT
ihlr-25462	182	3	.	.	PUNCT
ihlr-25462	183	1	59	59	NUM
ihlr-25462	183	2	.	.	PUNCT
ihlr-25462	183	3	brief	brief	NOUN
ihlr-25462	183	4	for	for	ADP
ihlr-25462	183	5	biotechnology	biotechnology	NOUN
ihlr-25462	183	6	innovation	innovation	NOUN
ihlr-25462	183	7	org	org	PROPN
ihlr-25462	183	8	.	.	PUNCT
ihlr-25462	183	9	&	&	CCONJ
ihlr-25462	183	10	croplife	croplife	PROPN
ihlr-25462	183	11	int’l	int’l	NUM
ihlr-25462	183	12	as	as	SCONJ
ihlr-25462	183	13	amici	amici	PROPN
ihlr-25462	183	14	curiae	curiae	NOUN
ihlr-25462	183	15	in	in	ADP
ihlr-25462	183	16	support	support	NOUN
ihlr-25462	183	17	of	of	ADP
ihlr-25462	183	18	respondent	respondent	NOUN
ihlr-25462	183	19	at	at	ADP
ihlr-25462	183	20	17	17	NUM
ihlr-25462	183	21	,	,	PUNCT
ihlr-25462	183	22	impression	impression	NOUN
ihlr-25462	183	23	prods	prod	VERB
ihlr-25462	183	24	.	.	PUNCT
ihlr-25462	183	25	,	,	PUNCT
ihlr-25462	183	26	inc	inc	PROPN
ihlr-25462	183	27	.	.	PROPN
ihlr-25462	184	1	v.	v.	ADP
ihlr-25462	184	2	lexmark	lexmark	PROPN
ihlr-25462	184	3	int’l	int’l	NUM
ihlr-25462	184	4	,	,	PUNCT
ihlr-25462	184	5	inc	inc	PROPN
ihlr-25462	184	6	.	.	PROPN
ihlr-25462	184	7	,	,	PUNCT
ihlr-25462	184	8	137	137	NUM
ihlr-25462	184	9	s.	s.	PROPN
ihlr-25462	184	10	ct	ct	PROPN
ihlr-25462	184	11	.	.	PROPN
ihlr-25462	184	12	1523	1523	NUM
ihlr-25462	184	13	(	(	PUNCT
ihlr-25462	184	14	2017	2017	NUM
ihlr-25462	184	15	)	)	PUNCT
ihlr-25462	184	16	(	(	PUNCT
ihlr-25462	184	17	stating	state	VERB
ihlr-25462	184	18	that	that	SCONJ
ihlr-25462	184	19	“	"	PUNCT
ihlr-25462	184	20	[	[	X
ihlr-25462	184	21	a]ny	a]ny	X
ihlr-25462	184	22	benefits	benefit	NOUN
ihlr-25462	184	23	to	to	ADP
ihlr-25462	184	24	u.s	u.s	PROPN
ihlr-25462	184	25	.	.	PROPN
ihlr-25462	184	26	consumers	consumer	NOUN
ihlr-25462	184	27	would	would	AUX
ihlr-25462	184	28	likely	likely	ADV
ihlr-25462	184	29	accrue	accrue	VERB
ihlr-25462	184	30	at	at	ADP
ihlr-25462	184	31	the	the	DET
ihlr-25462	184	32	expense	expense	NOUN
ihlr-25462	184	33	of	of	ADP
ihlr-25462	184	34	poorer	poor	ADJ
ihlr-25462	184	35	consumers	consumer	NOUN
ihlr-25462	184	36	elsewhere	elsewhere	ADV
ihlr-25462	184	37	”	"	PUNCT
ihlr-25462	184	38	)	)	PUNCT
ihlr-25462	184	39	.	.	PUNCT
ihlr-25462	185	1	60	60	NUM
ihlr-25462	185	2	.	.	PUNCT
ihlr-25462	186	1	hemel	hemel	PROPN
ihlr-25462	186	2	&	&	CCONJ
ihlr-25462	186	3	ouellette	ouellette	PROPN
ihlr-25462	186	4	,	,	PUNCT
ihlr-25462	186	5	supra	supra	PROPN
ihlr-25462	186	6	note	note	PROPN
ihlr-25462	186	7	57	57	NUM
ihlr-25462	186	8	,	,	PUNCT
ihlr-25462	186	9	at	at	ADP
ihlr-25462	186	10	25	25	NUM
ihlr-25462	186	11	61	61	NUM
ihlr-25462	186	12	.	.	PUNCT
ihlr-25462	187	1	herbert	herbert	PROPN
ihlr-25462	187	2	hovenkamp	hovenkamp	PROPN
ihlr-25462	187	3	,	,	PUNCT
ihlr-25462	187	4	reasonable	reasonable	ADJ
ihlr-25462	187	5	patent	patent	NOUN
ihlr-25462	187	6	exhaustion	exhaustion	NOUN
ihlr-25462	187	7	,	,	PUNCT
ihlr-25462	187	8	35	35	NUM
ihlr-25462	187	9	yale	yale	NOUN
ihlr-25462	187	10	j.	j.	PROPN
ihlr-25462	187	11	on	on	ADP
ihlr-25462	187	12	reg	reg	PROPN
ihlr-25462	187	13	.	.	PUNCT
ihlr-25462	187	14	513	513	NUM
ihlr-25462	187	15	,	,	PUNCT
ihlr-25462	187	16	515	515	NUM
ihlr-25462	187	17	-	-	SYM
ihlr-25462	187	18	16	16	NUM
ihlr-25462	187	19	2021	2021	NUM
ihlr-25462	187	20	]	]	PUNCT
ihlr-25462	187	21	a	a	DET
ihlr-25462	187	22	survey	survey	NOUN
ihlr-25462	187	23	of	of	ADP
ihlr-25462	187	24	three	three	NUM
ihlr-25462	187	25	patent	patent	NOUN
ihlr-25462	187	26	-	-	PUNCT
ihlr-25462	187	27	based	base	VERB
ihlr-25462	187	28	approaches	approach	NOUN
ihlr-25462	187	29	405	405	NUM
ihlr-25462	187	30	under	under	ADP
ihlr-25462	187	31	a	a	DET
ihlr-25462	187	32	new	new	ADJ
ihlr-25462	187	33	definition	definition	NOUN
ihlr-25462	187	34	of	of	ADP
ihlr-25462	187	35	patent	patent	NOUN
ihlr-25462	187	36	exhaustion	exhaustion	NOUN
ihlr-25462	187	37	,	,	PUNCT
ihlr-25462	187	38	in	in	ADP
ihlr-25462	187	39	a	a	DET
ihlr-25462	187	40	drug	drug	NOUN
ihlr-25462	187	41	context	context	NOUN
ihlr-25462	187	42	,	,	PUNCT
ihlr-25462	187	43	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	187	44	companies	company	NOUN
ihlr-25462	187	45	may	may	AUX
ihlr-25462	187	46	be	be	AUX
ihlr-25462	187	47	left	leave	VERB
ihlr-25462	187	48	with	with	ADP
ihlr-25462	187	49	few	few	ADJ
ihlr-25462	187	50	appealing	appealing	ADJ
ihlr-25462	187	51	options	option	NOUN
ihlr-25462	187	52	.	.	PUNCT
ihlr-25462	188	1	in	in	ADP
ihlr-25462	188	2	theory	theory	NOUN
ihlr-25462	188	3	,	,	PUNCT
ihlr-25462	188	4	u.s	u.s	PROPN
ihlr-25462	188	5	.	.	PROPN
ihlr-25462	188	6	manufacturers	manufacturer	NOUN
ihlr-25462	188	7	may	may	AUX
ihlr-25462	188	8	need	need	VERB
ihlr-25462	188	9	to	to	PART
ihlr-25462	188	10	raise	raise	VERB
ihlr-25462	188	11	prices	price	NOUN
ihlr-25462	188	12	in	in	ADP
ihlr-25462	188	13	foreign	foreign	ADJ
ihlr-25462	188	14	markets	market	NOUN
ihlr-25462	188	15	and	and	CCONJ
ihlr-25462	188	16	lower	low	ADJ
ihlr-25462	188	17	prices	price	NOUN
ihlr-25462	188	18	in	in	ADP
ihlr-25462	188	19	u.s	u.s	PROPN
ihlr-25462	188	20	.	.	PROPN
ihlr-25462	188	21	markets	market	NOUN
ihlr-25462	188	22	under	under	ADP
ihlr-25462	188	23	a	a	DET
ihlr-25462	188	24	rule	rule	NOUN
ihlr-25462	188	25	of	of	ADP
ihlr-25462	188	26	international	international	ADJ
ihlr-25462	188	27	exhaustion	exhaustion	NOUN
ihlr-25462	188	28	.	.	PUNCT
ihlr-25462	189	1	in	in	ADP
ihlr-25462	189	2	other	other	ADJ
ihlr-25462	189	3	words	word	NOUN
ihlr-25462	189	4	,	,	PUNCT
ihlr-25462	189	5	the	the	DET
ihlr-25462	189	6	u.s	u.s	PROPN
ihlr-25462	189	7	.	.	PROPN
ihlr-25462	189	8	may	may	AUX
ihlr-25462	189	9	need	need	VERB
ihlr-25462	189	10	to	to	PART
ihlr-25462	189	11	move	move	VERB
ihlr-25462	189	12	toward	toward	ADP
ihlr-25462	189	13	global	global	ADJ
ihlr-25462	189	14	prices	price	NOUN
ihlr-25462	189	15	.	.	PUNCT
ihlr-25462	190	1	“	"	PUNCT
ihlr-25462	190	2	benefits	benefit	NOUN
ihlr-25462	190	3	should	should	AUX
ihlr-25462	190	4	accrue	accrue	VERB
ihlr-25462	190	5	to	to	ADP
ihlr-25462	190	6	u.s	u.s	PROPN
ihlr-25462	190	7	.	.	PROPN
ihlr-25462	190	8	consumers	consumer	NOUN
ihlr-25462	190	9	who	who	PRON
ihlr-25462	190	10	would	would	AUX
ihlr-25462	190	11	pay	pay	VERB
ihlr-25462	190	12	something	something	PRON
ihlr-25462	190	13	between	between	ADP
ihlr-25462	190	14	the	the	DET
ihlr-25462	190	15	former	former	ADJ
ihlr-25462	190	16	u.s	u.s	PROPN
ihlr-25462	190	17	.	.	PROPN
ihlr-25462	190	18	‘	'	PUNCT
ihlr-25462	190	19	surplus	surplus	NOUN
ihlr-25462	190	20	’	'	PUNCT
ihlr-25462	190	21	price	price	NOUN
ihlr-25462	190	22	and	and	CCONJ
ihlr-25462	190	23	the	the	DET
ihlr-25462	190	24	adjusted	adjust	VERB
ihlr-25462	190	25	global	global	ADJ
ihlr-25462	190	26	price	price	NOUN
ihlr-25462	190	27	,	,	PUNCT
ihlr-25462	190	28	assuming	assume	VERB
ihlr-25462	190	29	that	that	SCONJ
ihlr-25462	190	30	the	the	DET
ihlr-25462	190	31	pre	pre	ADJ
ihlr-25462	190	32	-	-	ADJ
ihlr-25462	190	33	international	international	ADJ
ihlr-25462	190	34	exhaustion	exhaustion	NOUN
ihlr-25462	190	35	price	price	NOUN
ihlr-25462	190	36	was	be	AUX
ihlr-25462	190	37	higher	high	ADJ
ihlr-25462	190	38	.	.	PUNCT
ihlr-25462	191	1	”62	”62	NOUN
ihlr-25462	191	2	one	one	NUM
ihlr-25462	191	3	possibility	possibility	NOUN
ihlr-25462	191	4	for	for	ADP
ihlr-25462	191	5	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	191	6	companies	company	NOUN
ihlr-25462	191	7	is	be	AUX
ihlr-25462	191	8	to	to	PART
ihlr-25462	191	9	evaluate	evaluate	VERB
ihlr-25462	191	10	their	their	PRON
ihlr-25462	191	11	contracts	contract	NOUN
ihlr-25462	191	12	with	with	ADP
ihlr-25462	191	13	distributors	distributor	NOUN
ihlr-25462	191	14	“	"	PUNCT
ihlr-25462	191	15	to	to	PART
ihlr-25462	191	16	ensure	ensure	VERB
ihlr-25462	191	17	that	that	SCONJ
ihlr-25462	191	18	those	those	DET
ihlr-25462	191	19	contracts	contract	NOUN
ihlr-25462	191	20	prohibit	prohibit	VERB
ihlr-25462	191	21	redistribution	redistribution	NOUN
ihlr-25462	191	22	into	into	ADP
ihlr-25462	191	23	the	the	DET
ihlr-25462	191	24	u.s	u.s	PROPN
ihlr-25462	191	25	.	.	PROPN
ihlr-25462	191	26	,	,	PUNCT
ihlr-25462	191	27	”	"	PUNCT
ihlr-25462	191	28	providing	provide	VERB
ihlr-25462	191	29	them	they	PRON
ihlr-25462	191	30	with	with	ADP
ihlr-25462	191	31	a	a	DET
ihlr-25462	191	32	contractual	contractual	ADJ
ihlr-25462	191	33	cause	cause	NOUN
ihlr-25462	191	34	of	of	ADP
ihlr-25462	191	35	action	action	NOUN
ihlr-25462	191	36	against	against	ADP
ihlr-25462	191	37	the	the	DET
ihlr-25462	191	38	distributor	distributor	NOUN
ihlr-25462	191	39	if	if	SCONJ
ihlr-25462	191	40	the	the	DET
ihlr-25462	191	41	distributor	distributor	NOUN
ihlr-25462	191	42	were	be	AUX
ihlr-25462	191	43	to	to	PART
ihlr-25462	191	44	attempt	attempt	VERB
ihlr-25462	191	45	to	to	PART
ihlr-25462	191	46	import	import	VERB
ihlr-25462	191	47	its	its	PRON
ihlr-25462	191	48	products	product	NOUN
ihlr-25462	191	49	back	back	ADV
ihlr-25462	191	50	into	into	ADP
ihlr-25462	191	51	the	the	DET
ihlr-25462	191	52	u.s.63	u.s.63	PROPN
ihlr-25462	191	53	another	another	DET
ihlr-25462	191	54	creative	creative	ADJ
ihlr-25462	191	55	approach	approach	NOUN
ihlr-25462	191	56	is	be	AUX
ihlr-25462	191	57	to	to	PART
ihlr-25462	191	58	restrict	restrict	VERB
ihlr-25462	191	59	re	re	NOUN
ihlr-25462	191	60	-	-	NOUN
ihlr-25462	191	61	importation	importation	NOUN
ihlr-25462	191	62	via	via	ADP
ihlr-25462	191	63	license	license	NOUN
ihlr-25462	191	64	.	.	PUNCT
ihlr-25462	192	1	as	as	SCONJ
ihlr-25462	192	2	pointed	point	VERB
ihlr-25462	192	3	out	out	ADP
ihlr-25462	192	4	in	in	ADP
ihlr-25462	192	5	one	one	NUM
ihlr-25462	192	6	editorial	editorial	NOUN
ihlr-25462	192	7	by	by	ADP
ihlr-25462	192	8	daniel	daniel	PROPN
ihlr-25462	192	9	hemel	hemel	PROPN
ihlr-25462	192	10	and	and	CCONJ
ihlr-25462	192	11	lisa	lisa	PROPN
ihlr-25462	192	12	larrimore	larrimore	PROPN
ihlr-25462	192	13	ouellette	ouellette	NOUN
ihlr-25462	192	14	,	,	PUNCT
ihlr-25462	192	15	instead	instead	ADV
ihlr-25462	192	16	of	of	ADP
ihlr-25462	192	17	selling	sell	VERB
ihlr-25462	192	18	medicines	medicine	NOUN
ihlr-25462	192	19	to	to	ADP
ihlr-25462	192	20	foreign	foreign	ADJ
ihlr-25462	192	21	countries	country	NOUN
ihlr-25462	192	22	,	,	PUNCT
ihlr-25462	192	23	the	the	DET
ihlr-25462	192	24	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	192	25	company	company	NOUN
ihlr-25462	192	26	could	could	AUX
ihlr-25462	192	27	“	"	PUNCT
ihlr-25462	192	28	license	license	VERB
ihlr-25462	192	29	”	"	PUNCT
ihlr-25462	192	30	the	the	DET
ihlr-25462	192	31	pill	pill	NOUN
ihlr-25462	192	32	to	to	ADP
ihlr-25462	192	33	patients	patient	NOUN
ihlr-25462	192	34	on	on	ADP
ihlr-25462	192	35	the	the	DET
ihlr-25462	192	36	condition	condition	NOUN
ihlr-25462	192	37	that	that	SCONJ
ihlr-25462	192	38	they	they	PRON
ihlr-25462	192	39	either	either	CCONJ
ihlr-25462	192	40	“	"	PUNCT
ihlr-25462	192	41	return	return	VERB
ihlr-25462	192	42	the	the	DET
ihlr-25462	192	43	pill	pill	NOUN
ihlr-25462	192	44	or	or	CCONJ
ihlr-25462	192	45	ingest	ingest	VERB
ihlr-25462	192	46	it	it	PRON
ihlr-25462	192	47	,	,	PUNCT
ihlr-25462	192	48	”	"	PUNCT
ihlr-25462	192	49	utilizing	utilize	VERB
ihlr-25462	192	50	a	a	DET
ihlr-25462	192	51	principle	principle	NOUN
ihlr-25462	192	52	that	that	PRON
ihlr-25462	192	53	is	be	AUX
ihlr-25462	192	54	popular	popular	ADJ
ihlr-25462	192	55	in	in	ADP
ihlr-25462	192	56	many	many	ADJ
ihlr-25462	192	57	other	other	ADJ
ihlr-25462	192	58	industries	industry	NOUN
ihlr-25462	192	59	with	with	ADP
ihlr-25462	192	60	this	this	DET
ihlr-25462	192	61	issue.64	issue.64	NOUN
ihlr-25462	192	62	further	far	ADV
ihlr-25462	192	63	,	,	PUNCT
ihlr-25462	192	64	the	the	DET
ihlr-25462	192	65	u.s	u.s	PROPN
ihlr-25462	192	66	.	.	PROPN
ihlr-25462	192	67	patent	patent	NOUN
ihlr-25462	192	68	exhaustion	exhaustion	NOUN
ihlr-25462	192	69	rule	rule	NOUN
ihlr-25462	192	70	still	still	ADV
ihlr-25462	192	71	starkly	starkly	ADV
ihlr-25462	192	72	contrasts	contrast	VERB
ihlr-25462	192	73	with	with	ADP
ihlr-25462	192	74	the	the	DET
ihlr-25462	192	75	law	law	NOUN
ihlr-25462	192	76	in	in	ADP
ihlr-25462	192	77	other	other	ADJ
ihlr-25462	192	78	areas	area	NOUN
ihlr-25462	192	79	of	of	ADP
ihlr-25462	192	80	the	the	DET
ihlr-25462	192	81	world	world	NOUN
ihlr-25462	192	82	.	.	PUNCT
ihlr-25462	193	1	for	for	ADP
ihlr-25462	193	2	example	example	NOUN
ihlr-25462	193	3	,	,	PUNCT
ihlr-25462	193	4	canada	canada	PROPN
ihlr-25462	193	5	’s	’s	PART
ihlr-25462	193	6	patent	patent	NOUN
ihlr-25462	193	7	act	act	NOUN
ihlr-25462	193	8	has	have	VERB
ihlr-25462	193	9	no	no	DET
ihlr-25462	193	10	express	express	ADJ
ihlr-25462	193	11	provisions	provision	NOUN
ihlr-25462	193	12	analogous	analogous	ADJ
ihlr-25462	193	13	to	to	ADP
ihlr-25462	193	14	the	the	DET
ihlr-25462	193	15	exhaustion	exhaustion	NOUN
ihlr-25462	193	16	doctrine.65	doctrine.65	NOUN
ihlr-25462	193	17	additionally	additionally	ADV
ihlr-25462	193	18	,	,	PUNCT
ihlr-25462	193	19	the	the	DET
ihlr-25462	193	20	world	world	NOUN
ihlr-25462	193	21	trade	trade	PROPN
ihlr-25462	193	22	organization	organization	PROPN
ihlr-25462	193	23	’s	’s	PART
ihlr-25462	193	24	trade	trade	NOUN
ihlr-25462	193	25	related	relate	VERB
ihlr-25462	193	26	aspects	aspect	NOUN
ihlr-25462	193	27	of	of	ADP
ihlr-25462	193	28	intellectual	intellectual	ADJ
ihlr-25462	193	29	property	property	NOUN
ihlr-25462	193	30	rights	right	NOUN
ihlr-25462	193	31	allows	allow	VERB
ihlr-25462	193	32	member	member	NOUN
ihlr-25462	193	33	nations	nation	NOUN
ihlr-25462	193	34	discretion	discretion	NOUN
ihlr-25462	193	35	regarding	regard	VERB
ihlr-25462	193	36	their	their	PRON
ihlr-25462	193	37	own	own	ADJ
ihlr-25462	193	38	interpretations	interpretation	NOUN
ihlr-25462	193	39	of	of	ADP
ihlr-25462	193	40	the	the	DET
ihlr-25462	193	41	exhaustion	exhaustion	NOUN
ihlr-25462	193	42	doctrine	doctrine	NOUN
ihlr-25462	193	43	“	"	PUNCT
ihlr-25462	193	44	whether	whether	SCONJ
ihlr-25462	193	45	by	by	ADP
ihlr-25462	193	46	statute	statute	NOUN
ihlr-25462	193	47	,	,	PUNCT
ihlr-25462	193	48	judicial	judicial	ADJ
ihlr-25462	193	49	opinion	opinion	NOUN
ihlr-25462	193	50	,	,	PUNCT
ihlr-25462	193	51	or	or	CCONJ
ihlr-25462	193	52	agency	agency	NOUN
ihlr-25462	193	53	regulations	regulation	NOUN
ihlr-25462	193	54	.	.	PUNCT
ihlr-25462	194	1	”66	”66	PROPN
ihlr-25462	194	2	d.	d.	PROPN
ihlr-25462	194	3	legislation	legislation	NOUN
ihlr-25462	194	4	addressing	address	VERB
ihlr-25462	194	5	drug	drug	NOUN
ihlr-25462	194	6	re	re	NOUN
ihlr-25462	194	7	-	-	NOUN
ihlr-25462	194	8	importation	importation	NOUN
ihlr-25462	194	9	&	&	CCONJ
ihlr-25462	194	10	u.s	u.s	PROPN
ihlr-25462	194	11	.	.	PROPN
ihlr-25462	194	12	price	price	NOUN
ihlr-25462	194	13	controls	control	VERB
ihlr-25462	194	14	the	the	DET
ihlr-25462	194	15	post	post	ADJ
ihlr-25462	194	16	-	-	ADJ
ihlr-25462	194	17	lexmark	lexmark	ADJ
ihlr-25462	194	18	blogosphere	blogosphere	NOUN
ihlr-25462	194	19	was	be	AUX
ihlr-25462	194	20	active	active	ADJ
ihlr-25462	194	21	in	in	ADP
ihlr-25462	194	22	declaring	declare	VERB
ihlr-25462	194	23	that	that	SCONJ
ihlr-25462	194	24	the	the	DET
ihlr-25462	194	25	patent	patent	NOUN
ihlr-25462	194	26	exhaustion	exhaustion	NOUN
ihlr-25462	194	27	doctrine	doctrine	NOUN
ihlr-25462	194	28	would	would	AUX
ihlr-25462	194	29	not	not	PART
ihlr-25462	194	30	“	"	PUNCT
ihlr-25462	194	31	throw	throw	VERB
ihlr-25462	194	32	open	open	ADJ
ihlr-25462	194	33	the	the	DET
ihlr-25462	194	34	gates	gate	NOUN
ihlr-25462	194	35	for	for	ADP
ihlr-25462	194	36	access	access	NOUN
ihlr-25462	194	37	to	to	ADP
ihlr-25462	194	38	cheaper	cheap	ADJ
ihlr-25462	194	39	foreign	foreign	ADJ
ihlr-25462	194	40	(	(	PUNCT
ihlr-25462	194	41	2018	2018	NUM
ihlr-25462	194	42	)	)	PUNCT
ihlr-25462	194	43	.	.	PUNCT
ihlr-25462	195	1	62	62	NUM
ihlr-25462	195	2	.	.	PUNCT
ihlr-25462	195	3	brief	brief	ADJ
ihlr-25462	195	4	for	for	ADP
ihlr-25462	195	5	professor	professor	PROPN
ihlr-25462	195	6	frederick	frederick	PROPN
ihlr-25462	195	7	m.	m.	PROPN
ihlr-25462	195	8	abbot	abbot	PROPN
ihlr-25462	195	9	as	as	ADP
ihlr-25462	195	10	amicus	amicus	NOUN
ihlr-25462	195	11	curiae	curiae	NOUN
ihlr-25462	195	12	in	in	ADP
ihlr-25462	195	13	support	support	NOUN
ihlr-25462	195	14	of	of	ADP
ihlr-25462	195	15	petitioner	petitioner	NOUN
ihlr-25462	195	16	at	at	ADP
ihlr-25462	195	17	20	20	NUM
ihlr-25462	195	18	,	,	PUNCT
ihlr-25462	195	19	impression	impression	NOUN
ihlr-25462	195	20	prods	prod	VERB
ihlr-25462	195	21	.	.	PUNCT
ihlr-25462	195	22	,	,	PUNCT
ihlr-25462	195	23	inc	inc	PROPN
ihlr-25462	195	24	.	.	PROPN
ihlr-25462	196	1	v.	v.	ADP
ihlr-25462	196	2	lexmark	lexmark	PROPN
ihlr-25462	196	3	int’l	int’l	NUM
ihlr-25462	196	4	,	,	PUNCT
ihlr-25462	196	5	inc	inc	PROPN
ihlr-25462	196	6	.	.	PROPN
ihlr-25462	196	7	,	,	PUNCT
ihlr-25462	196	8	137	137	NUM
ihlr-25462	196	9	s.	s.	PROPN
ihlr-25462	196	10	ct	ct	PROPN
ihlr-25462	196	11	.	.	PROPN
ihlr-25462	196	12	1523	1523	NUM
ihlr-25462	196	13	(	(	PUNCT
ihlr-25462	196	14	2017	2017	NUM
ihlr-25462	196	15	)	)	PUNCT
ihlr-25462	196	16	.	.	PUNCT
ihlr-25462	197	1	63	63	NUM
ihlr-25462	197	2	.	.	PUNCT
ihlr-25462	197	3	doug	doug	PROPN
ihlr-25462	197	4	robinson	robinson	PROPN
ihlr-25462	197	5	,	,	PUNCT
ihlr-25462	197	6	lexmark	lexmark	NOUN
ihlr-25462	197	7	case	case	NOUN
ihlr-25462	197	8	:	:	PUNCT
ihlr-25462	197	9	pharma	pharma	PROPN
ihlr-25462	197	10	should	should	AUX
ihlr-25462	197	11	review	review	VERB
ihlr-25462	197	12	distribution	distribution	NOUN
ihlr-25462	197	13	networks	network	NOUN
ihlr-25462	197	14	,	,	PUNCT
ihlr-25462	197	15	pharmaphorum	pharmaphorum	NOUN
ihlr-25462	197	16	(	(	PUNCT
ihlr-25462	197	17	oct	oct	PROPN
ihlr-25462	197	18	.	.	PROPN
ihlr-25462	197	19	9	9	NUM
ihlr-25462	197	20	,	,	PUNCT
ihlr-25462	197	21	2017	2017	NUM
ihlr-25462	197	22	)	)	PUNCT
ihlr-25462	197	23	,	,	PUNCT
ihlr-25462	197	24	https://pharmaphorum.com/views-and-analysis/pharmadistribution-channel-review/	https://pharmaphorum.com/views-and-analysis/pharmadistribution-channel-review/	NOUN
ihlr-25462	197	25	[	[	X
ihlr-25462	197	26	https://perma.cc/j7gr-tsvd	https://perma.cc/j7gr-tsvd	NOUN
ihlr-25462	197	27	]	]	PUNCT
ihlr-25462	197	28	.	.	PUNCT
ihlr-25462	198	1	64	64	NUM
ihlr-25462	198	2	.	.	PUNCT
ihlr-25462	199	1	daniel	daniel	PROPN
ihlr-25462	199	2	hemel	hemel	PROPN
ihlr-25462	199	3	&	&	CCONJ
ihlr-25462	199	4	lisa	lisa	PROPN
ihlr-25462	199	5	larrimore	larrimore	PROPN
ihlr-25462	199	6	ouellette	ouellette	PROPN
ihlr-25462	199	7	,	,	PUNCT
ihlr-25462	199	8	licensing	license	VERB
ihlr-25462	199	9	in	in	ADP
ihlr-25462	199	10	the	the	DET
ihlr-25462	199	11	shadow	shadow	NOUN
ihlr-25462	199	12	of	of	ADP
ihlr-25462	199	13	impression	impression	NOUN
ihlr-25462	199	14	products	product	NOUN
ihlr-25462	199	15	(	(	PUNCT
ihlr-25462	199	16	with	with	ADP
ihlr-25462	199	17	lisa	lisa	PROPN
ihlr-25462	199	18	larrimore	larrimore	PROPN
ihlr-25462	199	19	ouellette	ouellette	PROPN
ihlr-25462	199	20	)	)	PUNCT
ihlr-25462	199	21	,	,	PUNCT
ihlr-25462	199	22	medium	medium	NOUN
ihlr-25462	199	23	(	(	PUNCT
ihlr-25462	199	24	may	may	PROPN
ihlr-25462	199	25	31	31	NUM
ihlr-25462	199	26	,	,	PUNCT
ihlr-25462	199	27	2017	2017	NUM
ihlr-25462	199	28	)	)	PUNCT
ihlr-25462	199	29	,	,	PUNCT
ihlr-25462	199	30	https://medium.com/whateversource-derived/licensing-in-the-shadow-of-impression-products-with-lisa-larrimore-ouellette9bbf8c350c65	https://medium.com/whateversource-derived/licensing-in-the-shadow-of-impression-products-with-lisa-larrimore-ouellette9bbf8c350c65	X
ihlr-25462	200	1	[	[	X
ihlr-25462	200	2	https://perma.cc/j7tr-4rgg	https://perma.cc/j7tr-4rgg	NOUN
ihlr-25462	200	3	]	]	PUNCT
ihlr-25462	200	4	.	.	PUNCT
ihlr-25462	201	1	65	65	NUM
ihlr-25462	201	2	.	.	PUNCT
ihlr-25462	202	1	olena	olena	PROPN
ihlr-25462	202	2	ivus	ivus	PROPN
ihlr-25462	202	3	,	,	PUNCT
ihlr-25462	202	4	ctr	ctr	PROPN
ihlr-25462	202	5	.	.	PUNCT
ihlr-25462	203	1	for	for	ADP
ihlr-25462	203	2	int’l	int’l	NUM
ihlr-25462	203	3	governance	governance	NOUN
ihlr-25462	203	4	innovation	innovation	NOUN
ihlr-25462	203	5	,	,	PUNCT
ihlr-25462	203	6	patent	patent	NOUN
ihlr-25462	203	7	exhaustion	exhaustion	NOUN
ihlr-25462	203	8	in	in	ADP
ihlr-25462	203	9	the	the	DET
ihlr-25462	203	10	united	united	PROPN
ihlr-25462	203	11	states	states	PROPN
ihlr-25462	203	12	and	and	CCONJ
ihlr-25462	203	13	canada	canada	PROPN
ihlr-25462	203	14	2	2	NUM
ihlr-25462	203	15	(	(	PUNCT
ihlr-25462	203	16	2018	2018	NUM
ihlr-25462	203	17	)	)	PUNCT
ihlr-25462	203	18	,	,	PUNCT
ihlr-25462	203	19	https://www.cigionline.org/sites/default/files/documents/	https://www.cigionline.org/sites/default/files/documents/	NOUN
ihlr-25462	203	20	paper%20159web.pdf	paper%20159web.pdf	PROPN
ihlr-25462	204	1	[	[	X
ihlr-25462	204	2	https://perma.cc/5zpu-n9ac	https://perma.cc/5zpu-n9ac	X
ihlr-25462	204	3	]	]	X
ihlr-25462	204	4	.	.	PUNCT
ihlr-25462	205	1	66	66	NUM
ihlr-25462	205	2	.	.	PUNCT
ihlr-25462	205	3	lucas	lucas	PROPN
ihlr-25462	205	4	brown	brown	PROPN
ihlr-25462	205	5	,	,	PUNCT
ihlr-25462	205	6	intellectual	intellectual	ADJ
ihlr-25462	205	7	property	property	NOUN
ihlr-25462	205	8	rights	right	NOUN
ihlr-25462	205	9	require	require	VERB
ihlr-25462	205	10	a	a	DET
ihlr-25462	205	11	balancing	balance	VERB
ihlr-25462	205	12	act	act	NOUN
ihlr-25462	205	13	:	:	PUNCT
ihlr-25462	205	14	the	the	DET
ihlr-25462	205	15	exhaustion	exhaustion	NOUN
ihlr-25462	205	16	doctrine	doctrine	NOUN
ihlr-25462	205	17	and	and	CCONJ
ihlr-25462	205	18	patentee	patentee	NOUN
ihlr-25462	205	19	rights	right	NOUN
ihlr-25462	205	20	vs.	vs.	ADP
ihlr-25462	205	21	consumer	consumer	NOUN
ihlr-25462	205	22	protection	protection	NOUN
ihlr-25462	205	23	,	,	PUNCT
ihlr-25462	205	24	wake	wake	VERB
ihlr-25462	205	25	forest	forest	NOUN
ihlr-25462	205	26	j.	j.	PROPN
ihlr-25462	205	27	bus	bus	PROPN
ihlr-25462	205	28	.	.	PROPN
ihlr-25462	205	29	&	&	CCONJ
ihlr-25462	205	30	intell	intell	PROPN
ihlr-25462	205	31	.	.	PUNCT
ihlr-25462	206	1	prop	prop	PROPN
ihlr-25462	206	2	.	.	PUNCT
ihlr-25462	207	1	l.	l.	PROPN
ihlr-25462	207	2	204	204	NUM
ihlr-25462	207	3	,	,	PUNCT
ihlr-25462	207	4	207	207	NUM
ihlr-25462	207	5	(	(	PUNCT
ihlr-25462	207	6	2019	2019	NUM
ihlr-25462	207	7	)	)	PUNCT
ihlr-25462	207	8	.	.	PUNCT
ihlr-25462	208	1	406	406	NUM
ihlr-25462	208	2	indiana	indiana	PROPN
ihlr-25462	208	3	health	health	PROPN
ihlr-25462	208	4	law	law	NOUN
ihlr-25462	208	5	review	review	NOUN
ihlr-25462	208	6	[	[	X
ihlr-25462	208	7	vol	vol	NOUN
ihlr-25462	208	8	.	.	PUNCT
ihlr-25462	208	9	18:397	18:397	NUM
ihlr-25462	208	10	medicines	medicine	NOUN
ihlr-25462	208	11	”	"	PUNCT
ihlr-25462	208	12	because	because	SCONJ
ihlr-25462	208	13	section	section	NOUN
ihlr-25462	208	14	804	804	NUM
ihlr-25462	208	15	of	of	ADP
ihlr-25462	208	16	the	the	DET
ihlr-25462	208	17	fdca	fdca	NOUN
ihlr-25462	208	18	,	,	PUNCT
ihlr-25462	208	19	which	which	PRON
ihlr-25462	208	20	“	"	PUNCT
ihlr-25462	208	21	directs	direct	VERB
ihlr-25462	208	22	[	[	X
ihlr-25462	208	23	the	the	X
ihlr-25462	208	24	]	]	X
ihlr-25462	208	25	fda	fda	PROPN
ihlr-25462	208	26	to	to	PART
ihlr-25462	208	27	promulgate	promulgate	VERB
ihlr-25462	208	28	regulations	regulation	NOUN
ihlr-25462	208	29	permitting	permit	VERB
ihlr-25462	208	30	pharmacists	pharmacist	NOUN
ihlr-25462	208	31	and	and	CCONJ
ihlr-25462	208	32	wholesalers	wholesaler	NOUN
ihlr-25462	208	33	to	to	PART
ihlr-25462	208	34	import	import	VERB
ihlr-25462	208	35	prescription	prescription	NOUN
ihlr-25462	208	36	drugs	drug	NOUN
ihlr-25462	208	37	from	from	ADP
ihlr-25462	208	38	canada	canada	PROPN
ihlr-25462	208	39	,	,	PUNCT
ihlr-25462	208	40	”	"	PUNCT
ihlr-25462	208	41	had	have	AUX
ihlr-25462	208	42	never	never	ADV
ihlr-25462	208	43	been	be	AUX
ihlr-25462	208	44	certified	certify	VERB
ihlr-25462	208	45	by	by	ADP
ihlr-25462	208	46	the	the	DET
ihlr-25462	208	47	secretary	secretary	PROPN
ihlr-25462	208	48	of	of	ADP
ihlr-25462	208	49	hhs.67	hhs.67	PROPN
ihlr-25462	208	50	there	there	PRON
ihlr-25462	208	51	are	be	VERB
ihlr-25462	208	52	a	a	DET
ihlr-25462	208	53	few	few	ADJ
ihlr-25462	208	54	reasons	reason	NOUN
ihlr-25462	208	55	for	for	ADP
ihlr-25462	208	56	this	this	PRON
ihlr-25462	208	57	.	.	PUNCT
ihlr-25462	209	1	first	first	ADV
ihlr-25462	209	2	,	,	PUNCT
ihlr-25462	209	3	previous	previous	ADJ
ihlr-25462	209	4	hhs	hhs	PROPN
ihlr-25462	209	5	guidance	guidance	NOUN
ihlr-25462	209	6	estimated	estimate	VERB
ihlr-25462	209	7	that	that	SCONJ
ihlr-25462	209	8	insurance	insurance	NOUN
ihlr-25462	209	9	companies	company	NOUN
ihlr-25462	209	10	,	,	PUNCT
ihlr-25462	209	11	importers	importer	NOUN
ihlr-25462	209	12	,	,	PUNCT
ihlr-25462	209	13	and	and	CCONJ
ihlr-25462	209	14	exporters	exporter	NOUN
ihlr-25462	209	15	would	would	AUX
ihlr-25462	209	16	take	take	VERB
ihlr-25462	209	17	a	a	DET
ihlr-25462	209	18	large	large	ADJ
ihlr-25462	209	19	portion	portion	NOUN
ihlr-25462	209	20	of	of	ADP
ihlr-25462	209	21	the	the	DET
ihlr-25462	209	22	savings	saving	NOUN
ihlr-25462	209	23	that	that	PRON
ihlr-25462	209	24	were	be	AUX
ihlr-25462	209	25	intended	intend	VERB
ihlr-25462	209	26	for	for	ADP
ihlr-25462	209	27	consumers	consumer	NOUN
ihlr-25462	209	28	.	.	PUNCT
ihlr-25462	210	1	also	also	ADV
ihlr-25462	210	2	,	,	PUNCT
ihlr-25462	210	3	sanctioning	sanction	VERB
ihlr-25462	210	4	parallel	parallel	ADJ
ihlr-25462	210	5	trade	trade	NOUN
ihlr-25462	210	6	could	could	AUX
ihlr-25462	210	7	cripple	cripple	VERB
ihlr-25462	210	8	the	the	DET
ihlr-25462	210	9	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	210	10	industry	industry	NOUN
ihlr-25462	210	11	’s	’s	PART
ihlr-25462	210	12	ability	ability	NOUN
ihlr-25462	210	13	to	to	PART
ihlr-25462	210	14	fund	fund	VERB
ihlr-25462	210	15	research	research	NOUN
ihlr-25462	210	16	and	and	CCONJ
ihlr-25462	210	17	development	development	NOUN
ihlr-25462	210	18	(	(	PUNCT
ihlr-25462	210	19	“	"	PUNCT
ihlr-25462	210	20	r&d	r&d	NOUN
ihlr-25462	210	21	”	"	PUNCT
ihlr-25462	210	22	)	)	PUNCT
ihlr-25462	210	23	and	and	CCONJ
ihlr-25462	210	24	innovation	innovation	NOUN
ihlr-25462	210	25	,	,	PUNCT
ihlr-25462	210	26	which	which	PRON
ihlr-25462	210	27	are	be	AUX
ihlr-25462	210	28	“	"	PUNCT
ihlr-25462	210	29	paramount	paramount	ADJ
ihlr-25462	210	30	to	to	ADP
ihlr-25462	210	31	survival	survival	NOUN
ihlr-25462	210	32	”	"	PUNCT
ihlr-25462	210	33	and	and	CCONJ
ihlr-25462	210	34	the	the	DET
ihlr-25462	210	35	costs	cost	NOUN
ihlr-25462	210	36	of	of	ADP
ihlr-25462	210	37	which	which	PRON
ihlr-25462	210	38	have	have	AUX
ihlr-25462	210	39	continued	continue	VERB
ihlr-25462	210	40	to	to	PART
ihlr-25462	210	41	rise	rise	VERB
ihlr-25462	210	42	over	over	ADP
ihlr-25462	210	43	the	the	DET
ihlr-25462	210	44	past	past	ADJ
ihlr-25462	210	45	three	three	NUM
ihlr-25462	210	46	decades.68	decades.68	NOUN
ihlr-25462	210	47	finally	finally	ADV
ihlr-25462	210	48	,	,	PUNCT
ihlr-25462	210	49	the	the	DET
ihlr-25462	210	50	prospect	prospect	NOUN
ihlr-25462	210	51	of	of	ADP
ihlr-25462	210	52	health	health	NOUN
ihlr-25462	210	53	risks	risk	NOUN
ihlr-25462	210	54	seemed	seem	VERB
ihlr-25462	210	55	too	too	ADV
ihlr-25462	210	56	high	high	ADJ
ihlr-25462	210	57	,	,	PUNCT
ihlr-25462	210	58	meaning	mean	VERB
ihlr-25462	210	59	that	that	SCONJ
ihlr-25462	210	60	many	many	ADJ
ihlr-25462	210	61	steps	step	NOUN
ihlr-25462	210	62	must	must	AUX
ihlr-25462	210	63	be	be	AUX
ihlr-25462	210	64	taken	take	VERB
ihlr-25462	210	65	to	to	PART
ihlr-25462	210	66	ensure	ensure	VERB
ihlr-25462	210	67	that	that	SCONJ
ihlr-25462	210	68	drug	drug	NOUN
ihlr-25462	210	69	re	re	NOUN
ihlr-25462	210	70	-	-	NOUN
ihlr-25462	210	71	importation	importation	NOUN
ihlr-25462	210	72	would	would	AUX
ihlr-25462	210	73	not	not	PART
ihlr-25462	210	74	increase	increase	VERB
ihlr-25462	210	75	the	the	DET
ihlr-25462	210	76	risk	risk	NOUN
ihlr-25462	210	77	of	of	ADP
ihlr-25462	210	78	harm	harm	NOUN
ihlr-25462	210	79	to	to	ADP
ihlr-25462	210	80	the	the	DET
ihlr-25462	210	81	american	american	ADJ
ihlr-25462	210	82	consumer.69	consumer.69	NOUN
ihlr-25462	210	83	then	then	ADV
ihlr-25462	210	84	,	,	PUNCT
ihlr-25462	210	85	in	in	ADP
ihlr-25462	210	86	july	july	PROPN
ihlr-25462	210	87	of	of	ADP
ihlr-25462	210	88	2019	2019	NUM
ihlr-25462	210	89	,	,	PUNCT
ihlr-25462	210	90	former	former	ADJ
ihlr-25462	210	91	hhs	hhs	PROPN
ihlr-25462	210	92	secretary	secretary	PROPN
ihlr-25462	210	93	alex	alex	PROPN
ihlr-25462	210	94	azar	azar	PROPN
ihlr-25462	210	95	ii	ii	PROPN
ihlr-25462	210	96	proposed	propose	VERB
ihlr-25462	210	97	a	a	DET
ihlr-25462	210	98	“	"	PUNCT
ihlr-25462	210	99	safe	safe	ADJ
ihlr-25462	210	100	importation	importation	NOUN
ihlr-25462	210	101	action	action	NOUN
ihlr-25462	210	102	plan	plan	NOUN
ihlr-25462	210	103	”	"	PUNCT
ihlr-25462	210	104	that	that	PRON
ihlr-25462	210	105	would	would	AUX
ihlr-25462	210	106	begin	begin	VERB
ihlr-25462	210	107	to	to	PART
ihlr-25462	210	108	eliminate	eliminate	VERB
ihlr-25462	210	109	roadblocks	roadblock	NOUN
ihlr-25462	210	110	to	to	ADP
ihlr-25462	210	111	reimporting	reimporte	VERB
ihlr-25462	210	112	drugs	drug	NOUN
ihlr-25462	210	113	from	from	ADP
ihlr-25462	210	114	foreign	foreign	ADJ
ihlr-25462	210	115	countries	country	NOUN
ihlr-25462	210	116	,	,	PUNCT
ihlr-25462	210	117	such	such	ADJ
ihlr-25462	210	118	as	as	ADP
ihlr-25462	210	119	canada	canada	PROPN
ihlr-25462	210	120	,	,	PUNCT
ihlr-25462	210	121	under	under	ADP
ihlr-25462	210	122	two	two	NUM
ihlr-25462	210	123	potential	potential	ADJ
ihlr-25462	210	124	pathways	pathway	NOUN
ihlr-25462	210	125	,	,	PUNCT
ihlr-25462	210	126	and	and	CCONJ
ihlr-25462	210	127	attempted	attempt	VERB
ihlr-25462	210	128	to	to	PART
ihlr-25462	210	129	address	address	VERB
ihlr-25462	210	130	many	many	ADJ
ihlr-25462	210	131	of	of	ADP
ihlr-25462	210	132	these	these	PRON
ihlr-25462	210	133	concerns.70	concerns.70	NOUN
ihlr-25462	210	134	under	under	ADP
ihlr-25462	210	135	pathway	pathway	NOUN
ihlr-25462	210	136	one	one	NOUN
ihlr-25462	210	137	,	,	PUNCT
ihlr-25462	210	138	a	a	DET
ihlr-25462	210	139	notice	notice	NOUN
ihlr-25462	210	140	of	of	ADP
ihlr-25462	210	141	proposed	propose	VERB
ihlr-25462	210	142	rulemaking	rulemaking	NOUN
ihlr-25462	210	143	(	(	PUNCT
ihlr-25462	210	144	“	"	PUNCT
ihlr-25462	210	145	nprm	nprm	NOUN
ihlr-25462	210	146	”	"	PUNCT
ihlr-25462	210	147	)	)	PUNCT
ihlr-25462	210	148	would	would	AUX
ihlr-25462	210	149	rely	rely	VERB
ihlr-25462	210	150	on	on	ADP
ihlr-25462	210	151	section	section	NOUN
ihlr-25462	210	152	804	804	NUM
ihlr-25462	210	153	of	of	ADP
ihlr-25462	210	154	the	the	DET
ihlr-25462	210	155	fdca	fdca	NOUN
ihlr-25462	210	156	“	"	PUNCT
ihlr-25462	210	157	to	to	PART
ihlr-25462	210	158	authorize	authorize	VERB
ihlr-25462	210	159	demonstration	demonstration	NOUN
ihlr-25462	210	160	projects	project	NOUN
ihlr-25462	210	161	to	to	PART
ihlr-25462	210	162	allow	allow	VERB
ihlr-25462	210	163	importation	importation	NOUN
ihlr-25462	210	164	of	of	ADP
ihlr-25462	210	165	drugs	drug	NOUN
ihlr-25462	210	166	from	from	ADP
ihlr-25462	210	167	canada	canada	PROPN
ihlr-25462	210	168	.	.	PUNCT
ihlr-25462	211	1	”71	”71	PROPN
ihlr-25462	211	2	section	section	NOUN
ihlr-25462	211	3	804	804	NUM
ihlr-25462	211	4	can	can	AUX
ihlr-25462	211	5	only	only	ADV
ihlr-25462	211	6	be	be	AUX
ihlr-25462	211	7	used	use	VERB
ihlr-25462	211	8	if	if	SCONJ
ihlr-25462	211	9	the	the	DET
ihlr-25462	211	10	secretary	secretary	PROPN
ihlr-25462	211	11	of	of	ADP
ihlr-25462	211	12	hhs	hhs	PROPN
ihlr-25462	211	13	certifies	certifie	NOUN
ihlr-25462	211	14	that	that	SCONJ
ihlr-25462	211	15	importation	importation	NOUN
ihlr-25462	211	16	would	would	AUX
ihlr-25462	211	17	impose	impose	VERB
ihlr-25462	211	18	“	"	PUNCT
ihlr-25462	211	19	no	no	DET
ihlr-25462	211	20	additional	additional	ADJ
ihlr-25462	211	21	risk	risk	NOUN
ihlr-25462	211	22	”	"	PUNCT
ihlr-25462	211	23	to	to	ADP
ihlr-25462	211	24	u.s	u.s	PROPN
ihlr-25462	211	25	.	.	PROPN
ihlr-25462	211	26	consumers	consumer	NOUN
ihlr-25462	211	27	and	and	CCONJ
ihlr-25462	211	28	that	that	SCONJ
ihlr-25462	211	29	it	it	PRON
ihlr-25462	211	30	would	would	AUX
ihlr-25462	211	31	“	"	PUNCT
ihlr-25462	211	32	result	result	VERB
ihlr-25462	211	33	in	in	ADP
ihlr-25462	211	34	a	a	DET
ihlr-25462	211	35	significant	significant	ADJ
ihlr-25462	211	36	reduction	reduction	NOUN
ihlr-25462	211	37	in	in	ADP
ihlr-25462	211	38	the	the	DET
ihlr-25462	211	39	cost	cost	NOUN
ihlr-25462	211	40	”	"	PUNCT
ihlr-25462	211	41	of	of	ADP
ihlr-25462	211	42	those	those	DET
ihlr-25462	211	43	prescription	prescription	NOUN
ihlr-25462	211	44	drugs.72	drugs.72	NOUN
ihlr-25462	211	45	of	of	ADP
ihlr-25462	211	46	note	note	NOUN
ihlr-25462	211	47	,	,	PUNCT
ihlr-25462	211	48	in	in	ADP
ihlr-25462	211	49	the	the	DET
ihlr-25462	211	50	sixteen	sixteen	NUM
ihlr-25462	211	51	years	year	NOUN
ihlr-25462	211	52	since	since	SCONJ
ihlr-25462	211	53	its	its	PRON
ihlr-25462	211	54	enactment	enactment	NOUN
ihlr-25462	211	55	,	,	PUNCT
ihlr-25462	211	56	no	no	DET
ihlr-25462	211	57	secretary	secretary	NOUN
ihlr-25462	211	58	has	have	AUX
ihlr-25462	211	59	ever	ever	ADV
ihlr-25462	211	60	given	give	VERB
ihlr-25462	211	61	such	such	ADJ
ihlr-25462	211	62	approval.73	approval.73	PROPN
ihlr-25462	211	63	alex	alex	PROPN
ihlr-25462	211	64	azar	azar	PROPN
ihlr-25462	211	65	was	be	AUX
ihlr-25462	211	66	also	also	ADV
ihlr-25462	211	67	initially	initially	ADV
ihlr-25462	211	68	opposed.74	opposed.74	VERB
ihlr-25462	211	69	67	67	NUM
ihlr-25462	211	70	.	.	PUNCT
ihlr-25462	212	1	dennis	dennis	PROPN
ihlr-25462	212	2	crouch	crouch	PROPN
ihlr-25462	212	3	,	,	PUNCT
ihlr-25462	212	4	demystifying	demystify	VERB
ihlr-25462	212	5	drug	drug	NOUN
ihlr-25462	212	6	importation	importation	NOUN
ihlr-25462	212	7	after	after	ADP
ihlr-25462	212	8	impression	impression	NOUN
ihlr-25462	212	9	v.	v.	ADP
ihlr-25462	212	10	lexmark	lexmark	NOUN
ihlr-25462	212	11	,	,	PUNCT
ihlr-25462	212	12	patentlyo	patentlyo	NOUN
ihlr-25462	212	13	(	(	PUNCT
ihlr-25462	212	14	june	june	PROPN
ihlr-25462	212	15	6	6	NUM
ihlr-25462	212	16	,	,	PUNCT
ihlr-25462	212	17	2017	2017	NUM
ihlr-25462	212	18	)	)	PUNCT
ihlr-25462	212	19	,	,	PUNCT
ihlr-25462	212	20	https://patentlyo.com/patent/2017/06/demystifying-importation-impression.html	https://patentlyo.com/patent/2017/06/demystifying-importation-impression.html	PROPN
ihlr-25462	213	1	[	[	X
ihlr-25462	213	2	https://perma.cc/lhl2-vndq	https://perma.cc/lhl2-vndq	PROPN
ihlr-25462	213	3	]	]	PUNCT
ihlr-25462	213	4	.	.	PUNCT
ihlr-25462	214	1	68	68	NUM
ihlr-25462	214	2	.	.	PUNCT
ihlr-25462	215	1	jacob	jacob	PROPN
ihlr-25462	215	2	arfwedson	arfwedson	PROPN
ihlr-25462	215	3	,	,	PUNCT
ihlr-25462	215	4	inst	inst	PROPN
ihlr-25462	215	5	.	.	PROPN
ihlr-25462	216	1	for	for	ADP
ihlr-25462	216	2	pol’y	pol’y	NOUN
ihlr-25462	216	3	innovation	innovation	NOUN
ihlr-25462	216	4	,	,	PUNCT
ihlr-25462	216	5	re	re	NOUN
ihlr-25462	216	6	-	-	NOUN
ihlr-25462	216	7	importation	importation	NOUN
ihlr-25462	216	8	(	(	PUNCT
ihlr-25462	216	9	parallel	parallel	ADJ
ihlr-25462	216	10	trade	trade	NOUN
ihlr-25462	216	11	)	)	PUNCT
ihlr-25462	216	12	in	in	ADP
ihlr-25462	216	13	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	216	14	6	6	NUM
ihlr-25462	216	15	(	(	PUNCT
ihlr-25462	216	16	2004	2004	NUM
ihlr-25462	216	17	)	)	PUNCT
ihlr-25462	216	18	,	,	PUNCT
ihlr-25462	216	19	https://www.ipi.org/doclib/pr182-paralleltrade.pdfopenelement.pdf	https://www.ipi.org/doclib/pr182-paralleltrade.pdfopenelement.pdf	VERB
ihlr-25462	216	20	[	[	X
ihlr-25462	216	21	https://perma.cc/tk3d-t3y7	https://perma.cc/tk3d-t3y7	NOUN
ihlr-25462	216	22	]	]	X
ihlr-25462	216	23	.	.	PUNCT
ihlr-25462	217	1	69	69	NUM
ihlr-25462	217	2	.	.	PUNCT
ihlr-25462	218	1	i	i	PRON
ihlr-25462	218	2	d.	d.	PROPN
ihlr-25462	218	3	at	at	ADP
ihlr-25462	218	4	25	25	NUM
ihlr-25462	218	5	(	(	PUNCT
ihlr-25462	218	6	“	"	PUNCT
ihlr-25462	218	7	re	re	NOUN
ihlr-25462	218	8	-	-	NOUN
ihlr-25462	218	9	importation	importation	NOUN
ihlr-25462	218	10	has	have	AUX
ihlr-25462	218	11	been	be	AUX
ihlr-25462	218	12	opposed	oppose	VERB
ihlr-25462	218	13	by	by	ADP
ihlr-25462	218	14	[	[	X
ihlr-25462	218	15	ten	ten	NUM
ihlr-25462	218	16	]	]	PUNCT
ihlr-25462	218	17	of	of	ADP
ihlr-25462	218	18	the	the	DET
ihlr-25462	218	19	last	last	ADJ
ihlr-25462	218	20	[	[	X
ihlr-25462	218	21	eleven	eleven	NUM
ihlr-25462	218	22	]	]	X
ihlr-25462	218	23	food	food	NOUN
ihlr-25462	218	24	and	and	CCONJ
ihlr-25462	218	25	drug	drug	PROPN
ihlr-25462	218	26	administration	administration	NOUN
ihlr-25462	218	27	commissioners	commissioner	NOUN
ihlr-25462	218	28	since	since	SCONJ
ihlr-25462	218	29	1969	1969	NUM
ihlr-25462	218	30	.	.	PUNCT
ihlr-25462	219	1	all	all	PRON
ihlr-25462	219	2	cited	cite	VERB
ihlr-25462	219	3	public	public	ADJ
ihlr-25462	219	4	safety	safety	NOUN
ihlr-25462	219	5	concerns	concern	NOUN
ihlr-25462	219	6	(	(	PUNCT
ihlr-25462	219	7	including	include	VERB
ihlr-25462	219	8	risks	risk	NOUN
ihlr-25462	219	9	of	of	ADP
ihlr-25462	219	10	mishandling	mishandle	VERB
ihlr-25462	219	11	,	,	PUNCT
ihlr-25462	219	12	mislabeling	mislabeling	NOUN
ihlr-25462	219	13	,	,	PUNCT
ihlr-25462	219	14	improper	improper	ADJ
ihlr-25462	219	15	storage	storage	NOUN
ihlr-25462	219	16	,	,	PUNCT
ihlr-25462	219	17	ineffective	ineffective	ADJ
ihlr-25462	219	18	product	product	NOUN
ihlr-25462	219	19	recalls	recall	VERB
ihlr-25462	219	20	,	,	PUNCT
ihlr-25462	219	21	and	and	CCONJ
ihlr-25462	219	22	expiration	expiration	NOUN
ihlr-25462	219	23	date	date	NOUN
ihlr-25462	219	24	violations	violation	NOUN
ihlr-25462	219	25	)	)	PUNCT
ihlr-25462	219	26	.	.	PUNCT
ihlr-25462	220	1	some	some	PRON
ihlr-25462	220	2	also	also	ADV
ihlr-25462	220	3	expressed	express	VERB
ihlr-25462	220	4	concern	concern	NOUN
ihlr-25462	220	5	about	about	ADP
ihlr-25462	220	6	the	the	DET
ihlr-25462	220	7	potential	potential	NOUN
ihlr-25462	220	8	for	for	SCONJ
ihlr-25462	220	9	opportunists	opportunist	NOUN
ihlr-25462	220	10	to	to	PART
ihlr-25462	220	11	manufacture	manufacture	VERB
ihlr-25462	220	12	and	and	CCONJ
ihlr-25462	220	13	sell	sell	VERB
ihlr-25462	220	14	counterfeit	counterfeit	ADJ
ihlr-25462	220	15	drugs	drug	NOUN
ihlr-25462	220	16	.	.	PUNCT
ihlr-25462	220	17	”	"	PUNCT
ihlr-25462	220	18	)	)	PUNCT
ihlr-25462	220	19	.	.	PUNCT
ihlr-25462	221	1	70	70	X
ihlr-25462	221	2	.	.	PUNCT
ihlr-25462	221	3	safe	safe	ADJ
ihlr-25462	221	4	importation	importation	NOUN
ihlr-25462	221	5	action	action	NOUN
ihlr-25462	221	6	plan	plan	NOUN
ihlr-25462	221	7	,	,	PUNCT
ihlr-25462	221	8	supra	supra	PROPN
ihlr-25462	221	9	note	note	NOUN
ihlr-25462	221	10	11	11	NUM
ihlr-25462	221	11	.	.	PUNCT
ihlr-25462	222	1	71	71	NUM
ihlr-25462	222	2	.	.	PUNCT
ihlr-25462	223	1	i	i	PRON
ihlr-25462	223	2	d.	d.	PROPN
ihlr-25462	223	3	at	at	ADP
ihlr-25462	223	4	1	1	NUM
ihlr-25462	223	5	.	.	PUNCT
ihlr-25462	223	6	72	72	NUM
ihlr-25462	223	7	.	.	PUNCT
ihlr-25462	224	1	i	i	PRON
ihlr-25462	224	2	d.	d.	PROPN
ihlr-25462	224	3	73	73	NUM
ihlr-25462	224	4	.	.	PUNCT
ihlr-25462	225	1	i	i	PRON
ihlr-25462	225	2	d.	d.	PROPN
ihlr-25462	225	3	74	74	NUM
ihlr-25462	225	4	.	.	PUNCT
ihlr-25462	226	1	alex	alex	PROPN
ihlr-25462	226	2	m.	m.	PROPN
ihlr-25462	226	3	azar	azar	PROPN
ihlr-25462	226	4	ii	ii	PROPN
ihlr-25462	226	5	,	,	PUNCT
ihlr-25462	226	6	secretary	secretary	NOUN
ihlr-25462	226	7	,	,	PUNCT
ihlr-25462	226	8	u.s	u.s	PROPN
ihlr-25462	226	9	.	.	PROPN
ihlr-25462	226	10	dep’t	dep’t	PROPN
ihlr-25462	226	11	of	of	ADP
ihlr-25462	226	12	health	health	PROPN
ihlr-25462	226	13	&	&	CCONJ
ihlr-25462	226	14	hum	hum	PROPN
ihlr-25462	226	15	.	.	PUNCT
ihlr-25462	227	1	servs	servs	PROPN
ihlr-25462	227	2	.	.	PUNCT
ihlr-25462	227	3	,	,	PUNCT
ihlr-25462	227	4	remarks	remark	NOUN
ihlr-25462	227	5	on	on	ADP
ihlr-25462	227	6	drug	drug	NOUN
ihlr-25462	227	7	pricing	pricing	NOUN
ihlr-25462	227	8	blueprint	blueprint	NOUN
ihlr-25462	227	9	in	in	ADP
ihlr-25462	227	10	washington	washington	PROPN
ihlr-25462	227	11	,	,	PUNCT
ihlr-25462	227	12	d.c	d.c	PROPN
ihlr-25462	227	13	.	.	PUNCT
ihlr-25462	228	1	(	(	PUNCT
ihlr-25462	228	2	may	may	PROPN
ihlr-25462	228	3	14	14	NUM
ihlr-25462	228	4	,	,	PUNCT
ihlr-25462	228	5	2018	2018	NUM
ihlr-25462	228	6	)	)	PUNCT
ihlr-25462	228	7	,	,	PUNCT
ihlr-25462	228	8	https://www.hhs.gov/about/leadership/	https://www.hhs.gov/about/leadership/	PROPN
ihlr-25462	228	9	secretary	secretary	NOUN
ihlr-25462	228	10	/	/	SYM
ihlr-25462	228	11	speeches/2018	speeches/2018	NOUN
ihlr-25462	228	12	-	-	PUNCT
ihlr-25462	228	13	speeches	speech	NOUN
ihlr-25462	228	14	/	/	SYM
ihlr-25462	228	15	remarks	remark	NOUN
ihlr-25462	228	16	-	-	PUNCT
ihlr-25462	228	17	on	on	ADP
ihlr-25462	228	18	-	-	PUNCT
ihlr-25462	228	19	drug	drug	NOUN
ihlr-25462	228	20	-	-	PUNCT
ihlr-25462	228	21	pricing	pricing	NOUN
ihlr-25462	228	22	-	-	PUNCT
ihlr-25462	228	23	blueprint.html	blueprint.html	NOUN
ihlr-25462	229	1	[	[	X
ihlr-25462	229	2	https://perma.cc/ua9sx6sg	https://perma.cc/ua9sx6sg	X
ihlr-25462	229	3	]	]	X
ihlr-25462	229	4	(	(	PUNCT
ihlr-25462	229	5	“	"	PUNCT
ihlr-25462	229	6	[	[	X
ihlr-25462	229	7	t]he	t]he	ADV
ihlr-25462	229	8	last	last	ADJ
ihlr-25462	229	9	four	four	NUM
ihlr-25462	229	10	fda	fda	PROPN
ihlr-25462	229	11	commissioners	commissioner	NOUN
ihlr-25462	229	12	have	have	AUX
ihlr-25462	229	13	said	say	VERB
ihlr-25462	229	14	there	there	PRON
ihlr-25462	229	15	is	be	VERB
ihlr-25462	229	16	no	no	DET
ihlr-25462	229	17	effective	effective	ADJ
ihlr-25462	229	18	way	way	NOUN
ihlr-25462	229	19	to	to	PART
ihlr-25462	229	20	ensure	ensure	VERB
ihlr-25462	229	21	drugs	drug	NOUN
ihlr-25462	229	22	coming	come	VERB
ihlr-25462	229	23	from	from	ADP
ihlr-25462	229	24	canada	canada	PROPN
ihlr-25462	229	25	really	really	ADV
ihlr-25462	229	26	are	be	AUX
ihlr-25462	229	27	coming	come	VERB
ihlr-25462	229	28	from	from	ADP
ihlr-25462	229	29	canada	canada	PROPN
ihlr-25462	229	30	,	,	PUNCT
ihlr-25462	229	31	rather	rather	ADV
ihlr-25462	229	32	than	than	ADP
ihlr-25462	229	33	being	be	AUX
ihlr-25462	229	34	routed	route	VERB
ihlr-25462	229	35	from	from	ADP
ihlr-25462	229	36	,	,	PUNCT
ihlr-25462	229	37	say	say	INTJ
ihlr-25462	229	38	,	,	PUNCT
ihlr-25462	229	39	a	a	DET
ihlr-25462	229	40	counterfeit	counterfeit	ADJ
ihlr-25462	229	41	factory	factory	NOUN
ihlr-25462	229	42	in	in	ADP
ihlr-25462	229	43	china	china	PROPN
ihlr-25462	229	44	.	.	PUNCT
ihlr-25462	230	1	the	the	PRON
ihlr-25462	230	2	[	[	X
ihlr-25462	230	3	u.s	u.s	PROPN
ihlr-25462	230	4	.	.	PROPN
ihlr-25462	230	5	]	]	PUNCT
ihlr-25462	230	6	has	have	VERB
ihlr-25462	230	7	the	the	DET
ihlr-25462	230	8	safest	safe	ADJ
ihlr-25462	230	9	regulatory	regulatory	ADJ
ihlr-25462	230	10	system	system	NOUN
ihlr-25462	230	11	in	in	ADP
ihlr-25462	230	12	the	the	DET
ihlr-25462	230	13	world	world	NOUN
ihlr-25462	230	14	.	.	PUNCT
ihlr-25462	231	1	the	the	DET
ihlr-25462	231	2	last	last	ADJ
ihlr-25462	231	3	thing	thing	NOUN
ihlr-25462	231	4	https://perma.cc/lhl2-vndq	https://perma.cc/lhl2-vndq	PROPN
ihlr-25462	231	5	2021	2021	NUM
ihlr-25462	231	6	]	]	PUNCT
ihlr-25462	231	7	a	a	DET
ihlr-25462	231	8	survey	survey	NOUN
ihlr-25462	231	9	of	of	ADP
ihlr-25462	231	10	three	three	NUM
ihlr-25462	231	11	patent	patent	NOUN
ihlr-25462	231	12	-	-	PUNCT
ihlr-25462	231	13	based	base	VERB
ihlr-25462	231	14	approaches	approach	NOUN
ihlr-25462	231	15	407	407	NUM
ihlr-25462	231	16	demonstration	demonstration	NOUN
ihlr-25462	231	17	projects	project	NOUN
ihlr-25462	231	18	,	,	PUNCT
ihlr-25462	231	19	which	which	PRON
ihlr-25462	231	20	would	would	AUX
ihlr-25462	231	21	“	"	PUNCT
ihlr-25462	231	22	outlin[e	outlin[e	VERB
ihlr-25462	231	23	]	]	PUNCT
ihlr-25462	231	24	how	how	SCONJ
ihlr-25462	231	25	they	they	PRON
ihlr-25462	231	26	import	import	VERB
ihlr-25462	231	27	healthcanada	healthcanada	NOUN
ihlr-25462	231	28	approved	approve	VERB
ihlr-25462	231	29	drugs	drug	NOUN
ihlr-25462	231	30	in	in	ADP
ihlr-25462	231	31	compliance	compliance	NOUN
ihlr-25462	231	32	with	with	ADP
ihlr-25462	231	33	[	[	X
ihlr-25462	231	34	s]ection	s]ection	NOUN
ihlr-25462	231	35	505	505	NUM
ihlr-25462	231	36	of	of	ADP
ihlr-25462	231	37	the	the	DET
ihlr-25462	231	38	[	[	X
ihlr-25462	231	39	fdca	fdca	NOUN
ihlr-25462	231	40	]	]	X
ihlr-25462	231	41	,	,	PUNCT
ihlr-25462	231	42	”	"	PUNCT
ihlr-25462	231	43	could	could	AUX
ihlr-25462	231	44	be	be	AUX
ihlr-25462	231	45	submitted	submit	VERB
ihlr-25462	231	46	by	by	ADP
ihlr-25462	231	47	states	state	NOUN
ihlr-25462	231	48	,	,	PUNCT
ihlr-25462	231	49	wholesalers	wholesaler	NOUN
ihlr-25462	231	50	,	,	PUNCT
ihlr-25462	231	51	or	or	CCONJ
ihlr-25462	231	52	pharmacists.75	pharmacists.75	PROPN
ihlr-25462	231	53	further	far	ADV
ihlr-25462	231	54	,	,	PUNCT
ihlr-25462	231	55	there	there	PRON
ihlr-25462	231	56	are	be	VERB
ihlr-25462	231	57	a	a	DET
ihlr-25462	231	58	number	number	NOUN
ihlr-25462	231	59	of	of	ADP
ihlr-25462	231	60	medications	medication	NOUN
ihlr-25462	231	61	excluded	exclude	VERB
ihlr-25462	231	62	under	under	ADP
ihlr-25462	231	63	pathway	pathway	NOUN
ihlr-25462	231	64	one	one	NUM
ihlr-25462	231	65	:	:	PUNCT
ihlr-25462	231	66	controlled	control	VERB
ihlr-25462	231	67	substances	substance	NOUN
ihlr-25462	231	68	,	,	PUNCT
ihlr-25462	231	69	biological	biological	ADJ
ihlr-25462	231	70	products	product	NOUN
ihlr-25462	231	71	,	,	PUNCT
ihlr-25462	231	72	infused	infuse	VERB
ihlr-25462	231	73	medications	medication	NOUN
ihlr-25462	231	74	,	,	PUNCT
ihlr-25462	231	75	intravenous	intravenous	ADJ
ihlr-25462	231	76	injected	inject	VERB
ihlr-25462	231	77	medications	medication	NOUN
ihlr-25462	231	78	,	,	PUNCT
ihlr-25462	231	79	medications	medication	NOUN
ihlr-25462	231	80	inhaled	inhale	VERB
ihlr-25462	231	81	during	during	ADP
ihlr-25462	231	82	surgery	surgery	NOUN
ihlr-25462	231	83	,	,	PUNCT
ihlr-25462	231	84	certain	certain	ADJ
ihlr-25462	231	85	parenteral	parenteral	ADJ
ihlr-25462	231	86	medications	medication	NOUN
ihlr-25462	231	87	,	,	PUNCT
ihlr-25462	231	88	and	and	CCONJ
ihlr-25462	231	89	medications	medication	NOUN
ihlr-25462	231	90	associated	associate	VERB
ihlr-25462	231	91	with	with	ADP
ihlr-25462	231	92	risk	risk	NOUN
ihlr-25462	231	93	evaluation	evaluation	NOUN
ihlr-25462	231	94	and	and	CCONJ
ihlr-25462	231	95	mitigation	mitigation	NOUN
ihlr-25462	231	96	strategies.76	strategies.76	VERB
ihlr-25462	231	97	under	under	ADP
ihlr-25462	231	98	pathway	pathway	NOUN
ihlr-25462	231	99	two	two	NUM
ihlr-25462	231	100	,	,	PUNCT
ihlr-25462	231	101	the	the	DET
ihlr-25462	231	102	drug	drug	NOUN
ihlr-25462	231	103	manufacturers	manufacturer	NOUN
ihlr-25462	231	104	themselves	themselves	PRON
ihlr-25462	231	105	would	would	AUX
ihlr-25462	231	106	re	re	VERB
ihlr-25462	231	107	-	-	VERB
ihlr-25462	231	108	import	import	VERB
ihlr-25462	231	109	their	their	PRON
ihlr-25462	231	110	own	own	ADJ
ihlr-25462	231	111	drugs	drug	NOUN
ihlr-25462	231	112	after	after	ADP
ihlr-25462	231	113	establishing	establish	VERB
ihlr-25462	231	114	with	with	ADP
ihlr-25462	231	115	the	the	DET
ihlr-25462	231	116	fda	fda	PROPN
ihlr-25462	231	117	that	that	SCONJ
ihlr-25462	231	118	the	the	DET
ihlr-25462	231	119	foreign	foreign	ADJ
ihlr-25462	231	120	version	version	NOUN
ihlr-25462	231	121	is	be	AUX
ihlr-25462	231	122	the	the	DET
ihlr-25462	231	123	same	same	ADJ
ihlr-25462	231	124	as	as	ADP
ihlr-25462	231	125	the	the	DET
ihlr-25462	231	126	u.s	u.s	PROPN
ihlr-25462	231	127	.	.	PROPN
ihlr-25462	231	128	version.77	version.77	NOUN
ihlr-25462	231	129	this	this	PRON
ihlr-25462	231	130	would	would	AUX
ihlr-25462	231	131	allow	allow	VERB
ihlr-25462	231	132	a	a	DET
ihlr-25462	231	133	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	231	134	manufacturer	manufacturer	NOUN
ihlr-25462	231	135	to	to	PART
ihlr-25462	231	136	sell	sell	VERB
ihlr-25462	231	137	a	a	DET
ihlr-25462	231	138	foreign	foreign	ADJ
ihlr-25462	231	139	version	version	NOUN
ihlr-25462	231	140	of	of	ADP
ihlr-25462	231	141	a	a	DET
ihlr-25462	231	142	drug	drug	NOUN
ihlr-25462	231	143	product	product	NOUN
ihlr-25462	231	144	in	in	ADP
ihlr-25462	231	145	the	the	DET
ihlr-25462	231	146	u.s	u.s	PROPN
ihlr-25462	231	147	.	.	PROPN
ihlr-25462	231	148	under	under	ADP
ihlr-25462	231	149	a	a	DET
ihlr-25462	231	150	unique	unique	ADJ
ihlr-25462	231	151	national	national	ADJ
ihlr-25462	231	152	drug	drug	NOUN
ihlr-25462	231	153	code	code	NOUN
ihlr-25462	231	154	number	number	NOUN
ihlr-25462	231	155	compared	compare	VERB
ihlr-25462	231	156	to	to	ADP
ihlr-25462	231	157	the	the	DET
ihlr-25462	231	158	u.s	u.s	PROPN
ihlr-25462	231	159	.	.	PROPN
ihlr-25462	231	160	version	version	PROPN
ihlr-25462	231	161	,	,	PUNCT
ihlr-25462	231	162	which	which	PRON
ihlr-25462	231	163	would	would	AUX
ihlr-25462	231	164	allow	allow	VERB
ihlr-25462	231	165	the	the	DET
ihlr-25462	231	166	manufacturer	manufacturer	NOUN
ihlr-25462	231	167	,	,	PUNCT
ihlr-25462	231	168	if	if	SCONJ
ihlr-25462	231	169	they	they	PRON
ihlr-25462	231	170	desired	desire	VERB
ihlr-25462	231	171	,	,	PUNCT
ihlr-25462	231	172	to	to	PART
ihlr-25462	231	173	sell	sell	VERB
ihlr-25462	231	174	the	the	DET
ihlr-25462	231	175	product	product	NOUN
ihlr-25462	231	176	at	at	ADP
ihlr-25462	231	177	a	a	DET
ihlr-25462	231	178	lower	low	ADJ
ihlr-25462	231	179	price.78	price.78	NOUN
ihlr-25462	231	180	because	because	SCONJ
ihlr-25462	231	181	the	the	DET
ihlr-25462	231	182	manufacturer	manufacturer	NOUN
ihlr-25462	231	183	would	would	AUX
ihlr-25462	231	184	be	be	AUX
ihlr-25462	231	185	able	able	ADJ
ihlr-25462	231	186	to	to	PART
ihlr-25462	231	187	import	import	VERB
ihlr-25462	231	188	its	its	PRON
ihlr-25462	231	189	drug	drug	NOUN
ihlr-25462	231	190	through	through	ADP
ihlr-25462	231	191	conventional	conventional	ADJ
ihlr-25462	231	192	supply	supply	NOUN
ihlr-25462	231	193	channels	channel	NOUN
ihlr-25462	231	194	,	,	PUNCT
ihlr-25462	231	195	this	this	DET
ihlr-25462	231	196	pathway	pathway	NOUN
ihlr-25462	231	197	generally	generally	ADV
ihlr-25462	231	198	would	would	AUX
ihlr-25462	231	199	rely	rely	VERB
ihlr-25462	231	200	on	on	ADP
ihlr-25462	231	201	applicable	applicable	ADJ
ihlr-25462	231	202	existing	exist	VERB
ihlr-25462	231	203	safeguards	safeguard	NOUN
ihlr-25462	231	204	to	to	PART
ihlr-25462	231	205	ensure	ensure	VERB
ihlr-25462	231	206	supply	supply	NOUN
ihlr-25462	231	207	chain	chain	NOUN
ihlr-25462	231	208	integrity.79	integrity.79	NOUN
ihlr-25462	231	209	for	for	ADP
ihlr-25462	231	210	supporters	supporter	NOUN
ihlr-25462	231	211	of	of	ADP
ihlr-25462	231	212	importation	importation	NOUN
ihlr-25462	231	213	,	,	PUNCT
ihlr-25462	231	214	there	there	PRON
ihlr-25462	231	215	are	be	VERB
ihlr-25462	231	216	some	some	DET
ihlr-25462	231	217	potential	potential	ADJ
ihlr-25462	231	218	challenges	challenge	NOUN
ihlr-25462	231	219	.	.	PUNCT
ihlr-25462	232	1	proposing	propose	VERB
ihlr-25462	232	2	a	a	DET
ihlr-25462	232	3	demonstration	demonstration	NOUN
ihlr-25462	232	4	project	project	NOUN
ihlr-25462	232	5	,	,	PUNCT
ihlr-25462	232	6	as	as	SCONJ
ihlr-25462	232	7	required	require	VERB
ihlr-25462	232	8	for	for	ADP
ihlr-25462	232	9	pathway	pathway	NOUN
ihlr-25462	232	10	one	one	NOUN
ihlr-25462	232	11	,	,	PUNCT
ihlr-25462	232	12	that	that	PRON
ihlr-25462	232	13	could	could	AUX
ihlr-25462	232	14	allow	allow	VERB
ihlr-25462	232	15	these	these	DET
ihlr-25462	232	16	types	type	NOUN
ihlr-25462	232	17	of	of	ADP
ihlr-25462	232	18	certifications	certification	NOUN
ihlr-25462	232	19	will	will	AUX
ihlr-25462	232	20	take	take	VERB
ihlr-25462	232	21	extensive	extensive	ADJ
ihlr-25462	232	22	resources	resource	NOUN
ihlr-25462	232	23	and	and	CCONJ
ihlr-25462	232	24	time	time	NOUN
ihlr-25462	232	25	,	,	PUNCT
ihlr-25462	232	26	potentially	potentially	ADV
ihlr-25462	232	27	decreasing	decrease	VERB
ihlr-25462	232	28	savings	saving	NOUN
ihlr-25462	232	29	to	to	ADP
ihlr-25462	232	30	the	the	DET
ihlr-25462	232	31	consumer.80	consumer.80	NOUN
ihlr-25462	232	32	because	because	SCONJ
ihlr-25462	232	33	pathway	pathway	NOUN
ihlr-25462	232	34	one	one	NOUN
ihlr-25462	232	35	is	be	AUX
ihlr-25462	232	36	also	also	ADV
ihlr-25462	232	37	subject	subject	ADJ
ihlr-25462	232	38	to	to	ADP
ihlr-25462	232	39	the	the	DET
ihlr-25462	232	40	formal	formal	ADJ
ihlr-25462	232	41	rulemaking	rulemaking	NOUN
ihlr-25462	232	42	process	process	NOUN
ihlr-25462	232	43	,	,	PUNCT
ihlr-25462	232	44	which	which	PRON
ihlr-25462	232	45	includes	include	VERB
ihlr-25462	232	46	a	a	DET
ihlr-25462	232	47	required	require	VERB
ihlr-25462	232	48	notice	notice	NOUN
ihlr-25462	232	49	and	and	CCONJ
ihlr-25462	232	50	comment	comment	NOUN
ihlr-25462	232	51	period	period	NOUN
ihlr-25462	232	52	,	,	PUNCT
ihlr-25462	232	53	this	this	DET
ihlr-25462	232	54	process	process	NOUN
ihlr-25462	232	55	could	could	AUX
ihlr-25462	232	56	take	take	VERB
ihlr-25462	232	57	several	several	ADJ
ihlr-25462	232	58	years	year	NOUN
ihlr-25462	232	59	before	before	SCONJ
ihlr-25462	232	60	interested	interested	ADJ
ihlr-25462	232	61	parties	party	NOUN
ihlr-25462	232	62	could	could	AUX
ihlr-25462	232	63	begin	begin	VERB
ihlr-25462	232	64	submitting	submit	VERB
ihlr-25462	232	65	plans	plan	NOUN
ihlr-25462	232	66	for	for	ADP
ihlr-25462	232	67	demonstration	demonstration	NOUN
ihlr-25462	232	68	projects.81	projects.81	NOUN
ihlr-25462	232	69	further	far	ADV
ihlr-25462	232	70	,	,	PUNCT
ihlr-25462	232	71	there	there	PRON
ihlr-25462	232	72	are	be	VERB
ihlr-25462	232	73	restrictions	restriction	NOUN
ihlr-25462	232	74	on	on	ADP
ihlr-25462	232	75	the	the	DET
ihlr-25462	232	76	types	type	NOUN
ihlr-25462	232	77	of	of	ADP
ihlr-25462	232	78	medicines	medicine	NOUN
ihlr-25462	232	79	that	that	PRON
ihlr-25462	232	80	may	may	AUX
ihlr-25462	232	81	be	be	AUX
ihlr-25462	232	82	imported	import	VERB
ihlr-25462	232	83	through	through	ADP
ihlr-25462	232	84	this	this	DET
ihlr-25462	232	85	pathway	pathway	NOUN
ihlr-25462	232	86	,	,	PUNCT
ihlr-25462	232	87	and	and	CCONJ
ihlr-25462	232	88	it	it	PRON
ihlr-25462	232	89	excludes	exclude	VERB
ihlr-25462	232	90	some	some	PRON
ihlr-25462	232	91	of	of	ADP
ihlr-25462	232	92	the	the	DET
ihlr-25462	232	93	more	more	ADV
ihlr-25462	232	94	expensive	expensive	ADJ
ihlr-25462	232	95	categories	category	NOUN
ihlr-25462	232	96	of	of	ADP
ihlr-25462	232	97	drugs	drug	NOUN
ihlr-25462	232	98	(	(	PUNCT
ihlr-25462	232	99	e.g.	e.g.	ADV
ihlr-25462	232	100	,	,	PUNCT
ihlr-25462	232	101	biologics	biologic	NOUN
ihlr-25462	232	102	,	,	PUNCT
ihlr-25462	232	103	such	such	ADJ
ihlr-25462	232	104	as	as	ADP
ihlr-25462	232	105	insulin).82	insulin).82	NOUN
ihlr-25462	232	106	some	some	PRON
ihlr-25462	232	107	of	of	ADP
ihlr-25462	232	108	the	the	DET
ihlr-25462	232	109	groups	group	NOUN
ihlr-25462	232	110	eligible	eligible	ADJ
ihlr-25462	232	111	to	to	PART
ihlr-25462	232	112	use	use	VERB
ihlr-25462	232	113	this	this	DET
ihlr-25462	232	114	pathway	pathway	NOUN
ihlr-25462	232	115	,	,	PUNCT
ihlr-25462	232	116	such	such	ADJ
ihlr-25462	232	117	as	as	ADP
ihlr-25462	232	118	pharmacy	pharmacy	NOUN
ihlr-25462	232	119	groups	group	NOUN
ihlr-25462	232	120	,	,	PUNCT
ihlr-25462	232	121	oppose	oppose	VERB
ihlr-25462	232	122	it	it	PRON
ihlr-25462	232	123	because	because	SCONJ
ihlr-25462	232	124	of	of	ADP
ihlr-25462	232	125	concerns	concern	NOUN
ihlr-25462	232	126	about	about	ADP
ihlr-25462	232	127	patient	patient	ADJ
ihlr-25462	232	128	safety	safety	NOUN
ihlr-25462	232	129	and	and	CCONJ
ihlr-25462	232	130	the	the	DET
ihlr-25462	232	131	desire	desire	NOUN
ihlr-25462	232	132	to	to	PART
ihlr-25462	232	133	preserve	preserve	VERB
ihlr-25462	232	134	their	their	PRON
ihlr-25462	232	135	relationship	relationship	NOUN
ihlr-25462	232	136	with	with	ADP
ihlr-25462	232	137	patients	patient	NOUN
ihlr-25462	232	138	,	,	PUNCT
ihlr-25462	232	139	“	"	PUNCT
ihlr-25462	232	140	particularly	particularly	ADV
ihlr-25462	232	141	for	for	ADP
ihlr-25462	232	142	vulnerable	vulnerable	ADJ
ihlr-25462	232	143	patients	patient	NOUN
ihlr-25462	232	144	with	with	ADP
ihlr-25462	232	145	complex	complex	ADJ
ihlr-25462	232	146	medication	medication	NOUN
ihlr-25462	232	147	regimens	regimen	NOUN
ihlr-25462	232	148	.	.	PUNCT
ihlr-25462	233	1	”83	”83	PROPN
ihlr-25462	233	2	next	next	ADV
ihlr-25462	233	3	,	,	PUNCT
ihlr-25462	233	4	section	section	NOUN
ihlr-25462	233	5	804	804	NUM
ihlr-25462	233	6	of	of	ADP
ihlr-25462	233	7	the	the	DET
ihlr-25462	233	8	fdca	fdca	NOUN
ihlr-25462	233	9	can	can	AUX
ihlr-25462	233	10	only	only	ADV
ihlr-25462	233	11	become	become	VERB
ihlr-25462	233	12	effective	effective	ADJ
ihlr-25462	233	13	if	if	SCONJ
ihlr-25462	233	14	the	the	DET
ihlr-25462	233	15	secretary	secretary	PROPN
ihlr-25462	233	16	of	of	ADP
ihlr-25462	233	17	hhs	hhs	PROPN
ihlr-25462	233	18	certifies	certifie	NOUN
ihlr-25462	233	19	that	that	SCONJ
ihlr-25462	233	20	its	its	PRON
ihlr-25462	233	21	“	"	PUNCT
ihlr-25462	233	22	implementation	implementation	NOUN
ihlr-25462	233	23	.	.	PUNCT
ihlr-25462	233	24	.	.	PUNCT
ihlr-25462	233	25	.	.	PUNCT
ihlr-25462	234	1	will	will	AUX
ihlr-25462	234	2	pose	pose	VERB
ihlr-25462	234	3	no	no	DET
ihlr-25462	234	4	additional	additional	ADJ
ihlr-25462	234	5	risk	risk	NOUN
ihlr-25462	234	6	to	to	ADP
ihlr-25462	234	7	the	the	PRON
ihlr-25462	234	8	we	we	PRON
ihlr-25462	234	9	need	need	VERB
ihlr-25462	234	10	is	be	AUX
ihlr-25462	234	11	to	to	PART
ihlr-25462	234	12	open	open	VERB
ihlr-25462	234	13	borders	border	NOUN
ihlr-25462	234	14	for	for	ADP
ihlr-25462	234	15	unsafe	unsafe	ADJ
ihlr-25462	234	16	drugs	drug	NOUN
ihlr-25462	234	17	in	in	ADP
ihlr-25462	234	18	search	search	NOUN
ihlr-25462	234	19	of	of	ADP
ihlr-25462	234	20	savings	saving	NOUN
ihlr-25462	234	21	that	that	PRON
ihlr-25462	234	22	can	can	AUX
ihlr-25462	234	23	not	not	PART
ihlr-25462	234	24	be	be	AUX
ihlr-25462	234	25	safely	safely	ADV
ihlr-25462	234	26	achieved	achieve	VERB
ihlr-25462	234	27	.	.	PUNCT
ihlr-25462	234	28	”	"	PUNCT
ihlr-25462	234	29	)	)	PUNCT
ihlr-25462	234	30	.	.	PUNCT
ihlr-25462	235	1	75	75	NUM
ihlr-25462	235	2	.	.	PUNCT
ihlr-25462	236	1	safe	safe	ADJ
ihlr-25462	236	2	importation	importation	NOUN
ihlr-25462	236	3	action	action	NOUN
ihlr-25462	236	4	plan	plan	NOUN
ihlr-25462	236	5	,	,	PUNCT
ihlr-25462	236	6	supra	supra	PROPN
ihlr-25462	236	7	note	note	NOUN
ihlr-25462	236	8	11	11	NUM
ihlr-25462	236	9	.	.	PUNCT
ihlr-25462	237	1	76	76	NUM
ihlr-25462	237	2	.	.	PUNCT
ihlr-25462	238	1	i	i	PRON
ihlr-25462	238	2	d.	d.	PROPN
ihlr-25462	238	3	at	at	ADP
ihlr-25462	238	4	3	3	NUM
ihlr-25462	238	5	.	.	PROPN
ihlr-25462	238	6	77	77	NUM
ihlr-25462	238	7	.	.	PUNCT
ihlr-25462	239	1	i	i	PRON
ihlr-25462	239	2	d.	d.	PROPN
ihlr-25462	239	3	78	78	NUM
ihlr-25462	239	4	.	.	PUNCT
ihlr-25462	240	1	i	i	PRON
ihlr-25462	240	2	d.	d.	PROPN
ihlr-25462	240	3	79	79	NUM
ihlr-25462	240	4	.	.	PUNCT
ihlr-25462	241	1	i	i	PRON
ihlr-25462	241	2	d.	d.	PROPN
ihlr-25462	241	3	80	80	NUM
ihlr-25462	241	4	.	.	PUNCT
ihlr-25462	242	1	benjamin	benjamin	PROPN
ihlr-25462	242	2	m.	m.	PROPN
ihlr-25462	242	3	zegarelli	zegarelli	PROPN
ihlr-25462	242	4	,	,	PUNCT
ihlr-25462	242	5	in	in	ADP
ihlr-25462	242	6	policy	policy	NOUN
ihlr-25462	242	7	reversal	reversal	NOUN
ihlr-25462	242	8	,	,	PUNCT
ihlr-25462	242	9	hhs	hhs	PROPN
ihlr-25462	242	10	and	and	CCONJ
ihlr-25462	242	11	fda	fda	PROPN
ihlr-25462	242	12	propose	propose	VERB
ihlr-25462	242	13	plan	plan	NOUN
ihlr-25462	242	14	to	to	PART
ihlr-25462	242	15	import	import	VERB
ihlr-25462	242	16	foreign	foreign	ADJ
ihlr-25462	242	17	drugs	drug	NOUN
ihlr-25462	242	18	,	,	PUNCT
ihlr-25462	242	19	mintz	mintz	PROPN
ihlr-25462	242	20	(	(	PUNCT
ihlr-25462	242	21	aug	aug	PROPN
ihlr-25462	242	22	.	.	PROPN
ihlr-25462	242	23	8	8	NUM
ihlr-25462	242	24	,	,	PUNCT
ihlr-25462	242	25	2019	2019	NUM
ihlr-25462	242	26	)	)	PUNCT
ihlr-25462	242	27	,	,	PUNCT
ihlr-25462	242	28	https://www.mintz.com/insights-center/viewpoints/2791/	https://www.mintz.com/insights-center/viewpoints/2791/	NOUN
ihlr-25462	242	29	2019	2019	NUM
ihlr-25462	242	30	-	-	SYM
ihlr-25462	242	31	08	08	NUM
ihlr-25462	242	32	-	-	PUNCT
ihlr-25462	242	33	policy	policy	NOUN
ihlr-25462	242	34	-	-	PUNCT
ihlr-25462	242	35	reversal	reversal	NOUN
ihlr-25462	242	36	-	-	PUNCT
ihlr-25462	242	37	hhs	hhs	NOUN
ihlr-25462	242	38	-	-	PUNCT
ihlr-25462	242	39	and	and	CCONJ
ihlr-25462	242	40	-	-	PUNCT
ihlr-25462	242	41	fda	fda	NOUN
ihlr-25462	242	42	-	-	PUNCT
ihlr-25462	242	43	propose	propose	ADJ
ihlr-25462	242	44	-	-	PUNCT
ihlr-25462	242	45	plan	plan	NOUN
ihlr-25462	242	46	-	-	PUNCT
ihlr-25462	242	47	import	import	NOUN
ihlr-25462	242	48	-	-	PUNCT
ihlr-25462	242	49	foreign	foreign	ADJ
ihlr-25462	242	50	[	[	X
ihlr-25462	242	51	https://perma.cc/3cdc-ezlj	https://perma.cc/3cdc-ezlj	NOUN
ihlr-25462	242	52	]	]	X
ihlr-25462	242	53	.	.	PUNCT
ihlr-25462	243	1	81	81	NUM
ihlr-25462	243	2	.	.	PUNCT
ihlr-25462	244	1	i	i	PRON
ihlr-25462	244	2	d.	d.	PROPN
ihlr-25462	244	3	82	82	NUM
ihlr-25462	244	4	.	.	PUNCT
ihlr-25462	245	1	i	i	PRON
ihlr-25462	245	2	d.	d.	PROPN
ihlr-25462	245	3	83	83	NUM
ihlr-25462	245	4	.	.	PUNCT
ihlr-25462	246	1	issue	issue	NOUN
ihlr-25462	246	2	brief	brief	NOUN
ihlr-25462	246	3	:	:	PUNCT
ihlr-25462	246	4	safe	safe	ADJ
ihlr-25462	246	5	importation	importation	NOUN
ihlr-25462	246	6	action	action	NOUN
ihlr-25462	246	7	plan	plan	NOUN
ihlr-25462	246	8	,	,	PUNCT
ihlr-25462	246	9	am	be	AUX
ihlr-25462	246	10	.	.	X
ihlr-25462	246	11	soc’y	soc’y	VERB
ihlr-25462	246	12	health	health	NOUN
ihlr-25462	246	13	-	-	PUNCT
ihlr-25462	246	14	system	system	NOUN
ihlr-25462	246	15	pharmacists	pharmacist	NOUN
ihlr-25462	246	16	,	,	PUNCT
ihlr-25462	246	17	https://www.ashp.org/advocacy-and-issues/key-issues/drug-pricing/issue-brief-safe-importationaction-plan	https://www.ashp.org/advocacy-and-issues/key-issues/drug-pricing/issue-brief-safe-importationaction-plan	VERB
ihlr-25462	247	1	[	[	X
ihlr-25462	247	2	https://perma.cc/gep6-aslf	https://perma.cc/gep6-aslf	X
ihlr-25462	247	3	]	]	PUNCT
ihlr-25462	247	4	(	(	PUNCT
ihlr-25462	247	5	last	last	ADV
ihlr-25462	247	6	visited	visit	VERB
ihlr-25462	247	7	mar	mar	PROPN
ihlr-25462	247	8	.	.	PROPN
ihlr-25462	247	9	14	14	NUM
ihlr-25462	247	10	,	,	PUNCT
ihlr-25462	247	11	2021	2021	NUM
ihlr-25462	247	12	)	)	PUNCT
ihlr-25462	247	13	.	.	PUNCT
ihlr-25462	248	1	408	408	NUM
ihlr-25462	248	2	indiana	indiana	PROPN
ihlr-25462	248	3	health	health	PROPN
ihlr-25462	248	4	law	law	PROPN
ihlr-25462	248	5	review	review	NOUN
ihlr-25462	249	1	[	[	X
ihlr-25462	249	2	vol	vol	NOUN
ihlr-25462	249	3	.	.	PUNCT
ihlr-25462	249	4	18:397	18:397	NUM
ihlr-25462	250	1	public	public	NOUN
ihlr-25462	250	2	’s	’s	PART
ihlr-25462	250	3	health	health	NOUN
ihlr-25462	250	4	and	and	CCONJ
ihlr-25462	250	5	safety	safety	NOUN
ihlr-25462	251	1	and	and	CCONJ
ihlr-25462	251	2	will	will	AUX
ihlr-25462	251	3	result	result	VERB
ihlr-25462	251	4	in	in	ADP
ihlr-25462	251	5	a	a	DET
ihlr-25462	251	6	significant	significant	ADJ
ihlr-25462	251	7	reduction	reduction	NOUN
ihlr-25462	251	8	in	in	ADP
ihlr-25462	251	9	the	the	DET
ihlr-25462	251	10	cost	cost	NOUN
ihlr-25462	251	11	of	of	ADP
ihlr-25462	251	12	covered	cover	VERB
ihlr-25462	251	13	products	product	NOUN
ihlr-25462	251	14	to	to	ADP
ihlr-25462	251	15	the	the	DET
ihlr-25462	251	16	american	american	ADJ
ihlr-25462	251	17	consumer	consumer	NOUN
ihlr-25462	251	18	.	.	PUNCT
ihlr-25462	252	1	”84	”84	NOUN
ihlr-25462	252	2	however	however	ADV
ihlr-25462	252	3	,	,	PUNCT
ihlr-25462	252	4	since	since	SCONJ
ihlr-25462	252	5	the	the	DET
ihlr-25462	252	6	passage	passage	NOUN
ihlr-25462	252	7	of	of	ADP
ihlr-25462	252	8	the	the	DET
ihlr-25462	252	9	medicare	medicare	PROPN
ihlr-25462	252	10	modernization	modernization	PROPN
ihlr-25462	252	11	act	act	NOUN
ihlr-25462	252	12	in	in	ADP
ihlr-25462	252	13	2003	2003	NUM
ihlr-25462	252	14	,	,	PUNCT
ihlr-25462	252	15	“	"	PUNCT
ihlr-25462	252	16	no	no	DET
ihlr-25462	252	17	subsequent	subsequent	ADJ
ihlr-25462	252	18	hhs	hhs	PROPN
ihlr-25462	252	19	secretary	secretary	NOUN
ihlr-25462	252	20	,	,	PUNCT
ihlr-25462	252	21	republican	republican	PROPN
ihlr-25462	252	22	or	or	CCONJ
ihlr-25462	252	23	democrat	democrat	PROPN
ihlr-25462	252	24	,	,	PUNCT
ihlr-25462	252	25	”	"	PUNCT
ihlr-25462	252	26	has	have	AUX
ihlr-25462	252	27	been	be	AUX
ihlr-25462	252	28	willing	willing	ADJ
ihlr-25462	252	29	to	to	PART
ihlr-25462	252	30	certify	certify	VERB
ihlr-25462	252	31	that	that	SCONJ
ihlr-25462	252	32	they	they	PRON
ihlr-25462	252	33	are	be	AUX
ihlr-25462	252	34	safe.85	safe.85	NOUN
ihlr-25462	252	35	however	however	ADV
ihlr-25462	252	36	,	,	PUNCT
ihlr-25462	252	37	secretary	secretary	NOUN
ihlr-25462	252	38	azar	azar	PROPN
ihlr-25462	252	39	is	be	AUX
ihlr-25462	252	40	not	not	PART
ihlr-25462	252	41	planning	plan	VERB
ihlr-25462	252	42	to	to	PART
ihlr-25462	252	43	make	make	VERB
ihlr-25462	252	44	that	that	DET
ihlr-25462	252	45	broad	broad	NOUN
ihlr-25462	252	46	of	of	ADP
ihlr-25462	252	47	a	a	DET
ihlr-25462	252	48	certification	certification	NOUN
ihlr-25462	252	49	.	.	PUNCT
ihlr-25462	253	1	instead	instead	ADV
ihlr-25462	253	2	,	,	PUNCT
ihlr-25462	253	3	he	he	PRON
ihlr-25462	253	4	will	will	AUX
ihlr-25462	253	5	“	"	PUNCT
ihlr-25462	253	6	propose	propose	VERB
ihlr-25462	253	7	to	to	ADP
ihlr-25462	253	8	condition	condition	NOUN
ihlr-25462	253	9	certification	certification	NOUN
ihlr-25462	253	10	on	on	ADP
ihlr-25462	253	11	the	the	DET
ihlr-25462	253	12	ability	ability	NOUN
ihlr-25462	253	13	to	to	PART
ihlr-25462	253	14	limit	limit	VERB
ihlr-25462	253	15	the	the	DET
ihlr-25462	253	16	program	program	NOUN
ihlr-25462	253	17	to	to	ADP
ihlr-25462	253	18	demonstration	demonstration	NOUN
ihlr-25462	253	19	projects	project	NOUN
ihlr-25462	253	20	under	under	ADP
ihlr-25462	253	21	[	[	X
ihlr-25462	253	22	s]ection	s]ection	NOUN
ihlr-25462	253	23	804(b)-(h	804(b)-(h	NUM
ihlr-25462	253	24	)	)	PUNCT
ihlr-25462	253	25	and	and	CCONJ
ihlr-25462	253	26	would	would	AUX
ihlr-25462	253	27	seek	seek	VERB
ihlr-25462	253	28	comments	comment	NOUN
ihlr-25462	253	29	on	on	ADP
ihlr-25462	253	30	that	that	DET
ihlr-25462	253	31	proposal	proposal	NOUN
ihlr-25462	253	32	.	.	PUNCT
ihlr-25462	254	1	”86	”86	VERB
ihlr-25462	254	2	“	"	PUNCT
ihlr-25462	254	3	it	it	PRON
ihlr-25462	254	4	is	be	AUX
ihlr-25462	254	5	not	not	PART
ihlr-25462	254	6	clear	clear	ADJ
ihlr-25462	254	7	that	that	SCONJ
ihlr-25462	254	8	the	the	DET
ihlr-25462	254	9	secretary	secretary	NOUN
ihlr-25462	254	10	has	have	VERB
ihlr-25462	254	11	the	the	DET
ihlr-25462	254	12	legal	legal	ADJ
ihlr-25462	254	13	authority	authority	NOUN
ihlr-25462	254	14	to	to	PART
ihlr-25462	254	15	make	make	VERB
ihlr-25462	254	16	a	a	DET
ihlr-25462	254	17	‘	'	PUNCT
ihlr-25462	254	18	conditional	conditional	ADJ
ihlr-25462	254	19	’	'	PUNCT
ihlr-25462	254	20	certification	certification	NOUN
ihlr-25462	254	21	that	that	PRON
ihlr-25462	254	22	is	be	AUX
ihlr-25462	254	23	far	far	ADV
ihlr-25462	254	24	short	short	ADJ
ihlr-25462	254	25	of	of	ADP
ihlr-25462	254	26	the	the	DET
ihlr-25462	254	27	complete	complete	ADJ
ihlr-25462	254	28	certification	certification	NOUN
ihlr-25462	254	29	required	require	VERB
ihlr-25462	254	30	by	by	ADP
ihlr-25462	254	31	statute	statute	PROPN
ihlr-25462	254	32	.	.	PUNCT
ihlr-25462	255	1	”87	”87	PROPN
ihlr-25462	255	2	second	second	PROPN
ihlr-25462	255	3	,	,	PUNCT
ihlr-25462	255	4	hhs	hhs	PROPN
ihlr-25462	255	5	is	be	AUX
ihlr-25462	255	6	proposing	propose	VERB
ihlr-25462	255	7	to	to	PART
ihlr-25462	255	8	include	include	VERB
ihlr-25462	255	9	“	"	PUNCT
ihlr-25462	255	10	states	state	NOUN
ihlr-25462	255	11	”	"	PUNCT
ihlr-25462	255	12	as	as	ADP
ihlr-25462	255	13	sponsors	sponsor	NOUN
ihlr-25462	255	14	of	of	ADP
ihlr-25462	255	15	demonstration	demonstration	NOUN
ihlr-25462	255	16	projects.88	projects.88	NOUN
ihlr-25462	255	17	unfortunately	unfortunately	ADV
ihlr-25462	255	18	,	,	PUNCT
ihlr-25462	255	19	“	"	PUNCT
ihlr-25462	255	20	states	state	NOUN
ihlr-25462	255	21	”	"	PUNCT
ihlr-25462	255	22	are	be	AUX
ihlr-25462	255	23	not	not	PART
ihlr-25462	255	24	authorized	authorize	VERB
ihlr-25462	255	25	importers	importer	NOUN
ihlr-25462	255	26	under	under	ADP
ihlr-25462	255	27	the	the	DET
ihlr-25462	255	28	law	law	NOUN
ihlr-25462	255	29	.	.	PUNCT
ihlr-25462	256	1	for	for	ADP
ihlr-25462	256	2	example	example	NOUN
ihlr-25462	256	3	,	,	PUNCT
ihlr-25462	256	4	“	"	PUNCT
ihlr-25462	256	5	[	[	X
ihlr-25462	256	6	t]he	t]he	X
ihlr-25462	256	7	secretary	secretary	NOUN
ihlr-25462	256	8	,	,	PUNCT
ihlr-25462	256	9	after	after	ADP
ihlr-25462	256	10	consultation	consultation	NOUN
ihlr-25462	256	11	with	with	ADP
ihlr-25462	256	12	the	the	DET
ihlr-25462	256	13	[	[	X
ihlr-25462	256	14	u.s	u.s	PROPN
ihlr-25462	256	15	.	.	PROPN
ihlr-25462	256	16	]	]	PUNCT
ihlr-25462	256	17	trade	trade	NOUN
ihlr-25462	256	18	representative	representative	NOUN
ihlr-25462	256	19	and	and	CCONJ
ihlr-25462	256	20	the	the	DET
ihlr-25462	256	21	commissioner	commissioner	NOUN
ihlr-25462	256	22	of	of	ADP
ihlr-25462	256	23	u.s	u.s	PROPN
ihlr-25462	256	24	.	.	PROPN
ihlr-25462	256	25	customs	customs	PROPN
ihlr-25462	256	26	and	and	CCONJ
ihlr-25462	256	27	border	border	NOUN
ihlr-25462	256	28	protection	protection	NOUN
ihlr-25462	256	29	,	,	PUNCT
ihlr-25462	256	30	shall	shall	AUX
ihlr-25462	256	31	promulgate	promulgate	VERB
ihlr-25462	256	32	regulations	regulation	NOUN
ihlr-25462	256	33	permitting	permit	VERB
ihlr-25462	256	34	pharmacists	pharmacist	NOUN
ihlr-25462	256	35	and	and	CCONJ
ihlr-25462	256	36	wholesalers	wholesaler	NOUN
ihlr-25462	256	37	to	to	PART
ihlr-25462	256	38	import	import	VERB
ihlr-25462	256	39	prescription	prescription	NOUN
ihlr-25462	256	40	drugs	drug	NOUN
ihlr-25462	256	41	from	from	ADP
ihlr-25462	256	42	canada	canada	PROPN
ihlr-25462	256	43	into	into	ADP
ihlr-25462	256	44	the	the	DET
ihlr-25462	256	45	[	[	X
ihlr-25462	256	46	u.s.].”89	u.s.].”89	NOUN
ihlr-25462	256	47	thus	thus	ADV
ihlr-25462	256	48	,	,	PUNCT
ihlr-25462	256	49	it	it	PRON
ihlr-25462	256	50	is	be	AUX
ihlr-25462	256	51	unclear	unclear	ADJ
ihlr-25462	256	52	whether	whether	SCONJ
ihlr-25462	256	53	hhs	hhs	PROPN
ihlr-25462	256	54	could	could	AUX
ihlr-25462	256	55	authorize	authorize	VERB
ihlr-25462	256	56	a	a	DET
ihlr-25462	256	57	demonstration	demonstration	NOUN
ihlr-25462	256	58	project	project	NOUN
ihlr-25462	256	59	from	from	ADP
ihlr-25462	256	60	any	any	PRON
ihlr-25462	256	61	of	of	ADP
ihlr-25462	256	62	the	the	DET
ihlr-25462	256	63	states	state	NOUN
ihlr-25462	256	64	.	.	PUNCT
ihlr-25462	257	1	pathway	pathway	NOUN
ihlr-25462	257	2	two	two	NUM
ihlr-25462	257	3	has	have	VERB
ihlr-25462	257	4	a	a	DET
ihlr-25462	257	5	significant	significant	ADJ
ihlr-25462	257	6	advantage	advantage	NOUN
ihlr-25462	257	7	for	for	ADP
ihlr-25462	257	8	u.s	u.s	PROPN
ihlr-25462	257	9	.	.	PROPN
ihlr-25462	257	10	consumers	consumer	NOUN
ihlr-25462	257	11	because	because	SCONJ
ihlr-25462	257	12	“	"	PUNCT
ihlr-25462	257	13	[	[	X
ihlr-25462	257	14	i]t	i]t	PRON
ihlr-25462	257	15	would	would	AUX
ihlr-25462	257	16	apply	apply	VERB
ihlr-25462	257	17	to	to	ADP
ihlr-25462	257	18	any	any	DET
ihlr-25462	257	19	‘	'	PUNCT
ihlr-25462	257	20	versions	version	NOUN
ihlr-25462	257	21	of	of	ADP
ihlr-25462	257	22	fda	fda	PROPN
ihlr-25462	257	23	-	-	PUNCT
ihlr-25462	257	24	approved	approve	VERB
ihlr-25462	257	25	drug	drug	NOUN
ihlr-25462	257	26	products	product	NOUN
ihlr-25462	257	27	’	'	PUNCT
ihlr-25462	257	28	that	that	PRON
ihlr-25462	257	29	a	a	DET
ihlr-25462	257	30	manufacturer	manufacturer	NOUN
ihlr-25462	257	31	sells	sell	VERB
ihlr-25462	257	32	abroad	abroad	ADV
ihlr-25462	257	33	.	.	PUNCT
ihlr-25462	258	1	”90	”90	PROPN
ihlr-25462	258	2	this	this	PRON
ihlr-25462	258	3	includes	include	VERB
ihlr-25462	258	4	,	,	PUNCT
ihlr-25462	258	5	for	for	ADP
ihlr-25462	258	6	example	example	NOUN
ihlr-25462	258	7	,	,	PUNCT
ihlr-25462	258	8	generic	generic	ADJ
ihlr-25462	258	9	versions	version	NOUN
ihlr-25462	258	10	that	that	PRON
ihlr-25462	258	11	are	be	AUX
ihlr-25462	258	12	sometimes	sometimes	ADV
ihlr-25462	258	13	produced	produce	VERB
ihlr-25462	258	14	,	,	PUNCT
ihlr-25462	258	15	or	or	CCONJ
ihlr-25462	258	16	authorized	authorize	VERB
ihlr-25462	258	17	to	to	PART
ihlr-25462	258	18	be	be	AUX
ihlr-25462	258	19	produced	produce	VERB
ihlr-25462	258	20	,	,	PUNCT
ihlr-25462	258	21	by	by	ADP
ihlr-25462	258	22	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	258	23	manufacturers	manufacturer	NOUN
ihlr-25462	258	24	themselves.91	themselves.91	PROPN
ihlr-25462	258	25	phrma	phrma	PROPN
ihlr-25462	258	26	and	and	CCONJ
ihlr-25462	258	27	bio	bio	NOUN
ihlr-25462	258	28	,	,	PUNCT
ihlr-25462	258	29	industry	industry	NOUN
ihlr-25462	258	30	trade	trade	NOUN
ihlr-25462	258	31	groups	group	NOUN
ihlr-25462	258	32	that	that	PRON
ihlr-25462	258	33	often	often	ADV
ihlr-25462	258	34	represent	represent	VERB
ihlr-25462	258	35	the	the	DET
ihlr-25462	258	36	voice	voice	NOUN
ihlr-25462	258	37	of	of	ADP
ihlr-25462	258	38	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	258	39	manufacturers	manufacturer	NOUN
ihlr-25462	258	40	,	,	PUNCT
ihlr-25462	258	41	have	have	AUX
ihlr-25462	258	42	spoken	speak	VERB
ihlr-25462	258	43	in	in	ADP
ihlr-25462	258	44	opposition	opposition	NOUN
ihlr-25462	258	45	to	to	ADP
ihlr-25462	258	46	pathway	pathway	NOUN
ihlr-25462	258	47	two	two	NUM
ihlr-25462	258	48	,	,	PUNCT
ihlr-25462	258	49	making	make	VERB
ihlr-25462	258	50	it	it	PRON
ihlr-25462	258	51	“	"	PUNCT
ihlr-25462	258	52	reasonable	reasonable	ADJ
ihlr-25462	258	53	to	to	PART
ihlr-25462	258	54	expect	expect	VERB
ihlr-25462	258	55	that	that	SCONJ
ihlr-25462	258	56	most	most	ADJ
ihlr-25462	258	57	manufacturers	manufacturer	NOUN
ihlr-25462	258	58	may	may	AUX
ihlr-25462	258	59	choose	choose	VERB
ihlr-25462	258	60	to	to	PART
ihlr-25462	258	61	ignore	ignore	VERB
ihlr-25462	258	62	[	[	X
ihlr-25462	258	63	it].”92	it].”92	ADV
ihlr-25462	258	64	further	far	ADV
ihlr-25462	258	65	,	,	PUNCT
ihlr-25462	258	66	canada	canada	PROPN
ihlr-25462	258	67	tends	tend	VERB
ihlr-25462	258	68	to	to	PART
ihlr-25462	258	69	be	be	AUX
ihlr-25462	258	70	generally	generally	ADV
ihlr-25462	258	71	opposed	oppose	VERB
ihlr-25462	258	72	due	due	ADP
ihlr-25462	258	73	to	to	ADP
ihlr-25462	258	74	concerns	concern	NOUN
ihlr-25462	258	75	about	about	ADP
ihlr-25462	258	76	their	their	PRON
ihlr-25462	258	77	own	own	ADJ
ihlr-25462	258	78	drug	drug	NOUN
ihlr-25462	258	79	supply	supply	NOUN
ihlr-25462	258	80	:	:	PUNCT
ihlr-25462	258	81	“	"	PUNCT
ihlr-25462	258	82	[	[	X
ihlr-25462	258	83	a	a	X
ihlr-25462	258	84	]	]	X
ihlr-25462	258	85	recent	recent	ADJ
ihlr-25462	258	86	study	study	NOUN
ihlr-25462	258	87	estimates	estimate	VERB
ihlr-25462	258	88	that	that	SCONJ
ihlr-25462	258	89	the	the	DET
ihlr-25462	258	90	entire	entire	ADJ
ihlr-25462	258	91	canadian	canadian	ADJ
ihlr-25462	258	92	drug	drug	NOUN
ihlr-25462	258	93	supply	supply	NOUN
ihlr-25462	258	94	would	would	AUX
ihlr-25462	258	95	be	be	AUX
ihlr-25462	258	96	exhausted	exhaust	VERB
ihlr-25462	258	97	in	in	ADP
ihlr-25462	258	98	183	183	NUM
ihlr-25462	258	99	days	day	NOUN
ihlr-25462	258	100	if	if	SCONJ
ihlr-25462	258	101	only	only	ADV
ihlr-25462	258	102	20	20	NUM
ihlr-25462	258	103	%	%	NOUN
ihlr-25462	258	104	of	of	ADP
ihlr-25462	258	105	u.s	u.s	PROPN
ihlr-25462	258	106	.	.	PROPN
ihlr-25462	258	107	prescriptions	prescription	NOUN
ihlr-25462	258	108	were	be	AUX
ihlr-25462	258	109	filled	fill	VERB
ihlr-25462	258	110	84	84	NUM
ihlr-25462	258	111	.	.	PUNCT
ihlr-25462	259	1	safe	safe	ADJ
ihlr-25462	259	2	importation	importation	NOUN
ihlr-25462	259	3	action	action	NOUN
ihlr-25462	259	4	plan	plan	NOUN
ihlr-25462	259	5	,	,	PUNCT
ihlr-25462	259	6	supra	supra	PROPN
ihlr-25462	259	7	note	note	PROPN
ihlr-25462	259	8	11	11	NUM
ihlr-25462	259	9	;	;	PUNCT
ihlr-25462	259	10	see	see	AUX
ihlr-25462	259	11	generally	generally	ADV
ihlr-25462	259	12	medicare	medicare	VERB
ihlr-25462	259	13	prescription	prescription	NOUN
ihlr-25462	259	14	drug	drug	NOUN
ihlr-25462	259	15	,	,	PUNCT
ihlr-25462	259	16	improvement	improvement	NOUN
ihlr-25462	259	17	,	,	PUNCT
ihlr-25462	259	18	and	and	CCONJ
ihlr-25462	259	19	modernization	modernization	NOUN
ihlr-25462	259	20	act	act	NOUN
ihlr-25462	259	21	of	of	ADP
ihlr-25462	259	22	2003	2003	NUM
ihlr-25462	259	23	,	,	PUNCT
ihlr-25462	259	24	pub	pub	NOUN
ihlr-25462	259	25	.	.	PUNCT
ihlr-25462	260	1	l.	l.	PROPN
ihlr-25462	260	2	no	no	INTJ
ihlr-25462	260	3	.	.	PROPN
ihlr-25462	261	1	108	108	NUM
ihlr-25462	261	2	-	-	SYM
ihlr-25462	261	3	173	173	NUM
ihlr-25462	261	4	,	,	PUNCT
ihlr-25462	261	5	117	117	NUM
ihlr-25462	261	6	stat	stat	NOUN
ihlr-25462	261	7	.	.	PUNCT
ihlr-25462	262	1	2066	2066	NUM
ihlr-25462	262	2	.	.	PUNCT
ihlr-25462	263	1	85	85	NUM
ihlr-25462	263	2	.	.	PUNCT
ihlr-25462	264	1	merrill	merrill	PROPN
ihlr-25462	264	2	matthews	matthews	PROPN
ihlr-25462	264	3	,	,	PUNCT
ihlr-25462	264	4	vermont	vermont	PROPN
ihlr-25462	264	5	’s	’s	PART
ihlr-25462	264	6	prescription	prescription	NOUN
ihlr-25462	264	7	for	for	ADP
ihlr-25462	264	8	failure	failure	NOUN
ihlr-25462	264	9	,	,	PUNCT
ihlr-25462	264	10	inst	inst	NOUN
ihlr-25462	264	11	.	.	PUNCT
ihlr-25462	264	12	pol’y	pol’y	NOUN
ihlr-25462	264	13	innovation	innovation	NOUN
ihlr-25462	264	14	(	(	PUNCT
ihlr-25462	264	15	may	may	PROPN
ihlr-25462	264	16	22	22	NUM
ihlr-25462	264	17	,	,	PUNCT
ihlr-25462	264	18	2018	2018	NUM
ihlr-25462	264	19	)	)	PUNCT
ihlr-25462	264	20	,	,	PUNCT
ihlr-25462	264	21	https://www.ipi.org/ipi_issues/detail/vermonts-prescription-for-failure	https://www.ipi.org/ipi_issues/detail/vermonts-prescription-for-failure	NOUN
ihlr-25462	265	1	[	[	X
ihlr-25462	265	2	https://perma	https://perma	X
ihlr-25462	265	3	.	.	PUNCT
ihlr-25462	265	4	cc	cc	NOUN
ihlr-25462	265	5	/	/	SYM
ihlr-25462	265	6	br4d-292	br4d-292	ADP
ihlr-25462	265	7	t	t	NOUN
ihlr-25462	265	8	]	]	PUNCT
ihlr-25462	265	9	(	(	PUNCT
ihlr-25462	265	10	providing	provide	VERB
ihlr-25462	265	11	the	the	DET
ihlr-25462	265	12	oppositions	opposition	NOUN
ihlr-25462	265	13	of	of	ADP
ihlr-25462	265	14	secretary	secretary	NOUN
ihlr-25462	265	15	donna	donna	PROPN
ihlr-25462	265	16	shalala	shalala	PROPN
ihlr-25462	265	17	,	,	PUNCT
ihlr-25462	265	18	secretary	secretary	PROPN
ihlr-25462	265	19	tommy	tommy	PROPN
ihlr-25462	265	20	thompson	thompson	PROPN
ihlr-25462	265	21	,	,	PUNCT
ihlr-25462	265	22	commissioner	commissioner	PROPN
ihlr-25462	265	23	andrew	andrew	PROPN
ihlr-25462	265	24	c.	c.	PROPN
ihlr-25462	265	25	von	von	PROPN
ihlr-25462	265	26	eschenbach	eschenbach	PROPN
ihlr-25462	265	27	,	,	PUNCT
ihlr-25462	265	28	and	and	CCONJ
ihlr-25462	265	29	commissioner	commissioner	PROPN
ihlr-25462	265	30	margaret	margaret	PROPN
ihlr-25462	265	31	hamburg	hamburg	PROPN
ihlr-25462	265	32	)	)	PUNCT
ihlr-25462	265	33	.	.	PUNCT
ihlr-25462	266	1	86	86	NUM
ihlr-25462	266	2	.	.	PUNCT
ihlr-25462	267	1	safe	safe	ADJ
ihlr-25462	267	2	importation	importation	NOUN
ihlr-25462	267	3	action	action	NOUN
ihlr-25462	267	4	plan	plan	NOUN
ihlr-25462	267	5	,	,	PUNCT
ihlr-25462	267	6	supra	supra	PROPN
ihlr-25462	267	7	note	note	NOUN
ihlr-25462	267	8	11	11	NUM
ihlr-25462	267	9	.	.	PUNCT
ihlr-25462	267	10	87	87	NUM
ihlr-25462	267	11	.	.	PUNCT
ihlr-25462	268	1	a	a	DET
ihlr-25462	268	2	gimmick	gimmick	NOUN
ihlr-25462	268	3	no	no	ADV
ihlr-25462	268	4	more	more	ADV
ihlr-25462	268	5	?	?	PUNCT
ihlr-25462	269	1	hhs	hhs	PROPN
ihlr-25462	269	2	moves	move	NOUN
ihlr-25462	269	3	to	to	PART
ihlr-25462	269	4	authorize	authorize	VERB
ihlr-25462	269	5	prescription	prescription	NOUN
ihlr-25462	269	6	drug	drug	NOUN
ihlr-25462	269	7	importation	importation	NOUN
ihlr-25462	269	8	,	,	PUNCT
ihlr-25462	269	9	king	king	NOUN
ihlr-25462	269	10	&	&	CCONJ
ihlr-25462	269	11	spaulding	spaulding	PROPN
ihlr-25462	269	12	(	(	PUNCT
ihlr-25462	269	13	aug	aug	PROPN
ihlr-25462	269	14	.	.	PROPN
ihlr-25462	269	15	6	6	NUM
ihlr-25462	269	16	.	.	NOUN
ihlr-25462	269	17	2019	2019	NUM
ihlr-25462	269	18	)	)	PUNCT
ihlr-25462	269	19	,	,	PUNCT
ihlr-25462	269	20	https://www.kslaw.com/news-and-insights/a-gimmick-no-more-hhsmoves-to-authorize-prescription-drug-importation#_edn13https://www.kslaw.com/news-andinsights/a-gimmick-no-more-hhs-moves-to-authorize-prescription-drug-importation#_edn13	https://www.kslaw.com/news-and-insights/a-gimmick-no-more-hhsmoves-to-authorize-prescription-drug-importation#_edn13https://www.kslaw.com/news-andinsights/a-gimmick-no-more-hhs-moves-to-authorize-prescription-drug-importation#_edn13	PROPN
ihlr-25462	270	1	[	[	X
ihlr-25462	270	2	https://perma.cc/fhm7-eklz	https://perma.cc/fhm7-eklz	X
ihlr-25462	270	3	]	]	X
ihlr-25462	271	1	[	[	X
ihlr-25462	271	2	hereinafter	hereinafter	NOUN
ihlr-25462	271	3	king	king	NOUN
ihlr-25462	271	4	&	&	CCONJ
ihlr-25462	271	5	spaulding	spaulding	PROPN
ihlr-25462	271	6	]	]	X
ihlr-25462	271	7	.	.	PUNCT
ihlr-25462	272	1	88	88	NUM
ihlr-25462	272	2	.	.	PUNCT
ihlr-25462	273	1	safe	safe	ADJ
ihlr-25462	273	2	importation	importation	NOUN
ihlr-25462	273	3	action	action	NOUN
ihlr-25462	273	4	plan	plan	NOUN
ihlr-25462	273	5	,	,	PUNCT
ihlr-25462	273	6	supra	supra	PROPN
ihlr-25462	273	7	note	note	NOUN
ihlr-25462	273	8	11	11	NUM
ihlr-25462	273	9	.	.	SYM
ihlr-25462	273	10	89	89	NUM
ihlr-25462	273	11	.	.	PUNCT
ihlr-25462	273	12	21	21	NUM
ihlr-25462	273	13	u.s.c	u.s.c	NOUN
ihlr-25462	273	14	.	.	PUNCT
ihlr-25462	274	1	§	§	PROPN
ihlr-25462	274	2	384	384	NUM
ihlr-25462	274	3	(	(	PUNCT
ihlr-25462	274	4	2020	2020	NUM
ihlr-25462	274	5	)	)	PUNCT
ihlr-25462	274	6	(	(	PUNCT
ihlr-25462	274	7	emphasis	emphasis	NOUN
ihlr-25462	274	8	added	add	VERB
ihlr-25462	274	9	)	)	PUNCT
ihlr-25462	274	10	.	.	PUNCT
ihlr-25462	275	1	90	90	NUM
ihlr-25462	275	2	.	.	PUNCT
ihlr-25462	275	3	king	king	PROPN
ihlr-25462	275	4	&	&	CCONJ
ihlr-25462	275	5	spaulding	spaulding	PROPN
ihlr-25462	275	6	,	,	PUNCT
ihlr-25462	275	7	supra	supra	PROPN
ihlr-25462	275	8	note	note	VERB
ihlr-25462	275	9	87	87	NUM
ihlr-25462	275	10	.	.	PUNCT
ihlr-25462	276	1	91	91	NUM
ihlr-25462	276	2	.	.	PUNCT
ihlr-25462	277	1	zegarelli	zegarelli	PROPN
ihlr-25462	277	2	,	,	PUNCT
ihlr-25462	277	3	supra	supra	PROPN
ihlr-25462	277	4	note	note	PROPN
ihlr-25462	277	5	80	80	NUM
ihlr-25462	277	6	.	.	PUNCT
ihlr-25462	278	1	92	92	NUM
ihlr-25462	278	2	.	.	PUNCT
ihlr-25462	279	1	i	i	PRON
ihlr-25462	279	2	d.	d.	PROPN
ihlr-25462	279	3	2021	2021	NUM
ihlr-25462	279	4	]	]	PUNCT
ihlr-25462	280	1	a	a	DET
ihlr-25462	280	2	survey	survey	NOUN
ihlr-25462	280	3	of	of	ADP
ihlr-25462	280	4	three	three	NUM
ihlr-25462	280	5	patent	patent	NOUN
ihlr-25462	280	6	-	-	PUNCT
ihlr-25462	280	7	based	base	VERB
ihlr-25462	280	8	approaches	approach	NOUN
ihlr-25462	280	9	409	409	NUM
ihlr-25462	280	10	using	use	VERB
ihlr-25462	280	11	canadian	canadian	ADJ
ihlr-25462	280	12	prescription	prescription	NOUN
ihlr-25462	280	13	drug	drug	NOUN
ihlr-25462	280	14	sources	source	NOUN
ihlr-25462	280	15	.	.	PUNCT
ihlr-25462	281	1	”93	”93	ADV
ihlr-25462	281	2	in	in	ADP
ihlr-25462	281	3	the	the	DET
ihlr-25462	281	4	past	past	NOUN
ihlr-25462	281	5	,	,	PUNCT
ihlr-25462	281	6	plans	plan	VERB
ihlr-25462	281	7	to	to	PART
ihlr-25462	281	8	import	import	VERB
ihlr-25462	281	9	drugs	drug	NOUN
ihlr-25462	281	10	from	from	ADP
ihlr-25462	281	11	canada	canada	PROPN
ihlr-25462	281	12	had	have	AUX
ihlr-25462	281	13	been	be	AUX
ihlr-25462	281	14	met	meet	VERB
ihlr-25462	281	15	with	with	ADP
ihlr-25462	281	16	resistance	resistance	NOUN
ihlr-25462	281	17	from	from	ADP
ihlr-25462	281	18	the	the	DET
ihlr-25462	281	19	u.s	u.s	PROPN
ihlr-25462	281	20	.	.	PROPN
ihlr-25462	281	21	over	over	ADP
ihlr-25462	281	22	concerns	concern	NOUN
ihlr-25462	281	23	about	about	ADP
ihlr-25462	281	24	drug	drug	NOUN
ihlr-25462	281	25	safety	safety	NOUN
ihlr-25462	281	26	and	and	CCONJ
ihlr-25462	281	27	the	the	DET
ihlr-25462	281	28	introduction	introduction	NOUN
ihlr-25462	281	29	of	of	ADP
ihlr-25462	281	30	counterfeit	counterfeit	ADJ
ihlr-25462	281	31	drugs	drug	NOUN
ihlr-25462	281	32	into	into	ADP
ihlr-25462	281	33	the	the	DET
ihlr-25462	281	34	u.s	u.s	PROPN
ihlr-25462	281	35	.	.	PROPN
ihlr-25462	281	36	drug	drug	PROPN
ihlr-25462	281	37	supply.94	supply.94	PROPN
ihlr-25462	281	38	but	but	CCONJ
ihlr-25462	281	39	,	,	PUNCT
ihlr-25462	281	40	as	as	SCONJ
ihlr-25462	281	41	drug	drug	NOUN
ihlr-25462	281	42	prices	price	NOUN
ihlr-25462	281	43	in	in	ADP
ihlr-25462	281	44	the	the	DET
ihlr-25462	281	45	u.s	u.s	PROPN
ihlr-25462	281	46	.	.	PROPN
ihlr-25462	281	47	have	have	AUX
ihlr-25462	281	48	risen	rise	VERB
ihlr-25462	281	49	,	,	PUNCT
ihlr-25462	281	50	the	the	DET
ihlr-25462	281	51	idea	idea	NOUN
ihlr-25462	281	52	has	have	AUX
ihlr-25462	281	53	gained	gain	VERB
ihlr-25462	281	54	support	support	NOUN
ihlr-25462	281	55	.	.	PUNCT
ihlr-25462	282	1	states	state	NOUN
ihlr-25462	282	2	,	,	PUNCT
ihlr-25462	282	3	including	include	VERB
ihlr-25462	282	4	florida	florida	PROPN
ihlr-25462	282	5	,	,	PUNCT
ihlr-25462	282	6	maine	maine	PROPN
ihlr-25462	282	7	,	,	PUNCT
ihlr-25462	282	8	colorado	colorado	PROPN
ihlr-25462	282	9	,	,	PUNCT
ihlr-25462	282	10	and	and	CCONJ
ihlr-25462	282	11	vermont	vermont	PROPN
ihlr-25462	282	12	,	,	PUNCT
ihlr-25462	282	13	have	have	AUX
ihlr-25462	282	14	passed	pass	VERB
ihlr-25462	282	15	laws	law	NOUN
ihlr-25462	282	16	to	to	PART
ihlr-25462	282	17	allow	allow	VERB
ihlr-25462	282	18	imports	import	NOUN
ihlr-25462	282	19	,	,	PUNCT
ihlr-25462	282	20	subject	subject	ADJ
ihlr-25462	282	21	to	to	ADP
ihlr-25462	282	22	the	the	DET
ihlr-25462	282	23	approval	approval	NOUN
ihlr-25462	282	24	of	of	ADP
ihlr-25462	282	25	hhs.95	hhs.95	PROPN
ihlr-25462	282	26	‘	'	PUNCT
ihlr-25462	282	27	“	"	PUNCT
ihlr-25462	282	28	this	this	PRON
ihlr-25462	282	29	is	be	AUX
ihlr-25462	282	30	going	go	VERB
ihlr-25462	282	31	to	to	PART
ihlr-25462	282	32	exacerbate	exacerbate	VERB
ihlr-25462	282	33	some	some	PRON
ihlr-25462	282	34	of	of	ADP
ihlr-25462	282	35	the	the	DET
ihlr-25462	282	36	drug	drug	NOUN
ihlr-25462	282	37	shortages	shortage	NOUN
ihlr-25462	282	38	that	that	PRON
ihlr-25462	282	39	[	[	X
ihlr-25462	282	40	we	we	PRON
ihlr-25462	282	41	are	be	AUX
ihlr-25462	282	42	]	]	PUNCT
ihlr-25462	282	43	already	already	ADV
ihlr-25462	282	44	seeing	see	VERB
ihlr-25462	282	45	in	in	ADP
ihlr-25462	282	46	canada	canada	PROPN
ihlr-25462	282	47	,	,	PUNCT
ihlr-25462	282	48	’	'	PUNCT
ihlr-25462	282	49	said	say	VERB
ihlr-25462	282	50	joelle	joelle	PROPN
ihlr-25462	282	51	walker	walker	PROPN
ihlr-25462	282	52	,	,	PUNCT
ihlr-25462	282	53	the	the	DET
ihlr-25462	282	54	vice	vice	NOUN
ihlr-25462	282	55	president	president	NOUN
ihlr-25462	282	56	of	of	ADP
ihlr-25462	282	57	public	public	ADJ
ihlr-25462	282	58	affairs	affair	NOUN
ihlr-25462	282	59	for	for	ADP
ihlr-25462	282	60	the	the	DET
ihlr-25462	282	61	canadian	canadian	ADJ
ihlr-25462	282	62	pharmacists	pharmacist	NOUN
ihlr-25462	282	63	association	association	PROPN
ihlr-25462	282	64	.	.	PUNCT
ihlr-25462	283	1	‘	'	PUNCT
ihlr-25462	283	2	we	we	PRON
ihlr-25462	283	3	[	[	AUX
ihlr-25462	283	4	are	be	AUX
ihlr-25462	283	5	not	not	PART
ihlr-25462	283	6	]	]	PUNCT
ihlr-25462	283	7	equipped	equip	VERB
ihlr-25462	283	8	to	to	PART
ihlr-25462	283	9	deal	deal	VERB
ihlr-25462	283	10	with	with	ADP
ihlr-25462	283	11	a	a	DET
ihlr-25462	283	12	country	country	NOUN
ihlr-25462	283	13	that	that	PRON
ihlr-25462	283	14	is	be	AUX
ihlr-25462	283	15	ten	ten	NUM
ihlr-25462	283	16	times	time	NOUN
ihlr-25462	283	17	our	our	PRON
ihlr-25462	283	18	size	size	NOUN
ihlr-25462	283	19	.	.	PUNCT
ihlr-25462	283	20	’”96	’”96	ADV
ihlr-25462	283	21	further	far	ADV
ihlr-25462	283	22	,	,	PUNCT
ihlr-25462	283	23	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	283	24	companies	company	NOUN
ihlr-25462	283	25	,	,	PUNCT
ihlr-25462	283	26	although	although	SCONJ
ihlr-25462	283	27	they	they	PRON
ihlr-25462	283	28	partner	partner	VERB
ihlr-25462	283	29	with	with	ADP
ihlr-25462	283	30	government	government	NOUN
ihlr-25462	283	31	research	research	NOUN
ihlr-25462	283	32	and	and	CCONJ
ihlr-25462	283	33	academia	academia	NOUN
ihlr-25462	283	34	,	,	PUNCT
ihlr-25462	283	35	are	be	AUX
ihlr-25462	283	36	largely	largely	ADV
ihlr-25462	283	37	responsible	responsible	ADJ
ihlr-25462	283	38	for	for	ADP
ihlr-25462	283	39	developing	develop	VERB
ihlr-25462	283	40	new	new	ADJ
ihlr-25462	283	41	medicines	medicine	NOUN
ihlr-25462	283	42	,	,	PUNCT
ihlr-25462	283	43	which	which	PRON
ihlr-25462	283	44	is	be	AUX
ihlr-25462	283	45	an	an	DET
ihlr-25462	283	46	expensive	expensive	ADJ
ihlr-25462	283	47	process	process	NOUN
ihlr-25462	283	48	that	that	PRON
ihlr-25462	283	49	can	can	AUX
ihlr-25462	283	50	take	take	VERB
ihlr-25462	283	51	many	many	ADJ
ihlr-25462	283	52	years.97	years.97	NOUN
ihlr-25462	283	53	consequently	consequently	ADV
ihlr-25462	283	54	,	,	PUNCT
ihlr-25462	283	55	r&d	r&d	NOUN
ihlr-25462	283	56	expenditure	expenditure	NOUN
ihlr-25462	283	57	is	be	AUX
ihlr-25462	283	58	much	much	ADV
ihlr-25462	283	59	greater	great	ADJ
ihlr-25462	283	60	than	than	ADP
ihlr-25462	283	61	that	that	PRON
ihlr-25462	283	62	of	of	ADP
ihlr-25462	283	63	either	either	PRON
ihlr-25462	283	64	government	government	NOUN
ihlr-25462	283	65	or	or	CCONJ
ihlr-25462	283	66	academia	academia	NOUN
ihlr-25462	283	67	.	.	PUNCT
ihlr-25462	284	1	as	as	ADP
ihlr-25462	284	2	an	an	DET
ihlr-25462	284	3	example	example	NOUN
ihlr-25462	284	4	,	,	PUNCT
ihlr-25462	284	5	the	the	DET
ihlr-25462	284	6	r&d	r&d	NOUN
ihlr-25462	284	7	expenditure	expenditure	NOUN
ihlr-25462	284	8	of	of	ADP
ihlr-25462	284	9	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	284	10	companies	company	NOUN
ihlr-25462	284	11	was	be	AUX
ihlr-25462	284	12	nearly	nearly	ADV
ihlr-25462	284	13	triple	triple	DET
ihlr-25462	284	14	the	the	DET
ihlr-25462	284	15	national	national	PROPN
ihlr-25462	284	16	institutes	institutes	PROPN
ihlr-25462	284	17	of	of	ADP
ihlr-25462	284	18	health	health	PROPN
ihlr-25462	284	19	’s	’s	PART
ihlr-25462	284	20	r&d	r&d	NOUN
ihlr-25462	284	21	expenditure	expenditure	NOUN
ihlr-25462	284	22	in	in	ADP
ihlr-25462	284	23	2017	2017	NUM
ihlr-25462	284	24	,	,	PUNCT
ihlr-25462	284	25	the	the	DET
ihlr-25462	284	26	budget	budget	NOUN
ihlr-25462	284	27	of	of	ADP
ihlr-25462	284	28	which	which	PRON
ihlr-25462	284	29	does	do	AUX
ihlr-25462	284	30	not	not	PART
ihlr-25462	284	31	go	go	VERB
ihlr-25462	284	32	entirely	entirely	ADV
ihlr-25462	284	33	to	to	ADP
ihlr-25462	284	34	drug	drug	NOUN
ihlr-25462	284	35	development	development	NOUN
ihlr-25462	284	36	research.98	research.98	PROPN
ihlr-25462	284	37	if	if	SCONJ
ihlr-25462	284	38	a	a	DET
ihlr-25462	284	39	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	284	40	manufacturer	manufacturer	NOUN
ihlr-25462	284	41	’s	’s	PART
ihlr-25462	284	42	profitability	profitability	NOUN
ihlr-25462	284	43	is	be	AUX
ihlr-25462	284	44	reduced	reduce	VERB
ihlr-25462	284	45	,	,	PUNCT
ihlr-25462	284	46	they	they	PRON
ihlr-25462	284	47	may	may	AUX
ihlr-25462	284	48	choose	choose	VERB
ihlr-25462	284	49	to	to	PART
ihlr-25462	284	50	invest	invest	VERB
ihlr-25462	284	51	fewer	few	ADJ
ihlr-25462	284	52	dollars	dollar	NOUN
ihlr-25462	284	53	in	in	ADP
ihlr-25462	284	54	r&d	r&d	NOUN
ihlr-25462	284	55	and	and	CCONJ
ihlr-25462	284	56	could	could	AUX
ihlr-25462	284	57	“	"	PUNCT
ihlr-25462	284	58	shift	shift	VERB
ihlr-25462	284	59	their	their	PRON
ihlr-25462	284	60	focus	focus	NOUN
ihlr-25462	284	61	from	from	ADP
ihlr-25462	284	62	very	very	ADV
ihlr-25462	284	63	high	high	ADJ
ihlr-25462	284	64	-	-	PUNCT
ihlr-25462	284	65	cost	cost	NOUN
ihlr-25462	284	66	biological	biological	ADJ
ihlr-25462	284	67	drugs	drug	NOUN
ihlr-25462	284	68	for	for	ADP
ihlr-25462	284	69	rare	rare	ADJ
ihlr-25462	284	70	diseases	disease	NOUN
ihlr-25462	284	71	back	back	ADV
ihlr-25462	284	72	to	to	ADP
ihlr-25462	284	73	more	more	ADV
ihlr-25462	284	74	reasonably	reasonably	ADV
ihlr-25462	284	75	priced	price	VERB
ihlr-25462	284	76	drugs	drug	NOUN
ihlr-25462	284	77	for	for	ADP
ihlr-25462	284	78	more	more	ADJ
ihlr-25462	284	79	common	common	ADJ
ihlr-25462	284	80	diseases	disease	NOUN
ihlr-25462	284	81	.	.	PUNCT
ihlr-25462	285	1	”99	”99	PROPN
ihlr-25462	285	2	as	as	ADP
ihlr-25462	285	3	with	with	ADP
ihlr-25462	285	4	all	all	DET
ihlr-25462	285	5	things	thing	NOUN
ihlr-25462	285	6	,	,	PUNCT
ihlr-25462	285	7	“	"	PUNCT
ihlr-25462	285	8	[	[	X
ihlr-25462	285	9	t]he	t]he	ADJ
ihlr-25462	285	10	system	system	NOUN
ihlr-25462	285	11	will	will	AUX
ihlr-25462	285	12	be	be	AUX
ihlr-25462	285	13	better	well	ADJ
ihlr-25462	285	14	for	for	ADP
ihlr-25462	285	15	some	some	PRON
ihlr-25462	285	16	and	and	CCONJ
ihlr-25462	285	17	worse	bad	ADJ
ihlr-25462	285	18	for	for	ADP
ihlr-25462	285	19	others	other	NOUN
ihlr-25462	285	20	.	.	PUNCT
ihlr-25462	286	1	”100	”100	PROPN
ihlr-25462	286	2	iii	iii	PROPN
ihlr-25462	286	3	.	.	PUNCT
ihlr-25462	287	1	patent	patent	NOUN
ihlr-25462	287	2	thicketing	thickete	VERB
ihlr-25462	287	3	patent	patent	NOUN
ihlr-25462	287	4	thicketing	thicketing	NOUN
ihlr-25462	287	5	is	be	AUX
ihlr-25462	287	6	a	a	DET
ihlr-25462	287	7	patent	patent	NOUN
ihlr-25462	287	8	strategy	strategy	NOUN
ihlr-25462	287	9	with	with	ADP
ihlr-25462	287	10	origins	origin	NOUN
ihlr-25462	287	11	outside	outside	ADP
ihlr-25462	287	12	of	of	ADP
ihlr-25462	287	13	the	the	DET
ihlr-25462	287	14	93	93	NUM
ihlr-25462	287	15	.	.	PUNCT
ihlr-25462	288	1	c.	c.	PROPN
ihlr-25462	288	2	michael	michael	PROPN
ihlr-25462	288	3	white	white	PROPN
ihlr-25462	288	4	,	,	PUNCT
ihlr-25462	288	5	cheaper	cheap	ADJ
ihlr-25462	288	6	drugs	drug	NOUN
ihlr-25462	288	7	from	from	ADP
ihlr-25462	288	8	canada	canada	PROPN
ihlr-25462	288	9	likely	likely	ADV
ihlr-25462	288	10	wo	will	AUX
ihlr-25462	288	11	n’t	not	PART
ihlr-25462	288	12	cure	cure	VERB
ihlr-25462	288	13	what	what	PRON
ihlr-25462	288	14	ails	ail	VERB
ihlr-25462	288	15	us	we	PRON
ihlr-25462	288	16	,	,	PUNCT
ihlr-25462	288	17	ct	ct	NUM
ihlr-25462	288	18	mirror	mirror	NOUN
ihlr-25462	288	19	(	(	PUNCT
ihlr-25462	288	20	oct	oct	PROPN
ihlr-25462	288	21	.	.	PROPN
ihlr-25462	288	22	4	4	NUM
ihlr-25462	288	23	,	,	PUNCT
ihlr-25462	288	24	2019	2019	NUM
ihlr-25462	288	25	)	)	PUNCT
ihlr-25462	288	26	,	,	PUNCT
ihlr-25462	288	27	https://ctmirror.org/category/ct-viewpoints/why-cheaper-drugs-fromcanada-likely-wont-cure-what-ails-us/	https://ctmirror.org/category/ct-viewpoints/why-cheaper-drugs-fromcanada-likely-wont-cure-what-ails-us/	VERB
ihlr-25462	289	1	[	[	X
ihlr-25462	289	2	https://perma.cc/3j78-795n	https://perma.cc/3j78-795n	X
ihlr-25462	289	3	]	]	X
ihlr-25462	289	4	;	;	PUNCT
ihlr-25462	289	5	see	see	VERB
ihlr-25462	289	6	allison	allison	PROPN
ihlr-25462	289	7	martell	martell	PROPN
ihlr-25462	289	8	,	,	PUNCT
ihlr-25462	289	9	exclusive	exclusive	ADJ
ihlr-25462	289	10	:	:	PUNCT
ihlr-25462	289	11	canada	canada	PROPN
ihlr-25462	289	12	warns	warn	VERB
ihlr-25462	289	13	u.s	u.s	PROPN
ihlr-25462	289	14	.	.	PROPN
ihlr-25462	289	15	against	against	ADP
ihlr-25462	289	16	drug	drug	NOUN
ihlr-25462	289	17	import	import	NOUN
ihlr-25462	289	18	plans	plan	NOUN
ihlr-25462	289	19	,	,	PUNCT
ihlr-25462	289	20	citing	cite	VERB
ihlr-25462	289	21	shortage	shortage	NOUN
ihlr-25462	289	22	concerns	concern	NOUN
ihlr-25462	289	23	,	,	PUNCT
ihlr-25462	289	24	reuters	reuter	NOUN
ihlr-25462	289	25	(	(	PUNCT
ihlr-25462	289	26	july	july	PROPN
ihlr-25462	289	27	18	18	NUM
ihlr-25462	289	28	,	,	PUNCT
ihlr-25462	289	29	2019	2019	NUM
ihlr-25462	289	30	)	)	PUNCT
ihlr-25462	289	31	,	,	PUNCT
ihlr-25462	289	32	https://www.reuters.com/article/us-canada-pharmaceuticals-exports-exclus/	https://www.reuters.com/article/us-canada-pharmaceuticals-exports-exclus/	PROPN
ihlr-25462	289	33	exclusive	exclusive	ADJ
ihlr-25462	289	34	-	-	PUNCT
ihlr-25462	289	35	canada	canada	NOUN
ihlr-25462	289	36	-	-	PUNCT
ihlr-25462	289	37	warns	warn	VERB
ihlr-25462	289	38	-	-	PUNCT
ihlr-25462	289	39	us	we	PRON
ihlr-25462	289	40	-	-	PUNCT
ihlr-25462	289	41	against	against	ADP
ihlr-25462	289	42	-	-	PUNCT
ihlr-25462	289	43	drug	drug	NOUN
ihlr-25462	289	44	-	-	PUNCT
ihlr-25462	289	45	import	import	NOUN
ihlr-25462	289	46	-	-	PUNCT
ihlr-25462	289	47	plans	plan	NOUN
ihlr-25462	289	48	-	-	PUNCT
ihlr-25462	289	49	citing	cite	VERB
ihlr-25462	289	50	-	-	PUNCT
ihlr-25462	289	51	shortage	shortage	NOUN
ihlr-25462	289	52	-	-	PUNCT
ihlr-25462	289	53	concerns	concern	NOUN
ihlr-25462	289	54	-	-	PUNCT
ihlr-25462	289	55	iduskcn1ud2ln	iduskcn1ud2ln	NOUN
ihlr-25462	290	1	[	[	X
ihlr-25462	290	2	https://perma.cc/x9h4-fl4b	https://perma.cc/x9h4-fl4b	X
ihlr-25462	290	3	]	]	X
ihlr-25462	290	4	94	94	NUM
ihlr-25462	290	5	.	.	PUNCT
ihlr-25462	290	6	white	white	ADJ
ihlr-25462	290	7	,	,	PUNCT
ihlr-25462	290	8	supra	supra	PROPN
ihlr-25462	290	9	note	note	NOUN
ihlr-25462	290	10	93	93	NUM
ihlr-25462	290	11	.	.	PUNCT
ihlr-25462	291	1	95	95	NUM
ihlr-25462	291	2	.	.	PUNCT
ihlr-25462	292	1	findlay	findlay	PROPN
ihlr-25462	292	2	,	,	PUNCT
ihlr-25462	292	3	supra	supra	PROPN
ihlr-25462	292	4	note	note	NOUN
ihlr-25462	292	5	31	31	NUM
ihlr-25462	292	6	.	.	PUNCT
ihlr-25462	293	1	96	96	NUM
ihlr-25462	293	2	.	.	PUNCT
ihlr-25462	294	1	amanda	amanda	PROPN
ihlr-25462	294	2	coletta	coletta	PROPN
ihlr-25462	294	3	,	,	PUNCT
ihlr-25462	294	4	trump	trump	NOUN
ihlr-25462	294	5	and	and	CCONJ
ihlr-25462	294	6	sanders	sander	NOUN
ihlr-25462	294	7	want	want	VERB
ihlr-25462	294	8	to	to	PART
ihlr-25462	294	9	ease	ease	VERB
ihlr-25462	294	10	imports	import	NOUN
ihlr-25462	294	11	of	of	ADP
ihlr-25462	294	12	drugs	drug	NOUN
ihlr-25462	294	13	from	from	ADP
ihlr-25462	294	14	canada	canada	PROPN
ihlr-25462	294	15	.	.	PUNCT
ihlr-25462	295	1	canada	canada	PROPN
ihlr-25462	295	2	says	say	VERB
ihlr-25462	295	3	not	not	PART
ihlr-25462	295	4	so	so	ADV
ihlr-25462	295	5	fast	fast	ADJ
ihlr-25462	295	6	,	,	PUNCT
ihlr-25462	295	7	wash	wash	NOUN
ihlr-25462	295	8	.	.	PUNCT
ihlr-25462	296	1	post	post	NOUN
ihlr-25462	296	2	(	(	PUNCT
ihlr-25462	296	3	aug	aug	PROPN
ihlr-25462	296	4	.	.	PROPN
ihlr-25462	296	5	1	1	NUM
ihlr-25462	296	6	,	,	PUNCT
ihlr-25462	296	7	2019	2019	NUM
ihlr-25462	296	8	)	)	PUNCT
ihlr-25462	296	9	,	,	PUNCT
ihlr-25462	296	10	https://www.washingtonpost.com/world/	https://www.washingtonpost.com/world/	X
ihlr-25462	296	11	the_americas	the_americas	NOUN
ihlr-25462	296	12	/	/	SYM
ihlr-25462	296	13	trump	trump	NOUN
ihlr-25462	296	14	-	-	PUNCT
ihlr-25462	296	15	and	and	CCONJ
ihlr-25462	296	16	-	-	PUNCT
ihlr-25462	296	17	sanders	sander	NOUN
ihlr-25462	296	18	-	-	PUNCT
ihlr-25462	296	19	want	want	VERB
ihlr-25462	296	20	-	-	PUNCT
ihlr-25462	296	21	to	to	ADP
ihlr-25462	296	22	-	-	PUNCT
ihlr-25462	296	23	ease	ease	NOUN
ihlr-25462	296	24	-	-	PUNCT
ihlr-25462	296	25	imports	import	NOUN
ihlr-25462	296	26	-	-	PUNCT
ihlr-25462	296	27	of	of	ADP
ihlr-25462	296	28	-	-	PUNCT
ihlr-25462	296	29	drugs	drug	NOUN
ihlr-25462	296	30	-	-	PUNCT
ihlr-25462	296	31	from	from	ADP
ihlr-25462	296	32	-	-	PUNCT
ihlr-25462	296	33	canada	canada	PROPN
ihlr-25462	296	34	-	-	PUNCT
ihlr-25462	296	35	canada	canada	PROPN
ihlr-25462	296	36	-	-	PUNCT
ihlr-25462	296	37	says	say	VERB
ihlr-25462	296	38	-	-	PUNCT
ihlr-25462	296	39	not	not	PART
ihlr-25462	296	40	-	-	PUNCT
ihlr-25462	296	41	sofast/2019/08/01/1f0f91a6	sofast/2019/08/01/1f0f91a6	NOUN
ihlr-25462	296	42	-	-	PUNCT
ihlr-25462	296	43	b463	b463	PROPN
ihlr-25462	296	44	-	-	PUNCT
ihlr-25462	296	45	11e9	11e9	NUM
ihlr-25462	296	46	-	-	PUNCT
ihlr-25462	296	47	acc8	acc8	NOUN
ihlr-25462	296	48	-	-	PUNCT
ihlr-25462	296	49	1d847bacca73_story.html	1d847bacca73_story.html	PROPN
ihlr-25462	297	1	[	[	X
ihlr-25462	297	2	https://perma.cc/84f3-9zl3	https://perma.cc/84f3-9zl3	X
ihlr-25462	297	3	]	]	PUNCT
ihlr-25462	297	4	.	.	PUNCT
ihlr-25462	298	1	97	97	NUM
ihlr-25462	298	2	.	.	PUNCT
ihlr-25462	299	1	andrew	andrew	PROPN
ihlr-25462	299	2	powaleny	powaleny	PROPN
ihlr-25462	299	3	,	,	PUNCT
ihlr-25462	299	4	ip	ip	PROPN
ihlr-25462	299	5	explained	explain	VERB
ihlr-25462	299	6	:	:	PUNCT
ihlr-25462	299	7	understanding	understand	VERB
ihlr-25462	299	8	biopharmaceutical	biopharmaceutical	ADJ
ihlr-25462	299	9	innovation	innovation	NOUN
ihlr-25462	299	10	,	,	PUNCT
ihlr-25462	299	11	catalyst	catalyst	NOUN
ihlr-25462	299	12	(	(	PUNCT
ihlr-25462	299	13	july	july	PROPN
ihlr-25462	299	14	30	30	NUM
ihlr-25462	299	15	,	,	PUNCT
ihlr-25462	299	16	2019	2019	NUM
ihlr-25462	299	17	)	)	PUNCT
ihlr-25462	299	18	,	,	PUNCT
ihlr-25462	299	19	https://catalyst.phrma.org/ip-explained-understanding-biopharma	https://catalyst.phrma.org/ip-explained-understanding-biopharma	PROPN
ihlr-25462	299	20	ceutical	ceutical	ADJ
ihlr-25462	299	21	-	-	PUNCT
ihlr-25462	299	22	innovation	innovation	NOUN
ihlr-25462	299	23	[	[	X
ihlr-25462	299	24	https://perma.cc/59ta-9q7v	https://perma.cc/59ta-9q7v	NOUN
ihlr-25462	299	25	]	]	X
ihlr-25462	299	26	.	.	PUNCT
ihlr-25462	300	1	98	98	NUM
ihlr-25462	300	2	.	.	PUNCT
ihlr-25462	301	1	i	i	PRON
ihlr-25462	301	2	d.	d.	PROPN
ihlr-25462	301	3	99	99	NUM
ihlr-25462	301	4	.	.	PUNCT
ihlr-25462	302	1	white	white	ADJ
ihlr-25462	302	2	,	,	PUNCT
ihlr-25462	302	3	supra	supra	PROPN
ihlr-25462	302	4	note	note	NOUN
ihlr-25462	302	5	93	93	NUM
ihlr-25462	302	6	.	.	PUNCT
ihlr-25462	303	1	100	100	NUM
ihlr-25462	303	2	.	.	PUNCT
ihlr-25462	304	1	i	i	PRON
ihlr-25462	304	2	d.	d.	PROPN
ihlr-25462	304	3	410	410	NUM
ihlr-25462	304	4	indiana	indiana	PROPN
ihlr-25462	304	5	health	health	PROPN
ihlr-25462	304	6	law	law	PROPN
ihlr-25462	304	7	review	review	NOUN
ihlr-25462	304	8	[	[	X
ihlr-25462	304	9	vol	vol	NOUN
ihlr-25462	304	10	.	.	PUNCT
ihlr-25462	304	11	18:397	18:397	NUM
ihlr-25462	304	12	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	304	13	drug	drug	NOUN
ihlr-25462	304	14	industry	industry	NOUN
ihlr-25462	304	15	and	and	CCONJ
ihlr-25462	304	16	is	be	AUX
ihlr-25462	304	17	used	use	VERB
ihlr-25462	304	18	to	to	PART
ihlr-25462	304	19	describe	describe	VERB
ihlr-25462	304	20	a	a	DET
ihlr-25462	304	21	practice	practice	NOUN
ihlr-25462	304	22	allegedly	allegedly	ADV
ihlr-25462	304	23	intended	intend	VERB
ihlr-25462	304	24	to	to	PART
ihlr-25462	304	25	extend	extend	VERB
ihlr-25462	304	26	the	the	DET
ihlr-25462	304	27	patent	patent	NOUN
ihlr-25462	304	28	life	life	NOUN
ihlr-25462	304	29	of	of	ADP
ihlr-25462	304	30	a	a	DET
ihlr-25462	304	31	product	product	NOUN
ihlr-25462	304	32	by	by	ADP
ihlr-25462	304	33	protecting	protect	VERB
ihlr-25462	304	34	said	say	VERB
ihlr-25462	304	35	product	product	NOUN
ihlr-25462	304	36	with	with	ADP
ihlr-25462	304	37	as	as	ADV
ihlr-25462	304	38	many	many	ADJ
ihlr-25462	304	39	patents	patent	NOUN
ihlr-25462	304	40	as	as	ADP
ihlr-25462	304	41	possible.101	possible.101	PROPN
ihlr-25462	304	42	despite	despite	SCONJ
ihlr-25462	304	43	the	the	DET
ihlr-25462	304	44	fact	fact	NOUN
ihlr-25462	304	45	that	that	SCONJ
ihlr-25462	304	46	thicketing	thickete	VERB
ihlr-25462	304	47	is	be	AUX
ihlr-25462	304	48	prominent	prominent	ADJ
ihlr-25462	304	49	in	in	ADP
ihlr-25462	304	50	crowded	crowded	ADJ
ihlr-25462	304	51	industries	industry	NOUN
ihlr-25462	304	52	like	like	ADP
ihlr-25462	304	53	computer	computer	NOUN
ihlr-25462	304	54	software,102	software,102	NOUN
ihlr-25462	304	55	examples	example	NOUN
ihlr-25462	304	56	are	be	AUX
ihlr-25462	304	57	also	also	ADV
ihlr-25462	304	58	present	present	ADJ
ihlr-25462	304	59	in	in	ADP
ihlr-25462	304	60	the	the	DET
ihlr-25462	304	61	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	304	62	industry	industry	NOUN
ihlr-25462	304	63	.	.	PUNCT
ihlr-25462	305	1	this	this	PRON
ihlr-25462	305	2	certainly	certainly	ADV
ihlr-25462	305	3	is	be	AUX
ihlr-25462	305	4	not	not	PART
ihlr-25462	305	5	intended	intend	VERB
ihlr-25462	305	6	to	to	PART
ihlr-25462	305	7	imply	imply	VERB
ihlr-25462	305	8	that	that	SCONJ
ihlr-25462	305	9	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	305	10	innovation	innovation	NOUN
ihlr-25462	305	11	is	be	AUX
ihlr-25462	305	12	not	not	PART
ihlr-25462	305	13	happening	happen	VERB
ihlr-25462	305	14	–	–	PUNCT
ihlr-25462	305	15	the	the	DET
ihlr-25462	305	16	center	center	NOUN
ihlr-25462	305	17	for	for	ADP
ihlr-25462	305	18	drug	drug	NOUN
ihlr-25462	305	19	evaluation	evaluation	NOUN
ihlr-25462	305	20	and	and	CCONJ
ihlr-25462	305	21	research	research	NOUN
ihlr-25462	305	22	approved	approve	VERB
ihlr-25462	305	23	forty	forty	NUM
ihlr-25462	305	24	-	-	PUNCT
ihlr-25462	305	25	eight	eight	NUM
ihlr-25462	305	26	“	"	PUNCT
ihlr-25462	305	27	novel	novel	ADJ
ihlr-25462	305	28	drugs	drug	NOUN
ihlr-25462	305	29	”	"	PUNCT
ihlr-25462	305	30	in	in	ADP
ihlr-25462	305	31	2019	2019	NUM
ihlr-25462	305	32	,	,	PUNCT
ihlr-25462	305	33	twenty	twenty	NUM
ihlr-25462	305	34	of	of	ADP
ihlr-25462	305	35	which	which	PRON
ihlr-25462	305	36	were	be	AUX
ihlr-25462	305	37	“	"	PUNCT
ihlr-25462	305	38	first	first	ADV
ihlr-25462	305	39	in	in	ADP
ihlr-25462	305	40	class	class	NOUN
ihlr-25462	305	41	.	.	PUNCT
ihlr-25462	305	42	”103	”103	PUNCT
ihlr-25462	306	1	in	in	ADP
ihlr-25462	306	2	fact	fact	NOUN
ihlr-25462	306	3	,	,	PUNCT
ihlr-25462	306	4	cumulative	cumulative	ADJ
ihlr-25462	306	5	innovation	innovation	NOUN
ihlr-25462	306	6	is	be	AUX
ihlr-25462	306	7	often	often	ADV
ihlr-25462	306	8	considered	consider	VERB
ihlr-25462	306	9	the	the	DET
ihlr-25462	306	10	essence	essence	NOUN
ihlr-25462	306	11	of	of	ADP
ihlr-25462	306	12	science.104	science.104	NOUN
ihlr-25462	306	13	“	"	PUNCT
ihlr-25462	306	14	as	as	SCONJ
ihlr-25462	306	15	sir	sir	PROPN
ihlr-25462	306	16	isaac	isaac	PROPN
ihlr-25462	306	17	newton	newton	PROPN
ihlr-25462	306	18	put	put	VERB
ihlr-25462	306	19	it	it	PRON
ihlr-25462	306	20	,	,	PUNCT
ihlr-25462	306	21	each	each	DET
ihlr-25462	306	22	scientist	scientist	NOUN
ihlr-25462	306	23	‘	'	PUNCT
ihlr-25462	306	24	stands	stand	VERB
ihlr-25462	306	25	on	on	ADP
ihlr-25462	306	26	the	the	DET
ihlr-25462	306	27	shoulders	shoulder	NOUN
ihlr-25462	306	28	of	of	ADP
ihlr-25462	306	29	giants	giant	NOUN
ihlr-25462	306	30	’	'	PUNCT
ihlr-25462	306	31	to	to	PART
ihlr-25462	306	32	reach	reach	VERB
ihlr-25462	306	33	new	new	ADJ
ihlr-25462	306	34	heights	height	NOUN
ihlr-25462	306	35	.	.	PUNCT
ihlr-25462	306	36	”105	”105	ADJ
ihlr-25462	306	37	however	however	ADV
ihlr-25462	306	38	,	,	PUNCT
ihlr-25462	306	39	while	while	SCONJ
ihlr-25462	306	40	the	the	DET
ihlr-25462	306	41	practice	practice	NOUN
ihlr-25462	306	42	of	of	ADP
ihlr-25462	306	43	patenting	patent	VERB
ihlr-25462	306	44	incremental	incremental	ADJ
ihlr-25462	306	45	innovations	innovation	NOUN
ihlr-25462	306	46	is	be	AUX
ihlr-25462	306	47	common	common	ADJ
ihlr-25462	306	48	,	,	PUNCT
ihlr-25462	306	49	even	even	ADV
ihlr-25462	306	50	necessary	necessary	ADJ
ihlr-25462	306	51	,	,	PUNCT
ihlr-25462	306	52	it	it	PRON
ihlr-25462	306	53	has	have	AUX
ihlr-25462	306	54	gained	gain	VERB
ihlr-25462	306	55	notoriety	notoriety	NOUN
ihlr-25462	306	56	in	in	ADP
ihlr-25462	306	57	the	the	DET
ihlr-25462	306	58	public	public	ADJ
ihlr-25462	306	59	eye	eye	NOUN
ihlr-25462	306	60	.	.	PUNCT
ihlr-25462	307	1	medications	medication	NOUN
ihlr-25462	307	2	,	,	PUNCT
ihlr-25462	307	3	like	like	ADP
ihlr-25462	307	4	humira	humira	PROPN
ihlr-25462	307	5	(	(	PUNCT
ihlr-25462	307	6	adalimumab	adalimumab	PROPN
ihlr-25462	307	7	)	)	PUNCT
ihlr-25462	307	8	,	,	PUNCT
ihlr-25462	307	9	have	have	AUX
ihlr-25462	307	10	received	receive	VERB
ihlr-25462	307	11	public	public	ADJ
ihlr-25462	307	12	scrutiny	scrutiny	NOUN
ihlr-25462	307	13	for	for	ADP
ihlr-25462	307	14	the	the	DET
ihlr-25462	307	15	disproportionate	disproportionate	ADJ
ihlr-25462	307	16	numbers	number	NOUN
ihlr-25462	307	17	of	of	ADP
ihlr-25462	307	18	patents	patent	NOUN
ihlr-25462	307	19	that	that	PRON
ihlr-25462	307	20	are	be	AUX
ihlr-25462	307	21	obtained	obtain	VERB
ihlr-25462	307	22	to	to	PART
ihlr-25462	307	23	retain	retain	VERB
ihlr-25462	307	24	market	market	NOUN
ihlr-25462	307	25	exclusivity	exclusivity	NOUN
ihlr-25462	307	26	decades	decade	NOUN
ihlr-25462	307	27	beyond	beyond	ADP
ihlr-25462	307	28	their	their	PRON
ihlr-25462	307	29	original	original	ADJ
ihlr-25462	307	30	date	date	NOUN
ihlr-25462	307	31	of	of	ADP
ihlr-25462	307	32	introduction	introduction	NOUN
ihlr-25462	307	33	.	.	PUNCT
ihlr-25462	308	1	humira	humira	PROPN
ihlr-25462	308	2	is	be	AUX
ihlr-25462	308	3	currently	currently	ADV
ihlr-25462	308	4	the	the	DET
ihlr-25462	308	5	best	well	ADV
ihlr-25462	308	6	-	-	PUNCT
ihlr-25462	308	7	selling	sell	VERB
ihlr-25462	308	8	prescription	prescription	NOUN
ihlr-25462	308	9	drug	drug	NOUN
ihlr-25462	308	10	in	in	ADP
ihlr-25462	308	11	the	the	DET
ihlr-25462	308	12	world.106	world.106	NOUN
ihlr-25462	308	13	it	it	PRON
ihlr-25462	308	14	is	be	AUX
ihlr-25462	308	15	the	the	DET
ihlr-25462	308	16	single	single	ADJ
ihlr-25462	308	17	largest	large	ADJ
ihlr-25462	308	18	revenue	revenue	NOUN
ihlr-25462	308	19	source	source	NOUN
ihlr-25462	308	20	for	for	ADP
ihlr-25462	308	21	abbvie	abbvie	NOUN
ihlr-25462	308	22	,	,	PUNCT
ihlr-25462	308	23	with	with	ADP
ihlr-25462	308	24	sales	sale	NOUN
ihlr-25462	308	25	of	of	ADP
ihlr-25462	308	26	over	over	ADP
ihlr-25462	308	27	$	$	SYM
ihlr-25462	308	28	20	20	NUM
ihlr-25462	308	29	billion	billion	NUM
ihlr-25462	308	30	in	in	ADP
ihlr-25462	308	31	2018	2018	NUM
ihlr-25462	308	32	alone.107	alone.107	NOUN
ihlr-25462	308	33	in	in	ADP
ihlr-25462	308	34	december	december	PROPN
ihlr-25462	308	35	2016	2016	NUM
ihlr-25462	308	36	,	,	PUNCT
ihlr-25462	308	37	humira	humira	PROPN
ihlr-25462	308	38	’s	’s	PART
ihlr-25462	308	39	composition	composition	NOUN
ihlr-25462	308	40	of	of	ADP
ihlr-25462	308	41	matter	matter	NOUN
ihlr-25462	308	42	patent	patent	NOUN
ihlr-25462	308	43	expired.108	expired.108	NOUN
ihlr-25462	308	44	however	however	ADV
ihlr-25462	308	45	,	,	PUNCT
ihlr-25462	308	46	companies	company	NOUN
ihlr-25462	308	47	with	with	ADP
ihlr-25462	308	48	fda	fda	PROPN
ihlr-25462	308	49	-	-	PUNCT
ihlr-25462	308	50	approved	approve	VERB
ihlr-25462	308	51	biosimilars	biosimilar	NOUN
ihlr-25462	308	52	(	(	PUNCT
ihlr-25462	308	53	e.g.	e.g.	ADV
ihlr-25462	308	54	,	,	PUNCT
ihlr-25462	308	55	amgen	amgen	PROPN
ihlr-25462	308	56	,	,	PUNCT
ihlr-25462	308	57	boehringer	boehringer	PROPN
ihlr-25462	308	58	ingelheim	ingelheim	PROPN
ihlr-25462	308	59	,	,	PUNCT
ihlr-25462	308	60	and	and	CCONJ
ihlr-25462	308	61	novartis	novartis	NOUN
ihlr-25462	308	62	)	)	PUNCT
ihlr-25462	308	63	have	have	AUX
ihlr-25462	308	64	not	not	PART
ihlr-25462	308	65	been	be	AUX
ihlr-25462	308	66	able	able	ADJ
ihlr-25462	308	67	to	to	PART
ihlr-25462	308	68	enter	enter	VERB
ihlr-25462	308	69	the	the	DET
ihlr-25462	308	70	market	market	NOUN
ihlr-25462	308	71	and	and	CCONJ
ihlr-25462	308	72	have	have	AUX
ihlr-25462	308	73	instead	instead	ADV
ihlr-25462	308	74	reached	reach	VERB
ihlr-25462	308	75	deals	deal	NOUN
ihlr-25462	308	76	with	with	ADP
ihlr-25462	308	77	abbvie	abbvie	NOUN
ihlr-25462	308	78	to	to	PART
ihlr-25462	308	79	delay	delay	VERB
ihlr-25462	308	80	their	their	PRON
ihlr-25462	308	81	products	product	NOUN
ihlr-25462	308	82	’	'	PUNCT
ihlr-25462	308	83	market	market	NOUN
ihlr-25462	308	84	entry	entry	NOUN
ihlr-25462	308	85	until	until	SCONJ
ihlr-25462	308	86	2023.109	2023.109	NUM
ihlr-25462	308	87	this	this	PRON
ihlr-25462	308	88	was	be	AUX
ihlr-25462	308	89	done	do	VERB
ihlr-25462	308	90	because	because	SCONJ
ihlr-25462	308	91	the	the	DET
ihlr-25462	308	92	company	company	NOUN
ihlr-25462	308	93	now	now	ADV
ihlr-25462	308	94	holds	hold	VERB
ihlr-25462	308	95	approximately	approximately	ADV
ihlr-25462	308	96	136	136	NUM
ihlr-25462	308	97	humira	humira	PROPN
ihlr-25462	308	98	patents.110	patents.110	PROPN
ihlr-25462	308	99	of	of	ADP
ihlr-25462	308	100	these	these	PRON
ihlr-25462	308	101	,	,	PUNCT
ihlr-25462	308	102	the	the	DET
ihlr-25462	308	103	uspto	uspto	NOUN
ihlr-25462	308	104	has	have	AUX
ihlr-25462	308	105	granted	grant	VERB
ihlr-25462	308	106	the	the	DET
ihlr-25462	308	107	company	company	NOUN
ihlr-25462	308	108	more	more	ADJ
ihlr-25462	308	109	than	than	ADP
ihlr-25462	308	110	[	[	X
ihlr-25462	308	111	thirty	thirty	NUM
ihlr-25462	308	112	]	]	PUNCT
ihlr-25462	308	113	patents	patent	NOUN
ihlr-25462	308	114	on	on	ADP
ihlr-25462	308	115	the	the	DET
ihlr-25462	308	116	ways	way	NOUN
ihlr-25462	308	117	in	in	ADP
ihlr-25462	308	118	which	which	PRON
ihlr-25462	308	119	the	the	DET
ihlr-25462	308	120	drug	drug	NOUN
ihlr-25462	308	121	is	be	AUX
ihlr-25462	308	122	administered	administer	VERB
ihlr-25462	308	123	;	;	PUNCT
ihlr-25462	308	124	more	more	ADJ
ihlr-25462	308	125	than	than	ADP
ihlr-25462	308	126	[	[	X
ihlr-25462	308	127	twenty	twenty	NUM
ihlr-25462	308	128	-	-	PUNCT
ihlr-25462	308	129	five	five	NUM
ihlr-25462	308	130	]	]	PUNCT
ihlr-25462	308	131	patents	patent	NOUN
ihlr-25462	308	132	on	on	ADP
ihlr-25462	308	133	various	various	ADJ
ihlr-25462	308	134	formulations	formulation	NOUN
ihlr-25462	308	135	of	of	ADP
ihlr-25462	308	136	the	the	DET
ihlr-25462	308	137	drug	drug	NOUN
ihlr-25462	308	138	;	;	PUNCT
ihlr-25462	308	139	more	more	ADJ
ihlr-25462	308	140	than	than	ADP
ihlr-25462	308	141	[	[	X
ihlr-25462	308	142	fifty	fifty	NUM
ihlr-25462	308	143	]	]	PUNCT
ihlr-25462	308	144	patents	patent	NOUN
ihlr-25462	308	145	related	relate	VERB
ihlr-25462	308	146	to	to	ADP
ihlr-25462	308	147	humira	humira	PROPN
ihlr-25462	308	148	’s	’s	PART
ihlr-25462	308	149	manufacturing	manufacturing	NOUN
ihlr-25462	308	150	processes	process	NOUN
ihlr-25462	308	151	;	;	PUNCT
ihlr-25462	308	152	and	and	CCONJ
ihlr-25462	308	153	about	about	ADP
ihlr-25462	308	154	[	[	X
ihlr-25462	308	155	twenty	twenty	NUM
ihlr-25462	308	156	]	]	ADJ
ihlr-25462	308	157	patents	patent	NOUN
ihlr-25462	308	158	on	on	ADP
ihlr-25462	308	159	the	the	DET
ihlr-25462	308	160	delivery	delivery	NOUN
ihlr-25462	308	161	101	101	NUM
ihlr-25462	308	162	.	.	PUNCT
ihlr-25462	309	1	carl	carl	PROPN
ihlr-25462	309	2	shapiro	shapiro	PROPN
ihlr-25462	309	3	,	,	PUNCT
ihlr-25462	309	4	navigating	navigate	VERB
ihlr-25462	309	5	the	the	DET
ihlr-25462	309	6	patent	patent	NOUN
ihlr-25462	309	7	thicket	thicket	NOUN
ihlr-25462	309	8	:	:	PUNCT
ihlr-25462	309	9	cross	cross	VERB
ihlr-25462	309	10	licenses	license	NOUN
ihlr-25462	309	11	,	,	PUNCT
ihlr-25462	309	12	patent	patent	NOUN
ihlr-25462	309	13	pools	pool	NOUN
ihlr-25462	309	14	,	,	PUNCT
ihlr-25462	309	15	and	and	CCONJ
ihlr-25462	309	16	standard	standard	ADJ
ihlr-25462	309	17	setting	setting	NOUN
ihlr-25462	309	18	,	,	PUNCT
ihlr-25462	309	19	1	1	NUM
ihlr-25462	309	20	innovation	innovation	NOUN
ihlr-25462	309	21	pol’y	pol’y	NOUN
ihlr-25462	309	22	&	&	CCONJ
ihlr-25462	309	23	econ	econ	PROPN
ihlr-25462	309	24	.	.	PUNCT
ihlr-25462	310	1	119	119	NUM
ihlr-25462	310	2	,	,	PUNCT
ihlr-25462	310	3	119	119	NUM
ihlr-25462	310	4	-	-	SYM
ihlr-25462	310	5	21	21	NUM
ihlr-25462	310	6	(	(	PUNCT
ihlr-25462	310	7	2001	2001	NUM
ihlr-25462	310	8	)	)	PUNCT
ihlr-25462	310	9	.	.	PUNCT
ihlr-25462	311	1	102	102	NUM
ihlr-25462	311	2	.	.	PUNCT
ihlr-25462	312	1	i	i	PRON
ihlr-25462	312	2	d.	d.	PROPN
ihlr-25462	312	3	103	103	NUM
ihlr-25462	312	4	.	.	PUNCT
ihlr-25462	313	1	novel	novel	ADJ
ihlr-25462	313	2	drug	drug	NOUN
ihlr-25462	313	3	approvals	approval	NOUN
ihlr-25462	313	4	for	for	ADP
ihlr-25462	313	5	2019	2019	NUM
ihlr-25462	313	6	,	,	PUNCT
ihlr-25462	313	7	food	food	NOUN
ihlr-25462	313	8	&	&	CCONJ
ihlr-25462	313	9	drug	drug	PROPN
ihlr-25462	313	10	admin	admin	PROPN
ihlr-25462	313	11	.	.	PUNCT
ihlr-25462	313	12	,	,	PUNCT
ihlr-25462	313	13	https://www.fda.gov/drugs/newdrugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drugapprovals-2019	https://www.fda.gov/drugs/newdrugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drugapprovals-2019	X
ihlr-25462	314	1	[	[	X
ihlr-25462	314	2	https://perma.cc/cts9-ftfb	https://perma.cc/cts9-ftfb	X
ihlr-25462	314	3	]	]	PUNCT
ihlr-25462	314	4	(	(	PUNCT
ihlr-25462	314	5	last	last	ADJ
ihlr-25462	314	6	updated	update	VERB
ihlr-25462	314	7	jan	jan	PROPN
ihlr-25462	314	8	.	.	PROPN
ihlr-25462	314	9	14	14	NUM
ihlr-25462	314	10	,	,	PUNCT
ihlr-25462	314	11	2020	2020	NUM
ihlr-25462	314	12	)	)	PUNCT
ihlr-25462	314	13	.	.	PUNCT
ihlr-25462	315	1	104	104	NUM
ihlr-25462	315	2	.	.	PUNCT
ihlr-25462	316	1	shapiro	shapiro	PROPN
ihlr-25462	316	2	,	,	PUNCT
ihlr-25462	316	3	supra	supra	PROPN
ihlr-25462	316	4	note	note	NOUN
ihlr-25462	316	5	101	101	NUM
ihlr-25462	316	6	,	,	PUNCT
ihlr-25462	316	7	at	at	ADP
ihlr-25462	316	8	119	119	NUM
ihlr-25462	316	9	105	105	NUM
ihlr-25462	316	10	.	.	PUNCT
ihlr-25462	317	1	i	i	PRON
ihlr-25462	317	2	d.	d.	PROPN
ihlr-25462	317	3	at	at	ADP
ihlr-25462	317	4	119	119	NUM
ihlr-25462	317	5	-	-	SYM
ihlr-25462	317	6	20	20	NUM
ihlr-25462	317	7	.	.	PUNCT
ihlr-25462	318	1	106	106	NUM
ihlr-25462	318	2	.	.	PUNCT
ihlr-25462	319	1	sy	sy	PROPN
ihlr-25462	319	2	mukherjee	mukherjee	PROPN
ihlr-25462	319	3	,	,	PUNCT
ihlr-25462	319	4	protect	protect	VERB
ihlr-25462	319	5	at	at	ADP
ihlr-25462	319	6	all	all	DET
ihlr-25462	319	7	costs	cost	NOUN
ihlr-25462	319	8	:	:	PUNCT
ihlr-25462	319	9	how	how	SCONJ
ihlr-25462	319	10	the	the	DET
ihlr-25462	319	11	maker	maker	NOUN
ihlr-25462	319	12	of	of	ADP
ihlr-25462	319	13	the	the	DET
ihlr-25462	319	14	world	world	NOUN
ihlr-25462	319	15	’s	’s	PART
ihlr-25462	319	16	bestselling	bestselle	VERB
ihlr-25462	319	17	drug	drug	NOUN
ihlr-25462	319	18	keeps	keep	VERB
ihlr-25462	319	19	prices	price	NOUN
ihlr-25462	319	20	sky	sky	NOUN
ihlr-25462	319	21	-	-	PUNCT
ihlr-25462	319	22	high	high	ADJ
ihlr-25462	319	23	,	,	PUNCT
ihlr-25462	319	24	fortune	fortune	NOUN
ihlr-25462	319	25	(	(	PUNCT
ihlr-25462	319	26	july	july	PROPN
ihlr-25462	319	27	18	18	NUM
ihlr-25462	319	28	,	,	PUNCT
ihlr-25462	319	29	2019	2019	NUM
ihlr-25462	319	30	)	)	PUNCT
ihlr-25462	319	31	,	,	PUNCT
ihlr-25462	319	32	https://fortune.com/longform/abbvie-humiradrug-costs-innovation/	https://fortune.com/longform/abbvie-humiradrug-costs-innovation/	X
ihlr-25462	320	1	[	[	X
ihlr-25462	320	2	https://perma.cc/aq5f-wbhc	https://perma.cc/aq5f-wbhc	X
ihlr-25462	320	3	]	]	PUNCT
ihlr-25462	320	4	.	.	PUNCT
ihlr-25462	321	1	107	107	NUM
ihlr-25462	321	2	.	.	PUNCT
ihlr-25462	322	1	i	i	PRON
ihlr-25462	322	2	d.	d.	PROPN
ihlr-25462	322	3	108	108	NUM
ihlr-25462	322	4	.	.	PUNCT
ihlr-25462	323	1	i	i	PRON
ihlr-25462	323	2	d.	d.	PROPN
ihlr-25462	323	3	109	109	NUM
ihlr-25462	323	4	.	.	PUNCT
ihlr-25462	324	1	i	i	PRON
ihlr-25462	324	2	d.	d.	PROPN
ihlr-25462	324	3	110	110	NUM
ihlr-25462	324	4	.	.	PUNCT
ihlr-25462	325	1	i	i	PRON
ihlr-25462	325	2	d.	d.	PROPN
ihlr-25462	325	3	2021	2021	NUM
ihlr-25462	325	4	]	]	PUNCT
ihlr-25462	326	1	a	a	DET
ihlr-25462	326	2	survey	survey	NOUN
ihlr-25462	326	3	of	of	ADP
ihlr-25462	326	4	three	three	NUM
ihlr-25462	326	5	patent	patent	NOUN
ihlr-25462	326	6	-	-	PUNCT
ihlr-25462	326	7	based	base	VERB
ihlr-25462	326	8	approaches	approach	NOUN
ihlr-25462	326	9	411	411	NUM
ihlr-25462	326	10	devices	device	NOUN
ihlr-25462	326	11	that	that	PRON
ihlr-25462	326	12	customers	customer	NOUN
ihlr-25462	326	13	use	use	VERB
ihlr-25462	326	14	to	to	PART
ihlr-25462	326	15	take	take	VERB
ihlr-25462	326	16	the	the	DET
ihlr-25462	326	17	medicine.111	medicine.111	PROPN
ihlr-25462	326	18	notably	notably	ADV
ihlr-25462	326	19	,	,	PUNCT
ihlr-25462	326	20	a	a	DET
ihlr-25462	326	21	discovery	discovery	NOUN
ihlr-25462	326	22	order	order	NOUN
ihlr-25462	326	23	from	from	ADP
ihlr-25462	326	24	a	a	DET
ihlr-25462	326	25	case	case	NOUN
ihlr-25462	326	26	between	between	ADP
ihlr-25462	326	27	boehringer	boehringer	PROPN
ihlr-25462	326	28	ingelheim	ingelheim	PROPN
ihlr-25462	326	29	international	international	PROPN
ihlr-25462	326	30	gmbh	gmbh	PROPN
ihlr-25462	326	31	(	(	PUNCT
ihlr-25462	326	32	“	"	PUNCT
ihlr-25462	326	33	bi	bi	NOUN
ihlr-25462	326	34	”	"	PUNCT
ihlr-25462	326	35	)	)	PUNCT
ihlr-25462	326	36	and	and	CCONJ
ihlr-25462	326	37	abbvie	abbvie	NOUN
ihlr-25462	326	38	shows	show	VERB
ihlr-25462	326	39	a	a	DET
ihlr-25462	326	40	court	court	NOUN
ihlr-25462	326	41	acknowledging	acknowledge	VERB
ihlr-25462	326	42	that	that	SCONJ
ihlr-25462	326	43	it	it	PRON
ihlr-25462	326	44	remains	remain	VERB
ihlr-25462	326	45	unclear	unclear	ADJ
ihlr-25462	326	46	whether	whether	SCONJ
ihlr-25462	326	47	there	there	PRON
ihlr-25462	326	48	is	be	VERB
ihlr-25462	326	49	anything	anything	PRON
ihlr-25462	326	50	improper	improper	ADJ
ihlr-25462	326	51	about	about	ADP
ihlr-25462	326	52	filing	file	VERB
ihlr-25462	326	53	a	a	DET
ihlr-25462	326	54	large	large	ADJ
ihlr-25462	326	55	number	number	NOUN
ihlr-25462	326	56	of	of	ADP
ihlr-25462	326	57	patents.112	patents.112	PROPN
ihlr-25462	326	58	further	far	ADV
ihlr-25462	326	59	,	,	PUNCT
ihlr-25462	326	60	“	"	PUNCT
ihlr-25462	326	61	[	[	X
ihlr-25462	326	62	m]any	m]any	NOUN
ihlr-25462	326	63	of	of	ADP
ihlr-25462	326	64	abbvie	abbvie	PROPN
ihlr-25462	326	65	’s	’s	PART
ihlr-25462	326	66	patents	patent	NOUN
ihlr-25462	326	67	claim	claim	VERB
ihlr-25462	326	68	priority	priority	NOUN
ihlr-25462	326	69	back	back	ADV
ihlr-25462	326	70	to	to	ADP
ihlr-25462	326	71	original	original	ADJ
ihlr-25462	326	72	patent	patent	NOUN
ihlr-25462	326	73	applications	application	NOUN
ihlr-25462	326	74	filed	file	VERB
ihlr-25462	326	75	in	in	ADP
ihlr-25462	326	76	2000	2000	NUM
ihlr-25462	326	77	or	or	CCONJ
ihlr-25462	326	78	2001	2001	NUM
ihlr-25462	326	79	,	,	PUNCT
ihlr-25462	326	80	before	before	SCONJ
ihlr-25462	326	81	the	the	DET
ihlr-25462	326	82	drug	drug	NOUN
ihlr-25462	326	83	went	go	VERB
ihlr-25462	326	84	on	on	ADP
ihlr-25462	326	85	sale	sale	NOUN
ihlr-25462	326	86	.	.	PUNCT
ihlr-25462	327	1	”113	”113	PUNCT
ihlr-25462	327	2	therefore	therefore	ADV
ihlr-25462	327	3	,	,	PUNCT
ihlr-25462	327	4	part	part	NOUN
ihlr-25462	327	5	of	of	ADP
ihlr-25462	327	6	the	the	DET
ihlr-25462	327	7	reason	reason	NOUN
ihlr-25462	327	8	that	that	SCONJ
ihlr-25462	327	9	there	there	PRON
ihlr-25462	327	10	was	be	VERB
ihlr-25462	327	11	a	a	DET
ihlr-25462	327	12	large	large	ADJ
ihlr-25462	327	13	number	number	NOUN
ihlr-25462	327	14	of	of	ADP
ihlr-25462	327	15	patents	patent	NOUN
ihlr-25462	327	16	granted	grant	VERB
ihlr-25462	327	17	later	later	ADV
ihlr-25462	327	18	is	be	AUX
ihlr-25462	327	19	the	the	DET
ihlr-25462	327	20	result	result	NOUN
ihlr-25462	327	21	of	of	ADP
ihlr-25462	327	22	a	a	DET
ihlr-25462	327	23	series	series	NOUN
ihlr-25462	327	24	of	of	ADP
ihlr-25462	327	25	continuing	continue	VERB
ihlr-25462	327	26	applications	application	NOUN
ihlr-25462	327	27	that	that	PRON
ihlr-25462	327	28	were	be	AUX
ihlr-25462	327	29	filed	file	VERB
ihlr-25462	327	30	at	at	ADP
ihlr-25462	327	31	once	once	ADV
ihlr-25462	327	32	,	,	PUNCT
ihlr-25462	327	33	which	which	PRON
ihlr-25462	327	34	is	be	AUX
ihlr-25462	327	35	a	a	DET
ihlr-25462	327	36	common	common	ADJ
ihlr-25462	327	37	patent	patent	NOUN
ihlr-25462	327	38	tactic.114	tactic.114	NOUN
ihlr-25462	327	39	in	in	ADP
ihlr-25462	327	40	may	may	PROPN
ihlr-25462	327	41	of	of	ADP
ihlr-25462	327	42	2019	2019	NUM
ihlr-25462	327	43	,	,	PUNCT
ihlr-25462	327	44	abbvie	abbvie	PROPN
ihlr-25462	327	45	resolved	resolve	VERB
ihlr-25462	327	46	its	its	PRON
ihlr-25462	327	47	suit	suit	NOUN
ihlr-25462	327	48	with	with	ADP
ihlr-25462	327	49	bi.115	bi.115	PROPN
ihlr-25462	327	50	abbvie	abbvie	PROPN
ihlr-25462	327	51	fiercely	fiercely	ADV
ihlr-25462	327	52	defended	defend	VERB
ihlr-25462	327	53	its	its	PRON
ihlr-25462	327	54	patent	patent	NOUN
ihlr-25462	327	55	strategy	strategy	NOUN
ihlr-25462	327	56	,	,	PUNCT
ihlr-25462	327	57	stating	state	VERB
ihlr-25462	327	58	that	that	SCONJ
ihlr-25462	327	59	the	the	DET
ihlr-25462	327	60	“	"	PUNCT
ihlr-25462	327	61	allegations	allegation	NOUN
ihlr-25462	327	62	in	in	ADP
ihlr-25462	327	63	the	the	DET
ihlr-25462	327	64	lawsuit	lawsuit	NOUN
ihlr-25462	327	65	[	[	X
ihlr-25462	327	66	were	be	AUX
ihlr-25462	327	67	]	]	PUNCT
ihlr-25462	327	68	without	without	ADP
ihlr-25462	327	69	merit	merit	NOUN
ihlr-25462	327	70	.	.	PUNCT
ihlr-25462	327	71	”116	”116	PUNCT
ihlr-25462	328	1	despite	despite	SCONJ
ihlr-25462	328	2	the	the	DET
ihlr-25462	328	3	fact	fact	NOUN
ihlr-25462	328	4	that	that	SCONJ
ihlr-25462	328	5	each	each	DET
ihlr-25462	328	6	patent	patent	NOUN
ihlr-25462	328	7	is	be	AUX
ihlr-25462	328	8	,	,	PUNCT
ihlr-25462	328	9	in	in	ADP
ihlr-25462	328	10	fact	fact	NOUN
ihlr-25462	328	11	,	,	PUNCT
ihlr-25462	328	12	received	receive	VERB
ihlr-25462	328	13	through	through	ADP
ihlr-25462	328	14	legal	legal	ADJ
ihlr-25462	328	15	means	mean	NOUN
ihlr-25462	328	16	,	,	PUNCT
ihlr-25462	328	17	the	the	DET
ihlr-25462	328	18	principle	principle	NOUN
ihlr-25462	328	19	is	be	AUX
ihlr-25462	328	20	quite	quite	ADV
ihlr-25462	328	21	unpopular	unpopular	ADJ
ihlr-25462	328	22	in	in	ADP
ihlr-25462	328	23	the	the	DET
ihlr-25462	328	24	public	public	ADJ
ihlr-25462	328	25	eye.117	eye.117	NOUN
ihlr-25462	328	26	in	in	ADP
ihlr-25462	328	27	july	july	PROPN
ihlr-25462	328	28	2018	2018	NUM
ihlr-25462	328	29	,	,	PUNCT
ihlr-25462	328	30	fda	fda	PROPN
ihlr-25462	328	31	commissioner	commissioner	PROPN
ihlr-25462	328	32	scott	scott	PROPN
ihlr-25462	328	33	gottlieb	gottlieb	PROPN
ihlr-25462	328	34	lamented	lament	VERB
ihlr-25462	328	35	that	that	SCONJ
ihlr-25462	328	36	competition	competition	NOUN
ihlr-25462	328	37	for	for	ADP
ihlr-25462	328	38	biosimilars	biosimilar	NOUN
ihlr-25462	328	39	in	in	ADP
ihlr-25462	328	40	the	the	DET
ihlr-25462	328	41	u.s	u.s	PROPN
ihlr-25462	328	42	.	.	PROPN
ihlr-25462	328	43	is	be	AUX
ihlr-25462	328	44	“	"	PUNCT
ihlr-25462	328	45	anemic	anemic	ADJ
ihlr-25462	328	46	,	,	PUNCT
ihlr-25462	328	47	”	"	PUNCT
ihlr-25462	328	48	and	and	CCONJ
ihlr-25462	328	49	he	he	PRON
ihlr-25462	328	50	specifically	specifically	ADV
ihlr-25462	328	51	called	call	VERB
ihlr-25462	328	52	out	out	ADP
ihlr-25462	328	53	the	the	DET
ihlr-25462	328	54	case	case	NOUN
ihlr-25462	328	55	as	as	ADP
ihlr-25462	328	56	being	be	AUX
ihlr-25462	328	57	patent	patent	NOUN
ihlr-25462	328	58	litigation	litigation	NOUN
ihlr-25462	328	59	due	due	ADP
ihlr-25462	328	60	to	to	ADP
ihlr-25462	328	61	patent	patent	NOUN
ihlr-25462	328	62	thickets.118	thickets.118	NUM
ihlr-25462	328	63	because	because	SCONJ
ihlr-25462	328	64	these	these	DET
ihlr-25462	328	65	alleged	allege	VERB
ihlr-25462	328	66	patent	patent	NOUN
ihlr-25462	328	67	thickets	thicket	NOUN
ihlr-25462	328	68	generally	generally	ADV
ihlr-25462	328	69	adhere	adhere	VERB
ihlr-25462	328	70	to	to	ADP
ihlr-25462	328	71	current	current	ADJ
ihlr-25462	328	72	patent	patent	NOUN
ihlr-25462	328	73	laws	law	NOUN
ihlr-25462	328	74	,	,	PUNCT
ihlr-25462	328	75	legislators	legislator	NOUN
ihlr-25462	328	76	have	have	AUX
ihlr-25462	328	77	attempted	attempt	VERB
ihlr-25462	328	78	to	to	PART
ihlr-25462	328	79	introduce	introduce	VERB
ihlr-25462	328	80	legislation	legislation	NOUN
ihlr-25462	328	81	to	to	PART
ihlr-25462	328	82	define	define	VERB
ihlr-25462	328	83	and	and	CCONJ
ihlr-25462	328	84	address	address	VERB
ihlr-25462	328	85	patent	patent	NOUN
ihlr-25462	328	86	thicketing	thicketing	NOUN
ihlr-25462	328	87	.	.	PUNCT
ihlr-25462	329	1	currently	currently	ADV
ihlr-25462	329	2	,	,	PUNCT
ihlr-25462	329	3	there	there	PRON
ihlr-25462	329	4	is	be	VERB
ihlr-25462	329	5	one	one	NUM
ihlr-25462	329	6	major	major	ADJ
ihlr-25462	329	7	piece	piece	NOUN
ihlr-25462	329	8	of	of	ADP
ihlr-25462	329	9	legislation	legislation	NOUN
ihlr-25462	329	10	addressing	address	VERB
ihlr-25462	329	11	patent	patent	NOUN
ihlr-25462	329	12	thicketing	thicketing	NOUN
ihlr-25462	329	13	.	.	PUNCT
ihlr-25462	330	1	the	the	DET
ihlr-25462	330	2	affordable	affordable	ADJ
ihlr-25462	330	3	prescriptions	prescription	NOUN
ihlr-25462	330	4	for	for	ADP
ihlr-25462	330	5	patients	patient	NOUN
ihlr-25462	330	6	act	act	NOUN
ihlr-25462	330	7	was	be	AUX
ihlr-25462	330	8	introduced	introduce	VERB
ihlr-25462	330	9	in	in	ADP
ihlr-25462	330	10	the	the	DET
ihlr-25462	330	11	u.s	u.s	PROPN
ihlr-25462	330	12	.	.	PROPN
ihlr-25462	330	13	senate	senate	PROPN
ihlr-25462	330	14	on	on	ADP
ihlr-25462	330	15	may	may	PROPN
ihlr-25462	330	16	9	9	NUM
ihlr-25462	330	17	,	,	PUNCT
ihlr-25462	330	18	2019	2019	NUM
ihlr-25462	330	19	,	,	PUNCT
ihlr-25462	330	20	by	by	ADP
ihlr-25462	330	21	u.s	u.s	PROPN
ihlr-25462	330	22	.	.	PROPN
ihlr-25462	330	23	senators	senator	NOUN
ihlr-25462	330	24	john	john	PROPN
ihlr-25462	330	25	cornyn	cornyn	PROPN
ihlr-25462	330	26	and	and	CCONJ
ihlr-25462	330	27	richard	richard	PROPN
ihlr-25462	330	28	blumenthal	blumenthal	PROPN
ihlr-25462	330	29	to	to	PART
ihlr-25462	330	30	prevent	prevent	VERB
ihlr-25462	330	31	thicketing	thicketing	NOUN
ihlr-25462	330	32	or	or	CCONJ
ihlr-25462	330	33	risk	risk	NOUN
ihlr-25462	330	34	of	of	ADP
ihlr-25462	330	35	being	be	AUX
ihlr-25462	330	36	sued	sue	VERB
ihlr-25462	330	37	by	by	ADP
ihlr-25462	330	38	the	the	DET
ihlr-25462	330	39	federal	federal	PROPN
ihlr-25462	330	40	trade	trade	PROPN
ihlr-25462	330	41	commission	commission	PROPN
ihlr-25462	330	42	(	(	PUNCT
ihlr-25462	330	43	“	"	PUNCT
ihlr-25462	330	44	ftc”).119	ftc”).119	PROPN
ihlr-25462	330	45	this	this	PRON
ihlr-25462	330	46	could	could	AUX
ihlr-25462	330	47	happen	happen	VERB
ihlr-25462	330	48	to	to	ADP
ihlr-25462	330	49	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	330	50	manufacturers	manufacturer	NOUN
ihlr-25462	330	51	if	if	SCONJ
ihlr-25462	330	52	they	they	PRON
ihlr-25462	330	53	use	use	VERB
ihlr-25462	330	54	tactics	tactic	NOUN
ihlr-25462	330	55	like	like	ADP
ihlr-25462	330	56	obtaining	obtain	VERB
ihlr-25462	330	57	duplicative	duplicative	ADJ
ihlr-25462	330	58	patents	patent	NOUN
ihlr-25462	330	59	in	in	ADP
ihlr-25462	330	60	order	order	NOUN
ihlr-25462	330	61	to	to	PART
ihlr-25462	330	62	delay	delay	VERB
ihlr-25462	330	63	generic	generic	ADJ
ihlr-25462	330	64	111	111	NUM
ihlr-25462	330	65	.	.	PUNCT
ihlr-25462	331	1	i	i	PRON
ihlr-25462	331	2	d.	d.	PROPN
ihlr-25462	331	3	112	112	NUM
ihlr-25462	331	4	.	.	PUNCT
ihlr-25462	331	5	see	see	VERB
ihlr-25462	331	6	abbvie	abbvie	PROPN
ihlr-25462	331	7	inc	inc	PROPN
ihlr-25462	331	8	.	.	PROPN
ihlr-25462	332	1	v.	v.	PROPN
ihlr-25462	332	2	boehringer	boehringer	PROPN
ihlr-25462	332	3	ingelheim	ingelheim	PROPN
ihlr-25462	332	4	int’l	int’l	PROPN
ihlr-25462	332	5	gmbh	gmbh	PROPN
ihlr-25462	332	6	,	,	PUNCT
ihlr-25462	332	7	no	no	INTJ
ihlr-25462	332	8	.	.	NOUN
ihlr-25462	332	9	17	17	NUM
ihlr-25462	332	10	-	-	PUNCT
ihlr-25462	332	11	cv-01065	cv-01065	NOUN
ihlr-25462	332	12	-	-	PUNCT
ihlr-25462	332	13	msg	msg	NOUN
ihlr-25462	332	14	-	-	PUNCT
ihlr-25462	332	15	rl	rl	NOUN
ihlr-25462	332	16	,	,	PUNCT
ihlr-25462	332	17	2019	2019	NUM
ihlr-25462	332	18	u.s	u.s	PROPN
ihlr-25462	332	19	.	.	PROPN
ihlr-25462	332	20	dist	dist	PROPN
ihlr-25462	332	21	.	.	PUNCT
ihlr-25462	333	1	lexis	lexis	NOUN
ihlr-25462	333	2	28950	28950	NUM
ihlr-25462	333	3	,	,	PUNCT
ihlr-25462	333	4	at	at	ADP
ihlr-25462	333	5	*	*	PROPN
ihlr-25462	333	6	7	7	NUM
ihlr-25462	333	7	-	-	SYM
ihlr-25462	333	8	8	8	NUM
ihlr-25462	333	9	(	(	PUNCT
ihlr-25462	333	10	d.	d.	PROPN
ihlr-25462	333	11	del	del	PROPN
ihlr-25462	333	12	.	.	PROPN
ihlr-25462	333	13	feb	feb	PROPN
ihlr-25462	333	14	.	.	PROPN
ihlr-25462	333	15	25	25	NUM
ihlr-25462	333	16	,	,	PUNCT
ihlr-25462	333	17	2019	2019	NUM
ihlr-25462	333	18	)	)	PUNCT
ihlr-25462	333	19	.	.	PUNCT
ihlr-25462	334	1	113	113	NUM
ihlr-25462	334	2	.	.	X
ihlr-25462	335	1	zachary	zachary	PROPN
ihlr-25462	335	2	silbersher	silbersher	ADV
ihlr-25462	335	3	,	,	PUNCT
ihlr-25462	335	4	did	do	AUX
ihlr-25462	335	5	abbvie	abbvie	NOUN
ihlr-25462	335	6	create	create	VERB
ihlr-25462	335	7	a	a	DET
ihlr-25462	335	8	wrongful	wrongful	ADJ
ihlr-25462	335	9	“	"	PUNCT
ihlr-25462	335	10	patent	patent	NOUN
ihlr-25462	335	11	thicket	thicket	NOUN
ihlr-25462	335	12	”	"	PUNCT
ihlr-25462	335	13	around	around	ADP
ihlr-25462	335	14	humira	humira	PROPN
ihlr-25462	335	15	®	®	PROPN
ihlr-25462	335	16	?	?	PROPN
ihlr-25462	335	17	,	,	PUNCT
ihlr-25462	335	18	markman	markman	NOUN
ihlr-25462	335	19	advisors	advisor	NOUN
ihlr-25462	335	20	(	(	PUNCT
ihlr-25462	335	21	aug	aug	PROPN
ihlr-25462	335	22	.	.	PROPN
ihlr-25462	335	23	27	27	NUM
ihlr-25462	335	24	,	,	PUNCT
ihlr-25462	335	25	2018	2018	NUM
ihlr-25462	335	26	)	)	PUNCT
ihlr-25462	335	27	,	,	PUNCT
ihlr-25462	335	28	https://www.markmanadvisors.com/blog/2018/8/27/didabbvie-create-a-wrongful-patent-thicket-around-humira	https://www.markmanadvisors.com/blog/2018/8/27/didabbvie-create-a-wrongful-patent-thicket-around-humira	PROPN
ihlr-25462	336	1	[	[	X
ihlr-25462	336	2	https://perma.cc/mh7a-27t3	https://perma.cc/mh7a-27t3	X
ihlr-25462	336	3	]	]	X
ihlr-25462	336	4	.	.	PUNCT
ihlr-25462	337	1	114	114	NUM
ihlr-25462	337	2	.	.	PUNCT
ihlr-25462	338	1	i	i	PRON
ihlr-25462	338	2	d.	d.	PROPN
ihlr-25462	338	3	115	115	NUM
ihlr-25462	338	4	.	.	PUNCT
ihlr-25462	339	1	press	press	NOUN
ihlr-25462	339	2	release	release	NOUN
ihlr-25462	339	3	,	,	PUNCT
ihlr-25462	339	4	abbvie	abbvie	PROPN
ihlr-25462	339	5	inc	inc	PROPN
ihlr-25462	339	6	.	.	PROPN
ihlr-25462	339	7	,	,	PUNCT
ihlr-25462	339	8	abbvie	abbvie	PROPN
ihlr-25462	339	9	resolves	resolve	NOUN
ihlr-25462	339	10	humira	humira	PROPN
ihlr-25462	339	11	®	®	PROPN
ihlr-25462	339	12	(	(	PUNCT
ihlr-25462	339	13	adalimumab	adalimumab	PROPN
ihlr-25462	339	14	)	)	PUNCT
ihlr-25462	339	15	u.s	u.s	PROPN
ihlr-25462	339	16	.	.	PROPN
ihlr-25462	339	17	patent	patent	NOUN
ihlr-25462	339	18	litigation	litigation	NOUN
ihlr-25462	339	19	with	with	ADP
ihlr-25462	339	20	boehringer	boehringer	PROPN
ihlr-25462	339	21	ingelheim	ingelheim	PROPN
ihlr-25462	339	22	(	(	PUNCT
ihlr-25462	339	23	may	may	PROPN
ihlr-25462	339	24	14	14	NUM
ihlr-25462	339	25	,	,	PUNCT
ihlr-25462	339	26	2019	2019	NUM
ihlr-25462	339	27	)	)	PUNCT
ihlr-25462	339	28	,	,	PUNCT
ihlr-25462	339	29	https://news.abbvie.com/news/pressreleases/abbvie-resolves-humira-adalimumab-us-patent-litigation-with-boehringer-ingelheim.htm	https://news.abbvie.com/news/pressreleases/abbvie-resolves-humira-adalimumab-us-patent-litigation-with-boehringer-ingelheim.htm	X
ihlr-25462	340	1	[	[	X
ihlr-25462	340	2	https://perma.cc/r4xn-vxcs	https://perma.cc/r4xn-vxc	NOUN
ihlr-25462	340	3	]	]	X
ihlr-25462	340	4	.	.	PUNCT
ihlr-25462	341	1	116	116	NUM
ihlr-25462	341	2	.	.	PUNCT
ihlr-25462	342	1	mukherjee	mukherjee	PROPN
ihlr-25462	342	2	,	,	PUNCT
ihlr-25462	342	3	supra	supra	PROPN
ihlr-25462	342	4	note	note	NOUN
ihlr-25462	342	5	106	106	NUM
ihlr-25462	342	6	.	.	PUNCT
ihlr-25462	342	7	117	117	NUM
ihlr-25462	342	8	.	.	PUNCT
ihlr-25462	343	1	i	i	PRON
ihlr-25462	343	2	d.	d.	PROPN
ihlr-25462	343	3	(	(	PUNCT
ihlr-25462	343	4	describing	describe	VERB
ihlr-25462	343	5	how	how	SCONJ
ihlr-25462	343	6	new	new	PROPN
ihlr-25462	343	7	york	york	PROPN
ihlr-25462	343	8	law	law	PROPN
ihlr-25462	343	9	school	school	NOUN
ihlr-25462	343	10	professor	professor	NOUN
ihlr-25462	343	11	jacob	jacob	PROPN
ihlr-25462	343	12	sherkow	sherkow	PROPN
ihlr-25462	343	13	believes	believe	VERB
ihlr-25462	343	14	that	that	SCONJ
ihlr-25462	343	15	abbvie	abbvie	NOUN
ihlr-25462	343	16	is	be	AUX
ihlr-25462	343	17	“	"	PUNCT
ihlr-25462	343	18	just	just	ADV
ihlr-25462	343	19	taking	take	VERB
ihlr-25462	343	20	advantage	advantage	NOUN
ihlr-25462	343	21	of	of	ADP
ihlr-25462	343	22	existing	exist	VERB
ihlr-25462	343	23	law	law	NOUN
ihlr-25462	343	24	”	"	PUNCT
ihlr-25462	343	25	)	)	PUNCT
ihlr-25462	343	26	.	.	PUNCT
ihlr-25462	344	1	118	118	NUM
ihlr-25462	344	2	.	.	PUNCT
ihlr-25462	345	1	silbersher	silbersher	ADJ
ihlr-25462	345	2	,	,	PUNCT
ihlr-25462	345	3	supra	supra	PROPN
ihlr-25462	345	4	note	note	PROPN
ihlr-25462	345	5	113	113	NUM
ihlr-25462	345	6	.	.	PUNCT
ihlr-25462	346	1	119	119	NUM
ihlr-25462	346	2	.	.	PUNCT
ihlr-25462	347	1	susannah	susannah	PROPN
ihlr-25462	347	2	luthi	luthi	PROPN
ihlr-25462	347	3	&	&	CCONJ
ihlr-25462	347	4	sarah	sarah	PROPN
ihlr-25462	347	5	owermohle	owermohle	PROPN
ihlr-25462	347	6	,	,	PUNCT
ihlr-25462	347	7	‘	'	PUNCT
ihlr-25462	347	8	patent	patent	NOUN
ihlr-25462	347	9	thicket	thicket	NOUN
ihlr-25462	347	10	’	'	PUNCT
ihlr-25462	347	11	bill	bill	NOUN
ihlr-25462	347	12	caught	catch	VERB
ihlr-25462	347	13	in	in	ADP
ihlr-25462	347	14	tug	tug	NOUN
ihlr-25462	347	15	-	-	PUNCT
ihlr-25462	347	16	of	of	ADP
ihlr-25462	347	17	-	-	PUNCT
ihlr-25462	347	18	war	war	NOUN
ihlr-25462	347	19	over	over	ADP
ihlr-25462	347	20	drug	drug	NOUN
ihlr-25462	347	21	pricing	pricing	NOUN
ihlr-25462	347	22	reforms	reform	NOUN
ihlr-25462	347	23	,	,	PUNCT
ihlr-25462	347	24	politico	politico	NOUN
ihlr-25462	347	25	(	(	PUNCT
ihlr-25462	347	26	oct	oct	PROPN
ihlr-25462	347	27	.	.	PROPN
ihlr-25462	347	28	25	25	NUM
ihlr-25462	347	29	,	,	PUNCT
ihlr-25462	347	30	2019	2019	NUM
ihlr-25462	347	31	)	)	PUNCT
ihlr-25462	347	32	,	,	PUNCT
ihlr-25462	347	33	https://www.politico.com/news/2019/10/25/	https://www.politico.com/news/2019/10/25/	PUNCT
ihlr-25462	347	34	patent	patent	NOUN
ihlr-25462	347	35	-	-	PUNCT
ihlr-25462	347	36	thicket	thicket	NOUN
ihlr-25462	347	37	-	-	PUNCT
ihlr-25462	347	38	bill	bill	NOUN
ihlr-25462	347	39	-	-	PUNCT
ihlr-25462	347	40	caught	catch	VERB
ihlr-25462	347	41	-	-	PUNCT
ihlr-25462	347	42	in	in	ADP
ihlr-25462	347	43	-	-	PUNCT
ihlr-25462	347	44	tug	tug	NOUN
ihlr-25462	347	45	-	-	PUNCT
ihlr-25462	347	46	of	of	ADP
ihlr-25462	347	47	-	-	PUNCT
ihlr-25462	347	48	war	war	NOUN
ihlr-25462	347	49	-	-	PUNCT
ihlr-25462	347	50	over	over	ADP
ihlr-25462	347	51	-	-	PUNCT
ihlr-25462	347	52	drug	drug	NOUN
ihlr-25462	347	53	-	-	PUNCT
ihlr-25462	347	54	pricing	pricing	NOUN
ihlr-25462	347	55	-	-	PUNCT
ihlr-25462	347	56	reforms-056858	reforms-056858	NOUN
ihlr-25462	347	57	[	[	X
ihlr-25462	347	58	https://perma.cc/9n7rjldf	https://perma.cc/9n7rjldf	NOUN
ihlr-25462	347	59	]	]	PUNCT
ihlr-25462	347	60	.	.	PUNCT
ihlr-25462	348	1	412	412	NUM
ihlr-25462	348	2	indiana	indiana	PROPN
ihlr-25462	348	3	health	health	PROPN
ihlr-25462	348	4	law	law	PROPN
ihlr-25462	348	5	review	review	NOUN
ihlr-25462	349	1	[	[	X
ihlr-25462	349	2	vol	vol	NOUN
ihlr-25462	349	3	.	.	PUNCT
ihlr-25462	349	4	18:397	18:397	NUM
ihlr-25462	349	5	versions	version	NOUN
ihlr-25462	349	6	of	of	ADP
ihlr-25462	349	7	the	the	DET
ihlr-25462	349	8	medication	medication	NOUN
ihlr-25462	349	9	from	from	ADP
ihlr-25462	349	10	market	market	NOUN
ihlr-25462	349	11	entry.120	entry.120	NOUN
ihlr-25462	349	12	on	on	ADP
ihlr-25462	349	13	the	the	DET
ihlr-25462	349	14	other	other	ADJ
ihlr-25462	349	15	hand	hand	NOUN
ihlr-25462	349	16	,	,	PUNCT
ihlr-25462	349	17	industry	industry	NOUN
ihlr-25462	349	18	group	group	NOUN
ihlr-25462	349	19	phrma	phrma	NOUN
ihlr-25462	349	20	disagrees	disagree	VERB
ihlr-25462	349	21	with	with	ADP
ihlr-25462	349	22	the	the	DET
ihlr-25462	349	23	presumption	presumption	NOUN
ihlr-25462	349	24	of	of	ADP
ihlr-25462	349	25	guilt	guilt	NOUN
ihlr-25462	349	26	that	that	SCONJ
ihlr-25462	349	27	the	the	DET
ihlr-25462	349	28	bill	bill	NOUN
ihlr-25462	349	29	places	place	VERB
ihlr-25462	349	30	on	on	ADP
ihlr-25462	349	31	the	the	DET
ihlr-25462	349	32	manufacturer	manufacturer	NOUN
ihlr-25462	349	33	,	,	PUNCT
ihlr-25462	349	34	saying	say	VERB
ihlr-25462	349	35	it	it	PRON
ihlr-25462	349	36	would	would	AUX
ihlr-25462	349	37	create	create	VERB
ihlr-25462	349	38	“	"	PUNCT
ihlr-25462	349	39	a	a	DET
ihlr-25462	349	40	presumption	presumption	NOUN
ihlr-25462	349	41	of	of	ADP
ihlr-25462	349	42	anti	anti	ADJ
ihlr-25462	349	43	-	-	ADJ
ihlr-25462	349	44	trust	trust	ADJ
ihlr-25462	349	45	violation	violation	NOUN
ihlr-25462	349	46	for	for	ADP
ihlr-25462	349	47	almost	almost	ADV
ihlr-25462	349	48	any	any	DET
ihlr-25462	349	49	post	post	ADJ
ihlr-25462	349	50	-	-	ADJ
ihlr-25462	349	51	approval	approval	ADJ
ihlr-25462	349	52	innovation	innovation	NOUN
ihlr-25462	349	53	.	.	PUNCT
ihlr-25462	350	1	”121	”121	PROPN
ihlr-25462	351	1	vi	vi	PROPN
ihlr-25462	351	2	.	.	PROPN
ihlr-25462	351	3	product	product	NOUN
ihlr-25462	351	4	hopping	hop	VERB
ihlr-25462	351	5	product	product	NOUN
ihlr-25462	351	6	hopping	hop	VERB
ihlr-25462	351	7	refers	refer	VERB
ihlr-25462	351	8	to	to	ADP
ihlr-25462	351	9	an	an	DET
ihlr-25462	351	10	alleged	allege	VERB
ihlr-25462	351	11	practice	practice	NOUN
ihlr-25462	351	12	in	in	ADP
ihlr-25462	351	13	which	which	PRON
ihlr-25462	351	14	a	a	DET
ihlr-25462	351	15	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	351	16	company	company	NOUN
ihlr-25462	351	17	purportedly	purportedly	ADV
ihlr-25462	351	18	replaces	replace	VERB
ihlr-25462	351	19	prescription	prescription	NOUN
ihlr-25462	351	20	drugs	drug	NOUN
ihlr-25462	351	21	that	that	PRON
ihlr-25462	351	22	are	be	AUX
ihlr-25462	351	23	already	already	ADV
ihlr-25462	351	24	on	on	ADP
ihlr-25462	351	25	the	the	DET
ihlr-25462	351	26	market	market	NOUN
ihlr-25462	351	27	with	with	ADP
ihlr-25462	351	28	slightly	slightly	ADV
ihlr-25462	351	29	modified	modify	VERB
ihlr-25462	351	30	versions	version	NOUN
ihlr-25462	351	31	that	that	PRON
ihlr-25462	351	32	have	have	VERB
ihlr-25462	351	33	the	the	DET
ihlr-25462	351	34	same	same	ADJ
ihlr-25462	351	35	active	active	ADJ
ihlr-25462	351	36	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	351	37	ingredient	ingredient	NOUN
ihlr-25462	351	38	.	.	PUNCT
ihlr-25462	352	1	the	the	DET
ihlr-25462	352	2	fdca	fdca	NOUN
ihlr-25462	352	3	requires	require	VERB
ihlr-25462	352	4	fda	fda	PROPN
ihlr-25462	352	5	approval	approval	NOUN
ihlr-25462	352	6	before	before	SCONJ
ihlr-25462	352	7	any	any	DET
ihlr-25462	352	8	drug	drug	NOUN
ihlr-25462	352	9	may	may	AUX
ihlr-25462	352	10	be	be	AUX
ihlr-25462	352	11	marketed.122	marketed.122	NUM
ihlr-25462	352	12	generic	generic	ADJ
ihlr-25462	352	13	manufacturers	manufacturer	NOUN
ihlr-25462	352	14	must	must	AUX
ihlr-25462	352	15	submit	submit	VERB
ihlr-25462	352	16	an	an	DET
ihlr-25462	352	17	“	"	PUNCT
ihlr-25462	352	18	abbreviated	abbreviate	VERB
ihlr-25462	352	19	new	new	ADJ
ihlr-25462	352	20	drug	drug	NOUN
ihlr-25462	352	21	application	application	NOUN
ihlr-25462	352	22	”	"	PUNCT
ihlr-25462	352	23	to	to	PART
ihlr-25462	352	24	show	show	VERB
ihlr-25462	352	25	only	only	ADV
ihlr-25462	352	26	that	that	SCONJ
ihlr-25462	352	27	their	their	PRON
ihlr-25462	352	28	generic	generic	ADJ
ihlr-25462	352	29	product	product	NOUN
ihlr-25462	352	30	is	be	AUX
ihlr-25462	352	31	the	the	DET
ihlr-25462	352	32	bioequivalent	bioequivalent	NOUN
ihlr-25462	352	33	to	to	ADP
ihlr-25462	352	34	an	an	DET
ihlr-25462	352	35	already	already	ADV
ihlr-25462	352	36	approved	approve	VERB
ihlr-25462	352	37	“	"	PUNCT
ihlr-25462	352	38	reference	reference	NOUN
ihlr-25462	352	39	”	"	PUNCT
ihlr-25462	352	40	drug.123	drug.123	PROPN
ihlr-25462	352	41	if	if	SCONJ
ihlr-25462	352	42	the	the	DET
ihlr-25462	352	43	generic	generic	ADJ
ihlr-25462	352	44	product	product	NOUN
ihlr-25462	352	45	is	be	AUX
ihlr-25462	352	46	the	the	DET
ihlr-25462	352	47	branded	brand	VERB
ihlr-25462	352	48	medication	medication	NOUN
ihlr-25462	352	49	’s	’s	PART
ihlr-25462	352	50	bioequivalent	bioequivalent	NOUN
ihlr-25462	352	51	and	and	CCONJ
ihlr-25462	352	52	the	the	DET
ihlr-25462	352	53	two	two	NUM
ihlr-25462	352	54	are	be	AUX
ihlr-25462	352	55	the	the	DET
ihlr-25462	352	56	same	same	ADJ
ihlr-25462	352	57	dosage	dosage	NOUN
ihlr-25462	352	58	,	,	PUNCT
ihlr-25462	352	59	strength	strength	NOUN
ihlr-25462	352	60	,	,	PUNCT
ihlr-25462	352	61	and	and	CCONJ
ihlr-25462	352	62	form	form	NOUN
ihlr-25462	352	63	,	,	PUNCT
ihlr-25462	352	64	the	the	DET
ihlr-25462	352	65	fda	fda	PROPN
ihlr-25462	352	66	identifies	identify	VERB
ihlr-25462	352	67	the	the	DET
ihlr-25462	352	68	generic	generic	ADJ
ihlr-25462	352	69	product	product	NOUN
ihlr-25462	352	70	as	as	ADP
ihlr-25462	352	71	the	the	DET
ihlr-25462	352	72	branded	brand	VERB
ihlr-25462	352	73	version	version	NOUN
ihlr-25462	352	74	’s	’s	PART
ihlr-25462	352	75	“	"	PUNCT
ihlr-25462	352	76	ab	ab	X
ihlr-25462	352	77	-	-	PUNCT
ihlr-25462	352	78	rated	rate	VERB
ihlr-25462	352	79	”	"	PUNCT
ihlr-25462	352	80	equivalent.124	equivalent.124	NOUN
ihlr-25462	352	81	at	at	ADP
ihlr-25462	352	82	the	the	DET
ihlr-25462	352	83	pharmacy	pharmacy	NOUN
ihlr-25462	352	84	,	,	PUNCT
ihlr-25462	352	85	the	the	DET
ihlr-25462	352	86	generic	generic	ADJ
ihlr-25462	352	87	product	product	NOUN
ihlr-25462	352	88	can	can	AUX
ihlr-25462	352	89	then	then	ADV
ihlr-25462	352	90	be	be	AUX
ihlr-25462	352	91	substituted	substitute	VERB
ihlr-25462	352	92	for	for	ADP
ihlr-25462	352	93	the	the	DET
ihlr-25462	352	94	branded	brand	VERB
ihlr-25462	352	95	medication	medication	NOUN
ihlr-25462	352	96	,	,	PUNCT
ihlr-25462	352	97	which	which	PRON
ihlr-25462	352	98	is	be	AUX
ihlr-25462	352	99	usually	usually	ADV
ihlr-25462	352	100	less	less	ADV
ihlr-25462	352	101	expensive	expensive	ADJ
ihlr-25462	352	102	than	than	ADP
ihlr-25462	352	103	the	the	DET
ihlr-25462	352	104	branded	brand	VERB
ihlr-25462	352	105	version.125	version.125	NOUN
ihlr-25462	352	106	there	there	PRON
ihlr-25462	352	107	are	be	VERB
ihlr-25462	352	108	two	two	NUM
ihlr-25462	352	109	ways	way	NOUN
ihlr-25462	352	110	a	a	DET
ihlr-25462	352	111	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	352	112	manufacturer	manufacturer	NOUN
ihlr-25462	352	113	can	can	AUX
ihlr-25462	352	114	use	use	VERB
ihlr-25462	352	115	the	the	DET
ihlr-25462	352	116	ab	ab	NOUN
ihlr-25462	352	117	-	-	PUNCT
ihlr-25462	352	118	rating	rating	NOUN
ihlr-25462	352	119	necessity	necessity	NOUN
ihlr-25462	352	120	to	to	ADP
ihlr-25462	352	121	their	their	PRON
ihlr-25462	352	122	advantage	advantage	NOUN
ihlr-25462	352	123	.	.	PUNCT
ihlr-25462	353	1	the	the	DET
ihlr-25462	353	2	first	first	ADJ
ihlr-25462	353	3	is	be	AUX
ihlr-25462	353	4	through	through	ADP
ihlr-25462	353	5	a	a	DET
ihlr-25462	353	6	practice	practice	NOUN
ihlr-25462	353	7	called	call	VERB
ihlr-25462	353	8	a	a	DET
ihlr-25462	353	9	“	"	PUNCT
ihlr-25462	353	10	hard	hard	ADJ
ihlr-25462	353	11	switch	switch	NOUN
ihlr-25462	353	12	,	,	PUNCT
ihlr-25462	353	13	”	"	PUNCT
ihlr-25462	353	14	in	in	ADP
ihlr-25462	353	15	which	which	PRON
ihlr-25462	353	16	a	a	DET
ihlr-25462	353	17	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	353	18	company	company	NOUN
ihlr-25462	353	19	purportedly	purportedly	ADV
ihlr-25462	353	20	takes	take	VERB
ihlr-25462	353	21	a	a	DET
ihlr-25462	353	22	prescription	prescription	NOUN
ihlr-25462	353	23	drug	drug	NOUN
ihlr-25462	353	24	completely	completely	ADV
ihlr-25462	353	25	off	off	ADP
ihlr-25462	353	26	the	the	DET
ihlr-25462	353	27	market.126	market.126	NOUN
ihlr-25462	353	28	this	this	PRON
ihlr-25462	353	29	would	would	AUX
ihlr-25462	353	30	allegedly	allegedly	ADV
ihlr-25462	353	31	create	create	VERB
ihlr-25462	353	32	a	a	DET
ihlr-25462	353	33	forced	force	VERB
ihlr-25462	353	34	-	-	PUNCT
ihlr-25462	353	35	switch	switch	NOUN
ihlr-25462	353	36	because	because	SCONJ
ihlr-25462	353	37	generic	generic	ADJ
ihlr-25462	353	38	substitution	substitution	NOUN
ihlr-25462	353	39	is	be	AUX
ihlr-25462	353	40	not	not	PART
ihlr-25462	353	41	possible	possible	ADJ
ihlr-25462	353	42	if	if	SCONJ
ihlr-25462	353	43	the	the	DET
ihlr-25462	353	44	branded	brand	VERB
ihlr-25462	353	45	medication	medication	NOUN
ihlr-25462	353	46	is	be	AUX
ihlr-25462	353	47	no	no	ADV
ihlr-25462	353	48	longer	long	ADV
ihlr-25462	353	49	available.127	available.127	NOUN
ihlr-25462	353	50	the	the	DET
ihlr-25462	353	51	second	second	ADJ
ihlr-25462	353	52	so	so	ADV
ihlr-25462	353	53	-	-	PUNCT
ihlr-25462	353	54	called	call	VERB
ihlr-25462	353	55	product	product	NOUN
ihlr-25462	353	56	hopping	hop	VERB
ihlr-25462	353	57	scenario	scenario	NOUN
ihlr-25462	353	58	is	be	AUX
ihlr-25462	353	59	called	call	VERB
ihlr-25462	353	60	a	a	DET
ihlr-25462	353	61	“	"	PUNCT
ihlr-25462	353	62	soft	soft	ADJ
ihlr-25462	353	63	switch	switch	NOUN
ihlr-25462	353	64	,	,	PUNCT
ihlr-25462	353	65	”	"	PUNCT
ihlr-25462	353	66	in	in	ADP
ihlr-25462	353	67	which	which	PRON
ihlr-25462	353	68	the	the	DET
ihlr-25462	353	69	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	353	70	company	company	NOUN
ihlr-25462	353	71	allegedly	allegedly	ADV
ihlr-25462	353	72	leaves	leave	VERB
ihlr-25462	353	73	the	the	DET
ihlr-25462	353	74	original	original	ADJ
ihlr-25462	353	75	drug	drug	NOUN
ihlr-25462	353	76	on	on	ADP
ihlr-25462	353	77	the	the	DET
ihlr-25462	353	78	market	market	NOUN
ihlr-25462	353	79	,	,	PUNCT
ihlr-25462	353	80	though	though	SCONJ
ihlr-25462	353	81	a	a	DET
ihlr-25462	353	82	similar	similar	ADJ
ihlr-25462	353	83	outcome	outcome	NOUN
ihlr-25462	353	84	results.128	results.128	NOUN
ihlr-25462	353	85	a.	a.	NOUN
ihlr-25462	353	86	hard	hard	ADJ
ihlr-25462	353	87	switches	switch	VERB
ihlr-25462	353	88	a	a	DET
ihlr-25462	353	89	famous	famous	ADJ
ihlr-25462	353	90	example	example	NOUN
ihlr-25462	353	91	of	of	ADP
ihlr-25462	353	92	a	a	DET
ihlr-25462	353	93	so	so	ADV
ihlr-25462	353	94	-	-	PUNCT
ihlr-25462	353	95	called	call	VERB
ihlr-25462	353	96	hard	hard	ADJ
ihlr-25462	353	97	switch	switch	NOUN
ihlr-25462	353	98	is	be	AUX
ihlr-25462	353	99	the	the	DET
ihlr-25462	353	100	case	case	NOUN
ihlr-25462	353	101	of	of	ADP
ihlr-25462	353	102	new	new	PROPN
ihlr-25462	353	103	york	york	PROPN
ihlr-25462	353	104	ex	ex	PROPN
ihlr-25462	353	105	rel	rel	PROPN
ihlr-25462	353	106	.	.	PUNCT
ihlr-25462	354	1	schneiderman	schneiderman	PROPN
ihlr-25462	354	2	v.	v.	PROPN
ihlr-25462	354	3	actavis	actavis	PROPN
ihlr-25462	354	4	plc	plc	PROPN
ihlr-25462	354	5	,	,	PUNCT
ihlr-25462	354	6	in	in	ADP
ihlr-25462	354	7	which	which	PRON
ihlr-25462	354	8	the	the	DET
ihlr-25462	354	9	branded	brand	VERB
ihlr-25462	354	10	company	company	NOUN
ihlr-25462	354	11	actavis	actavis	PROPN
ihlr-25462	354	12	sought	seek	VERB
ihlr-25462	354	13	to	to	PART
ihlr-25462	354	14	replace	replace	VERB
ihlr-25462	354	15	its	its	PRON
ihlr-25462	354	16	twice	twice	ADV
ihlr-25462	354	17	-	-	PUNCT
ihlr-25462	354	18	daily	daily	ADJ
ihlr-25462	354	19	dosage	dosage	NOUN
ihlr-25462	354	20	of	of	ADP
ihlr-25462	354	21	the	the	DET
ihlr-25462	354	22	memantine	memantine	NOUN
ihlr-25462	354	23	molecule	molecule	NOUN
ihlr-25462	354	24	(	(	PUNCT
ihlr-25462	354	25	namenda	namenda	NOUN
ihlr-25462	354	26	ir	ir	PROPN
ihlr-25462	354	27	)	)	PUNCT
ihlr-25462	354	28	with	with	ADP
ihlr-25462	354	29	an	an	DET
ihlr-25462	354	30	extended	extend	VERB
ihlr-25462	354	31	-	-	PUNCT
ihlr-25462	354	32	release	release	NOUN
ihlr-25462	354	33	,	,	PUNCT
ihlr-25462	354	34	once	once	ADV
ihlr-25462	354	35	-	-	PUNCT
ihlr-25462	354	36	daily	daily	ADJ
ihlr-25462	354	37	version	version	NOUN
ihlr-25462	354	38	(	(	PUNCT
ihlr-25462	354	39	namenda	namenda	ADV
ihlr-25462	354	40	xr).129	xr).129	PROPN
ihlr-25462	354	41	actavis	actavis	PROPN
ihlr-25462	354	42	allegedly	allegedly	ADV
ihlr-25462	354	43	began	begin	VERB
ihlr-25462	354	44	120	120	NUM
ihlr-25462	354	45	.	.	PUNCT
ihlr-25462	355	1	i	i	PRON
ihlr-25462	355	2	d.	d.	PROPN
ihlr-25462	355	3	121	121	NUM
ihlr-25462	355	4	.	.	PUNCT
ihlr-25462	356	1	i	i	PRON
ihlr-25462	356	2	d.	d.	PROPN
ihlr-25462	356	3	122	122	NUM
ihlr-25462	356	4	.	.	PUNCT
ihlr-25462	356	5	see	see	VERB
ihlr-25462	356	6	21	21	NUM
ihlr-25462	356	7	u.s.c	u.s.c	ADJ
ihlr-25462	356	8	.	.	PUNCT
ihlr-25462	357	1	§	§	PROPN
ihlr-25462	357	2	355	355	NUM
ihlr-25462	357	3	(	(	PUNCT
ihlr-25462	357	4	2020	2020	NUM
ihlr-25462	357	5	)	)	PUNCT
ihlr-25462	357	6	.	.	PUNCT
ihlr-25462	358	1	123	123	NUM
ihlr-25462	358	2	.	.	PUNCT
ihlr-25462	359	1	jessie	jessie	PROPN
ihlr-25462	359	2	chang	chang	PROPN
ihlr-25462	359	3	,	,	PUNCT
ihlr-25462	359	4	an	an	DET
ihlr-25462	359	5	antitrust	antitrust	ADJ
ihlr-25462	359	6	analysis	analysis	NOUN
ihlr-25462	359	7	of	of	ADP
ihlr-25462	359	8	product	product	NOUN
ihlr-25462	359	9	hopping	hop	VERB
ihlr-25462	359	10	in	in	ADP
ihlr-25462	359	11	the	the	DET
ihlr-25462	359	12	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	359	13	industry	industry	NOUN
ihlr-25462	359	14	,	,	PUNCT
ihlr-25462	359	15	108	108	NUM
ihlr-25462	359	16	colum	colum	NOUN
ihlr-25462	359	17	.	.	PUNCT
ihlr-25462	360	1	l.	l.	PROPN
ihlr-25462	360	2	rev	rev	PROPN
ihlr-25462	360	3	.	.	PROPN
ihlr-25462	360	4	1471	1471	NUM
ihlr-25462	360	5	,	,	PUNCT
ihlr-25462	360	6	1479	1479	NUM
ihlr-25462	360	7	(	(	PUNCT
ihlr-25462	360	8	2008	2008	NUM
ihlr-25462	360	9	)	)	PUNCT
ihlr-25462	360	10	.	.	PUNCT
ihlr-25462	361	1	124	124	NUM
ihlr-25462	361	2	.	.	PUNCT
ihlr-25462	361	3	21	21	NUM
ihlr-25462	361	4	u.s.c	u.s.c	NOUN
ihlr-25462	361	5	.	.	PUNCT
ihlr-25462	362	1	§	§	PROPN
ihlr-25462	362	2	355	355	NUM
ihlr-25462	362	3	.	.	PUNCT
ihlr-25462	362	4	125	125	NUM
ihlr-25462	362	5	.	.	PUNCT
ihlr-25462	363	1	chang	chang	PROPN
ihlr-25462	363	2	,	,	PUNCT
ihlr-25462	363	3	supra	supra	PROPN
ihlr-25462	363	4	note	note	NOUN
ihlr-25462	363	5	123	123	NUM
ihlr-25462	363	6	,	,	PUNCT
ihlr-25462	363	7	at	at	ADP
ihlr-25462	363	8	1479	1479	NUM
ihlr-25462	363	9	.	.	PUNCT
ihlr-25462	364	1	126	126	NUM
ihlr-25462	364	2	.	.	PUNCT
ihlr-25462	365	1	see	see	VERB
ihlr-25462	365	2	,	,	PUNCT
ihlr-25462	365	3	e.g.	e.g.	ADV
ihlr-25462	365	4	,	,	PUNCT
ihlr-25462	365	5	new	new	PROPN
ihlr-25462	365	6	york	york	PROPN
ihlr-25462	365	7	ex	ex	PROPN
ihlr-25462	365	8	rel	rel	PROPN
ihlr-25462	365	9	.	.	PUNCT
ihlr-25462	366	1	schneiderman	schneiderman	PROPN
ihlr-25462	366	2	v.	v.	PROPN
ihlr-25462	366	3	actavis	actavis	PROPN
ihlr-25462	366	4	plc	plc	PROPN
ihlr-25462	366	5	,	,	PUNCT
ihlr-25462	366	6	787	787	NUM
ihlr-25462	366	7	f.3d	f.3d	NUM
ihlr-25462	366	8	638	638	NUM
ihlr-25462	366	9	,	,	PUNCT
ihlr-25462	366	10	647	647	NUM
ihlr-25462	366	11	-	-	SYM
ihlr-25462	366	12	49	49	NUM
ihlr-25462	366	13	(	(	PUNCT
ihlr-25462	366	14	2d	2d	NUM
ihlr-25462	366	15	cir	cir	NOUN
ihlr-25462	366	16	.	.	PROPN
ihlr-25462	366	17	2015	2015	NUM
ihlr-25462	366	18	)	)	PUNCT
ihlr-25462	366	19	.	.	PUNCT
ihlr-25462	367	1	127	127	NUM
ihlr-25462	367	2	.	.	PUNCT
ihlr-25462	368	1	i	i	PRON
ihlr-25462	368	2	d.	d.	PROPN
ihlr-25462	368	3	at	at	ADP
ihlr-25462	368	4	642	642	NUM
ihlr-25462	368	5	.	.	PUNCT
ihlr-25462	369	1	128	128	NUM
ihlr-25462	369	2	.	.	PUNCT
ihlr-25462	370	1	michael	michael	PROPN
ihlr-25462	370	2	a.	a.	PROPN
ihlr-25462	370	3	carrier	carrier	PROPN
ihlr-25462	370	4	&	&	CCONJ
ihlr-25462	370	5	steve	steve	PROPN
ihlr-25462	370	6	d.	d.	PROPN
ihlr-25462	370	7	shadowen	shadowen	PROPN
ihlr-25462	370	8	,	,	PUNCT
ihlr-25462	370	9	product	product	NOUN
ihlr-25462	370	10	hopping	hop	VERB
ihlr-25462	370	11	:	:	PUNCT
ihlr-25462	370	12	a	a	DET
ihlr-25462	370	13	new	new	ADJ
ihlr-25462	370	14	framework	framework	NOUN
ihlr-25462	370	15	,	,	PUNCT
ihlr-25462	370	16	92	92	NUM
ihlr-25462	370	17	n.d.l	n.d.l	NOUN
ihlr-25462	370	18	.	.	PUNCT
ihlr-25462	371	1	rev	rev	PROPN
ihlr-25462	371	2	.	.	PROPN
ihlr-25462	371	3	167	167	NUM
ihlr-25462	371	4	,	,	PUNCT
ihlr-25462	371	5	168	168	NUM
ihlr-25462	371	6	(	(	PUNCT
ihlr-25462	371	7	2016	2016	NUM
ihlr-25462	371	8	)	)	PUNCT
ihlr-25462	371	9	.	.	PUNCT
ihlr-25462	372	1	129	129	NUM
ihlr-25462	372	2	.	.	PUNCT
ihlr-25462	373	1	see	see	VERB
ihlr-25462	373	2	,	,	PUNCT
ihlr-25462	373	3	e.g.	e.g.	ADV
ihlr-25462	373	4	,	,	PUNCT
ihlr-25462	373	5	actavis	actavi	NOUN
ihlr-25462	373	6	,	,	PUNCT
ihlr-25462	373	7	787	787	NUM
ihlr-25462	373	8	f.3d	f.3d	NOUN
ihlr-25462	373	9	.	.	PUNCT
ihlr-25462	374	1	at	at	ADP
ihlr-25462	374	2	638	638	NUM
ihlr-25462	374	3	.	.	PUNCT
ihlr-25462	374	4	2021	2021	NUM
ihlr-25462	374	5	]	]	PUNCT
ihlr-25462	374	6	a	a	DET
ihlr-25462	374	7	survey	survey	NOUN
ihlr-25462	374	8	of	of	ADP
ihlr-25462	374	9	three	three	NUM
ihlr-25462	374	10	patent	patent	NOUN
ihlr-25462	374	11	-	-	PUNCT
ihlr-25462	374	12	based	base	VERB
ihlr-25462	374	13	approaches	approach	NOUN
ihlr-25462	374	14	413	413	NUM
ihlr-25462	374	15	marketing	marketing	NOUN
ihlr-25462	374	16	namenda	namenda	NOUN
ihlr-25462	374	17	xr	xr	PROPN
ihlr-25462	374	18	to	to	ADP
ihlr-25462	374	19	its	its	PRON
ihlr-25462	374	20	patients	patient	NOUN
ihlr-25462	374	21	and	and	CCONJ
ihlr-25462	374	22	made	make	VERB
ihlr-25462	374	23	use	use	NOUN
ihlr-25462	374	24	of	of	ADP
ihlr-25462	374	25	rebates	rebate	NOUN
ihlr-25462	374	26	to	to	PART
ihlr-25462	374	27	offer	offer	VERB
ihlr-25462	374	28	it	it	PRON
ihlr-25462	374	29	at	at	ADP
ihlr-25462	374	30	a	a	DET
ihlr-25462	374	31	low	low	ADJ
ihlr-25462	374	32	price	price	NOUN
ihlr-25462	374	33	,	,	PUNCT
ihlr-25462	374	34	a	a	DET
ihlr-25462	374	35	process	process	NOUN
ihlr-25462	374	36	believed	believe	VERB
ihlr-25462	374	37	to	to	PART
ihlr-25462	374	38	be	be	AUX
ihlr-25462	374	39	a	a	DET
ihlr-25462	374	40	“	"	PUNCT
ihlr-25462	374	41	soft	soft	ADJ
ihlr-25462	374	42	switch	switch	NOUN
ihlr-25462	374	43	.	.	PUNCT
ihlr-25462	374	44	”130	”130	PROPN
ihlr-25462	375	1	the	the	DET
ihlr-25462	375	2	purported	purport	VERB
ihlr-25462	375	3	reason	reason	NOUN
ihlr-25462	375	4	for	for	ADP
ihlr-25462	375	5	this	this	PRON
ihlr-25462	375	6	was	be	AUX
ihlr-25462	375	7	that	that	SCONJ
ihlr-25462	375	8	namenda	namenda	NOUN
ihlr-25462	375	9	xr	xr	PROPN
ihlr-25462	375	10	was	be	AUX
ihlr-25462	375	11	covered	cover	VERB
ihlr-25462	375	12	by	by	ADP
ihlr-25462	375	13	multiple	multiple	ADJ
ihlr-25462	375	14	patents	patent	NOUN
ihlr-25462	375	15	that	that	PRON
ihlr-25462	375	16	would	would	AUX
ihlr-25462	375	17	expire	expire	VERB
ihlr-25462	375	18	almost	almost	ADV
ihlr-25462	375	19	fifteen	fifteen	NUM
ihlr-25462	375	20	years	year	NOUN
ihlr-25462	375	21	after	after	ADP
ihlr-25462	375	22	the	the	DET
ihlr-25462	375	23	patents	patent	NOUN
ihlr-25462	375	24	that	that	PRON
ihlr-25462	375	25	covered	cover	VERB
ihlr-25462	375	26	namenda	namenda	NOUN
ihlr-25462	375	27	ir.131	ir.131	PROPN
ihlr-25462	375	28	then	then	ADV
ihlr-25462	375	29	,	,	PUNCT
ihlr-25462	375	30	nine	nine	NUM
ihlr-25462	375	31	months	month	NOUN
ihlr-25462	375	32	before	before	SCONJ
ihlr-25462	375	33	patents	patent	NOUN
ihlr-25462	375	34	for	for	ADP
ihlr-25462	375	35	namenda	namenda	NOUN
ihlr-25462	375	36	ir	ir	PROPN
ihlr-25462	375	37	expired	expire	VERB
ihlr-25462	375	38	,	,	PUNCT
ihlr-25462	375	39	actavis	actavis	PROPN
ihlr-25462	375	40	sought	seek	VERB
ihlr-25462	375	41	to	to	PART
ihlr-25462	375	42	remove	remove	VERB
ihlr-25462	375	43	it	it	PRON
ihlr-25462	375	44	from	from	ADP
ihlr-25462	375	45	the	the	DET
ihlr-25462	375	46	market.132	market.132	NOUN
ihlr-25462	375	47	this	this	PRON
ihlr-25462	375	48	was	be	AUX
ihlr-25462	375	49	purportedly	purportedly	ADV
ihlr-25462	375	50	the	the	DET
ihlr-25462	375	51	“	"	PUNCT
ihlr-25462	375	52	hard	hard	ADJ
ihlr-25462	375	53	switch	switch	NOUN
ihlr-25462	375	54	.	.	PUNCT
ihlr-25462	376	1	”133	”133	VERB
ihlr-25462	376	2	the	the	DET
ihlr-25462	376	3	new	new	PROPN
ihlr-25462	376	4	york	york	PROPN
ihlr-25462	376	5	state	state	PROPN
ihlr-25462	376	6	attorney	attorney	PROPN
ihlr-25462	376	7	general	general	NOUN
ihlr-25462	376	8	sued	sue	VERB
ihlr-25462	376	9	actavis	actavis	PROPN
ihlr-25462	376	10	under	under	ADP
ihlr-25462	376	11	antitrust	antitrust	ADJ
ihlr-25462	376	12	laws	law	NOUN
ihlr-25462	376	13	,	,	PUNCT
ihlr-25462	376	14	and	and	CCONJ
ihlr-25462	376	15	the	the	DET
ihlr-25462	376	16	trial	trial	NOUN
ihlr-25462	376	17	court	court	NOUN
ihlr-25462	376	18	granted	grant	VERB
ihlr-25462	376	19	its	its	PRON
ihlr-25462	376	20	request	request	NOUN
ihlr-25462	376	21	for	for	ADP
ihlr-25462	376	22	a	a	DET
ihlr-25462	376	23	preliminary	preliminary	ADJ
ihlr-25462	376	24	injunction.134	injunction.134	NOUN
ihlr-25462	376	25	the	the	DET
ihlr-25462	376	26	court	court	NOUN
ihlr-25462	376	27	of	of	ADP
ihlr-25462	376	28	appeals	appeal	NOUN
ihlr-25462	376	29	for	for	ADP
ihlr-25462	376	30	the	the	DET
ihlr-25462	376	31	second	second	ADJ
ihlr-25462	376	32	circuit	circuit	NOUN
ihlr-25462	376	33	affirmed	affirm	VERB
ihlr-25462	376	34	,	,	PUNCT
ihlr-25462	376	35	ruling	rule	VERB
ihlr-25462	376	36	that	that	SCONJ
ihlr-25462	376	37	actavis	actavis	PROPN
ihlr-25462	376	38	had	have	VERB
ihlr-25462	376	39	to	to	PART
ihlr-25462	376	40	keep	keep	VERB
ihlr-25462	376	41	namenda	namenda	NOUN
ihlr-25462	376	42	ir	ir	NOUN
ihlr-25462	376	43	on	on	ADP
ihlr-25462	376	44	the	the	DET
ihlr-25462	376	45	market	market	NOUN
ihlr-25462	376	46	for	for	ADP
ihlr-25462	376	47	thirty	thirty	NUM
ihlr-25462	376	48	days	day	NOUN
ihlr-25462	376	49	after	after	SCONJ
ihlr-25462	376	50	the	the	DET
ihlr-25462	376	51	generic	generic	NOUN
ihlr-25462	376	52	would	would	AUX
ihlr-25462	376	53	first	first	ADV
ihlr-25462	376	54	be	be	AUX
ihlr-25462	376	55	available.135	available.135	NOUN
ihlr-25462	376	56	interestingly	interestingly	ADV
ihlr-25462	376	57	,	,	PUNCT
ihlr-25462	376	58	the	the	DET
ihlr-25462	376	59	holding	holding	NOUN
ihlr-25462	376	60	in	in	ADP
ihlr-25462	376	61	actavis	actavis	PROPN
ihlr-25462	376	62	contrasts	contrast	VERB
ihlr-25462	376	63	with	with	ADP
ihlr-25462	376	64	the	the	DET
ihlr-25462	376	65	outcome	outcome	NOUN
ihlr-25462	376	66	in	in	ADP
ihlr-25462	376	67	mylan	mylan	PROPN
ihlr-25462	376	68	pharmaceuticals	pharmaceuticals	PROPN
ihlr-25462	376	69	inc	inc	PROPN
ihlr-25462	376	70	.	.	PROPN
ihlr-25462	377	1	v.	v.	PROPN
ihlr-25462	377	2	warner	warner	PROPN
ihlr-25462	377	3	chilcott	chilcott	PROPN
ihlr-25462	377	4	public	public	PROPN
ihlr-25462	377	5	limited	limit	VERB
ihlr-25462	377	6	company.136	company.136	PROPN
ihlr-25462	377	7	mylan	mylan	PROPN
ihlr-25462	377	8	,	,	PUNCT
ihlr-25462	377	9	the	the	DET
ihlr-25462	377	10	generic	generic	ADJ
ihlr-25462	377	11	company	company	NOUN
ihlr-25462	377	12	,	,	PUNCT
ihlr-25462	377	13	sued	sue	VERB
ihlr-25462	377	14	warner	warner	PROPN
ihlr-25462	377	15	chilcott	chilcott	PROPN
ihlr-25462	377	16	,	,	PUNCT
ihlr-25462	377	17	the	the	DET
ihlr-25462	377	18	drug	drug	NOUN
ihlr-25462	377	19	manufacturer	manufacturer	NOUN
ihlr-25462	377	20	,	,	PUNCT
ihlr-25462	377	21	alleging	allege	VERB
ihlr-25462	377	22	a	a	DET
ihlr-25462	377	23	number	number	NOUN
ihlr-25462	377	24	of	of	ADP
ihlr-25462	377	25	product	product	NOUN
ihlr-25462	377	26	-	-	PUNCT
ihlr-25462	377	27	hopping	hop	VERB
ihlr-25462	377	28	complaints	complaint	NOUN
ihlr-25462	377	29	about	about	ADP
ihlr-25462	377	30	its	its	PRON
ihlr-25462	377	31	product	product	NOUN
ihlr-25462	377	32	doryx.137	doryx.137	NOUN
ihlr-25462	377	33	the	the	DET
ihlr-25462	377	34	court	court	NOUN
ihlr-25462	377	35	found	find	VERB
ihlr-25462	377	36	that	that	SCONJ
ihlr-25462	377	37	warner	warner	PROPN
ihlr-25462	377	38	chilcott	chilcott	PROPN
ihlr-25462	377	39	“	"	PUNCT
ihlr-25462	377	40	made	make	VERB
ihlr-25462	377	41	four	four	NUM
ihlr-25462	377	42	critical	critical	ADJ
ihlr-25462	377	43	changes	change	NOUN
ihlr-25462	377	44	to	to	ADP
ihlr-25462	377	45	doryx	doryx	PROPN
ihlr-25462	377	46	,	,	PUNCT
ihlr-25462	377	47	all	all	PRON
ihlr-25462	377	48	of	of	ADP
ihlr-25462	377	49	which	which	PRON
ihlr-25462	377	50	required	require	VERB
ihlr-25462	377	51	generics	generic	NOUN
ihlr-25462	377	52	to	to	PART
ihlr-25462	377	53	apply	apply	VERB
ihlr-25462	377	54	for	for	ADP
ihlr-25462	377	55	ab	ab	NOUN
ihlr-25462	377	56	-	-	PUNCT
ihlr-25462	377	57	rating	rating	NOUN
ihlr-25462	377	58	if	if	SCONJ
ihlr-25462	377	59	they	they	PRON
ihlr-25462	377	60	wanted	want	VERB
ihlr-25462	377	61	to	to	PART
ihlr-25462	377	62	continue	continue	VERB
ihlr-25462	377	63	to	to	PART
ihlr-25462	377	64	benefit	benefit	VERB
ihlr-25462	377	65	from	from	ADP
ihlr-25462	377	66	state	state	NOUN
ihlr-25462	377	67	substitution	substitution	NOUN
ihlr-25462	377	68	laws	law	NOUN
ihlr-25462	377	69	.	.	PUNCT
ihlr-25462	378	1	”138	”138	PROPN
ihlr-25462	378	2	however	however	ADV
ihlr-25462	378	3	,	,	PUNCT
ihlr-25462	378	4	the	the	DET
ihlr-25462	378	5	court	court	NOUN
ihlr-25462	378	6	“	"	PUNCT
ihlr-25462	378	7	held	hold	VERB
ihlr-25462	378	8	that	that	SCONJ
ihlr-25462	378	9	mylan	mylan	PROPN
ihlr-25462	378	10	failed	fail	VERB
ihlr-25462	378	11	to	to	PART
ihlr-25462	378	12	muster	muster	VERB
ihlr-25462	378	13	sufficient	sufficient	ADJ
ihlr-25462	378	14	evidence	evidence	NOUN
ihlr-25462	378	15	of	of	ADP
ihlr-25462	378	16	defendant	defendant	NOUN
ihlr-25462	378	17	’s	’s	PART
ihlr-25462	378	18	monopoly	monopoly	NOUN
ihlr-25462	378	19	power	power	NOUN
ihlr-25462	378	20	.	.	PUNCT
ihlr-25462	378	21	”139	”139	PUNCT
ihlr-25462	379	1	warner	warner	PROPN
ihlr-25462	379	2	chilcott	chilcott	PROPN
ihlr-25462	379	3	public	public	PROPN
ihlr-25462	379	4	limited	limited	ADJ
ihlr-25462	379	5	company	company	NOUN
ihlr-25462	379	6	’s	’s	PART
ihlr-25462	379	7	(	(	PUNCT
ihlr-25462	379	8	“	"	PUNCT
ihlr-25462	379	9	warner	warner	PROPN
ihlr-25462	379	10	chilcott	chilcott	PROPN
ihlr-25462	379	11	”	"	PUNCT
ihlr-25462	379	12	)	)	PUNCT
ihlr-25462	379	13	market	market	NOUN
ihlr-25462	379	14	share	share	NOUN
ihlr-25462	379	15	“	"	PUNCT
ihlr-25462	379	16	was	be	AUX
ihlr-25462	379	17	–	–	PUNCT
ihlr-25462	379	18	at	at	ADP
ihlr-25462	379	19	most	most	ADV
ihlr-25462	379	20	–	–	PUNCT
ihlr-25462	379	21	only	only	ADV
ihlr-25462	379	22	about	about	ADV
ihlr-25462	379	23	18	18	NUM
ihlr-25462	379	24	%	%	NOUN
ihlr-25462	379	25	,	,	PUNCT
ihlr-25462	379	26	an	an	DET
ihlr-25462	379	27	amount	amount	NOUN
ihlr-25462	379	28	insufficient	insufficient	ADJ
ihlr-25462	379	29	to	to	PART
ihlr-25462	379	30	show	show	VERB
ihlr-25462	379	31	that	that	SCONJ
ihlr-25462	379	32	[	[	X
ihlr-25462	379	33	it	it	PRON
ihlr-25462	379	34	]	]	PUNCT
ihlr-25462	379	35	exercised	exercise	VERB
ihlr-25462	379	36	monopoly	monopoly	NOUN
ihlr-25462	379	37	power	power	NOUN
ihlr-25462	379	38	.	.	PUNCT
ihlr-25462	380	1	”140	”140	PROPN
ihlr-25462	380	2	thus	thus	ADV
ihlr-25462	380	3	,	,	PUNCT
ihlr-25462	380	4	warner	warner	PROPN
ihlr-25462	380	5	chilcott	chilcott	PROPN
ihlr-25462	380	6	was	be	AUX
ihlr-25462	380	7	said	say	VERB
ihlr-25462	380	8	not	not	PART
ihlr-25462	380	9	to	to	PART
ihlr-25462	380	10	be	be	AUX
ihlr-25462	380	11	engaging	engage	VERB
ihlr-25462	380	12	in	in	ADP
ihlr-25462	380	13	a	a	DET
ihlr-25462	380	14	hard	hard	ADJ
ihlr-25462	380	15	switch	switch	NOUN
ihlr-25462	380	16	product	product	NOUN
ihlr-25462	380	17	hopping	hopping	NOUN
ihlr-25462	380	18	.	.	PUNCT
ihlr-25462	381	1	b.	b.	PROPN
ihlr-25462	381	2	soft	soft	PROPN
ihlr-25462	381	3	switches	switch	NOUN
ihlr-25462	381	4	a	a	DET
ihlr-25462	381	5	so	so	ADV
ihlr-25462	381	6	-	-	PUNCT
ihlr-25462	381	7	called	call	VERB
ihlr-25462	381	8	soft	soft	ADJ
ihlr-25462	381	9	switch	switch	NOUN
ihlr-25462	381	10	is	be	AUX
ihlr-25462	381	11	when	when	SCONJ
ihlr-25462	381	12	the	the	DET
ihlr-25462	381	13	old	old	ADJ
ihlr-25462	381	14	drug	drug	NOUN
ihlr-25462	381	15	is	be	AUX
ihlr-25462	381	16	kept	keep	VERB
ihlr-25462	381	17	on	on	ADP
ihlr-25462	381	18	the	the	DET
ihlr-25462	381	19	market	market	NOUN
ihlr-25462	381	20	,	,	PUNCT
ihlr-25462	381	21	and	and	CCONJ
ihlr-25462	381	22	it	it	PRON
ihlr-25462	381	23	can	can	AUX
ihlr-25462	381	24	also	also	ADV
ihlr-25462	381	25	allegedly	allegedly	ADV
ihlr-25462	381	26	have	have	VERB
ihlr-25462	381	27	significant	significant	ADJ
ihlr-25462	381	28	drug	drug	NOUN
ihlr-25462	381	29	price	price	NOUN
ihlr-25462	381	30	implications	implication	NOUN
ihlr-25462	381	31	.	.	PUNCT
ihlr-25462	382	1	in	in	ADP
ihlr-25462	382	2	a	a	DET
ihlr-25462	382	3	soft	soft	ADJ
ihlr-25462	382	4	-	-	PUNCT
ihlr-25462	382	5	switch	switch	NOUN
ihlr-25462	382	6	situation	situation	NOUN
ihlr-25462	382	7	,	,	PUNCT
ihlr-25462	382	8	the	the	DET
ihlr-25462	382	9	original	original	ADJ
ihlr-25462	382	10	drug	drug	NOUN
ihlr-25462	382	11	stays	stay	VERB
ihlr-25462	382	12	on	on	ADP
ihlr-25462	382	13	the	the	DET
ihlr-25462	382	14	market	market	NOUN
ihlr-25462	382	15	,	,	PUNCT
ihlr-25462	382	16	allowing	allow	VERB
ihlr-25462	382	17	the	the	DET
ihlr-25462	382	18	consumer	consumer	NOUN
ihlr-25462	382	19	a	a	DET
ihlr-25462	382	20	choice	choice	NOUN
ihlr-25462	382	21	,	,	PUNCT
ihlr-25462	382	22	but	but	CCONJ
ihlr-25462	382	23	the	the	DET
ihlr-25462	382	24	process	process	NOUN
ihlr-25462	382	25	imparts	impart	VERB
ihlr-25462	382	26	what	what	PRON
ihlr-25462	382	27	is	be	AUX
ihlr-25462	382	28	known	know	VERB
ihlr-25462	382	29	as	as	ADP
ihlr-25462	382	30	a	a	DET
ihlr-25462	382	31	“	"	PUNCT
ihlr-25462	382	32	price	price	NOUN
ihlr-25462	382	33	disconnect	disconnect	NOUN
ihlr-25462	382	34	,	,	PUNCT
ihlr-25462	382	35	”	"	PUNCT
ihlr-25462	382	36	meaning	mean	VERB
ihlr-25462	382	37	the	the	DET
ihlr-25462	382	38	general	general	ADJ
ihlr-25462	382	39	market	market	NOUN
ihlr-25462	382	40	balance	balance	NOUN
ihlr-25462	382	41	between	between	ADP
ihlr-25462	382	42	price	price	NOUN
ihlr-25462	382	43	and	and	CCONJ
ihlr-25462	382	44	quality	quality	NOUN
ihlr-25462	382	45	is	be	AUX
ihlr-25462	382	46	disrupted	disrupt	VERB
ihlr-25462	382	47	because	because	SCONJ
ihlr-25462	382	48	the	the	DET
ihlr-25462	382	49	doctor	doctor	NOUN
ihlr-25462	382	50	130	130	NUM
ihlr-25462	382	51	.	.	PUNCT
ihlr-25462	383	1	see	see	VERB
ihlr-25462	383	2	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	383	3	antitrust	antitrust	ADJ
ihlr-25462	383	4	update	update	NOUN
ihlr-25462	383	5	:	:	PUNCT
ihlr-25462	383	6	courts	court	NOUN
ihlr-25462	383	7	address	address	VERB
ihlr-25462	383	8	how	how	SCONJ
ihlr-25462	383	9	and	and	CCONJ
ihlr-25462	383	10	when	when	SCONJ
ihlr-25462	383	11	product	product	NOUN
ihlr-25462	383	12	hopping	hop	VERB
ihlr-25462	383	13	may	may	AUX
ihlr-25462	383	14	violate	violate	VERB
ihlr-25462	383	15	the	the	DET
ihlr-25462	383	16	antitrust	antitrust	ADJ
ihlr-25462	383	17	laws	law	NOUN
ihlr-25462	383	18	,	,	PUNCT
ihlr-25462	383	19	haug	haug	VERB
ihlr-25462	383	20	partners	partner	NOUN
ihlr-25462	383	21	(	(	PUNCT
ihlr-25462	383	22	mar	mar	PROPN
ihlr-25462	383	23	.	.	PROPN
ihlr-25462	383	24	29	29	NUM
ihlr-25462	383	25	,	,	PUNCT
ihlr-25462	383	26	2017	2017	NUM
ihlr-25462	383	27	)	)	PUNCT
ihlr-25462	383	28	,	,	PUNCT
ihlr-25462	383	29	https://www.haugpartners	https://www.haugpartner	NOUN
ihlr-25462	383	30	.	.	PUNCT
ihlr-25462	383	31	com	com	NOUN
ihlr-25462	383	32	/	/	SYM
ihlr-25462	383	33	article	article	NOUN
ihlr-25462	383	34	/	/	SYM
ihlr-25462	383	35	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	383	36	-	-	PUNCT
ihlr-25462	383	37	antitrust	antitrust	ADJ
ihlr-25462	383	38	-	-	PUNCT
ihlr-25462	383	39	update	update	NOUN
ihlr-25462	383	40	-	-	PUNCT
ihlr-25462	383	41	courts	court	NOUN
ihlr-25462	383	42	-	-	PUNCT
ihlr-25462	383	43	address	address	NOUN
ihlr-25462	383	44	-	-	PUNCT
ihlr-25462	383	45	how	how	ADV
ihlr-25462	383	46	-	-	PUNCT
ihlr-25462	383	47	and	and	CCONJ
ihlr-25462	383	48	-	-	PUNCT
ihlr-25462	383	49	when	when	ADV
ihlr-25462	383	50	-	-	PUNCT
ihlr-25462	383	51	product	product	NOUN
ihlr-25462	383	52	-	-	PUNCT
ihlr-25462	383	53	hopping	hop	VERB
ihlr-25462	383	54	-	-	PUNCT
ihlr-25462	383	55	mayviolate	mayviolate	NOUN
ihlr-25462	383	56	-	-	PUNCT
ihlr-25462	383	57	the	the	DET
ihlr-25462	383	58	-	-	PUNCT
ihlr-25462	383	59	antirust	antirust	NOUN
ihlr-25462	383	60	-	-	PUNCT
ihlr-25462	383	61	laws/	laws/	NUM
ihlr-25462	384	1	[	[	X
ihlr-25462	384	2	https://perma.cc/w4zv-gcmj	https://perma.cc/w4zv-gcmj	NOUN
ihlr-25462	384	3	]	]	PUNCT
ihlr-25462	384	4	.	.	PUNCT
ihlr-25462	385	1	131	131	NUM
ihlr-25462	385	2	.	.	PUNCT
ihlr-25462	386	1	i	i	PRON
ihlr-25462	386	2	d.	d.	PROPN
ihlr-25462	386	3	132	132	NUM
ihlr-25462	386	4	.	.	PUNCT
ihlr-25462	387	1	i	i	PRON
ihlr-25462	387	2	d.	d.	PROPN
ihlr-25462	387	3	133	133	NUM
ihlr-25462	387	4	.	.	PUNCT
ihlr-25462	388	1	i	i	PRON
ihlr-25462	388	2	d.	d.	PROPN
ihlr-25462	388	3	134	134	NUM
ihlr-25462	388	4	.	.	PUNCT
ihlr-25462	389	1	actavis	actavi	NOUN
ihlr-25462	389	2	,	,	PUNCT
ihlr-25462	389	3	787	787	NUM
ihlr-25462	389	4	f.3d	f.3d	NOUN
ihlr-25462	389	5	.	.	PUNCT
ihlr-25462	390	1	at	at	ADP
ihlr-25462	390	2	649	649	NUM
ihlr-25462	390	3	.	.	PUNCT
ihlr-25462	390	4	135	135	NUM
ihlr-25462	390	5	.	.	PUNCT
ihlr-25462	391	1	i	i	PRON
ihlr-25462	391	2	d.	d.	PROPN
ihlr-25462	391	3	136	136	NUM
ihlr-25462	391	4	.	.	PUNCT
ihlr-25462	392	1	see	see	VERB
ihlr-25462	392	2	mylan	mylan	PROPN
ihlr-25462	392	3	pharm	pharm	PROPN
ihlr-25462	392	4	.	.	PUNCT
ihlr-25462	393	1	inc	inc	PROPN
ihlr-25462	393	2	.	.	PROPN
ihlr-25462	394	1	v.	v.	PROPN
ihlr-25462	394	2	warner	warner	PROPN
ihlr-25462	394	3	chilcott	chilcott	PROPN
ihlr-25462	394	4	pub	pub	PROPN
ihlr-25462	394	5	.	.	PUNCT
ihlr-25462	395	1	co.	co.	PROPN
ihlr-25462	395	2	,	,	PUNCT
ihlr-25462	395	3	838	838	NUM
ihlr-25462	395	4	f.3d	f.3d	NUM
ihlr-25462	395	5	421	421	NUM
ihlr-25462	395	6	(	(	PUNCT
ihlr-25462	395	7	3d	3d	PROPN
ihlr-25462	395	8	cir	cir	NOUN
ihlr-25462	395	9	.	.	PROPN
ihlr-25462	395	10	2016	2016	NUM
ihlr-25462	395	11	)	)	PUNCT
ihlr-25462	395	12	.	.	PUNCT
ihlr-25462	396	1	137	137	NUM
ihlr-25462	396	2	.	.	PUNCT
ihlr-25462	397	1	see	see	VERB
ihlr-25462	397	2	i	i	PRON
ihlr-25462	397	3	d.	d.	PROPN
ihlr-25462	397	4	138	138	NUM
ihlr-25462	397	5	.	.	PUNCT
ihlr-25462	398	1	i	i	PRON
ihlr-25462	398	2	d.	d.	PROPN
ihlr-25462	398	3	at	at	ADP
ihlr-25462	398	4	430	430	NUM
ihlr-25462	398	5	.	.	PUNCT
ihlr-25462	398	6	139	139	NUM
ihlr-25462	398	7	.	.	PUNCT
ihlr-25462	399	1	i	i	PRON
ihlr-25462	399	2	d.	d.	PROPN
ihlr-25462	399	3	at	at	ADP
ihlr-25462	399	4	431	431	NUM
ihlr-25462	399	5	.	.	PUNCT
ihlr-25462	400	1	140	140	NUM
ihlr-25462	400	2	.	.	PUNCT
ihlr-25462	401	1	i	i	PRON
ihlr-25462	401	2	d.	d.	PROPN
ihlr-25462	401	3	414	414	NUM
ihlr-25462	401	4	indiana	indiana	PROPN
ihlr-25462	401	5	health	health	PROPN
ihlr-25462	401	6	law	law	PROPN
ihlr-25462	401	7	review	review	NOUN
ihlr-25462	401	8	[	[	X
ihlr-25462	401	9	vol	vol	NOUN
ihlr-25462	401	10	.	.	PUNCT
ihlr-25462	401	11	18:397	18:397	NUM
ihlr-25462	401	12	prescribing	prescribing	NOUN
ihlr-25462	401	13	the	the	DET
ihlr-25462	401	14	medication	medication	NOUN
ihlr-25462	401	15	is	be	AUX
ihlr-25462	401	16	not	not	PART
ihlr-25462	401	17	the	the	DET
ihlr-25462	401	18	same	same	ADJ
ihlr-25462	401	19	person	person	NOUN
ihlr-25462	401	20	or	or	CCONJ
ihlr-25462	401	21	entity	entity	NOUN
ihlr-25462	401	22	paying	pay	VERB
ihlr-25462	401	23	for	for	ADP
ihlr-25462	401	24	it.141	it.141	PROPN
ihlr-25462	401	25	therefore	therefore	ADV
ihlr-25462	401	26	,	,	PUNCT
ihlr-25462	401	27	as	as	SCONJ
ihlr-25462	401	28	one	one	NUM
ihlr-25462	401	29	court	court	NOUN
ihlr-25462	401	30	explained	explain	VERB
ihlr-25462	401	31	in	in	ADP
ihlr-25462	401	32	an	an	DET
ihlr-25462	401	33	ongoing	ongoing	ADJ
ihlr-25462	401	34	antitrust	antitrust	ADJ
ihlr-25462	401	35	product	product	NOUN
ihlr-25462	401	36	hopping	hop	VERB
ihlr-25462	401	37	case	case	NOUN
ihlr-25462	401	38	,	,	PUNCT
ihlr-25462	401	39	“	"	PUNCT
ihlr-25462	401	40	the	the	DET
ihlr-25462	401	41	ordinary	ordinary	ADJ
ihlr-25462	401	42	market	market	NOUN
ihlr-25462	401	43	forces	force	NOUN
ihlr-25462	401	44	that	that	PRON
ihlr-25462	401	45	would	would	AUX
ihlr-25462	401	46	allow	allow	VERB
ihlr-25462	401	47	consumers	consumer	NOUN
ihlr-25462	401	48	to	to	PART
ihlr-25462	401	49	consider	consider	VERB
ihlr-25462	401	50	price	price	NOUN
ihlr-25462	401	51	when	when	SCONJ
ihlr-25462	401	52	selecting	select	VERB
ihlr-25462	401	53	a	a	DET
ihlr-25462	401	54	product	product	NOUN
ihlr-25462	401	55	are	be	AUX
ihlr-25462	401	56	derailed	derail	VERB
ihlr-25462	401	57	.	.	PUNCT
ihlr-25462	402	1	”142	”142	PUNCT
ihlr-25462	402	2	therefore	therefore	ADV
ihlr-25462	402	3	,	,	PUNCT
ihlr-25462	402	4	a	a	DET
ihlr-25462	402	5	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	402	6	company	company	NOUN
ihlr-25462	402	7	that	that	PRON
ihlr-25462	402	8	removes	remove	VERB
ihlr-25462	402	9	or	or	CCONJ
ihlr-25462	402	10	disparages	disparage	VERB
ihlr-25462	402	11	its	its	PRON
ihlr-25462	402	12	original	original	ADJ
ihlr-25462	402	13	product	product	NOUN
ihlr-25462	402	14	for	for	ADP
ihlr-25462	402	15	the	the	DET
ihlr-25462	402	16	alleged	alleged	ADJ
ihlr-25462	402	17	sole	sole	ADJ
ihlr-25462	402	18	purpose	purpose	NOUN
ihlr-25462	402	19	of	of	ADP
ihlr-25462	402	20	transitioning	transition	VERB
ihlr-25462	402	21	patients	patient	NOUN
ihlr-25462	402	22	to	to	ADP
ihlr-25462	402	23	a	a	DET
ihlr-25462	402	24	newer	new	ADJ
ihlr-25462	402	25	and	and	CCONJ
ihlr-25462	402	26	higher	higher	ADV
ihlr-25462	402	27	-	-	PUNCT
ihlr-25462	402	28	priced	price	VERB
ihlr-25462	402	29	product	product	NOUN
ihlr-25462	402	30	may	may	AUX
ihlr-25462	402	31	be	be	AUX
ihlr-25462	402	32	viewed	view	VERB
ihlr-25462	402	33	as	as	ADP
ihlr-25462	402	34	anti	anti	ADJ
ihlr-25462	402	35	-	-	ADJ
ihlr-25462	402	36	competitive.143	competitive.143	ADJ
ihlr-25462	402	37	numerous	numerous	ADJ
ihlr-25462	402	38	pieces	piece	NOUN
ihlr-25462	402	39	of	of	ADP
ihlr-25462	402	40	legislation	legislation	NOUN
ihlr-25462	402	41	are	be	AUX
ihlr-25462	402	42	currently	currently	ADV
ihlr-25462	402	43	attempting	attempt	VERB
ihlr-25462	402	44	to	to	PART
ihlr-25462	402	45	address	address	VERB
ihlr-25462	402	46	product	product	NOUN
ihlr-25462	402	47	hopping	hopping	NOUN
ihlr-25462	402	48	.	.	PUNCT
ihlr-25462	403	1	the	the	DET
ihlr-25462	403	2	affordable	affordable	ADJ
ihlr-25462	403	3	prescriptions	prescription	NOUN
ihlr-25462	403	4	for	for	ADP
ihlr-25462	403	5	patients	patient	NOUN
ihlr-25462	403	6	act	act	VERB
ihlr-25462	403	7	would	would	AUX
ihlr-25462	403	8	address	address	VERB
ihlr-25462	403	9	product	product	NOUN
ihlr-25462	403	10	hopping	hop	VERB
ihlr-25462	403	11	in	in	ADP
ihlr-25462	403	12	addition	addition	NOUN
ihlr-25462	403	13	to	to	ADP
ihlr-25462	403	14	its	its	PRON
ihlr-25462	403	15	sections	section	NOUN
ihlr-25462	403	16	regarding	regard	VERB
ihlr-25462	403	17	patent	patent	NOUN
ihlr-25462	403	18	thicketing.144	thicketing.144	NOUN
ihlr-25462	403	19	the	the	DET
ihlr-25462	403	20	bill	bill	NOUN
ihlr-25462	403	21	would	would	AUX
ihlr-25462	403	22	define	define	VERB
ihlr-25462	403	23	product	product	NOUN
ihlr-25462	403	24	hopping	hop	VERB
ihlr-25462	403	25	as	as	ADP
ihlr-25462	403	26	anti	anti	ADJ
ihlr-25462	403	27	-	-	ADJ
ihlr-25462	403	28	competitive	competitive	ADJ
ihlr-25462	403	29	behavior	behavior	NOUN
ihlr-25462	403	30	,	,	PUNCT
ihlr-25462	403	31	thereby	thereby	ADV
ihlr-25462	403	32	allowing	allow	VERB
ihlr-25462	403	33	the	the	DET
ihlr-25462	403	34	ftc	ftc	PROPN
ihlr-25462	403	35	to	to	PART
ihlr-25462	403	36	“	"	PUNCT
ihlr-25462	403	37	bring	bring	VERB
ihlr-25462	403	38	antitrust	antitrust	ADJ
ihlr-25462	403	39	suits	suit	NOUN
ihlr-25462	403	40	against	against	ADP
ihlr-25462	403	41	bad	bad	ADJ
ihlr-25462	403	42	actors	actor	NOUN
ihlr-25462	403	43	who	who	PRON
ihlr-25462	403	44	deliberately	deliberately	ADV
ihlr-25462	403	45	game	game	VERB
ihlr-25462	403	46	the	the	DET
ihlr-25462	403	47	system	system	NOUN
ihlr-25462	403	48	,	,	PUNCT
ihlr-25462	403	49	and	and	CCONJ
ihlr-25462	403	50	would	would	AUX
ihlr-25462	403	51	give	give	VERB
ihlr-25462	403	52	them	they	PRON
ihlr-25462	403	53	injunctive	injunctive	ADJ
ihlr-25462	403	54	authority	authority	NOUN
ihlr-25462	403	55	to	to	PART
ihlr-25462	403	56	make	make	VERB
ihlr-25462	403	57	the	the	DET
ihlr-25462	403	58	system	system	NOUN
ihlr-25462	403	59	fairer	fair	ADJ
ihlr-25462	403	60	and	and	CCONJ
ihlr-25462	403	61	operate	operate	VERB
ihlr-25462	403	62	as	as	SCONJ
ihlr-25462	403	63	congress	congress	PROPN
ihlr-25462	403	64	intended	intend	VERB
ihlr-25462	403	65	.	.	PUNCT
ihlr-25462	403	66	”145	”145	PUNCT
ihlr-25462	403	67	the	the	DET
ihlr-25462	403	68	affordable	affordable	ADJ
ihlr-25462	403	69	prescriptions	prescription	NOUN
ihlr-25462	403	70	for	for	ADP
ihlr-25462	403	71	patients	patient	NOUN
ihlr-25462	403	72	through	through	ADP
ihlr-25462	403	73	promoting	promote	VERB
ihlr-25462	403	74	competition	competition	NOUN
ihlr-25462	403	75	act	act	NOUN
ihlr-25462	403	76	of	of	ADP
ihlr-25462	403	77	2019	2019	NUM
ihlr-25462	403	78	was	be	AUX
ihlr-25462	403	79	introduced	introduce	VERB
ihlr-25462	403	80	in	in	ADP
ihlr-25462	403	81	the	the	DET
ihlr-25462	403	82	house	house	NOUN
ihlr-25462	403	83	on	on	ADP
ihlr-25462	403	84	september	september	PROPN
ihlr-25462	403	85	19	19	NUM
ihlr-25462	403	86	,	,	PUNCT
ihlr-25462	403	87	2019	2019	NUM
ihlr-25462	403	88	,	,	PUNCT
ihlr-25462	403	89	by	by	ADP
ihlr-25462	403	90	congressman	congressman	NOUN
ihlr-25462	403	91	cicilline.146	cicilline.146	NOUN
ihlr-25462	403	92	the	the	DET
ihlr-25462	403	93	bill	bill	NOUN
ihlr-25462	403	94	was	be	AUX
ihlr-25462	403	95	designed	design	VERB
ihlr-25462	403	96	to	to	PART
ihlr-25462	403	97	“	"	PUNCT
ihlr-25462	403	98	prohibit	prohibit	VERB
ihlr-25462	403	99	[	[	X
ihlr-25462	403	100	anti	anti	ADJ
ihlr-25462	403	101	-	-	ADJ
ihlr-25462	403	102	competitive	competitive	ADJ
ihlr-25462	403	103	]	]	PUNCT
ihlr-25462	403	104	behaviors	behavior	NOUN
ihlr-25462	403	105	by	by	ADP
ihlr-25462	403	106	drug	drug	NOUN
ihlr-25462	403	107	product	product	NOUN
ihlr-25462	403	108	manufacturers	manufacturer	NOUN
ihlr-25462	403	109	,	,	PUNCT
ihlr-25462	403	110	and	and	CCONJ
ihlr-25462	403	111	for	for	ADP
ihlr-25462	403	112	other	other	ADJ
ihlr-25462	403	113	purposes	purpose	NOUN
ihlr-25462	403	114	.	.	PUNCT
ihlr-25462	403	115	”147	”147	PROPN
ihlr-25462	404	1	also	also	ADV
ihlr-25462	404	2	,	,	PUNCT
ihlr-25462	404	3	it	it	PRON
ihlr-25462	404	4	specifically	specifically	ADV
ihlr-25462	404	5	prohibits	prohibit	VERB
ihlr-25462	404	6	product	product	NOUN
ihlr-25462	404	7	hopping.148	hopping.148	NOUN
ihlr-25462	404	8	the	the	DET
ihlr-25462	404	9	most	most	ADV
ihlr-25462	404	10	common	common	ADJ
ihlr-25462	404	11	tool	tool	NOUN
ihlr-25462	404	12	to	to	PART
ihlr-25462	404	13	combat	combat	NOUN
ihlr-25462	404	14	product	product	NOUN
ihlr-25462	404	15	hopping	hopping	NOUN
ihlr-25462	404	16	has	have	AUX
ihlr-25462	404	17	been	be	AUX
ihlr-25462	404	18	to	to	PART
ihlr-25462	404	19	sue	sue	VERB
ihlr-25462	404	20	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	404	21	manufacturers	manufacturer	NOUN
ihlr-25462	404	22	under	under	ADP
ihlr-25462	404	23	antitrust	antitrust	ADJ
ihlr-25462	404	24	laws.149	laws.149	NOUN
ihlr-25462	404	25	on	on	ADP
ihlr-25462	404	26	the	the	DET
ihlr-25462	404	27	other	other	ADJ
ihlr-25462	404	28	hand	hand	NOUN
ihlr-25462	404	29	,	,	PUNCT
ihlr-25462	404	30	because	because	SCONJ
ihlr-25462	404	31	product	product	NOUN
ihlr-25462	404	32	hopping	hop	VERB
ihlr-25462	404	33	nearly	nearly	ADV
ihlr-25462	404	34	always	always	ADV
ihlr-25462	404	35	involves	involve	VERB
ihlr-25462	404	36	medication	medication	NOUN
ihlr-25462	404	37	improvements	improvement	NOUN
ihlr-25462	404	38	with	with	ADP
ihlr-25462	404	39	benefits	benefit	NOUN
ihlr-25462	404	40	to	to	ADP
ihlr-25462	404	41	patients	patient	NOUN
ihlr-25462	404	42	,	,	PUNCT
ihlr-25462	404	43	some	some	PRON
ihlr-25462	404	44	argue	argue	VERB
ihlr-25462	404	45	that	that	SCONJ
ihlr-25462	404	46	it	it	PRON
ihlr-25462	404	47	should	should	AUX
ihlr-25462	404	48	be	be	AUX
ihlr-25462	404	49	generally	generally	ADV
ihlr-25462	404	50	viewed	view	VERB
ihlr-25462	404	51	as	as	ADP
ihlr-25462	404	52	lawful	lawful	ADJ
ihlr-25462	404	53	because	because	SCONJ
ihlr-25462	404	54	anything	anything	PRON
ihlr-25462	404	55	else	else	ADV
ihlr-25462	404	56	would	would	AUX
ihlr-25462	404	57	chill	chill	VERB
ihlr-25462	404	58	innovation.150	innovation.150	ADV
ihlr-25462	404	59	whether	whether	SCONJ
ihlr-25462	404	60	and	and	CCONJ
ihlr-25462	404	61	how	how	SCONJ
ihlr-25462	404	62	this	this	DET
ihlr-25462	404	63	trade	trade	NOUN
ihlr-25462	404	64	-	-	PUNCT
ihlr-25462	404	65	off	off	NOUN
ihlr-25462	404	66	should	should	AUX
ihlr-25462	404	67	be	be	AUX
ihlr-25462	404	68	managed	manage	VERB
ihlr-25462	404	69	as	as	ADP
ihlr-25462	404	70	a	a	DET
ihlr-25462	404	71	matter	matter	NOUN
ihlr-25462	404	72	of	of	ADP
ihlr-25462	404	73	regulatory	regulatory	ADJ
ihlr-25462	404	74	or	or	CCONJ
ihlr-25462	404	75	competition	competition	NOUN
ihlr-25462	404	76	policy	policy	NOUN
ihlr-25462	404	77	is	be	AUX
ihlr-25462	404	78	an	an	DET
ihlr-25462	404	79	important	important	ADJ
ihlr-25462	404	80	question	question	NOUN
ihlr-25462	404	81	that	that	PRON
ihlr-25462	404	82	has	have	VERB
ihlr-25462	404	83	yet	yet	ADV
ihlr-25462	404	84	to	to	PART
ihlr-25462	404	85	be	be	AUX
ihlr-25462	404	86	adequately	adequately	ADV
ihlr-25462	404	87	resolved	resolve	VERB
ihlr-25462	404	88	.	.	PUNCT
ihlr-25462	405	1	141	141	NUM
ihlr-25462	405	2	.	.	PUNCT
ihlr-25462	405	3	carrier	carrier	NOUN
ihlr-25462	405	4	&	&	CCONJ
ihlr-25462	405	5	shadowen	shadowen	PROPN
ihlr-25462	405	6	,	,	PUNCT
ihlr-25462	405	7	supra	supra	PROPN
ihlr-25462	405	8	note	note	PROPN
ihlr-25462	405	9	128	128	NUM
ihlr-25462	405	10	,	,	PUNCT
ihlr-25462	405	11	at	at	ADP
ihlr-25462	405	12	179	179	NUM
ihlr-25462	405	13	.	.	PUNCT
ihlr-25462	405	14	142	142	NUM
ihlr-25462	405	15	.	.	PUNCT
ihlr-25462	406	1	in	in	ADP
ihlr-25462	406	2	re	re	PROPN
ihlr-25462	406	3	suboxone	suboxone	NOUN
ihlr-25462	406	4	(	(	PUNCT
ihlr-25462	406	5	buprenorphine	buprenorphine	VERB
ihlr-25462	406	6	hydrochloride	hydrochloride	NOUN
ihlr-25462	406	7	and	and	CCONJ
ihlr-25462	406	8	naloxone	naloxone	NOUN
ihlr-25462	406	9	)	)	PUNCT
ihlr-25462	406	10	antitrust	antitrust	ADJ
ihlr-25462	406	11	litig	litig	NOUN
ihlr-25462	406	12	.	.	PUNCT
ihlr-25462	407	1	,	,	PUNCT
ihlr-25462	407	2	64	64	NUM
ihlr-25462	407	3	f.	f.	PROPN
ihlr-25462	407	4	supp	supp	PROPN
ihlr-25462	407	5	.	.	PUNCT
ihlr-25462	408	1	3d	3d	NUM
ihlr-25462	408	2	665	665	NUM
ihlr-25462	408	3	,	,	PUNCT
ihlr-25462	408	4	684	684	NUM
ihlr-25462	408	5	(	(	PUNCT
ihlr-25462	408	6	e.d	e.d	PROPN
ihlr-25462	408	7	.	.	PROPN
ihlr-25462	408	8	pa	pa	PROPN
ihlr-25462	408	9	.	.	PROPN
ihlr-25462	408	10	2014	2014	NUM
ihlr-25462	408	11	)	)	PUNCT
ihlr-25462	408	12	.	.	PUNCT
ihlr-25462	409	1	143	143	X
ihlr-25462	409	2	.	.	PUNCT
ihlr-25462	410	1	i	i	PRON
ihlr-25462	410	2	d.	d.	PROPN
ihlr-25462	410	3	144	144	NUM
ihlr-25462	410	4	.	.	PUNCT
ihlr-25462	411	1	affordable	affordable	ADJ
ihlr-25462	411	2	prescriptions	prescription	NOUN
ihlr-25462	411	3	for	for	ADP
ihlr-25462	411	4	patients	patient	NOUN
ihlr-25462	411	5	act	act	AUX
ihlr-25462	411	6	introduced	introduce	VERB
ihlr-25462	411	7	in	in	ADP
ihlr-25462	411	8	the	the	DET
ihlr-25462	411	9	senate	senate	PROPN
ihlr-25462	411	10	,	,	PUNCT
ihlr-25462	411	11	goodwin	goodwin	PROPN
ihlr-25462	411	12	l.	l.	PROPN
ihlr-25462	411	13	(	(	PUNCT
ihlr-25462	411	14	may	may	PROPN
ihlr-25462	411	15	15	15	NUM
ihlr-25462	411	16	,	,	PUNCT
ihlr-25462	411	17	2019	2019	NUM
ihlr-25462	411	18	)	)	PUNCT
ihlr-25462	411	19	,	,	PUNCT
ihlr-25462	411	20	https://www.goodwinlaw.com/publications/2019/05/affordable-prescriptions-forpatients-act-introduc	https://www.goodwinlaw.com/publications/2019/05/affordable-prescriptions-forpatients-act-introduc	PROPN
ihlr-25462	412	1	[	[	X
ihlr-25462	412	2	https://perma.cc/zm4a-wgjf	https://perma.cc/zm4a-wgjf	X
ihlr-25462	412	3	]	]	PUNCT
ihlr-25462	412	4	.	.	PUNCT
ihlr-25462	413	1	145	145	NUM
ihlr-25462	413	2	.	.	PUNCT
ihlr-25462	414	1	i	i	PRON
ihlr-25462	414	2	d.	d.	PROPN
ihlr-25462	414	3	146	146	NUM
ihlr-25462	414	4	.	.	PUNCT
ihlr-25462	415	1	cicilline	cicilline	NOUN
ihlr-25462	415	2	introduces	introduce	NOUN
ihlr-25462	415	3	bill	bill	NOUN
ihlr-25462	415	4	to	to	PART
ihlr-25462	415	5	drive	drive	VERB
ihlr-25462	415	6	down	down	ADP
ihlr-25462	415	7	costs	cost	NOUN
ihlr-25462	415	8	of	of	ADP
ihlr-25462	415	9	prescription	prescription	NOUN
ihlr-25462	415	10	drugs	drug	NOUN
ihlr-25462	415	11	,	,	PUNCT
ihlr-25462	415	12	congressman	congressman	PROPN
ihlr-25462	415	13	david	david	PROPN
ihlr-25462	415	14	cicilline	cicilline	PROPN
ihlr-25462	415	15	(	(	PUNCT
ihlr-25462	415	16	sept	sept	PROPN
ihlr-25462	415	17	.	.	PROPN
ihlr-25462	415	18	19	19	NUM
ihlr-25462	415	19	,	,	PUNCT
ihlr-25462	415	20	2019	2019	NUM
ihlr-25462	415	21	)	)	PUNCT
ihlr-25462	415	22	,	,	PUNCT
ihlr-25462	415	23	https://cicilline.house.gov/press-release/cicilline-introduces-billdrive-down-costs-prescription-drugs	https://cicilline.house.gov/press-release/cicilline-introduces-billdrive-down-costs-prescription-drug	VERB
ihlr-25462	415	24	[	[	X
ihlr-25462	415	25	https://perma	https://perma	NOUN
ihlr-25462	415	26	/	/	SYM
ihlr-25462	415	27	h7nh	h7nh	NOUN
ihlr-25462	415	28	-	-	NOUN
ihlr-25462	415	29	lwta	lwta	NOUN
ihlr-25462	415	30	]	]	PUNCT
ihlr-25462	415	31	.	.	PUNCT
ihlr-25462	416	1	147	147	NUM
ihlr-25462	416	2	.	.	PUNCT
ihlr-25462	417	1	see	see	VERB
ihlr-25462	417	2	h.r	h.r	PROPN
ihlr-25462	417	3	.	.	PROPN
ihlr-25462	417	4	4398	4398	NUM
ihlr-25462	417	5	,	,	PUNCT
ihlr-25462	417	6	116th	116th	PROPN
ihlr-25462	417	7	cong	cong	NOUN
ihlr-25462	417	8	.	.	PUNCT
ihlr-25462	418	1	(	(	PUNCT
ihlr-25462	418	2	2019	2019	NUM
ihlr-25462	418	3	)	)	PUNCT
ihlr-25462	418	4	.	.	PUNCT
ihlr-25462	419	1	148	148	NUM
ihlr-25462	419	2	.	.	PUNCT
ihlr-25462	420	1	i	i	PRON
ihlr-25462	420	2	d.	d.	PROPN
ihlr-25462	420	3	149	149	NUM
ihlr-25462	420	4	.	.	PUNCT
ihlr-25462	420	5	arti	arti	PROPN
ihlr-25462	420	6	k.	k.	PROPN
ihlr-25462	420	7	rai	rai	PROPN
ihlr-25462	420	8	&	&	CCONJ
ihlr-25462	420	9	barak	barak	PROPN
ihlr-25462	420	10	d.	d.	PROPN
ihlr-25462	420	11	richman	richman	PROPN
ihlr-25462	420	12	,	,	PUNCT
ihlr-25462	420	13	a	a	DET
ihlr-25462	420	14	preferable	preferable	ADJ
ihlr-25462	420	15	path	path	NOUN
ihlr-25462	420	16	for	for	ADP
ihlr-25462	420	17	thwarting	thwart	VERB
ihlr-25462	420	18	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	420	19	product	product	NOUN
ihlr-25462	420	20	hopping	hopping	NOUN
ihlr-25462	420	21	,	,	PUNCT
ihlr-25462	420	22	health	health	NOUN
ihlr-25462	420	23	aff	aff	PROPN
ihlr-25462	420	24	.	.	PUNCT
ihlr-25462	421	1	(	(	PUNCT
ihlr-25462	421	2	may	may	PROPN
ihlr-25462	421	3	22	22	NUM
ihlr-25462	421	4	,	,	PUNCT
ihlr-25462	421	5	2018	2018	NUM
ihlr-25462	421	6	)	)	PUNCT
ihlr-25462	421	7	,	,	PUNCT
ihlr-25462	421	8	https://www.healthaffairs.org/do/10.1377/	https://www.healthaffairs.org/do/10.1377/	ADV
ihlr-25462	421	9	hblog20180522.408497	hblog20180522.408497	NOUN
ihlr-25462	421	10	/	/	SYM
ihlr-25462	421	11	full/	full/	NUM
ihlr-25462	422	1	[	[	X
ihlr-25462	422	2	https://perma.cc/3vpu-4xeh	https://perma.cc/3vpu-4xeh	X
ihlr-25462	422	3	]	]	X
ihlr-25462	422	4	.	.	PUNCT
ihlr-25462	423	1	150	150	NUM
ihlr-25462	423	2	.	.	PUNCT
ihlr-25462	423	3	carrier	carrier	NOUN
ihlr-25462	423	4	&	&	CCONJ
ihlr-25462	423	5	shadowen	shadowen	PROPN
ihlr-25462	423	6	,	,	PUNCT
ihlr-25462	423	7	supra	supra	PROPN
ihlr-25462	423	8	note	note	PROPN
ihlr-25462	423	9	128	128	NUM
ihlr-25462	423	10	,	,	PUNCT
ihlr-25462	423	11	at	at	ADP
ihlr-25462	423	12	200	200	NUM
ihlr-25462	423	13	.	.	NOUN
ihlr-25462	423	14	2021	2021	NUM
ihlr-25462	423	15	]	]	PUNCT
ihlr-25462	423	16	a	a	DET
ihlr-25462	423	17	survey	survey	NOUN
ihlr-25462	423	18	of	of	ADP
ihlr-25462	423	19	three	three	NUM
ihlr-25462	423	20	patent	patent	NOUN
ihlr-25462	423	21	-	-	PUNCT
ihlr-25462	423	22	based	base	VERB
ihlr-25462	423	23	approaches	approach	NOUN
ihlr-25462	423	24	415	415	NUM
ihlr-25462	423	25	v.	v.	ADP
ihlr-25462	423	26	conclusion	conclusion	NOUN
ihlr-25462	423	27	there	there	PRON
ihlr-25462	423	28	are	be	VERB
ihlr-25462	423	29	several	several	ADJ
ihlr-25462	423	30	proposed	propose	VERB
ihlr-25462	423	31	congressional	congressional	ADJ
ihlr-25462	423	32	reforms	reform	NOUN
ihlr-25462	423	33	to	to	PART
ihlr-25462	423	34	address	address	VERB
ihlr-25462	423	35	drug	drug	NOUN
ihlr-25462	423	36	prices	price	NOUN
ihlr-25462	423	37	that	that	PRON
ihlr-25462	423	38	would	would	AUX
ihlr-25462	423	39	modify	modify	VERB
ihlr-25462	423	40	the	the	DET
ihlr-25462	423	41	existing	exist	VERB
ihlr-25462	423	42	legal	legal	ADJ
ihlr-25462	423	43	structure	structure	NOUN
ihlr-25462	423	44	of	of	ADP
ihlr-25462	423	45	ip	ip	DET
ihlr-25462	423	46	rights	right	NOUN
ihlr-25462	423	47	in	in	ADP
ihlr-25462	423	48	the	the	DET
ihlr-25462	423	49	context	context	NOUN
ihlr-25462	423	50	of	of	ADP
ihlr-25462	423	51	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	423	52	drugs.151	drugs.151	NOUN
ihlr-25462	423	53	because	because	SCONJ
ihlr-25462	423	54	patents	patent	NOUN
ihlr-25462	423	55	provide	provide	VERB
ihlr-25462	423	56	incentives	incentive	NOUN
ihlr-25462	423	57	for	for	ADP
ihlr-25462	423	58	innovation	innovation	NOUN
ihlr-25462	423	59	,	,	PUNCT
ihlr-25462	423	60	ip	ip	PRON
ihlr-25462	423	61	reforms	reform	NOUN
ihlr-25462	423	62	are	be	AUX
ihlr-25462	423	63	a	a	DET
ihlr-25462	423	64	matter	matter	NOUN
ihlr-25462	423	65	of	of	ADP
ihlr-25462	423	66	public	public	ADJ
ihlr-25462	423	67	policy	policy	NOUN
ihlr-25462	423	68	that	that	PRON
ihlr-25462	423	69	must	must	AUX
ihlr-25462	423	70	find	find	VERB
ihlr-25462	423	71	a	a	DET
ihlr-25462	423	72	“	"	PUNCT
ihlr-25462	423	73	balance	balance	NOUN
ihlr-25462	423	74	between	between	ADP
ihlr-25462	423	75	providing	provide	VERB
ihlr-25462	423	76	incentives	incentive	NOUN
ihlr-25462	423	77	to	to	PART
ihlr-25462	423	78	create	create	VERB
ihlr-25462	423	79	innovative	innovative	ADJ
ihlr-25462	423	80	new	new	ADJ
ihlr-25462	423	81	medicines	medicine	NOUN
ihlr-25462	423	82	versus	versus	ADP
ihlr-25462	423	83	the	the	DET
ihlr-25462	423	84	costs	cost	NOUN
ihlr-25462	423	85	those	those	DET
ihlr-25462	423	86	incentives	incentive	NOUN
ihlr-25462	423	87	may	may	AUX
ihlr-25462	423	88	impose	impose	VERB
ihlr-25462	423	89	on	on	ADP
ihlr-25462	423	90	the	the	DET
ihlr-25462	423	91	public	public	NOUN
ihlr-25462	423	92	.	.	PUNCT
ihlr-25462	424	1	”152	”152	VERB
ihlr-25462	424	2	the	the	DET
ihlr-25462	424	3	costs	cost	NOUN
ihlr-25462	424	4	associated	associate	VERB
ihlr-25462	424	5	with	with	ADP
ihlr-25462	424	6	developing	develop	VERB
ihlr-25462	424	7	a	a	DET
ihlr-25462	424	8	new	new	ADJ
ihlr-25462	424	9	prescription	prescription	NOUN
ihlr-25462	424	10	drug	drug	NOUN
ihlr-25462	424	11	are	be	AUX
ihlr-25462	424	12	enormous	enormous	ADJ
ihlr-25462	424	13	,	,	PUNCT
ihlr-25462	424	14	with	with	ADP
ihlr-25462	424	15	conservative	conservative	ADJ
ihlr-25462	424	16	estimates	estimate	NOUN
ihlr-25462	424	17	of	of	ADP
ihlr-25462	424	18	the	the	DET
ihlr-25462	424	19	cost	cost	NOUN
ihlr-25462	424	20	to	to	PART
ihlr-25462	424	21	develop	develop	VERB
ihlr-25462	424	22	a	a	DET
ihlr-25462	424	23	new	new	ADJ
ihlr-25462	424	24	medicine	medicine	NOUN
ihlr-25462	424	25	estimated	estimate	VERB
ihlr-25462	424	26	to	to	PART
ihlr-25462	424	27	be	be	AUX
ihlr-25462	424	28	somewhere	somewhere	ADV
ihlr-25462	424	29	between	between	ADP
ihlr-25462	424	30	$	$	SYM
ihlr-25462	424	31	500	500	NUM
ihlr-25462	424	32	million	million	NUM
ihlr-25462	424	33	to	to	PART
ihlr-25462	424	34	$	$	SYM
ihlr-25462	424	35	1	1	NUM
ihlr-25462	424	36	billion.153	billion.153	VERB
ihlr-25462	424	37	therefore	therefore	ADV
ihlr-25462	424	38	,	,	PUNCT
ihlr-25462	424	39	the	the	DET
ihlr-25462	424	40	patent	patent	NOUN
ihlr-25462	424	41	exclusivity	exclusivity	NOUN
ihlr-25462	424	42	that	that	SCONJ
ihlr-25462	424	43	the	the	DET
ihlr-25462	424	44	pharmaceutical	pharmaceutical	ADJ
ihlr-25462	424	45	manufacturer	manufacturer	NOUN
ihlr-25462	424	46	receives	receive	VERB
ihlr-25462	424	47	,	,	PUNCT
ihlr-25462	424	48	which	which	PRON
ihlr-25462	424	49	is	be	AUX
ihlr-25462	424	50	twenty	twenty	NUM
ihlr-25462	424	51	years	year	NOUN
ihlr-25462	424	52	from	from	ADP
ihlr-25462	424	53	the	the	DET
ihlr-25462	424	54	date	date	NOUN
ihlr-25462	424	55	on	on	ADP
ihlr-25462	424	56	which	which	PRON
ihlr-25462	424	57	the	the	DET
ihlr-25462	424	58	application	application	NOUN
ihlr-25462	424	59	for	for	ADP
ihlr-25462	424	60	the	the	DET
ihlr-25462	424	61	patent	patent	NOUN
ihlr-25462	424	62	was	be	AUX
ihlr-25462	424	63	filed	file	VERB
ihlr-25462	424	64	,	,	PUNCT
ihlr-25462	424	65	is	be	AUX
ihlr-25462	424	66	a	a	DET
ihlr-25462	424	67	valuable	valuable	ADJ
ihlr-25462	424	68	incentive.154	incentive.154	NOUN
ihlr-25462	424	69	however	however	ADV
ihlr-25462	424	70	,	,	PUNCT
ihlr-25462	424	71	that	that	PRON
ihlr-25462	424	72	sounds	sound	VERB
ihlr-25462	424	73	better	well	ADV
ihlr-25462	424	74	than	than	SCONJ
ihlr-25462	424	75	it	it	PRON
ihlr-25462	424	76	is	be	AUX
ihlr-25462	424	77	.	.	PUNCT
ihlr-25462	425	1	in	in	ADP
ihlr-25462	425	2	actuality	actuality	NOUN
ihlr-25462	425	3	,	,	PUNCT
ihlr-25462	425	4	by	by	ADP
ihlr-25462	425	5	the	the	DET
ihlr-25462	425	6	time	time	NOUN
ihlr-25462	425	7	most	most	ADJ
ihlr-25462	425	8	new	new	ADJ
ihlr-25462	425	9	drugs	drug	NOUN
ihlr-25462	425	10	are	be	AUX
ihlr-25462	425	11	approved	approve	VERB
ihlr-25462	425	12	,	,	PUNCT
ihlr-25462	425	13	the	the	DET
ihlr-25462	425	14	patents	patent	NOUN
ihlr-25462	425	15	covering	cover	VERB
ihlr-25462	425	16	the	the	DET
ihlr-25462	425	17	medicine	medicine	NOUN
ihlr-25462	425	18	often	often	ADV
ihlr-25462	425	19	have	have	VERB
ihlr-25462	425	20	less	less	ADJ
ihlr-25462	425	21	than	than	ADP
ihlr-25462	425	22	twelve	twelve	NUM
ihlr-25462	425	23	years	year	NOUN
ihlr-25462	425	24	remaining	remain	VERB
ihlr-25462	425	25	of	of	ADP
ihlr-25462	425	26	the	the	DET
ihlr-25462	425	27	patent	patent	NOUN
ihlr-25462	425	28	term	term	NOUN
ihlr-25462	425	29	“	"	PUNCT
ihlr-25462	425	30	due	due	ADP
ihlr-25462	425	31	to	to	ADP
ihlr-25462	425	32	the	the	DET
ihlr-25462	425	33	years	year	NOUN
ihlr-25462	425	34	required	require	VERB
ihlr-25462	425	35	for	for	ADP
ihlr-25462	425	36	development	development	NOUN
ihlr-25462	425	37	,	,	PUNCT
ihlr-25462	425	38	clinical	clinical	ADJ
ihlr-25462	425	39	studies	study	NOUN
ihlr-25462	425	40	,	,	PUNCT
ihlr-25462	425	41	and	and	CCONJ
ihlr-25462	425	42	regulatory	regulatory	ADJ
ihlr-25462	425	43	review	review	NOUN
ihlr-25462	425	44	.	.	PUNCT
ihlr-25462	425	45	”155	”155	PUNCT
ihlr-25462	426	1	despite	despite	SCONJ
ihlr-25462	426	2	this	this	PRON
ihlr-25462	426	3	,	,	PUNCT
ihlr-25462	426	4	many	many	ADJ
ihlr-25462	426	5	people	people	NOUN
ihlr-25462	426	6	feel	feel	VERB
ihlr-25462	426	7	that	that	SCONJ
ihlr-25462	426	8	their	their	PRON
ihlr-25462	426	9	prescription	prescription	NOUN
ihlr-25462	426	10	drug	drug	NOUN
ihlr-25462	426	11	prices	price	NOUN
ihlr-25462	426	12	are	be	AUX
ihlr-25462	426	13	too	too	ADV
ihlr-25462	426	14	high	high	ADJ
ihlr-25462	426	15	,	,	PUNCT
ihlr-25462	426	16	with	with	ADP
ihlr-25462	426	17	one	one	NUM
ihlr-25462	426	18	survey	survey	NOUN
ihlr-25462	426	19	finding	find	VERB
ihlr-25462	426	20	that	that	SCONJ
ihlr-25462	426	21	nearly	nearly	ADV
ihlr-25462	426	22	23	23	NUM
ihlr-25462	426	23	%	%	NOUN
ihlr-25462	426	24	of	of	ADP
ihlr-25462	426	25	americans	americans	PROPN
ihlr-25462	426	26	have	have	AUX
ihlr-25462	426	27	been	be	AUX
ihlr-25462	426	28	unable	unable	ADJ
ihlr-25462	426	29	to	to	PART
ihlr-25462	426	30	afford	afford	VERB
ihlr-25462	426	31	their	their	PRON
ihlr-25462	426	32	medications	medication	NOUN
ihlr-25462	426	33	in	in	ADP
ihlr-25462	426	34	the	the	DET
ihlr-25462	426	35	past	past	ADJ
ihlr-25462	426	36	year.156	year.156	PROPN
ihlr-25462	426	37	a.	a.	NOUN
ihlr-25462	426	38	patent	patent	NOUN
ihlr-25462	426	39	exhaustion	exhaustion	NOUN
ihlr-25462	426	40	the	the	DET
ihlr-25462	426	41	development	development	NOUN
ihlr-25462	426	42	of	of	ADP
ihlr-25462	426	43	an	an	DET
ihlr-25462	426	44	exhaustion	exhaustion	NOUN
ihlr-25462	426	45	doctrine	doctrine	NOUN
ihlr-25462	426	46	forces	force	NOUN
ihlr-25462	426	47	policymakers	policymaker	NOUN
ihlr-25462	426	48	to	to	PART
ihlr-25462	426	49	seek	seek	VERB
ihlr-25462	426	50	a	a	DET
ihlr-25462	426	51	balance	balance	NOUN
ihlr-25462	426	52	between	between	ADP
ihlr-25462	426	53	protecting	protect	VERB
ihlr-25462	426	54	consumer	consumer	NOUN
ihlr-25462	426	55	well	well	ADV
ihlr-25462	426	56	-	-	PUNCT
ihlr-25462	426	57	being	being	NOUN
ihlr-25462	426	58	and	and	CCONJ
ihlr-25462	426	59	providing	provide	VERB
ihlr-25462	426	60	economic	economic	ADJ
ihlr-25462	426	61	incentives	incentive	NOUN
ihlr-25462	426	62	for	for	ADP
ihlr-25462	426	63	innovators	innovator	NOUN
ihlr-25462	426	64	.	.	PUNCT
ihlr-25462	427	1	while	while	SCONJ
ihlr-25462	427	2	a	a	DET
ihlr-25462	427	3	strong	strong	ADJ
ihlr-25462	427	4	exhaustion	exhaustion	NOUN
ihlr-25462	427	5	doctrine	doctrine	NOUN
ihlr-25462	427	6	,	,	PUNCT
ihlr-25462	427	7	as	as	SCONJ
ihlr-25462	427	8	proposed	propose	VERB
ihlr-25462	427	9	in	in	ADP
ihlr-25462	427	10	lexmark	lexmark	NOUN
ihlr-25462	427	11	,	,	PUNCT
ihlr-25462	427	12	empowers	empower	VERB
ihlr-25462	427	13	consumers	consumer	NOUN
ihlr-25462	427	14	and	and	CCONJ
ihlr-25462	427	15	limits	limit	VERB
ihlr-25462	427	16	the	the	DET
ihlr-25462	427	17	ability	ability	NOUN
ihlr-25462	427	18	of	of	ADP
ihlr-25462	427	19	patent	patent	NOUN
ihlr-25462	427	20	owners	owner	NOUN
ihlr-25462	427	21	to	to	PART
ihlr-25462	427	22	control	control	VERB
ihlr-25462	427	23	the	the	DET
ihlr-25462	427	24	post	post	ADJ
ihlr-25462	427	25	-	-	ADJ
ihlr-25462	427	26	sale	sale	ADJ
ihlr-25462	427	27	conduct	conduct	NOUN
ihlr-25462	427	28	of	of	ADP
ihlr-25462	427	29	purchasers	purchaser	NOUN
ihlr-25462	427	30	,	,	PUNCT
ihlr-25462	427	31	it	it	PRON
ihlr-25462	427	32	also	also	ADV
ihlr-25462	427	33	can	can	AUX
ihlr-25462	427	34	have	have	VERB
ihlr-25462	427	35	the	the	DET
ihlr-25462	427	36	effect	effect	NOUN
ihlr-25462	427	37	of	of	ADP
ihlr-25462	427	38	deterring	deter	VERB
ihlr-25462	427	39	innovation	innovation	NOUN
ihlr-25462	427	40	,	,	PUNCT
ihlr-25462	427	41	as	as	SCONJ
ihlr-25462	427	42	a	a	DET
ihlr-25462	427	43	patent	patent	NOUN
ihlr-25462	427	44	owner	owner	NOUN
ihlr-25462	427	45	may	may	AUX
ihlr-25462	427	46	not	not	PART
ihlr-25462	427	47	“	"	PUNCT
ihlr-25462	427	48	reap	reap	VERB
ihlr-25462	427	49	the	the	DET
ihlr-25462	427	50	expected	expect	VERB
ihlr-25462	427	51	fruits	fruit	NOUN
ihlr-25462	427	52	of	of	ADP
ihlr-25462	427	53	his	his	PRON
ihlr-25462	427	54	or	or	CCONJ
ihlr-25462	427	55	her	her	PRON
ihlr-25462	427	56	labor	labor	NOUN
ihlr-25462	427	57	.	.	PUNCT
ihlr-25462	427	58	”157	”157	PROPN
ihlr-25462	427	59	while	while	SCONJ
ihlr-25462	427	60	blogs	blog	NOUN
ihlr-25462	427	61	,	,	PUNCT
ihlr-25462	427	62	scholars	scholar	NOUN
ihlr-25462	427	63	,	,	PUNCT
ihlr-25462	427	64	and	and	CCONJ
ihlr-25462	427	65	courts	court	NOUN
ihlr-25462	427	66	have	have	AUX
ihlr-25462	427	67	weighed	weigh	VERB
ihlr-25462	427	68	in	in	ADP
ihlr-25462	427	69	on	on	ADP
ihlr-25462	427	70	the	the	DET
ihlr-25462	427	71	doctrine	doctrine	NOUN
ihlr-25462	427	72	,	,	PUNCT
ihlr-25462	427	73	the	the	DET
ihlr-25462	427	74	reality	reality	NOUN
ihlr-25462	427	75	is	be	AUX
ihlr-25462	427	76	that	that	SCONJ
ihlr-25462	427	77	,	,	PUNCT
ihlr-25462	427	78	at	at	ADP
ihlr-25462	427	79	the	the	DET
ihlr-25462	427	80	current	current	ADJ
ihlr-25462	427	81	time	time	NOUN
ihlr-25462	427	82	,	,	PUNCT
ihlr-25462	427	83	“	"	PUNCT
ihlr-25462	427	84	the	the	DET
ihlr-25462	427	85	impact	impact	NOUN
ihlr-25462	427	86	of	of	ADP
ihlr-25462	427	87	re	re	NOUN
ihlr-25462	427	88	-	-	NOUN
ihlr-25462	427	89	importation	importation	NOUN
ihlr-25462	427	90	is	be	AUX
ihlr-25462	427	91	not	not	PART
ihlr-25462	427	92	clear	clear	ADJ
ihlr-25462	427	93	cut	cut	VERB
ihlr-25462	427	94	enough	enough	ADV
ihlr-25462	427	95	to	to	PART
ihlr-25462	427	96	confidently	confidently	ADV
ihlr-25462	427	97	make	make	VERB
ihlr-25462	427	98	policy	policy	NOUN
ihlr-25462	427	99	recommendations	recommendation	NOUN
ihlr-25462	427	100	on	on	ADP
ihlr-25462	427	101	economic	economic	ADJ
ihlr-25462	427	102	grounds	ground	NOUN
ihlr-25462	427	103	.	.	PUNCT
ihlr-25462	428	1	”158	”158	PUNCT
ihlr-25462	428	2	therefore	therefore	ADV
ihlr-25462	428	3	,	,	PUNCT
ihlr-25462	428	4	only	only	ADV
ihlr-25462	428	5	time	time	NOUN
ihlr-25462	428	6	will	will	AUX
ihlr-25462	428	7	tell	tell	VERB
ihlr-25462	428	8	how	how	SCONJ
ihlr-25462	428	9	the	the	DET
ihlr-25462	428	10	impact	impact	NOUN
ihlr-25462	428	11	of	of	ADP
ihlr-25462	428	12	the	the	DET
ihlr-25462	428	13	lexmark	lexmark	NOUN
ihlr-25462	428	14	decision	decision	NOUN
ihlr-25462	428	15	,	,	PUNCT
ihlr-25462	428	16	coupled	couple	VERB
ihlr-25462	428	17	with	with	ADP
ihlr-25462	428	18	the	the	DET
ihlr-25462	428	19	“	"	PUNCT
ihlr-25462	428	20	safe	safe	ADJ
ihlr-25462	428	21	importation	importation	NOUN
ihlr-25462	428	22	action	action	NOUN
ihlr-25462	428	23	plan	plan	NOUN
ihlr-25462	428	24	”	"	PUNCT
ihlr-25462	428	25	and	and	CCONJ
ihlr-25462	428	26	the	the	DET
ihlr-25462	428	27	behaviors	behavior	NOUN
ihlr-25462	428	28	of	of	ADP
ihlr-25462	428	29	motivated	motivated	ADJ
ihlr-25462	428	30	actors	actor	NOUN
ihlr-25462	428	31	,	,	PUNCT
ihlr-25462	428	32	may	may	AUX
ihlr-25462	428	33	affect	affect	VERB
ihlr-25462	428	34	drug	drug	NOUN
ihlr-25462	428	35	prices	price	NOUN
ihlr-25462	428	36	.	.	PUNCT
ihlr-25462	429	1	151	151	NUM
ihlr-25462	429	2	.	.	PUNCT
ihlr-25462	429	3	hickey	hickey	PROPN
ihlr-25462	429	4	et	et	PROPN
ihlr-25462	429	5	al	al	PROPN
ihlr-25462	429	6	.	.	PROPN
ihlr-25462	429	7	,	,	PUNCT
ihlr-25462	429	8	supra	supra	PROPN
ihlr-25462	429	9	note	note	NOUN
ihlr-25462	429	10	2	2	NUM
ihlr-25462	429	11	,	,	PUNCT
ihlr-25462	429	12	at	at	ADP
ihlr-25462	429	13	4	4	NUM
ihlr-25462	429	14	.	.	NOUN
ihlr-25462	429	15	152	152	NUM
ihlr-25462	429	16	.	.	PUNCT
ihlr-25462	430	1	i	i	PRON
ihlr-25462	430	2	d.	d.	PROPN
ihlr-25462	430	3	at	at	ADP
ihlr-25462	430	4	51	51	NUM
ihlr-25462	430	5	.	.	NOUN
ihlr-25462	430	6	153	153	NUM
ihlr-25462	430	7	.	.	PUNCT
ihlr-25462	431	1	o’connor	o’connor	ADV
ihlr-25462	431	2	,	,	PUNCT
ihlr-25462	431	3	supra	supra	PROPN
ihlr-25462	431	4	note	note	NOUN
ihlr-25462	431	5	6	6	NUM
ihlr-25462	431	6	.	.	NOUN
ihlr-25462	431	7	154	154	NUM
ihlr-25462	431	8	.	.	PUNCT
ihlr-25462	432	1	i	i	PRON
ihlr-25462	432	2	d.	d.	PROPN
ihlr-25462	432	3	155	155	NUM
ihlr-25462	432	4	.	.	PUNCT
ihlr-25462	433	1	i	i	PRON
ihlr-25462	433	2	d.	d.	PROPN
ihlr-25462	433	3	156	156	NUM
ihlr-25462	433	4	.	.	PUNCT
ihlr-25462	434	1	dan	dan	PROPN
ihlr-25462	434	2	witters	witters	PROPN
ihlr-25462	434	3	,	,	PUNCT
ihlr-25462	434	4	millions	million	NOUN
ihlr-25462	434	5	in	in	ADP
ihlr-25462	434	6	u.s	u.s	PROPN
ihlr-25462	434	7	.	.	PROPN
ihlr-25462	434	8	lost	lose	VERB
ihlr-25462	434	9	someone	someone	PRON
ihlr-25462	434	10	who	who	PRON
ihlr-25462	434	11	could	could	AUX
ihlr-25462	434	12	n’t	not	PART
ihlr-25462	434	13	afford	afford	VERB
ihlr-25462	434	14	treatment	treatment	NOUN
ihlr-25462	434	15	,	,	PUNCT
ihlr-25462	434	16	gallup	gallup	PROPN
ihlr-25462	434	17	(	(	PUNCT
ihlr-25462	434	18	nov	nov	PROPN
ihlr-25462	434	19	.	.	PROPN
ihlr-25462	434	20	12	12	NUM
ihlr-25462	434	21	,	,	PUNCT
ihlr-25462	434	22	2019	2019	NUM
ihlr-25462	434	23	)	)	PUNCT
ihlr-25462	434	24	,	,	PUNCT
ihlr-25462	434	25	https://www.csrxp.org/icymi-gallup-finds-nearly-58-million-americans-unable-toafford-their-prescription-drugs-up-four-percent-from-january/	https://www.csrxp.org/icymi-gallup-finds-nearly-58-million-americans-unable-toafford-their-prescription-drugs-up-four-percent-from-january/	X
ihlr-25462	435	1	[	[	X
ihlr-25462	435	2	https://perma.cc/quq8-s5fu	https://perma.cc/quq8-s5fu	NOUN
ihlr-25462	435	3	]	]	X
ihlr-25462	435	4	.	.	PUNCT
ihlr-25462	436	1	157	157	NUM
ihlr-25462	436	2	.	.	PUNCT
ihlr-25462	436	3	brown	brown	PROPN
ihlr-25462	436	4	,	,	PUNCT
ihlr-25462	436	5	supra	supra	PROPN
ihlr-25462	436	6	note	note	PROPN
ihlr-25462	436	7	66	66	NUM
ihlr-25462	436	8	,	,	PUNCT
ihlr-25462	436	9	at	at	ADP
ihlr-25462	436	10	208	208	NUM
ihlr-25462	436	11	.	.	PUNCT
ihlr-25462	437	1	158	158	NUM
ihlr-25462	437	2	.	.	PUNCT
ihlr-25462	438	1	arfwedson	arfwedson	PROPN
ihlr-25462	438	2	,	,	PUNCT
ihlr-25462	438	3	supra	supra	PROPN
ihlr-25462	438	4	note	note	PROPN
ihlr-25462	438	5	68	68	NUM
ihlr-25462	438	6	,	,	PUNCT
ihlr-25462	438	7	at	at	ADP
ihlr-25462	438	8	20	20	NUM
ihlr-25462	438	9	.	.	PUNCT
ihlr-25462	439	1	416	416	NUM
ihlr-25462	439	2	indiana	indiana	PROPN
ihlr-25462	439	3	health	health	PROPN
ihlr-25462	439	4	law	law	PROPN
ihlr-25462	439	5	review	review	NOUN
ihlr-25462	439	6	[	[	X
ihlr-25462	439	7	vol	vol	NOUN
ihlr-25462	439	8	.	.	PUNCT
ihlr-25462	439	9	18:397	18:397	NUM
ihlr-25462	439	10	b.	b.	PROPN
ihlr-25462	439	11	patent	patent	NOUN
ihlr-25462	439	12	thicketing	thickete	VERB
ihlr-25462	439	13	proposed	propose	VERB
ihlr-25462	439	14	legislation	legislation	NOUN
ihlr-25462	439	15	like	like	ADP
ihlr-25462	439	16	the	the	DET
ihlr-25462	439	17	affordable	affordable	ADJ
ihlr-25462	439	18	prescriptions	prescription	NOUN
ihlr-25462	439	19	for	for	ADP
ihlr-25462	439	20	patients	patient	NOUN
ihlr-25462	439	21	act	act	VERB
ihlr-25462	439	22	would	would	AUX
ihlr-25462	439	23	attempt	attempt	VERB
ihlr-25462	439	24	to	to	PART
ihlr-25462	439	25	prevent	prevent	VERB
ihlr-25462	439	26	patent	patent	NOUN
ihlr-25462	439	27	thicketing	thickete	VERB
ihlr-25462	439	28	by	by	ADP
ihlr-25462	439	29	allowing	allow	VERB
ihlr-25462	439	30	the	the	DET
ihlr-25462	439	31	ftc	ftc	PROPN
ihlr-25462	439	32	to	to	PART
ihlr-25462	439	33	challenge	challenge	VERB
ihlr-25462	439	34	the	the	DET
ihlr-25462	439	35	practice	practice	NOUN
ihlr-25462	439	36	as	as	ADP
ihlr-25462	439	37	anti	anti	ADJ
ihlr-25462	439	38	-	-	ADJ
ihlr-25462	439	39	competitive	competitive	ADJ
ihlr-25462	439	40	and	and	CCONJ
ihlr-25462	439	41	to	to	PART
ihlr-25462	439	42	enable	enable	VERB
ihlr-25462	439	43	the	the	DET
ihlr-25462	439	44	ftc	ftc	PROPN
ihlr-25462	439	45	to	to	PART
ihlr-25462	439	46	bring	bring	VERB
ihlr-25462	439	47	antitrust	antitrust	ADJ
ihlr-25462	439	48	suits	suit	NOUN
ihlr-25462	439	49	against	against	ADP
ihlr-25462	439	50	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	439	51	manufacturers.159	manufacturers.159	NOUN
ihlr-25462	439	52	while	while	SCONJ
ihlr-25462	439	53	the	the	DET
ihlr-25462	439	54	proposed	propose	VERB
ihlr-25462	439	55	legislation	legislation	NOUN
ihlr-25462	439	56	states	state	VERB
ihlr-25462	439	57	that	that	SCONJ
ihlr-25462	439	58	manufacturers	manufacturer	NOUN
ihlr-25462	439	59	will	will	AUX
ihlr-25462	439	60	be	be	AUX
ihlr-25462	439	61	allowed	allow	VERB
ihlr-25462	439	62	to	to	PART
ihlr-25462	439	63	argue	argue	VERB
ihlr-25462	439	64	that	that	SCONJ
ihlr-25462	439	65	their	their	PRON
ihlr-25462	439	66	actions	action	NOUN
ihlr-25462	439	67	are	be	AUX
ihlr-25462	439	68	not	not	PART
ihlr-25462	439	69	anti	anti	ADJ
ihlr-25462	439	70	-	-	ADJ
ihlr-25462	439	71	competitive	competitive	ADJ
ihlr-25462	439	72	by	by	ADP
ihlr-25462	439	73	submitting	submit	VERB
ihlr-25462	439	74	rebuttal	rebuttal	NOUN
ihlr-25462	439	75	evidence,160	evidence,160	PROPN
ihlr-25462	440	1	the	the	DET
ihlr-25462	440	2	situation	situation	NOUN
ihlr-25462	440	3	remains	remain	VERB
ihlr-25462	440	4	that	that	SCONJ
ihlr-25462	440	5	,	,	PUNCT
ihlr-25462	440	6	even	even	ADV
ihlr-25462	440	7	in	in	ADP
ihlr-25462	440	8	the	the	DET
ihlr-25462	440	9	most	most	ADV
ihlr-25462	440	10	extreme	extreme	ADJ
ihlr-25462	440	11	cases	case	NOUN
ihlr-25462	440	12	of	of	ADP
ihlr-25462	440	13	alleged	alleged	ADJ
ihlr-25462	440	14	thicketing	thicketing	NOUN
ihlr-25462	440	15	,	,	PUNCT
ihlr-25462	440	16	the	the	DET
ihlr-25462	440	17	patents	patent	NOUN
ihlr-25462	440	18	were	be	AUX
ihlr-25462	440	19	obtained	obtain	VERB
ihlr-25462	440	20	lawfully	lawfully	ADV
ihlr-25462	440	21	by	by	ADP
ihlr-25462	440	22	the	the	DET
ihlr-25462	440	23	uspto	uspto	NOUN
ihlr-25462	440	24	.	.	PUNCT
ihlr-25462	441	1	therefore	therefore	ADV
ihlr-25462	441	2	,	,	PUNCT
ihlr-25462	441	3	while	while	SCONJ
ihlr-25462	441	4	this	this	DET
ihlr-25462	441	5	legislation	legislation	NOUN
ihlr-25462	441	6	may	may	AUX
ihlr-25462	441	7	lower	lower	VERB
ihlr-25462	441	8	drug	drug	NOUN
ihlr-25462	441	9	prices	price	NOUN
ihlr-25462	441	10	,	,	PUNCT
ihlr-25462	441	11	it	it	PRON
ihlr-25462	441	12	also	also	ADV
ihlr-25462	441	13	may	may	AUX
ihlr-25462	441	14	have	have	VERB
ihlr-25462	441	15	a	a	DET
ihlr-25462	441	16	more	more	ADV
ihlr-25462	441	17	significant	significant	ADJ
ihlr-25462	441	18	impact	impact	NOUN
ihlr-25462	441	19	on	on	ADP
ihlr-25462	441	20	how	how	SCONJ
ihlr-25462	441	21	patents	patent	NOUN
ihlr-25462	441	22	are	be	AUX
ihlr-25462	441	23	granted	grant	VERB
ihlr-25462	441	24	generally	generally	ADV
ihlr-25462	441	25	by	by	ADP
ihlr-25462	441	26	the	the	DET
ihlr-25462	441	27	uspto	uspto	NOUN
ihlr-25462	441	28	or	or	CCONJ
ihlr-25462	441	29	how	how	SCONJ
ihlr-25462	441	30	innovators	innovator	NOUN
ihlr-25462	441	31	approach	approach	NOUN
ihlr-25462	441	32	bringing	bring	VERB
ihlr-25462	441	33	these	these	DET
ihlr-25462	441	34	new	new	ADJ
ihlr-25462	441	35	ideas	idea	NOUN
ihlr-25462	441	36	to	to	ADP
ihlr-25462	441	37	the	the	DET
ihlr-25462	441	38	market	market	NOUN
ihlr-25462	441	39	generally	generally	ADV
ihlr-25462	441	40	.	.	PUNCT
ihlr-25462	442	1	c.	c.	NOUN
ihlr-25462	442	2	product	product	NOUN
ihlr-25462	442	3	hopping	hop	VERB
ihlr-25462	442	4	while	while	SCONJ
ihlr-25462	442	5	the	the	DET
ihlr-25462	442	6	practice	practice	NOUN
ihlr-25462	442	7	of	of	ADP
ihlr-25462	442	8	so	so	ADV
ihlr-25462	442	9	-	-	PUNCT
ihlr-25462	442	10	called	call	VERB
ihlr-25462	442	11	“	"	PUNCT
ihlr-25462	442	12	product	product	NOUN
ihlr-25462	442	13	hopping	hopping	NOUN
ihlr-25462	442	14	”	"	PUNCT
ihlr-25462	442	15	may	may	AUX
ihlr-25462	442	16	not	not	PART
ihlr-25462	442	17	be	be	AUX
ihlr-25462	442	18	easy	easy	ADJ
ihlr-25462	442	19	to	to	PART
ihlr-25462	442	20	recognize	recognize	VERB
ihlr-25462	442	21	,	,	PUNCT
ihlr-25462	442	22	this	this	DET
ihlr-25462	442	23	practice	practice	NOUN
ihlr-25462	442	24	can	can	AUX
ihlr-25462	442	25	result	result	VERB
ihlr-25462	442	26	in	in	ADP
ihlr-25462	442	27	“	"	PUNCT
ihlr-25462	442	28	monopoly	monopoly	NOUN
ihlr-25462	442	29	pricing	pricing	NOUN
ihlr-25462	442	30	,	,	PUNCT
ihlr-25462	442	31	burdening	burden	VERB
ihlr-25462	442	32	patients	patient	NOUN
ihlr-25462	442	33	,	,	PUNCT
ihlr-25462	442	34	the	the	DET
ihlr-25462	442	35	government	government	NOUN
ihlr-25462	442	36	,	,	PUNCT
ihlr-25462	442	37	and	and	CCONJ
ihlr-25462	442	38	the	the	DET
ihlr-25462	442	39	health	health	NOUN
ihlr-25462	442	40	care	care	NOUN
ihlr-25462	442	41	system	system	NOUN
ihlr-25462	442	42	as	as	ADP
ihlr-25462	442	43	a	a	DET
ihlr-25462	442	44	whole	whole	NOUN
ihlr-25462	442	45	.	.	PUNCT
ihlr-25462	443	1	”161	”161	VERB
ihlr-25462	443	2	product	product	NOUN
ihlr-25462	443	3	hopping	hopping	NOUN
ihlr-25462	443	4	raises	raise	VERB
ihlr-25462	443	5	issues	issue	NOUN
ihlr-25462	443	6	that	that	PRON
ihlr-25462	443	7	intersect	intersect	ADJ
ihlr-25462	443	8	with	with	ADP
ihlr-25462	443	9	multiple	multiple	ADJ
ihlr-25462	443	10	areas	area	NOUN
ihlr-25462	443	11	of	of	ADP
ihlr-25462	443	12	the	the	DET
ihlr-25462	443	13	law	law	NOUN
ihlr-25462	443	14	:	:	PUNCT
ihlr-25462	443	15	patent	patent	NOUN
ihlr-25462	443	16	,	,	PUNCT
ihlr-25462	443	17	antitrust	antitrust	ADJ
ihlr-25462	443	18	,	,	PUNCT
ihlr-25462	443	19	and	and	CCONJ
ihlr-25462	443	20	state	state	NOUN
ihlr-25462	443	21	drug	drug	NOUN
ihlr-25462	443	22	product	product	NOUN
ihlr-25462	443	23	substitution	substitution	NOUN
ihlr-25462	443	24	laws	law	NOUN
ihlr-25462	443	25	,	,	PUNCT
ihlr-25462	443	26	for	for	ADP
ihlr-25462	443	27	example.162	example.162	PROPN
ihlr-25462	443	28	it	it	PRON
ihlr-25462	443	29	is	be	AUX
ihlr-25462	443	30	particularly	particularly	ADV
ihlr-25462	443	31	complicated	complicated	ADJ
ihlr-25462	443	32	due	due	ADP
ihlr-25462	443	33	to	to	ADP
ihlr-25462	443	34	the	the	DET
ihlr-25462	443	35	unique	unique	ADJ
ihlr-25462	443	36	market	market	NOUN
ihlr-25462	443	37	forces	force	NOUN
ihlr-25462	443	38	and	and	CCONJ
ihlr-25462	443	39	pricing	pricing	NOUN
ihlr-25462	443	40	disconnect	disconnect	NOUN
ihlr-25462	443	41	surrounding	surround	VERB
ihlr-25462	443	42	pharmaceuticals	pharmaceutical	NOUN
ihlr-25462	443	43	.	.	PUNCT
ihlr-25462	444	1	bills	bill	NOUN
ihlr-25462	444	2	such	such	ADJ
ihlr-25462	444	3	as	as	ADP
ihlr-25462	444	4	the	the	DET
ihlr-25462	444	5	affordable	affordable	ADJ
ihlr-25462	444	6	prescriptions	prescription	NOUN
ihlr-25462	444	7	for	for	ADP
ihlr-25462	444	8	patients	patient	NOUN
ihlr-25462	444	9	act	act	VERB
ihlr-25462	444	10	and	and	CCONJ
ihlr-25462	444	11	the	the	DET
ihlr-25462	444	12	affordable	affordable	ADJ
ihlr-25462	444	13	prescriptions	prescription	NOUN
ihlr-25462	444	14	for	for	ADP
ihlr-25462	444	15	patients	patient	NOUN
ihlr-25462	444	16	through	through	ADP
ihlr-25462	444	17	promoting	promote	VERB
ihlr-25462	444	18	price	price	NOUN
ihlr-25462	444	19	competition	competition	NOUN
ihlr-25462	444	20	act	act	NOUN
ihlr-25462	444	21	of	of	ADP
ihlr-25462	444	22	2019	2019	NUM
ihlr-25462	444	23	aim	aim	VERB
ihlr-25462	444	24	to	to	PART
ihlr-25462	444	25	curb	curb	VERB
ihlr-25462	444	26	anti	anti	ADJ
ihlr-25462	444	27	-	-	ADJ
ihlr-25462	444	28	competitive	competitive	ADJ
ihlr-25462	444	29	product	product	NOUN
ihlr-25462	444	30	hops	hop	VERB
ihlr-25462	444	31	but	but	CCONJ
ihlr-25462	444	32	must	must	AUX
ihlr-25462	444	33	do	do	VERB
ihlr-25462	444	34	so	so	ADV
ihlr-25462	444	35	cautiously	cautiously	ADV
ihlr-25462	444	36	as	as	SCONJ
ihlr-25462	444	37	these	these	DET
ihlr-25462	444	38	efforts	effort	NOUN
ihlr-25462	444	39	could	could	AUX
ihlr-25462	444	40	easily	easily	ADV
ihlr-25462	444	41	prevent	prevent	VERB
ihlr-25462	444	42	legitimate	legitimate	ADJ
ihlr-25462	444	43	product	product	NOUN
ihlr-25462	444	44	advances.163	advances.163	PROPN
ihlr-25462	444	45	159	159	NUM
ihlr-25462	444	46	.	.	PUNCT
ihlr-25462	445	1	senate	senate	PROPN
ihlr-25462	445	2	bill	bill	PROPN
ihlr-25462	445	3	seeks	seek	VERB
ihlr-25462	445	4	to	to	PART
ihlr-25462	445	5	give	give	VERB
ihlr-25462	445	6	ftc	ftc	PROPN
ihlr-25462	445	7	authority	authority	NOUN
ihlr-25462	445	8	to	to	PART
ihlr-25462	445	9	fight	fight	VERB
ihlr-25462	445	10	patent	patent	NOUN
ihlr-25462	445	11	thickets	thicket	NOUN
ihlr-25462	445	12	,	,	PUNCT
ihlr-25462	445	13	product	product	NOUN
ihlr-25462	445	14	hopping	hopping	NOUN
ihlr-25462	445	15	,	,	PUNCT
ihlr-25462	445	16	ctr	ctr	PROPN
ihlr-25462	445	17	.	.	PROPN
ihlr-25462	446	1	for	for	ADP
ihlr-25462	446	2	biosimilars	biosimilar	NOUN
ihlr-25462	446	3	(	(	PUNCT
ihlr-25462	446	4	may	may	PROPN
ihlr-25462	446	5	15	15	NUM
ihlr-25462	446	6	,	,	PUNCT
ihlr-25462	446	7	2019	2019	NUM
ihlr-25462	446	8	)	)	PUNCT
ihlr-25462	446	9	,	,	PUNCT
ihlr-25462	446	10	https://www.centerforbiosimilars.com/news/senate-bill-seeks-togive-ftc-authority-to-fight-patent-thickets-product-hopping	https://www.centerforbiosimilars.com/news/senate-bill-seeks-togive-ftc-authority-to-fight-patent-thickets-product-hoppe	VERB
ihlr-25462	446	11	[	[	X
ihlr-25462	446	12	https://perma.cc/k8km-gx9a	https://perma.cc/k8km-gx9a	NOUN
ihlr-25462	446	13	]	]	X
ihlr-25462	446	14	.	.	PUNCT
ihlr-25462	447	1	160	160	NUM
ihlr-25462	447	2	.	.	PUNCT
ihlr-25462	448	1	i	i	PRON
ihlr-25462	448	2	d.	d.	PROPN
ihlr-25462	448	3	161	161	NUM
ihlr-25462	448	4	.	.	PUNCT
ihlr-25462	449	1	michael	michael	PROPN
ihlr-25462	449	2	carrier	carrier	PROPN
ihlr-25462	449	3	&	&	CCONJ
ihlr-25462	449	4	steve	steve	PROPN
ihlr-25462	449	5	shadowen	shadowen	PROPN
ihlr-25462	449	6	,	,	PUNCT
ihlr-25462	449	7	pharmaceutical	pharmaceutical	NOUN
ihlr-25462	449	8	product	product	NOUN
ihlr-25462	449	9	hopping	hop	VERB
ihlr-25462	449	10	:	:	PUNCT
ihlr-25462	449	11	a	a	DET
ihlr-25462	449	12	proposed	propose	VERB
ihlr-25462	449	13	framework	framework	NOUN
ihlr-25462	449	14	for	for	ADP
ihlr-25462	449	15	antitrust	antitrust	ADJ
ihlr-25462	449	16	analysis	analysis	NOUN
ihlr-25462	449	17	,	,	PUNCT
ihlr-25462	449	18	health	health	NOUN
ihlr-25462	449	19	aff	aff	PROPN
ihlr-25462	449	20	.	.	PUNCT
ihlr-25462	450	1	(	(	PUNCT
ihlr-25462	450	2	june	june	PROPN
ihlr-25462	450	3	1	1	NUM
ihlr-25462	450	4	,	,	PUNCT
ihlr-25462	450	5	2017	2017	NUM
ihlr-25462	450	6	)	)	PUNCT
ihlr-25462	450	7	,	,	PUNCT
ihlr-25462	450	8	https://www.healthaffairs.org/	https://www.healthaffairs.org/	ADJ
ihlr-25462	450	9	do/10.1377	do/10.1377	NOUN
ihlr-25462	450	10	/	/	SYM
ihlr-25462	450	11	hblog20170601.060360	hblog20170601.060360	NOUN
ihlr-25462	450	12	/	/	SYM
ihlr-25462	450	13	full/	full/	NUM
ihlr-25462	451	1	[	[	X
ihlr-25462	451	2	https://perma.cc/y4f7-ahpy	https://perma.cc/y4f7-ahpy	NOUN
ihlr-25462	451	3	]	]	PUNCT
ihlr-25462	451	4	.	.	PUNCT
ihlr-25462	452	1	162	162	NUM
ihlr-25462	452	2	.	.	PUNCT
ihlr-25462	453	1	i	i	PRON
ihlr-25462	453	2	d.	d.	PROPN
ihlr-25462	453	3	163	163	NUM
ihlr-25462	453	4	.	.	PUNCT
ihlr-25462	454	1	i	i	PRON
ihlr-25462	454	2	d.	d.	PROPN
ihlr-25462	454	3	https://perma.cc/k8km-gx9a	https://perma.cc/k8km-gx9a	VERB